

PROGRAM GUIDE

— 30th —


CROI 2023

Conference on Retroviruses
and Opportunistic Infections

— February 19-22 | Seattle, WA —

 **IAS-USA**
International Antiviral Society-USA

Version 8 | Last updated March 23, 2023



CONTENTS

CROI FOUNDATION	2
IAS–USA	3
CROI 2023 SCIENTIFIC PROGRAM COMMITTEE	4
Scientific Program Committee	4
Community Liaison Subcommittee	6
EXTERNAL REVIEWERS	7
CONTINUING MEDICAL EDUCATION	10
GENERAL CONFERENCE INFORMATION	12
Overview	12
Funding and Grant Support	12
Affiliated and Proximate Activities	12
Conference Badges	13
Conference Etiquette	13
HEALTH AND SAFETY	13
COVID-19 Policies	13
Americans with Disabilities Act	14
Emergency Services	14
TECHNOLOGY AND CONNECTIVITY	15
Wi-Fi Access at the Conference	15
Conference Platform	15
Website	15
Webcasts	15
ABSTRACT PROCESS	16
Abstracts Related to Study Populations	17
PRECONFERENCE SESSIONS	18
OPENING SESSION, PLENARIES, AND SYMPOSIA BY DAY	22
ORAL ABSTRACT SESSIONS AND THEMED DISCUSSIONS BY DAY	33
POSTER SESSIONS BY DAY	58
POSTER SESSIONS BY CATEGORY	153
INDEX OF PRESENTERS	158
SCHOLARSHIP AWARDEE INFORMATION	165
CONFERENCE SERVICES	166
CONFERENCE SCHEDULE	Foldout
CONVENTION CENTER FLOOR PLANS	Foldout

CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Program Committee (CROI PC) and the CROI Organizer to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Organizer
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

Constance A. Benson, MD President

University of California San Diego
San Diego, CA, United States

John M. Coffin, PhD Secretary-Treasurer

Tufts University
Boston, MA, United States

Elaine J. Abrams, MD

Columbia University
New York, NY, United States

Susan P. Buchbinder, MD

San Francisco Department
of Public Health
San Francisco, CA, United States

Judith S. Currier, MD, MSc

University of California Los Angeles
Los Angeles, CA, United States

Diane V. Havlir, MD

University of California San Francisco
San Francisco, CA, United States

Sharon L. Hillier, PhD

University of Pittsburgh
Pittsburgh, PA, United States

James A. Hoxie, MD

University of Pennsylvania
Philadelphia, PA, United States

Richard A. Koup, MD

Vaccine Research Center within NIAID
Bethesda, MD, United States

John W. Mellors, MD

University of Pittsburgh
Pittsburgh, PA, United States

Landon Myer, MD, PhD

University of Cape Town
Cape Town, South Africa

Robert T. Schooley, MD

University of California San Diego
San Diego, CA, United States

IAS–USA

The International Antiviral (formerly AIDS)–USA (IAS–USA) serves as the Conference Organizer for the planning and organization of CROI in partnership with the CROI Foundation and Program Committee. The IAS–USA is a 501(c)(3) tax-exempt, not-for-profit organization guided by a volunteer board of directors. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access primary educational and informational programs sponsored by the IAS–USA, please visit www.iasusa.org for:

- Live CME courses, CME webinars, and dialogues available for signup
- Archived webcasts of CME courses and webinars
- *Topics in Antiviral Medicine*, including the annual CROI review
- Practice guidelines

CROI 2023 SCIENTIFIC PROGRAM COMMITTEE

The CROI Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee



James A. Hoxie, MD
CROI 2023 Chair
 University of Pennsylvania
 Philadelphia, PA,
 United States



Diane V. Havlir, MD
CROI 2023 Vice Chair
 University of California
 San Francisco
 San Francisco, CA, United
 States



Landon Myer, MD, PhD
CROI 2023 Vice Chair
 University of Cape Town
 Cape Town, South Africa



Elaine J. Abrams, MD
 Columbia University
 New York, NY, United States



Susan P. Buchbinder, MD
 San Francisco Department of
 Public Health
 San Francisco, CA,
 United States



Adaora Adimora, MD
 University of North Carolina
 at Chapel Hill
 Chapel Hill, NC, United States



Connie L. Celum, MD, MPH
 University of Washington
 Seattle, WA, United States



Katharine J. Bar, MD
 University of Pennsylvania
 Philadelphia, PA,
 United States



Richard E. Chaisson, MD
 The Johns Hopkins University
 Baltimore, MD, United States



**Ruanne Barnabas, MD,
 PhD**
 Massachusetts General
 Hospital
 Boston, MA, United States



Nicholas Chomont, PhD
 Université de Montréal
 Montreal, Canada



Constance A. Benson, MD
 University of California San
 Diego
 San Diego, CA, United States



John M. Coffin, PhD
 Tufts University
 Boston, MA, United States



Judith S. Currier, MD
University of California
Los Angeles
Los Angeles, CA,
United States



Angela Kashuba, PharmD
University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States



François Dabis, MD, PhD
University of Bordeaux
Bordeaux, France



Frank Kirchoff, PhD
Institute of Molecular
Virology
Ulm, Germany



Carlos del Rio, MD
Emory University
Atlanta, GA, United States



Richard A. Koup, MD
National Institute of Allergy
and Infectious Diseases
Bethesda, MD, United States



Wafaa M. El-Sadr, MD, MPH
Columbia University
New York, NY, United States



Raphael J. Landovitz, MD
University of California
Los Angeles
Los Angeles, CA,
United States



Joseph J. Eron, Jr, MD
University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States



James McIntyre, MBChB
University of Cape Town
Cape Town, South Africa



Monica Gandhi, MD, MPH
University of California
San Francisco
San Francisco, CA,
United States



John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, United States



Huldrych F. Günthard, MD
University Hospital Zurich
Zurich, Switzerland



**Jonathan Mermin, MD,
MPH**
Centers for Disease Control
and Prevention
Atlanta, GA, United States



**Theodora Hatzioannou,
MD**
The Rockefeller University
New York, NY, United States



**Jean-Michel Molina, MD,
PhD**
University of Paris
Paris, France



Sharon L. Hillier, PhD
University of Pittsburgh
Pittsburgh, PA, United States



Penny Moore, PhD
University of the
Witwatersrand
Johannesburg, South Africa



Peter Hunt, MD
University of California
San Francisco
San Francisco, CA,
United States



Stuart J. D. Neil, PhD
King's College
London, United Kingdom



Jennifer Jao, MD, MPH
Northwestern University
Chicago, IL, United States



Peter Reiss, MD, PhD
University of Amsterdam
Amsterdam, Netherlands



Douglas D. Richman, MD
University of California San Diego
San Diego, CA, United States



Annette H. Sohn, MD
amfAR
Bangkok, Thailand



Jürgen K. Rockstroh, MD
University of Bonn
Bonn, Germany



Serena S. Spudich, MD, MA
Yale University
New Haven, CT, United States



Robert T. Schooley, MD
University of California San Diego
San Diego, CA, United States



David L. Thomas, MD
The Johns Hopkins University
Baltimore, MD, United States



Guido Silvestri, MD
Emory University
Atlanta, GA, United States

Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.



Dawn Averitt
The Well Project
South Strafford, VT,
United States



Ntando Yola
Desmond Tutu HIV Foundation
Cape Town, South Africa



Jim Pickett
AVAC
Chicago, IL, United States

EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who, in addition to the scientific program committee members, served as volunteer external reviewers of abstract submissions for CROI 2023.

K. Rivet Amico, PhD

University of Michigan School of
Public Health
Ann Arbor, MI, United States

Peter L. Anderson, PharmD

University of Colorado Anschutz
Medical Campus
Aurora, CO, United States

Georg Behrens, MD, PhD

Medizinische Hochschule Hannover
Hannover, Germany

Marta Boffito, MD, PhD

Chelsea and Westminster Hospital
London, United Kingdom

Bruce Brew, MBBS, DMedSci, Dsc

St. Vincent's Hospital
Sydney, Australia

Todd T. Brown, MD, PhD

The John Hopkins University
Baltimore, MD, United States

David Burger, PharmD

Radboud University Medical Center
Nijmegen, Netherlands

Maria J. Buzon, PhD

Vall d'Hebron Research Institute
Barcelona, Spain

Carol Camlin, PhD

University of California San Francisco
San Francisco, CA, United States

Corey Casper, MD, MPH

Access to Advanced Health Institute
Seattle, WA, United States

Ellen Chadwick, MD

Northwestern University
Chicago, IL, United States

David B. Clifford, MD

Washington University in St. Louis
St. Louis, MO, United States

Elizabeth Connick, MD

University of Arizona
Tucson, AZ, United States

Blossom Damania, PhD

University of North Carolina at
Chapel Hill
Chapel Hill, NC, United States

Kevin M. De Cock, MD

Center for Disease Control
and Prevention
Nairobi, Kenya

Kelly E. Dooley, MD, PhD

Vanderbilt University
Nashville, TN, United States

Kristine Erlandson, MD

University of Colorado Anschutz
Medical Campus
Aurora, CO, United States

David Evans, PhD

University of Wisconsin Madison
Madison, WI, United States

Paul Farrell, PhD

Imperial College London
London, United Kingdom

Matthew Feinstein, MD, MSc

Northwestern University
Chicago, IL, United States

William Fischer, MD

University of North Carolina at
Chapel Hill
Chapel Hill, NC, United States

Courtney Fletcher, PharmD

University of Nebraska Medical Center
Omaha, NE, United States

Charles Flexner, MD

The John Hopkins University
Baltimore, MD, United States

Patricia Flynn, MD

St. Jude Children's Research Hospital
Memphis, TN, United States

Nathan Ford, MPH, DSc, PhD

World Health Organization
Geneva, Switzerland

John Frater, MD

University of Oxford
Headington, United Kingdom

Dana Gabuzda, MD

Dana Farber Cancer Institute
Boston, MA, United States

Gerardo Garcia-Lerma, PhD

Centers for Disease Control
and Prevention
Atlanta, GA, United States

Carlo Giaquinto, MD, PhD

University of Padova
Padova, Italy

Beatriz Grinsztejn, MD, PhD

Instituto de Pesquisa Clinica
Evandro Chagas
Rio de Janeiro, Brazil

Jessica Haberer, MD, MS

Massachusetts General Hospital
Boston, MA, United States

Richard Harrigan, PhD

University of British Columbia
Vancouver, Canada

Renee Heffron, PhD, MPH

University of Alabama at Birmingham
Birmingham, AL, United States

Sybil Hosek, PhD

Cook County Health
Chicago, IL, United States

Ya-Chi Ho, PhD

Yale University
New Haven, CT, United States

Jennifer Hoy, MBBS

Alfred Hospital
Melbourne, Australia

Priscilla Hsue, MD

University of California San Francisco
San Francisco, CA, United States

Harold Jaffe, MD

Centers for Disease Control
and Prevention
Atlanta, CA, United States

Sarah Joseph, PhD

University of North Carolina at
Chapel Hill
Chapel Hill, NC, United States

Dennis Kolson, MD, PhD

University of Pennsylvania
Philadelphia, PA, United States

Susan E. Krown, MD

Memorial Sloan Kettering Cancer Center
New York, NY, United States

Mohammed Lamorde, MD

Makerere University
Kampala, Uganda

Maud Lemoine, MD, PhD

Imperial College London
London, United Kingdom

Scott L. Letendre, MD

University of California San Diego
San Diego, CA, United States

Sharon Lewin, MD, PhD

Doherty Institute for Infection
and Immunity
Melbourne, Australia

Anne F. Luetkemeyer, MD

University of California San Francisco
San Francisco, CA, United States

Hermione Lyall, MD

Imperial College London
London, United Kingdom

Rebecca Lynch, PhD

George Washington University
Washington, DC, United States

Patrick Mallon, MD, PhD

University College Dublin
Dublin, Ireland

Jeanne Marrazzo, MD, MPH

University of Alabama at Birmingham
Birmingham, AL, United States

Grace A. McComsey, MD

Case Western Reserve University
Cleveland, OH, United States

Graeme Meintjes, MD, PhD

University of Cape Town
Cape Town, South Africa

Ronald Mitsuyasu, MD

University of California Los Angeles
Los Angeles, CA, United States

Victor Musiime, MBChB, MMed, PhD

Makerere University
Kampala, Uganda

Susanna Naggie, MD, MPH

Duke University School of Medicine
Durham, NC, United States

Martina Penazzato, MD, MSc, PhD

World Health Organization
Geneva, Switzerland

Sari L. Reisner, DSc

Brigham and Women's Hospital
Boston, MA, United States

Robert H. Remien, PhD

Columbia University
New York, NY, United States

Erle Robertson, PhD

University of Pennsylvania
Philadelphia, PA, United States

Michael Saag, MD

University of Alabama at Birmingham
Birmingham, AL, United States

Thomas Schulz, MD

Hannover Medical School
Hannover, Germany

Kenneth Sherman, MD, PhD

University of Cincinnati
Cincinnati, OH, United States

Euphemia Sibanda, PhD

Centre for Sexual Health and HIV/AIDS
Research Zimbabwe
Harare, Zimbabwe

Viviana Simon, MD, PhD

Icahn School of Medicine at Mount Sinai
New York, NY, United States

Lynda Stranix-Chibanda, MBChB

University of Zimbabwe
Harare, Zimbabwe

Patrick S. Sullivan, PhD

Emory University
Atlanta, GA, United States

Susan Swindells, MBBS

University of Nebraska Medical Center
Omaha, NE, United States

Alexandra Trkola, PhD

University of Zurich
Zurich, Switzerland

Alice Tseng, PharmD

University Health Network
Toronto, Canada

Heidi van Rooyen, PhD

Human Sciences Research Council
Johannesburg, South Africa

Gert van Zyl, MD, PhD

Stellenbosch University
Stellenbosch, South Africa

Timothy Wilkin, MD

Weill Cornell Medicine
New York, NY, United States

Alan Winston, MD

Imperial College London
London, United Kingdom

David Wyles, MD

Denver Health Medical Center
Denver, CO, United States

Robert Yarchoan, MD

National Cancer Institute
Bethesda, MD, United States

Markella V. Zanni, MD

Harvard Medical School
Boston, MA, United States

CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



The IAS—USA designates this live activity for a maximum of 17.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

After participating in CROI 2023, participants will be able to describe the following as they relate to research in HIV, hepatitis viruses, SARS-CoV-2, mpox, and other viral infections and their related conditions:

- Describe basic science research advances
- List the most recent findings from clinical trials and the implications of these data for state-of-the-art treatment strategies
- Describe current epidemiologic data on the prevalence of infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public health program planning; and current advances in biobehavioral prevention.

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993, by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections, such as Covid-19 and mpox.

CME Credit Information

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for their participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, symposia, meet the luminary sessions, and selected special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, certain special sessions, or poster sessions. For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).



ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 MOC points in the ABIM MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, links to the daily and final evaluations will be available on the CROI website. Detailed instructions will be provided. You will need the email address that you used to register for this conference and your reference number (on your badge) to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations and claim forms must be submitted by April 28, 2023. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile on the CROI or IAS—USA website.

To determine the number CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference activities, including premeeting workshops, opening session lectures, plenary lectures, selected special sessions, and symposia. For example, if you attended 2 plenary talks (8:30 to 9:30 AM), and a symposium (4:00 to 5:30 PM), you would have a total of 2.5 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended.

A CME/ABIM MOC hour worksheet can be found on the CROI website.

Disclosure of Financial Relationships

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS—USA requires all persons with control of content (eg, the Scientific Program Committee, Community Liaison Subcommittee, invited speakers, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The information is intended to make the audience aware of speaker and contributor financial relationships with ineligible companies, enabling the audience members to form their own judgments about such associations.

Each author, contributor, or person in control of content in the CME activity is required to complete this financial relationship disclosure declaration. In accordance with IAS—USA policy, the IAS—USA will identify and mitigate ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information will also be included at the beginning of each presentation.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

GENERAL CONFERENCE INFORMATION

Overview

CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Funding and Grant Support

CROI seeks grants from commercial (ineligible) companies, particularly from companies with competing products. These companies have no input or control over the selection of faculty or the content of the CME portions of the program or abstract review and selection processes. This support is used to cover some of the costs of the conference venue, audiovisual services, and other conference expenses. CROI 2023 received grant support commitments from the following:

PLATINUM LEVEL SUPPORT

Gilead Sciences, Inc.

Merck & Co, Inc

ViiV Healthcare

GOLD LEVEL SUPPORT

Janssen Therapeutics

BRONZE LEVEL SUPPORT

Hologic, Inc.

Theratechnologies, Inc.

Additional support received after the printing of this program book will be announced during the Conference.

Affiliated and Proximate Activities Policies

The goal of CROI is to promote meaningful and high-level interchange of scientific ideas to find better ways to prevent and treat HIV and AIDS and to one day see HIV and other viral infections, including hepatitis viruses, SARS-CoV-2, and mpox virus eradicated. In keeping with this goal, certain organizations (commercial companies and their agents, not-for-profit groups, research study groups, government agencies, etc) have been approved to host Affiliated or Proximate Activities occurring outside CROI sessions times. Affiliated or Proximate Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2023. **An Affiliated and Proximate Activity is any activity, event, or meeting held at any time from 3 days before (Thursday, February 16) through 2 days after (Friday, February 24) CROI 2023, and targeted toward or including any registrants of CROI.**

If an activity is found to have violated the Guidelines for Affiliated or Proximate Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated or Proximate Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and could negatively impact the registration and attendance of anyone attending an unapproved activity.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel

may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

Conference Badges

Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. The CROI badge must be worn at all times during the conference in order to gain entry to all official meeting activities, including the poster sessions. Attendees will not be admitted into the meeting spaces without their CROI badge. **THE CROI BADGE MAY ONLY BE USED BY THE PERSON NAMED ON THE BADGE AND CANNOT BE TRANSFERRED OR SHARED WITH OTHERS. USING ANOTHER INDIVIDUAL'S BADGE OR GIVING YOUR BADGE TO SOMEONE ELSE TO GAIN ACCESS TO THE CONFERENCE IS STRICTLY PROHIBITED AND IS A VIOLATION OF CROI POLICIES.**

DO NOT LOSE YOUR BADGE. Payment equivalent to the full registration fee will be required to replace a lost badge.

Conference Etiquette

Please ensure all mobile devices are turned off or set on SILENT mode in session rooms. In consideration for the work of the presenters at CROI and the CROI copyright policy, attendees may not photograph posters, record parts of talks, or post data without the presenter's consent.

Out of respect for the presenters and conference attendees, children are not permitted in meeting rooms, including the poster halls.

HEALTH AND SAFETY

COVID-19 Policies

For the health and safety of CROI attendees, staff, and surrounding communities, all attendees must be appropriately vaccinated. **All conference participants must wear a high-quality mask at all times (eg, N95, KN95, or KF94) while in the meeting rooms and other public spaces in the convention center. Please be conscious of physical distancing and airflow when lowering your mask to eat or drink.**

Per the World Health Organization, a fully vaccinated individual is 2 weeks or more post-initial vaccination series and may also receive a recommended booster dose after 4 to 6 months. Per the Center for Disease Control guidelines, you are up to date when you have completed a COVID-19 vaccine primary series and gotten the most recent booster dose recommended for you by the CDC.

- If you have completed your primary series – but are not yet eligible for a booster – you are considered up to date.
- If you become ill with COVID-19 after you received all vaccine doses recommended for you, you are also considered up to date. You do not need to be revaccinated or receive an additional booster.

All on-site conference attendees must verify their vaccination status with conference organizers, prior to departing for the CROI Conference via the CROI 2023 CrowdPass Site, provided in preconference communication. Visit the information desk at registration for any questions.

To accommodate any attendee who does not meet the vaccine requirement we will convert your registration to virtual attendee via the Conference Platform.



Rapid antigen tests are available on a first-come, first-served basis. Additional rapid tests are available at area pharmacies, or via a local COVID-19 testing site (see above). Contact CROIinfo@iasusa.org if you have concerns about your ability to present your abstract due to illness.

CROI conference organizers will continue to monitor the World Health Organization’s recommendations pertaining to COVID-19 and adapt these guidelines accordingly.

Americans With Disabilities Act

CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site during the conference, please visit the Conference Information desk in the registration area.

Emergency Services

In the event of an emergency, please notify CROI staff, or contact the Seattle Convention Center Security by dialing 4748 on a convention center phone or by calling +1 (206) 219-4748, available 24 hours daily. You may also use one of the red phones in the elevator lobbies for an automatic connection to security.

Emergency Medical Services are located on Level 2, near Flex C. If a medical emergency occurs while you are at the Seattle Convention Center, please contact Convention Center security directly. The Convention Center requests that guests do not contact 911 directly, when possible.

TECHNOLOGY AND CONNECTIVITY SERVICES

WiFi Access at the Conference

Complimentary WiFi access is provided at the Seattle Convention Center. Network information is as follows:

Network name: **CROI2023**

The WiFi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will help maximize the internet speeds for those devices actively in use. The password for each day of the conference is listed below and is case sensitive.

Saturday password: **2023saturday**

Sunday password: **2023sunday**

Monday password: **2023monday**

Tuesday password: **2023tuesday**

Wednesday password: **2023wednesday**

If you are having a problem with WiFi access, please contact an IAS-USA staff member.

CONFERENCE PLATFORM

The CROI 2023 Conference Platform has many features to enhance your conference experience, including to:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- Receive the latest changes to the CROI program
- View electronic posters
- Submit questions to live streamed presentations

To access the Conference Platform, select the appropriate platform option below and log in using the email you used to register for CROI and your registration ID.

To view sessions off-site and participate in session chat, Q & A, and polling, log in to the virtual platform: <https://CROI2023.e-attend.com>

To participate in Q & A and polling in-person, log in to the in-person platform: <https://CROIonsite.e-attend.com>

Website

For additional information about the conference and to access electronic materials, please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2020 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014 to 2022 are available at www.CROIconference.org/abstracts/search-abstracts/

Webcasts

Plenary lectures, symposia, oral abstract sessions, and themed discussions will be available as webcasts within 24 hours of the end of the relevant session. Webcasts are also available as streaming videos for the Apple iPad and iPhone.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts.

ABSTRACT PROCESS

Abstract Content

Author names, institutions, titles, and abstracts in the CROI Program and Information Guide, Abstract eBook, Mobile App, and other materials are presented largely as submitted by the submitting author. The submitting author is responsible for ensuring that all coauthors have reviewed and approved the abstract before submission and for providing complete, including email addresses. **THE SUBMITTING AUTHOR MUST ENSURE THAT THE EMAIL ADDRESSES OF ALL LISTED AUTHORS IN THEIR SUBMISSION ARE CORRECT** for authors to receive important information regarding dispositions, presentation details, registration and housing information, and other CROI-related announcements.

Special Notes on Abstract Content

Presentations from randomized trials and cohorts should follow the International Committee of Medical Journal Editors (ICMJE) guidelines, including reporting of study designs, (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables.

Appropriate information and correct terminology should be used regarding sex and gender. For human clinical or epidemiologic studies, sex-stratified results should be provided, who was included in the study (or if the study includes only a single population). Appropriate terminology such as cisgender (people whose gender match the sex assigned at birth) or transgender (people whose gender does not match the sex assigned at birth) should be used. Both sex and gender data should be provided in the presentation. Presentations of preclinical data including use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex and gender, this should be identified as a limitation in your presentation.

Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The **preferred terms** are study “participants” or “volunteers.”

Presenting Author Responsibilities

The presenting author is responsible for presenting the abstract at the conference and must be present at the poster during the entire session. **Submitting authors are responsible for ensuring that all coauthors have reviewed and approved the abstract contents before submission.**

Embargo Policies and Social Media

All research presented at CROI 2023 is embargoed until the conclusion of the study's presentation at the conference. For example, if a study is presented from 2:15 PM to 2:30 PM, as part of a session that begins at 2:00 PM and ends at 3:00 PM, the embargo on that study lifts at 2:30 PM. Embargoes on poster presentations lift at the beginning of the session in which the poster is presented.

If a study to be presented at CROI 2023 is included in an official CROI press conference that takes place before the scheduled presentation of the study, the embargo on that study lifts at the conclusion of the press conference panel in which the study is featured.

No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs), or social media (eg, Twitter, Instagram, Facebook, etc). Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Abstract Review Process

The PC and a panel of volunteer external reviewers reviewed more than 1500 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

Abstracts were reviewed for the quality and originality of the work and were scored numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate.

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores were discussed. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (distinct from a late submission, as they must meet a high threshold of scientific merit).

For more information, including common reasons for abstract rejection, visit the Abstract Guidelines page of www.CROIconference.org

Statistics for Abstracts

Abstract and Presentation Statistics for CROI 2023

Description	Number	Total
General Abstracts Submitted	1051	
General Abstracts Accepted	658	
Late-Breaking HIV, SARS-CoV-2, or mpox Abstracts Submitted	558	
Late-Breaking HIV, SARS-CoV-2, or mpox Abstracts Accepted	347	
Total Abstracts Submitted		1609
Total Abstracts Accepted		1005
Oral Abstract Presentations	115	
Themed Discussion Presentations*	56	
Poster Presentations	834	
Total Scientific Abstract Presentations		1005

*Abstracts accepted a for presentation as a themed discussion are also presented as a poster

Accepted Abstracts on Emerging Infections or Special Populations **

Description	Total
SARS-CoV-2	228
Mpox	61
Adolescents	76
Men who have sex with men (MSM)	152
People who inject drugs (PWID)	51
Transgender men or women	55
Women or girls	155

**As reported by the abstract submitter. Studies may include more than 1 special population (eg Adolescents and Transgender Men or Women)

PRECONFERENCE SESSIONS

SUNDAY, FEBRUARY 19, 2023

Workshop-01 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

CME

Flex A (Level 2)

8:30 AM - 12:30 PM

Objectives: At the completion of the session, participants will be able to:

- Understand fundamental aspects of HIV virology and relevant immunology, including emerging understandings of host-pathogen interactions
- Identify recent advances in HIV prevention and treatment
- Gain new understanding of the experiences of people with HIV

Target Audience: This session is directed to new investigators and trainees (eg, postdoctoral fellows, physician fellows, undergraduate students, and graduate students). Attendance is mandatory for all scholarship recipients, but the workshop is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for fewer than 3 years.

Moderators

Nicolas Chomont, *Université de Montréal, Montreal, QC, Canada*

Serena Spudich, *Yale University, New Haven, CT, USA*



1 OVERVIEW SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES UPDATE ON HIV VIROLOGY



ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2

Stuart J. D. Neil, *King's College London, London, United Kingdom*



ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY

Guido Silvestri, *Emory University, Atlanta, GA, USA*




ADVANCING RESEARCH: THE POWER OF COMMUNITY ENGAGEMENT

Dawn Averitt, *The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA*



ADVANCES IN HIV TREATMENT STRATEGIES

Monica Gandhi, *University of California San Francisco, San Francisco, CA, USA*



ADVANCES IN BIOMEDICAL PREVENTION OF HIV

Raphael J. Landovitz, *University of California Los Angeles, Los Angeles, CA, USA*



ADVANCES IN HIV CURE

John W. Mellors, *University of Pittsburgh, Pittsburgh, PA, USA*



A CALL TO ACTION FOR NEW INVESTIGATORS: OPPORTUNITIES IN RESEARCH AND PUBLIC HEALTH

Rochelle Walensky, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

SUNDAY, FEBRUARY 19, 2023

Workshop-02 FRONTIERS IN LABORATORY TECHNOLOGIES

CME

Ballroom 2 (Level 5)

1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe distinct techniques for single cell analyses, transcriptomics, and imaging, including strengths and limitations
- Describe how deep learning can be applied to characterize protein dynamics

Target Audience: This session is directed to scientists, clinicians, stakeholders, students, and members of the community at large, who are interested in understanding the impact of novel laboratory technologies.

Level of Knowledge: It is assumed that the participants are familiar with the main technologic and data analysis approaches used in research.

Moderators

Katharine Bar, *University of Pennsylvania, Philadelphia, PA, USA*

Frank Kirchoff, *Ulm University Medical Center, Ulm, Baden-Wuerttemberg, Germany*



2 SINGLE-CELL ANALYSIS OF THE RNA, PROTEIN, AND GLYCAN FEATURES OF HIV-INFECTED CELLS



Nadia R. Roan, *Gladstone Institutes, San Francisco, CA, USA*

3 SINGLE-CELL MULTIOMIC ANALYSES OF THE HIV RESERVOIR



Michael R. Betts, *University of Pennsylvania, Philadelphia, PA, USA*

4 SINGLE-CELL MULTIOMICS AND EXPANSION DYNAMICS OF HIV RESERVOIR OVER SPACE AND TIME



Ya-Chi Ho, *Yale University, New Haven, CT, USA*

5 NOVEL APPROACHES TO CHARACTERIZING IMMUNE RECOGNITION



Michael Birnbaum, *Massachusetts Institute of Technology, Cambridge, MA, USA*

SUNDAY, FEBRUARY 19, 2023

Workshop-03 CASE-BASED LIVER WORKSHOP

CME

Flex A (Level 2)

1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:

- Identify etiologies and diagnostic tests for children with severe viral hepatitis
- Describe strategies for the prevention of hepatitis B transmission
- Describe the burden of disease and the current treatment strategies for hepatitis D in people with HIV

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of key issues in viral hepatitis and liver disease in people living with and without HIV infection.**Level of Knowledge:** It is assumed that the participants are familiar with the major viral causes of hepatitis and other key issues related to liver disease in people living with and without HIV infection.**Moderators****Debika Bhattacharya**, *University of California Los Angeles, Los Angeles, CA, USA***Christoph Boesecke**, *Bonn University Hospital, Bonn, Nordrhein-Westfalen, Germany***6 FULMINANT HEPATITIS IN CHILDREN****Luz Helena Gutierrez Sanchez**, *University of Alabama at Birmingham, Birmingham, AL, USA***7 HBV PREVENTION: NEWER VACCINES AND THE BOUNDARIES OF HBV PROTECTION****H. Nina Kim**, *University of Washington, Seattle, WA, USA***8 HEPATITIS DELTA INFECTION AMONG PERSONS WITH HIV****Charles Béguelin**, *University of Bern, Bern, Switzerland*

SUNDAY, FEBRUARY 19, 2023

Workshop-04 CLINICAL TRIAL DESIGN AND ANALYSIS

CME

Ballroom 3 (Level 5)

1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe some key lessons we have learned from platform trials
- List some of the major types of modeling studies and how to interpret results from these studies
- Identify some of the central reasons why it is important to include behavioral and social science in clinical trials

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.**Level of Knowledge:** It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and epidemiologic studies of HIV, SARS-CoV-2, or mpox.**Moderators****Susan P. Buchbinder**, *San Francisco Department of Public Health, San Francisco, CA, USA***Richard Chaisson**, *The Johns Hopkins University, Baltimore, MD, USA***9 ADAPTIVE PLATFORM TRIALS: EXPERIENCE FROM THE COVID-19 PANDEMIC****Michael D. Hughes**, *Harvard TH Chan School of Public Health, Boston, Massachusetts, MA, USA***10 UNPACKING MODELING STUDIES****Viviane D. Lima**, *British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada***11 SOCIAL AND BEHAVIORAL SCIENCE: THE MISSING INGREDIENT TO SUCCESSFUL CLINICAL TRIALS****Heidi van Rooyen**, *Human Sciences Research Council, Cape Town, Western Cape, South Africa*

OPENING SESSION, PLENARIES, AND SYMPOSIA BY DAY

SUNDAY, FEBRUARY 19, 2023

OPENING-01 OPENING SESSION

CME

Flex C (Level 2)

5:00 PM - 7:20 PM

WELCOME FROM THE CROI 2023 CHAIR

James Hoxie, *University of Pennsylvania, Philadelphia, PA, USA*



12 MODELING THE DYNAMICS OF HIV INFECTION: ESTABLISHING PARADIGMS FOR TREATMENT AND CURE



Alan S. Perelson, *Los Alamos National Laboratory, Los Alamos, NM, USA*



INTRODUCTION OF THE N'GALY-MANN LECTURE

Diane V. Havlir, *University of California San Francisco, San Francisco, CA, USA*

13 HIV AND GLOBAL HEALTH IN A PANDEMIC ERA



Kevin M. De Cock, *Centers for Disease Control and Prevention (former), Nairobi, Kenya*



INTRODUCTION OF THE MARTIN DELANEY PRESENTATION

Dawn Averitt, *The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA*

14 COMMUNITY AND ADVOCATES ARE EQUAL PARTNERS IN RESEARCH AND DEVELOPMENT



Yvette A. Raphael, *Advocacy for Prevention of HIV and AIDS, Midrand, Gauteng, South Africa*

CROI AT 30: PROGRESS IN HIV THROUGH THE LENS OF CROI

INTRODUCTION OF DR ANTHONY FAUCI

Robert T. Schooley, *University of California San Diego, San Diego, CA, USA*



CROI: A 30-YEAR CHRONICLE OF HIV/AIDS RESEARCH PROGRESS

Anthony S. Fauci, *Former Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Washington, DC*



MONDAY, FEBRUARY 20, 2023

PLENARY-01 MONDAY PLENARY SESSION

CME

Flex C (Level 2)

8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE CHAIR WELCOME TO MONDAY

15 20 YEARS OF PEPFAR: LOOKING BACK, STRIDING FORWARD



John Nkengasong, *US Department of State, Washington, DC, USA*

16 THE PATH TO HEPATITIS B CURE



Anna S. Lok, *University of Michigan, Ann Arbor, MI, USA*

Symposium-01 VIRAL ORIGINS AND EVOLUTION OF HIV AND SARS-CoV-2

CME

Ballroom 2 (Level 5)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Understand conditions for virus zoonosis and spread in a new host
- Identify factors that influence virus spread and evolution in specific populations
- Identify tools used for global virus surveillance and information obtained from sequencing data

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of key issues in viral evolution of HIV and SARS-CoV-2

Level of Knowledge: It is assumed that participants are familiar with the basic virology of HIV and SARS-CoV-2.

Moderators

Theodora Hatziioannou, *The Rockefeller University, New York, NY, USA*

Julie M. Overbaugh, *University of Washington, Seattle, WA, USA*



17 ORIGINS OF HIV-1 AND SARS-CoV-2



Michael Worobey, *University of Arizona, Tucson, AZ, USA*

18 FROM PROMISE TO REALIZATION: SEQUENCING AND SURVEILLANCE FROM HIV-1 TO SARS-CoV-2



Emma B. Hodcroft, *University of Bern, Basel, Basel-Stadt, Switzerland*

19 ANTIBODY DRIVEN EVOLUTION OF HIV-1 AND SARS-CoV-2



Paul Bieniasz, *The Rockefeller University, New York, NY, USA*

MONDAY, FEBRUARY 20, 2023

**Symposium-02 FROM ROCKET SCIENCE TO REALITY:
MONITORING ANTIRETROVIRALS AND ADHERENCE**

CME

Flex A (Level 2)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Identify the strengths and weaknesses of current adherence measures; identify new adherence measures currently in development
- Describe current digital technologies for supporting patient adherence
- Identify what might be most useful in HIV treatment and prevention with advanced adherence forgiveness of current ARV therapies, list adherence implementation considerations in low and middle income countries

Target Audience: This session is directed to physicians and researchers interested in strategies for monitoring and improving antiretroviral therapy adherence.**Level of Knowledge:** It is assumed that participants are familiar with the basic understanding of monitoring and improving antiretroviral therapy adherence.**Moderators****K. Rivet Amico**, *University of Michigan, Ann Arbor, MI, USA***Alice Tseng**, *University Health Network, Toronto, ON, Canada***20 THE LANDSCAPE OF ADHERENCE TESTING****Peter L. Anderson**, *University of Colorado Anschutz Medical Campus, Aurora, CO, USA***21 DIGITAL TECHNOLOGIES FOR SUPPORTING ADHERENCE****Lisa Hightow-Weidman**, *Florida State University, Pittsboro, NC, USA***22 CONSIDERATIONS FOR MEASURING ADHERENCE WITH LA/ED THERAPIES IN LOW- AND MIDDLE-INCOME COUNTRIES****Catherine Orrell**, *Desmond Tutu Health Foundation, Cape Town, Western Cape, South Africa***Symposium-03 DELIVERING ON THE SUCCESS OF INJECTABLE PrEP**

CME

Ballroom 1 (Level 5)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe the current state of evidence for long-acting injectable cabotegravir across at-risk populations, including current guidelines for use
- Describe the barriers and data gaps that threaten the population-level impact of novel HIV PrEP strategies
- Identify actions that can mitigate or eliminate disparities in benefit of novel HIV PrEP strategies in key populations

Target Audience: This session is directed to physicians and researchers interested in injectable modalities for the delivery of preexposure prophylaxis.**Level of Knowledge:** It is assumed that participants are familiar with contemporary modalities for the delivery of preexposure prophylaxis.

Moderators

Raphael J. Landovitz, *University of California Los Angeles, Los Angeles, CA, USA*

Christina Psaros, *Massachusetts General Hospital, Boston, MA, USA*



23 FROM EFFICACY TO EFFECTIVENESS: CATALYZING ROLLOUT OF LONG ACTING PrEP



Nyaradzo M. Mgodzi, *University of Zimbabwe, Harare, Harare, Zimbabwe*

24 AVOIDING DISPARITIES: NOT MAKING THE SAME MISTAKE AGAIN



LaRon Nelson, *Yale University, New Haven, CT, USA*

25 LA PrEP: WHAT WE KNOW AND WHAT WE STILL NEED TO KNOW



Sunil S. Solomon, *The Johns Hopkins University School of Medicine, Baltimore, MD, USA*

TUESDAY, FEBRUARY 21, 2023

Plenary-02 TUESDAY PLENARY SESSION

CME

Flex C (Level 2)

8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO TUESDAY

Landon Myer, University of Cape Town, Cape Town, Western Cape, South Africa



26 HIV RESERVOIRS: OBSTACLES TO A CURE



Janet M. Siliciano, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

27 RESTRICTIONS ON REPRODUCTIVE RIGHTS AND THEIR IMPACT ON PEOPLE LIVING WITH HIV



Denise J. Jamieson, Emory University, Decatur, GA, USA

Symposium-04 PEDIATRIC HIV CURE

CME

Ballroom 2 (Level 5)

4:00 PM - 5:30 PM

Objectives:

At the completion of the session, participants will be able to:

- List contemporary approaches to research in pediatric cure of HIV
- Describe the progress in clinical trials of HIV prevention and cure

Target Audience: This session is directed to adult and pediatric HIV clinicians and clinical investigators as well as trainees in these areas.

Level of Knowledge: It is assumed that the participants are familiar with antiretroviral regimens commonly used for HIV treatment and prevention.

Moderator

Deborah Persaud, The Johns Hopkins University, Baltimore, MD, USA



28 APPROACHES TO PEDIATRIC CURE



Philip J.R. Goulder, University of Oxford, Oxford, United Kingdom

29 NONHUMAN PRIMATE STUDIES OF PEDIATRIC CURE INTERVENTIONS



Ann Chahroudi, Emory Vaccine Center, Atlanta, GA, USA

30 PROGRESS IN CLINICAL TRIALS OF PEDIATRIC HIV CURE



Roger Shapiro, Harvard University, Boston, MA, USA

TUESDAY, FEBRUARY 21, 2023

Symposium-05 COVID-19: WHERE ARE WE NOW?

CME

Flex A (Level 2)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Identify the strengths and weaknesses of current adherence measures, and describe existing and next generation approaches to outpatient antiviral and immune-based (monoclonal antibody) treatment for mild to moderate COVID-19 disease and the impact of treatment on attendant complications of SARS-CoV-2 infection.
- Identify key features of the biology and pathogenesis of SARS-CoV-2 viral rebound in the setting of acute infection and antiviral treatment.
- Describe emerging syndromes associated with Long COVID and emerging data about its pathogenesis, treatment, and prognosis

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of the state of the COVID-19 pandemic.**Level of Knowledge:** It is assumed that participants are familiar with the basic understanding of COVID-19 epidemiology.**Moderators****Brenda E. Crabtree-Ramirez**, *Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Distrito Federal, Mexico***Irini Sereti**, *National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA***31 FUTURE DIRECTIONS IN OUTPATIENT THERAPY FOR MILD TO MODERATE COVID-19****Kara W. Chew**, *University of California Los Angeles, Los Angeles, CA, USA***32 VIRAL REBOUND DURING AND AFTER SARS-CoV-2 TREATMENT****Jonathan Z. Li**, *Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA***33 WHAT WE KNOW NOW ABOUT LONG COVID SYNDROMES****Michael J. Peluso**, *University of California San Francisco, San Francisco, CA, USA*

TUESDAY, FEBRUARY 21, 2023

Symposium-06 GETTING PrEPped (AND PEPped) FOR SEX: FROM HIV TO STIs TO MPOX

CME

Ballroom 1 (Level 5)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- List strategies for incorporating HIV PEP/PrEP into clinical practice
- Describe different strategies for prevention of STIs in adults and adolescents
- Identify methods for prevention of mpox pre- and post-exposure

Target Audience: This session is directed to physicians interested in applying preventative strategies for HIV, sexually transmitted infections, and mpox in practice.

Level of Knowledge: It is assumed that participants are familiar with the contemporary strategies for preventing HIV, sexually transmitted infections, and mpox.

Moderators

Bridget G. Haire, Kirby Institute, Sydney, New South Wales, Australia

Maryam Shahmanesh, Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa



34 IMPLEMENTING THE PrEP AND PEP TOOLKIT



Colleen Kelley, Emory University School of Medicine, Atlanta, GA, USA

35 PREVENTION OF STIs IN ADULTS AND ADOLESCENTS A SEXUAL REPRODUCTIVE HEALTH PERSPECTIVE



James Kiarie, World Health Organization, Geneva, Geneva, Switzerland

36 MPOX PREVENTION



Jade Ghosn, University of Paris Cité Department: Infectious Diseases, Bichat hospital, Paris, Ile-de-France, France

SPECIAL SESSION-1 RESULTS FROM THE MOSAICO HIV VACCINE TRIAL AND FUTURE DIRECTIONS FOR HIV VACCINES

Flex A (Level 2)

5:40 PM - 6:00 PM

Moderators

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA



OVERVIEW OF THE MOSAICO HIV VACCINE TRIAL



Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

HIV VACCINE DEVELOPMENT POST-MOSAICO



Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

WEDNESDAY FEBRUARY 22, 2023

PLENARY-03 WEDNESDAY PLENARY SESSION

CME

Flex C (Level 2)

8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO WEDNESDAY**Diane V. Havlir**, *University of California San Francisco, San Francisco, California, USA***37 HOW THE HUSH COMPLEX PROTECTS YOUR GENOME FROM RNA-DERIVED RETROELEMENTS****Paul J. Lehner**, *Cambridge University, Cambridge, England, United Kingdom***38 THE SCIENCE OF AGING: LESSONS FOR HIV****George A. Kuchel**, *University of Connecticut, Farmington, CT, USA***SPECIAL SESSION-2 SPECIAL SESSION ON THE MPOX VIRUS OUTBREAK**

Ballroom 1 (Level 5)

12:15 PM - 1:15 PM

Moderators**Diane V. Havlir**, *University of California San Francisco, San Francisco, California, USA***Robert Schooley**, *University of California San Diego, San Diego, CA, USA***39 STAGE THE SETTING: THE EPIDEMIOLOGY OF THE MPOX VIRUS****John Brooks**, *Centers for Disease Control and Prevention, Atlanta, GA, USA***40 MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGETS FOR MPOX VIRUS****Stuart N. Isaacs**, *University of Pennsylvania, Philadelphia, PA, USA***41 IMMUNOLOGY AND VACCINOLOGY PERSPECTIVES FOR MPOX VIRUS****Sharon Frey**, *Saint Louis University, St. Louis, MO, USA*

SYMPOSIUM-07 THE VIRUSES THEY ARE A CHANGING: HOW THE IMMUNE SYSTEM RESPONDS**CME****Ballroom 3 (Level 5)****4:00 PM - 5:30 PM****Objectives:** At the completion of the session, participants will be able to:

- Describe how the presence of antibodies against a given epitope may affect the response to that epitope during vaccination
- Describe how B cells respond to new viral variants of SARS-CoV2 during infection and vaccination
- Describe how HIV and SARS-CoV-2 serum antibody responses adapt to virus variation

Target Audience: This session is directed to physicians and researchers interested in obtaining a contemporary understanding of the how the immune system responds to virus variation.**Level of Knowledge:** It is assumed that participants are familiar with the basic understanding of immune responses to virus variation.**Moderators****Shelly Krebs**, *Walter Reed Army Research Institute, Silver Spring, MD, USA***George K. Lewis**, *University of Maryland School of Medicine Baltimore, Baltimore, MD, USA***42 EFFECT OF NEW VIRAL VARIANTS ON NEUTRALIZING ANTIBODY POTENCY AND BREADTH****Penny L. Moore**, *University of the Witwatersrand, Johannesburg, Gauteng, South Africa***43 MEMORY B CELL RESPONSES TO NEW VIRUS VARIANTS: RELEVANCE TO THE CONCEPT OF ORIGINAL ANTIGENIC SIN****Marion Pepper**, *University of Washington, Seattle, WA, USA***44 EPITOPE MASKING DURING A RECALL RESPONSE: IMPLICATIONS FOR COVID AND HIV VACCINES****Facundo Batista**, *Harvard University, Cambridge, MA, USA*

SYMPOSIUM-08 CASE-BASED DISCUSSION OF CARDIO-METABOLIC COMPLICATIONS OF HIV AND CONSEQUENCES FOR MANAGEMENT

CME

Ballroom 1 (Level 5)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe implications of cardiovascular disease in patients with HIV infection
- Describe implications of patients with HIV experiencing weight gain or obesity
- Describe implications of NASH and nonalcoholic fatty liver disease (NAFLD) in patients with HIV infection

Target Audience: This session is directed towards clinical care providers and researchers with an interest in cardiometabolic complications of HIV and its treatment, including potential management implications.

Level of Knowledge: It is assumed that the participants are familiar with the management of HIV and cardiometabolic comorbidities associated with HIV.

Moderators

Georg Behrens, *Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany*

Vidya Mave, *Center for Infectious Diseases, Pune, Maharashtra, India*



SESSION FORMAT: This case-based and interactive session will provide an up-to-date overview of the pathogenesis, prevention, and treatment of cardiovascular disease and heart failure in HIV medicine.

Panelists



Pam S. Douglas, *Duke University School of Medicine, Durham, NC, USA*



Ntobeko Ntsui, *University of Cape Town, Cape Town, South Africa*



Donal O'Shea, *University College Dublin, Dublin, Ireland*



Giada Sebastiani, *McGill University, Montreal, QC, Canada*

SYMPOSIUM-09 SCIENCE COMMUNICATION IN THE AGE OF MISINFORMATION

CME

Ballroom 2 (Level 5)

4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe the history and current state of traditional media, social media and internet-based health information, misinformation, and disinformation
- Evaluate approaches to proactively address health literacy, vaccine uptake, and health communications
- Design effective communications to proactively address vaccine hesitancy

Target Audience: This session is directed to physicians and researchers interested in the communication of information to audiences with and without a training in science.

Level of Knowledge: It is assumed that participants are familiar with the contemporary issues in SARS-CoV-2, mpox, HIV, and related conditions.

Moderators

Jonathan Mermin, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

Jon Cohen, *Science, Cardiff By The Sea, CA, USA*



46 COUNTERING VACCINE AND HEALTH MIS AND DISINFORMATION: AN EVIDENCE-BASED APPROACH



Scott C. Ratzan, *City University of New York, Princeton, NJ, USA*

47 WHAT CAN I DO? THE CHALLENGE OF HEALTH MISINFORMATION ONLINE



Emily Vraga, *University of Minnesota, Minneapolis, MN, USA*

48 WHAT'S FUELING THE SPREAD OF MISINFORMATION: LOOKING BEYOND FAKE FACTS



Heidi J. Larson, *London School of Hygiene & Tropical Medicine, Brussels, Brussels Hoofdstedelijk Gewest, Belgium*

MONDAY FEBRUARY 20, 2023

ORAL ABSTRACTS AND THEMED DISCUSSIONS BY DAY

Oral Abstract Session-01 VIROLOGY/PATHOGENESIS
Ballroom 2 (Level 5)
10:00 AM - 12:00 PM
Moderators
Stuart Neil, *King's College London, London, United Kingdom*
Molly Ohainle, *University of California Berkeley, Berkeley, CA, USA*

100 **LENACAPAVIR INHIBITS VIRION MATURATION BY BLOCKING FORMATION OF CAPSID PENTAMERS**

10:05

 Szu-Wei Huang, Lorenzo Briganti, Guochao Wei, Arun Annamalai, Stephanie Bester, Nikoloz Shkriabai, **Mamuka Kvaratskhelia**
101 **INHIBITION OF NEUTRAL SPHINGOMYELINASE 2 BLOCKS HIV-1 MATURATION**

10:13

Abdul Waheed, Yanan Zhu, Seung-Wan Yoo, Ferri Soheilian, Eva Agostino, Lwar Naing, Pragney Deme, Yun Song, Peijun Zhang, Barbara S Slusher, Norman Haughey, Eric O. Freed

102 **INVESTIGATING THE ROLE OF CAPSID STABILITY IN INNATE IMMUNE SENSING OF HIV-1 CORES**

10:21

NIS

Jenna E. Eschbach, Sebla B. Kutluay

103 **MUTATIONS OUTSIDE INTEGRASE LEAD TO HIGH-LEVEL RESISTANCE TO DOLUTEGRAVIR**

10:29

NIS

Yuta Hikichi, Jennifer L. Groebner, Ann Wiegand, John W. Mellors, Mary F. Kearney, Eric O. Freed

104 **MX2 ANTIVIRAL SPECIFICITY IS AFFECTED BY GTPase ACTIVITY AND CAPSID-CypA INTERACTIONS**

11:00

 Bailey Layish, Haley Flick, Ram Goli, Mariah Cashbaugh, Robert Z Zhang, **Melissa Kane**
105 **HOST CELL GLYCOSYLATION DIFFERENTIALLY AFFECTS CCR5- AND CXCR4-TROPIC HIV-1 INFECTION**

11:08

NIS

Hannah L. Itell, Julie M. Overbaugh

106 **THE FRACTION OF CELLS WITH UNSPLICED HIV RNA IS NOT ASSOCIATED WITH PLASMA VIREMIA**

11:16

NIS

Adam A. Capoferri, Ann Wiegand, Francis Hong, Jana Jacobs, Jonathan Spindler, Andrew Musick, Michael J. Bale, Wei Shao, Michele D. Sobolewski, Anthony Cillo, Rebecca Hoh, Steven G. Deeks, John M. Coffin, John W. Mellors, Mary F. Kearney

107 **HUMAN ANTI-ACE2 MONOCLONAL ANTIBODIES AS PAN-SARBEVIRUS PROPHYLACTIC AGENTS**

11:24

 Fengwen Zhang, Jesse Jenkins, Renan de Carvalho, Sandra Nakandakari-Higa, Teresia Chen, Morgan Abernathy, Elisabeth Nyakatura, Ivo Lorenz, H.-Heinrich Hoffmann, Charles Rice, Gabriel Victora, Christopher Barnes, Theodora Hatzioannou, **Paul D. Bieniasz**

108 11:32 SARS-CoV-2 VARIANTS EVOLVED CONVERGENT STRATEGIES TO REMODEL THE HOST RESPONSE

Mehdi Bouhaddou, Ann-Kathrin Reuschl, Benjamin Polacco, Lucy Thorne, Manisha Ummadi, Chengjin Ye, Luis Martinez-Sobrido, Lisa Miorin, Kris White, Danielle Swaney, Adolfo Garcia-Sastre, Claire Jolly, Lorena Zuliani-Alvarez, Greg Towers, Nevan Krogan,
Research Group: Quantitative Biosciences Institute Coronavirus Research Group (QCRG)

**Oral Abstract Session-02 TB AND HEPATITIS
 Ballroom 1 (Level 5)**

10:00 AM - 12:00 PM

Moderators

Constance A. Benson, *University of California San Diego, San Diego, CA, USA*

David Wyles, *Denver Health Medical Center, Denver, CO, USA*



109 10:05 SimpliciTB RESULTS AND HEPATIC SAFETY OF PRETOMANID REGIMENS +/- PYRAZINAMIDE

Marika Eristavi, Ebrahim Variava, Fredrick Haraka, Margareth Pretti Dalcolmo, Harriet Mayanja-Kizza, Morounfolu Olugbosi, Mengchun Li, Leandra Lombard, **Muge Cevik**, Lindsay Thompson, Derek Sloan, Mel Spigelman, Jerry Nedelman, Maria Beumont, Eugene Sun

110 10:13 STANDARD VS DOUBLE DOSE DOLUTEGRAVIR IN HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS

Rulan Griesel, Ying Zhao, Bryony Simmons, Zaayid Omar, Andrew Hill, Graeme Meintjes, Gary Maartens

111 10:21 INCREASED TB PREVENTIVE THERAPY COVERAGE WITH INTEGRATED COMMUNITY-BASED IPT AND ART

Adrienne E. Shapiro, Adam Szpiro, Kombi Sausi, Nsika Sithole, Olivier Koole, Meighan Krows, Torin Schaafsma, Maryam Shahmanesh, Heidi van Rooyen, Connie Celum, Alastair van Heerden, Ruanne Barnabas
Research Group: DO ART Study Team

112 10:29 RCT OF ECONOMIC INCENTIVES FOR REDUCED ALCOHOL USE AND INH ADHERENCE AMONG PWH

Gabriel Chamie, Judith A. Hahn, Allen Kekibiina, Nneka Emenyonu, Brian Beesiga, Kara Marson, Robin Fatch, Sara Lodi, Julian Adong, Harsha Thirumurthy, Michael McDonell, Monica Gandhi, Kendall Bryant, Moses Kanya, Winnie Muyindike

113 11:00 EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL

LB

Nicholas Paton, Christopher Cousins, Qingshu Lu, Rajesh Moorakonda, Celina Suresh, Erlina Burhan, Vincent Balanag, Christine Sekaggya-Wiltshire, Anchalee Avihingsanon, Rohit Sarin, Angela Crook
Research Group: The TRUNCATE-TB trial team

114 11:08 PanACEA SUDOCU COMBINATION DOSE-FINDING TRIAL SHOWS SUTEZOLID IS A SAFE OXAZOLIDINONE

LB

Norbert Heinrich, Christina Manyama, Nyanda E. Ntinginya, Stellah Mpagama, Alphonse Liyoyo, Francis Mhimbira, Benno Mbeya, Modulakgotla Sebe, Robert Wallis, Patrick Phillips, Leticia Wildner, Rob Aarnoutse, Larissa Hoffmann, Michael Hoelscher, Elin Svensson,
Research Group: Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA)

- 115** **cccDNA SILENCING AND LIMITED DECAY OF INFECTED CELLS IN HIV-HBV (HBeAg-) DURING NUCs**
 11:16
 Chloe L. Thio, **Maraake Taddese**, Yasmeen S. Saad, Kristina Zambo, Tanner Grudda, Mark S. Sulkowski, Richard K. Sterling, Hyon Hwang, Ashwin Balagopal
- 116** **PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION**
 11:24
Anchalee Avihingsanon, Chee L. Leong, Chien-Ching Hung, Ellen Koenig, Man-Po Lee, Khuanchai Supparatpinyo, Fujie Zhang, Hongyuan Wang, Hal Martin, Jason Hindman, Jared M. Baeten, Sasisopin Kiertiburanakul
- 117** **PAGE-B SCORE TO ESTIMATE THE HEPATOCELLULAR CARCINOMA RISK IN PEOPLE WITH HIV AND HBV**
 11:32
Bernard Surial, Adrià Ramírez Mena, Marie Roumet, Andreas Limacher, Colette Smit, Olivier Leleux, Amanda Mocroft, Marc van der Valk, Fabrice Bonnet, Lars Peters, Juergen K. Rockstroh, Huldrych F. Günthard, Annalisa Berzigotti, Andri Rauch, Gilles Wandeler
Research Group: Swiss HIV Cohort Study, EuroSIDA, ATHENA and Aquitaine

Oral Abstract Session-03 HIV AND STI PREVENTION: NEW TOOLS AND APPROACHES

Flex C (Level 2)

10:00 AM - 12:00 PM

Moderators

Adaora Adimora, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

Renee Heffron, *University of Alabama at Birmingham, Birmingham, AL, USA*



- 118** **MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN**
 10:05
Richard Haaland, Jeffrey Fountain, Chuong Dinh, Tiancheng Edwards, Amy Martin, Deborah Omoyeje, Christopher Conway-Washington, Colleen Kelley, Walid Heneine
- 119** **ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP**
 10:13
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Algarte-Genin Michele, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Cecile Bebear, Nicolas Dupin, Jean-Paul Viard, Juliette Pavie, Claudine Duvivier, Jade Ghosn, Dominique Costagliola
Research Group: ANRS 174 Doxyvac Group
- 120** **DOXYPEP & ANTIMICROBIAL RESISTANCE IN *N. GONORRHOEAE*, COMMENSAL *NEISSERIA*, & *S. AUREUS***
 10:21
Anne F. Luetkemeyer, Deborah Donnell, Julia C. Dombrowski, Stephanie Cohen, Cole Grabow, Clare Brown, Cheryl Malinski, Sharon K. Martens, Alison Cohee, Veronica Viar, Phong Pham, Susan P. Buchbinder, Diane V. Havlir, Connie Celum, Olusegun O. Soge
Research Group: DoxyPEP Study Team

121 DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN

10:29

LB

Jenell Stewart, Kevin Oware, Deborah Donnell, Lauren R. Violette, Josephine Odoyo, Caitlin W. Scoville, Olusegun O. Soge, Victor Omollo, Felix Mogaka, Fredricka A. Sesay, R. Scott McClelland, Elizabeth A. Bukusi, Jared M. Baeten

Research Group: the dPEP Kenya Study Team

122 POTENTIAL IMPACT AND EFFICIENCY OF DOXY-PEP AMONG PEOPLE WITH OR AT RISK OF HIV

11:00

LB

Michael W. Traeger, Kenneth H. Mayer, Douglas S. Krakower, Sy Gitin, Samuel Jenness, Julia L. Marcus

123 CLUSTER RANDOMISED TRIAL OF RISK-DIFFERENTIATED CARE FOR FEMALE SEX WORKERS: AMETHIST

11:08

Frances M. Cowan, Fortunate Machingura, Sanni Ali, Sungai Chabata, Albert Takura, Loveleen Bansi-Matharu, Primrose Matambanadzo, Maryam Shahmanesh, Joanna Busza, Richard Steen, Raymond Yekeye, Amon Mpofo, Owen Mugurungi, Andrew Phillips, James Hargreaves

124 RANDOMIZED TRIAL OF COMMUNITY HEALTH WORKER DELIVERED DYNAMIC CHOICE HIV PREVENTION

11:16

Elijah Kakande, James Ayieko, Helen Sunday, Edith Biira, Marilyn Nyabuti, George Agengo, Jane Kabami, Gabriel Chamie, James Peng, Melanie Bacon, Moses Kanya, Diane V. Havlir, Maya Petersen, Laura Balzer

Research Group: SEARCH Study Team

125 CLUSTER RANDOMIZED TRIAL OF INTEGRATED HIV AND SEXUAL & REPRODUCTIVE HEALTH SERVICES

11:24

LB

Rashida Ferrand, Ethel Dauya, Chido Dziva Chikwari, Tsitsi Bandason, Sarah Bernays, Katharina Kranzer, Constance Mackworth-Young, Constancia Mavodza, Owen Mugurungi, Victoria Simms, Mandikudza Tembo, Richard Hayes

Research Group: CHIEDZA Trial Group

Oral Abstract Session-04 INSIGHTS INTO PREVENTION AND TREATMENT OF HIV IN WOMEN AND CHILDREN

Flex A (Level 2)

10:00 AM - 12:00 PM

Moderators

Jennifer Jao, Northwestern University, Chicago, IL, USA

John Kinuthia, Kenyatta National Hospital, Nairobi, Kenya



126 RECENT HIV INFECTION SURVEILLANCE IN BREASTFEEDING WOMEN IN MALAWI: JUL 2019-JUL 2022

10:05

Davie D. Chalira, Bridget Miller, Danielle Payne, Melissa Arons, Alinune N. Kabaghe, Joe Theu, Romance Thawi, Reno Stephens, Ireen Namakhoma, Joseph Njala, Alexandra Ernst, Gabrielle O'Malley, Kerry A. Thomson, Nellie Wandonda-Kabondo

127 DELIVER: A SAFETY STUDY OF A DAPIVIRINE VAGINAL RING AND ORAL PrEP DURING PREGNANCY

10:13

Katherine E. Bunge, Jennifer Balkus, Felix Mhlanga, Ashley Mayo, Lee Fairlie, Clemensia Nakabiito, Luis Gadama, Catherine Chappell, Nyaradzo M. Mgodi, Jeanna Piper, Nahida Chakhtoura, Daniel szydlo, Barbra Richardson, Sharon L. Hillier

Research Group: MTN-042 DELIVER Study Team

128 RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV PREVENTION IN ANTE/POSTNATAL CARE CLINICS

10:21

Jane Kabami, Catherine Koss, Helen Sunday, Edith Biira, Marilyn Nyabuti, Laura Balzer, Shalika Gupta, Gabriel Chamie, James Ayieko, Elijah Kakande, Melanie Bacon, Diane V. Havlir, **Moses Kanya**, Maya Petersen

Research Group: SEARCH Study Team

- 129** **MATERNAL POINT-OF-CARE VIRAL LOAD AT DELIVERY IMPACTS INFANT ARV PROPHYLAXIS REGIMEN**
 10:29
NIS
Anage F. Lwilla, Kira Elsbernd, Arlete Mahumane, Bindiya Meggi, W. Chris Buck, Sirel Boniface, Raphael Edom, Joaquim Lequechane, Chishamiso Mudenyanga, Mariana Mueller, Arne Kroidl, Ilesh Jani, Issa Sabi
Research Group: LIFE Study consortium
- 130** **MULTICOMPONENT INTERVENTION IMPROVES VIRAL SUPPRESSION FOR PREGNANT/POSTPARTUM WOMEN**
 11:00
LB
Jane Kabami, Laura Balzer, Faith Kagoya, Jaffer Okiring, Joanita Nangendo, Elizabeth Arinitwe, Stella Kabageni, Michael Ayebare, Anne Katahoire, Philippa Musoke, Moses Kamyá
- 131** **IMPROVED STRATEGY TO PREVENT HIV POSTNATAL TRANSMISSION: A RANDOMIZED TRIAL**
 11:08
Chipepo Kankasa, Anaís Mennecier, Souleymane Tassebedo, Catherine Chunda-Liyoka, Leticia Sakana, Morgana D'Ottavi, Melany Tonga, Dramane Kania, Jean-Pierre Moles, Mwiya Mwiya, Paulin Fao, David Rutagwera, Thorkild Tylleskär, Nicolas Nagot, Philippe Van de Perre
Research Group: ANRS 12397 PROMISE-EPI Study group
- 132** **BIRTH POINT-OF-CARE TEST & TREAT REDUCES EARLY MORTALITY AMONG HIV INFECTED INFANTS**
 11:16
Arne Kroidl, Kira Elsbernd, Bindiya Meggi, Arlete Mahumane, Anage F. Lwilla, Kassia Pereira, Sirel Boniface, Raphael Edom, Joaquim Lequechane, Falume Chale, Chishamiso Mudenyanga, Mariana Mueller, W. Chris Buck, Issa Sabi, Ilesh Jani
Research Group: LIFE Study Consortium
- 133** **POSTMORTEM CHARACTERIZATION OF HIV-ASSOCIATED UNDER-5 DEATHS IN FOUR CHAMPS SITES**
 11:24
LB
Inacio Mandomando, Dickens Onyango, Zachary Madewell, Kurt Vyas, Sana Mahtab, Portia Mutevedzi, Victor Akelo, Dianna Blau, Tacilta Helena Francisco Nhampossa, Ikechukwu Ogbuanu, Carrie Cain, Cynthia Whitney, Beth Tippet Barr, Quique Bassat
- 134** **SARS-CoV-2 IN CHILDREN & ADOLESCENTS LIVING WITH HIV IN EUROPE & SOUTH AFRICA**
 11:32
Charlotte Jackson, Siobhan Crichton, Alasdair Bamford, Arantxa Berzosa, Kimberly Gilmour, Tessa Goetghebuer, Sarah May Johnson, Ali Judd, Antoni Noguera, Marthe Le Prevost, Vana Spoulou, Kate Sturgeon, Alla Volokha, Heather J Zar, Intira Jeannie Collins
Research Group: EPPICC (European Pregnancy and Paediatric Infections Cohort Collaboration)

Themed Discussion-01 HIV AND THE MICROBIOME: NEW THEMES
Flex C (Level 2) **1:30 PM - 2:30 PM**

Moderator

Ronald G. Collman, *University of Pennsylvania, Philadelphia, PA, USA*



248 **CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF**
 1:35

Sandra Pinto-Cardoso, Monserrat Chávez-Torres, Adriana Aguilar, Santiago Ávila-Ríos

- 249** **PROTEOMIC ANALYSIS OF TRANSLOCATING BACTERIAL TAXA REVEALS NOVEL THERAPEUTIC TARGET**
 1:40
Jacob K. Flynn, Alexandra Ortiz, Marlon DeLeon, Samantha Knodel, Kenzie Birse, Laura Noel-Romas, Adam Burgener, Jason Brenchley
- 250** **THE EFFECTS OF CD4+ LYMPHOPENIA ON THE HUMAN SKIN MICROBIOME**
 1:45
Irini Sereti, Jungmin Han, Andrea Lisco, Julia A. Segre, Heidi H. Kong
- 251** **COMMENSAL BACTERIA WITHIN THE FAMILY LACHNOSPIRACEAE ROBUSTLY INHIBIT HIV INFECTION**
 1:50
Danting Jiang, Sedem Dankwa, Amir Ardeshir, Koen Van Rompay, Kristina De Paris, Sallie R. Permar, Ria Goswami, Neeraj K. Surana
- 252** **BACTERIAL DYSBIOSIS PERSISTS IN WOMEN LIVING WITH HIV-1 AFTER ART-TREATMENT**
 1:55
NIS
Katherine M. Bricker, Andrea Lisco, Alessandra Borgognone, Maura Manion, Andrew Redd, Frances Galindo, Sarah Kalibbala, Aggrey Anok, Stephen Tomusange, Steven J. Reynolds, Marc Noguera Julian, Irini Sereti

Themed Discussion-02 STEATOHEPATITIS: SEX DIFFERENCES AND OTHER RISK FACTORS

Ballroom 2 (Level 5)

1:30 PM - 2:30 PM

Moderator

Susanna Naggie, *Duke University, Durham, NC, USA*



- 609** **PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV**
 1:35
Louise E. van Eekeren, Marc J.T. Blaauw, Nadira Vadaq, Vasiliki Matzaraki, Wilhelm A.J.W. Vos, Albert L. Groenendijk, Adriana Navas, Gert Weijers, Mike van der Kolk, Andre J.A.M. van der Ven, Quirijn De Mast, Leo Joosten, Eric Tjwa
Research Group: 2000HIV
- 610** **LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE**
 1:40
Cecile D. Lahiri, Michael Yu, Logan Gerig, Cyra C. Mehta, Joffi Musonge-Effoe, Jennifer C. Price, Phyllis C. Tien, Amanda B. Spence, Svenja Albrecht, Maria L. Alcaide, Adaora Adimora, Audrey French, Michael H. Augenbraun, Kathryn Anastos, Jessica A. Alvarez
- 611** **SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE**
 1:45
NIS
Dana Kablawi, Thierry Fotsing Tadjjo, Jovana Milic, Wesal Elgretli, Claudia Gioe, Bertrand Lebouché, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola, Giada Sebastiani
- 612** **NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV**
 1:50
NIS
Win Min Han, Tanakorn Apornpong, Jedsadakorn Bonrungsirisap, Thanathip Wichiangsan, Hay Mar Su Lwin, Sivaporn Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsanon

Themed Discussion-03 PREDICTORS OF TB TREATMENT OUTCOMES
Ballroom 1 (Level 5)

1:30 PM - 2:30 PM

Moderator

Amita Gupta, *The Johns Hopkins University School of Medicine, Baltimore, MD, USA*



740 TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS

1:35

NIS

Rob van Wijk, Vincent Chang, Marjorie Imperial, Patrick Phillips, Susan Swindells, Richard Chaisson, Payam Nahid, Rodney Dawson, Ian Sanne, Ziyaad Waja, Susan Dorman, Ekaterina Kurbatova, Rada Savic
Research Group: Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team

742 PREDICTORS OF POOR OUTCOMES IN PATIENTS WITH TUBERCULOSIS SYMPTOMS AT HIV DIAGNOSIS

1:40

Nancy Dorvil, Vanessa Rivera, Cynthia Riviere, Patrice Severe, Heejung Bang, Kerlyne Lavoile, Giovanni Saintyl, Samuel Pierre, Margaret McNairy, Richard B. Berman, Pierre Cremieux, Jean William Pape, Serena Koenig

745 TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT

1:45

Salome Charalambous, Noriah Maraba, Lauren Jennings, Kavindhran Velen, Piotr Hippner, Israel Rabothata, Rachel Mukora, Stemberidge Mpemba, Lihle Mchunu, Dolphina Cogill, Pren Naidoo, **Catherine Orrell**, Katherine Fielding

Themed Discussion-04 UNDERSTANDING MORTALITY IN PEOPLE WITH HIV

Ballroom 3 (Level 5)

1:30 PM - 2:30 PM

Moderator

Maureen Syowai, *ICAP at Columbia University, Nairobi, Nairobi Area, Kenya*



870 TRENDS IN MORTALITY IN PEOPLE LIVING WITH HIV IN AN INTERNATIONAL COHORT (RESPOND)

1:35

NIS

Erich Tusch
Research Group: The RESPOND Study Group

872 PROPORTION OF DEATHS OCCURRING OUTSIDE OF HEALTH FACILITIES ATTRIBUTABLE TO HIV/AIDS

1:40

Newton L. Kalata, Alinune N. Kabaghe, George Mtonga, Emmanuel Mkambankhani, Masauso Mussa, Amos Nyaka, Kondwani Nkanaunena, Verita Buie, Ramesh Sethi, Rodrick Langwe, Kelsey Mirkovic, Nellie Wandonda-Kabondo

873 MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT

1:45

Shannon M. Farley, Giles Reid, Katharine Yuengling, Connor Wright, George Bello, James M. Juma, Stephane Helleringer, Jessica Justman

874 ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION

1:50

Nicholas Bakewell, **Caroline Sabin**, Tanmay Kanitkar, Maggie Symonds, Oshani Dissanayake, Stephanie Rimmer, Amit Adlakha, Marc Lipman, Sanjay Bhagani, Banwari Agarwal, Robert Miller

875 **REGISTRY LINKAGE IMPROVES SURVIVAL ESTIMATION AMONG PEOPLE WITH HIV IN LATIN AMERICA**
1:55

Gabriela Carriquiry, Yanink Caro-Vega, Paula Luz, Ahra Kim, Karu Jayathilake, Eduardo Gotuzzo, Lara E. Coelho, Antonio G. Pacheco, Claudia M. Cortes, Regina Succi, Lorena Guerrero-Torres, Bryan E. Shepherd, Stephany Duda, **Peter F. Rebeiro**
Research Group: Caribbean, Central and South America network for HIV epidemiology (CCASAnet)

Themed Discussion-05 NEW INSIGHTS THROUGH REGENCY TESTING Flex A (Level 2) **1:30 PM - 2:30 PM**

Moderator

George W. Rutherford, *University of California San Francisco, San Francisco, CA, USA*



847 **HOTSPOTS OF RECENT HIV INFECTIONS AMONG ADULT PEOPLE LIVING WITH HIV IN NIGERIA**
1:35

NIS **Amobi A. Onovo**, Pamela Gado, Angela Agweye, Abiye Kalaiwo, Ughweroghene Omo-Emmanuel, Konrad Bradley, Kristina Bishop, Helina Meri, Rachel Goldstein

848 **PROGRAMMATIC IMPLICATIONS OF NATIONAL RECENT HIV INFECTION SURVEILLANCE IN CAMBODIA**
1:40

Vichea Ouk, Sovannarith Samreth, Bora Ngauv, Bunthoeun Eng, Rommel Bain, Chhaily Hy, Alexandra Ernst, George W. Rutherford, Chunfu Yang, Vanthy Ly, **Amitabh B Suthar**, Rachel Albalak

849 **AN ANALYSIS OF HIV RECENT INFECTION SURVEILLANCE DATA AMONG YOUNG PEOPLE IN MALAWI**
1:45

NIS Alinune N. Kabaghe, **Reno Stephens**, Danielle Payne, Joe Theu, Misheck Luhanga, Davie D. Chalira, Melissa Arons, Gabrielle O'Malley, Kerry A. Thomson, Mtemwa Nyangulu, Trudy Dobbs, Vedapuri Shanmugam, Rose Nyirenda, Pragna Patel, Nellie Wandonda-Kabondo

850 **HIV RECENT INFECTION IN SEXUAL AND GENDER MINORITIES IN BRAZIL AND PERU: ImPrEP STUDY**
1:50

Thiago S. Torres, Sylvia L. M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Derrico, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Silver K. Vargas, Cristina Pimenta, Beatriz Grinsztejn, Celia Landmann Szwarcwald, Carlos Caceres, Valdilea Veloso

851 **HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES: 2018-2021**

Camden J. Hallmark, Laurie Linley, Agha Ajmal, Olivia O. Russell, Mary Plaster, Sheryl B. Lyss, Nivedha Panneer, Rashida Hassan, Anne Marie France, Alexandra M. Oster

TUESDAY FEBRUARY 21, 2023

Oral Abstract Session-05 HIV RESERVOIRS AND CURE STRATEGIES

Ballroom 1 (Level 5)

10:00 AM - 12:00 PM

Moderators

Katharine J. Bar, *University of Pennsylvania, Philadelphia, PA, USA*

Linos Vandekerckhove, *HIV Cure Research Center, Ghent University, Ghent, Oost-Vlaanderen, Belgium*



135 SINGLE-CELL PROTEOGENOMIC PROFILING OF HIV-1 RESERVOIR CELLS

10:05

NIS

Weiwei Sun, Ce Gao, Ciputra A. Hartana, Matthew R. Osborn, Kevin B. Einkauf, Xiaodong Lian, Benjamin R. Bone, Nathalie Bonheur, Tae-Wook Chun, Eric S. Rosenberg, Bruce D. Walker, Xu G. Yu, Mathias Lichterfeld

136 THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL

10:13

Jesper D. Gunst, Dag Henrik Reikvam, James H. McMahon, Marie H. Pahun, Jesper F. Højen, Isik S. Johansen, Henrik Nielsen, Thomas Lars Benfield, Jan Gerstoft, Sharon Lewin, Martin Tolstrup, Thomas A. Rasmussen, Marina Caskey, Michel C. Nussenzweig, **Ole S. Søgaard**

137 VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA

10:21

NIS

Abbas Mohammadi, Behzad Etemad, Xin Zhang, Yijia Li, Steven G. Deeks, Michael M. Lederman, Sigal Yawetz, Daniel Kuritzkes, Mathias Lichterfeld, Athe Tsibris, Mary Carrington, Zabrina Brumme, Jose R. Castillo Mancilla, Gaurav Gaiha, Jonathan Z. Li

138 PROVIRUSES IN SELF-REACTIVE CD4+ T CELLS ARE A COMMON SOURCE OF RESIDUAL HIV VIREMIA

10:29

NIS

Fengting Wu, Milica Moskovljevic, Hao Zhang, Angelica Camilo-Contreras, Filippo Dragoni, Nathan L. Board, Anushka Singhal, Jun Lai, Luis J. Montaner, Janet M. Siliciano, Robert F. Siliciano, Francesco R. Simonetti

139 EX VIVO HIV DNA INTEGRATION IN STAT3 DRIVES T CELL PERSISTENCE AND OVERGROWTH

11:00

NIS

Michael Rist, Machika Kaku, Michael Freeman, John M. Coffin

140 THERAPEUTIC VACCINATION OF SHIV-INFECTED, ART-SUPPRESSED INFANT RHESUS MACAQUES

11:08

NIS

Bhruyu Yagnik, Tiffany Styles, Stella J. Berendam, Caroline Phan, Ria Goswami, Sedem Dankwa, Chiamaka A. Enemu, Diane G. Carnathan, Veronica Obregon-Perko, Ann Chahroudi, Guido Silvestri, Sallie R. Permar, Genevieve G. Fouda, Rama R. Amara

141 VIRAL RESERVOIR LANDSCAPE OF CHILDREN WITH HIV IN BOTSWANA TREATED WITH DUAL bNabs

11:16

NIS

Aischa Niesar, Xiaodong Lian, Renee Hua, Gbolahan Ajibola, Molly Pretorius Holme, Kenneth Maswabi, Sikhulile Moyo, Nyaladze C. Maphorisa, Terence Mohammed, Maureen Moseithi, Kathleen M. Powis, Daniel Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld

142 SINGLE-CELL EPIGENETIC, TRANSCRIPTIONAL, AND PROTEIN STATES OF HIV RESERVOIR

11:24

LB

Yulong Wei, Timothy C. Davenport, Jack Collora, Katherine H. Ma, Delia Pinto-Santini, Javier Lama, Ricardo Alfaro, Ann Duerr, Ya-Chi Ho

143 ANTI-IL-10/PD-1 IMMUNE MEDIATED CONTROL OF VIRAL REBOUND IN SIV INFECTED MACAQUES

11:32

LB

Susan Pereira Ribeiro, Zachary Strongin, Felipe Ten Caten, Khader Ghneim, Mohamed Abdel Hakeem, Timothy N. Hoang, Kevin Nguyen, Justin Harper, Luca Micci, Jeffrey D. Lifson, Bonnie Howell, Daniel Gorman, Daria J. Hazuda, Mirko Paiardini, Rafick P. Sékaly

Oral Abstract Session-06 CONSTERNATION ABOUT COMPLICATIONS Flex A (Level 2) 10:00 AM - 12:00 PM

Moderators

Judith S. Currier, *University of California Los Angeles, Los Angeles, CA, USA*

Roger Bedimo, *University of Texas Southwestern, Dallas, TX, USA*



144 EFFECTS OF EPLERENONE ON MYOCARDIAL PERFUSION AND FUNCTION: THE MIRACLE HIV STUDY

10:05

Suman Srinivasa, Allie Walpert, Teresa Thomas, Daniel Huck, Michael Jerosch-Herold, Sabeeh Islam, Hang Lee, Gregory Robbins, Tricia H. Burdo, Christopher DeFilippi, Carolyn Dunderdale, Raymond Kwong, Marcelo DiCarli, Gail Adler, Steven K. Grinspoon

145 DEPRESSION AND ANXIETY ASSOCIATED WITH INCIDENT TYPE I AND II MI AMONG PWH

10:13

Emily P. Hyle, Elizabeth Humes, Shibani Mukerji, Sally B. Coburn, Heidi Crane, Svetlana Eden, Kelly Gebo, Maile Karris, Raynell Lang, Vincent C. Marconi, Richard Moore, Sonia Napravnik, Leah H. Rubin, Virginia Triant, Keri Althoff

Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

146 WEIGHT AND METABOLIC CHANGES WITH CABOTEGRAVIR+RILPIVIRINE LONG-ACTING OR BICTEGRAVIR

10:21

Darrell H. S. Tan, Andrea Antinori, Beng Eu, Maria José Galindo, Clifford Kinder, Donna Sweet, Cornelius N. Van Dam, Kenneth Sutton, Denise Sutherland-Phillips, Alessandro Berni, Feifan Zhang, William R. Spreen, Harmony P. Garges, Parul Patel, Ronald D'Amico

147 A LOSS OF ERA ATTENUATES DTG-MEDIATED DISRUPTION OF THERMOGENESIS IN BROWN ADIPOCYTES

10:29

Flkrak Jung, Sunghee Jin, Becky Tu-Sekine, Frederick Anokye-Danso, Todd T. Brown, **Sangwon Kim**

148 MICROBIOTA-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION

11:00

Sergio Serrano-Villar, Camilla Tincati, Sajan C Raju, Johan Sebastian Saenz Medina, Elena Moreno, Rafael Bargiela, Alfonso Cabello, Elena Sendagorta, José A. Pérez-Molina, Johaness Roklund, Laura Fernández-López, Amparo de Benito, Marius Troseid, Jana Seifert, Manuel Ferrer

149 IMPACT OF INTEGRASE INHIBITORS ON CARDIOVASCULAR EVENTS IN PERSONS STARTING ART

11:08

LB

Bernard Surial, Frédérique Chammartin, José Damas, Alexandra Calmy, David Haerry, Marcel Stöckle, Patrick Schmid, Enos Bernasconi, Philip Tarr, Huldrych F. Günthard, Gilles Wandeler, Andri Rauch

Research Group: Swiss HIV Cohort Study

150 HIV-RELATED KAPOSI SARCOMA IN EAST AFRICA: CONTEMPORARY UPDATE ON STAGE AND SURVIVAL

11:16

LB

Helen Byakwaga, Aggrey Semeere, Miriam Laker-Oketta, Megan Wenger, Elyne Rotich, Charles Kasozi, Winnie Muyindike, Philippa Kadama-Makanga, Sigrid Collier, Hilda Muwando, Toby Maurer, Esther Freeman, Samson Kiprono, Andrew Kambugu, Jeffrey Martin

NEW RECOMMENDATIONS FOR INFANT FEEDING AND PREVENTION OF PEDIATRIC HIV INFECTION IN THE US: WHAT AND WHY NOW?

11:50– **Moderator:** Elaine Abrams, *Columbia University, New York, NY, USA*

12:10 **Presenter:** Judy Levison, *Baylor College of Medicine, Houston TX, USA*

Oral Abstract Session-07 GLOBAL EPIDEMIOLOGY OF HIV

Ballroom 2 (Level 5)

10:00 AM - 12:00 PM

Moderators

Connie Celum, *University of Washington, Seattle, WA, USA*

Andrew Mujugira, *Makerere University, Auburn, WA, USA*



151 PHYLODYNAMICS OF HIV-1 VARIANT ACROSS POLAND AND UKRAINE

10:05

NIS

Karol Serwin, Miłosz Parczewski, Kaja Scheibe, Bogusz Aksak-Wąs, Piotr Ząbek, Iwona Cielniak, Monika Bociąga-Jasik, Adam Witor, Szymczak Aleksandra, Paweł Jakubowski, Antoine Chaillon

152 TIME TO KEY MILESTONES IN THE HIV INDEX TESTING/CONTACT TRACING PATHWAY IN INDIA

10:13

Parthasarathy Mugundu Ramien, Padum Narayan, Shruti H. Mehta, Ajay Enugu, Allison M. McFall, Devanga Ashok, Anthony Reddy, Jade Bell, Viswanathan Arumugam, Maria Salvat Ballester, Sunil S. Solomon, Aditya Singh

153 ASSISTED PARTNER SERVICES FOR PWID TO IDENTIFY PARTNERS LIVING WITH HIV & HCV

10:21

Aliza Monroe-Wise, Loice W. Mbogo, Betsy Sambai, Natasha T. Ludwig-Barron, Brandon L. Guthrie, David Bukusi, Bhavna H. Chohan, Sarah Masyuko, John Scott, William Sinkele, Carey Farquhar, Joshua Herbeck

154 HIV INCIDENCE DIFFERENCES MEASURED BY SERIAL CROSS-SECTIONAL TESTING: HPTN 071

10:29

Oliver Laeyendecker, Ethan Wilson, Owen Baker, Estelle Piwowar-Manning, Barry Kosloff, Anneen van Deventer, Ayana Moore, Peter Bock, Helen Ayles, Sian Floyd, Sarah Fidler, Richard Hayes, Susan H. Eshleman, Deborah Donnell

Research Group: HPTN 071 (PopART study team)

155 INCIDENCE OF CANCER AMONG MEDICAID BENEFICIARIES WITH AND WITHOUT HIV: 2001-2015

11:00

Jacqueline E. Rudolph, Keri Calkins, Bryan Lau, Corinne Joshu

Research Group: HPTN 071 (PopART study team)

156 CAUSES OF DEATH AMONG ADULTS WITH HIV ON ART IN EUROPE AND NORTH AMERICA: 1996-2019

11:08

Adam Trickey, Kathleen McGinnis, M John Gill, Sophie Abgrall, Juan Berenguer, Christoph Wyen, Mojgan Hessamfar, Peter Reiss, Lei Zhang, Suzanne M Ingle, Jonathan AC Sterne

Research Group: Antiretroviral Therapy Cohort Collaboration (ART-CC)

157 MOLECULAR HIV CLUSTERING OF INDIVIDUALS WITH MPOX/HIV CO-MORBIDITY

11:16

Randall Collura, Thomas O'Grady, Carol-Ann Swain, Wendy Patterson, Deepa Rajulu

158 ISOLATING THE EFFECT OF COVID-19 RELATED DISRUPTION ON HIV DIAGNOSES IN THE US, 2020

11:24

Alex Viguerie, Ruiguang Song, Anna Satcher Johnson, Cynthia Lyles, Angela Hernandez, Paul Farnham

**Oral Abstract Session-08 ALL MODES LEAD TO PrEP
Ballroom 3 (Level 5)**

10:00 AM - 12:00 PM

Moderators

Jean-Michel Molina, *University of Paris Cité, Hospital Saint Louis/Lariboisière, Paris, Ile-de-France, France*

Valdilea Veloso, *Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil*



159 CABOTEGRAVIR PHARMACOLOGY IN THE BACKGROUND OF DELAYED INJECTIONS IN HPTN 084

10:05

Mark A. Marzinke, Xu Guo, James Hughes, Brett Hanscom, Estelle Piwowar-Manning, Craig Hendrix, Scott Rose, Jim Rooney, Alex R. Rinehart, Susan Ford, Adeola Adeyeye, Myron S. Cohen, Mina Hosseinipour, Sinead Delany-Moretlwe
Research Group: HPTN 084 Study Team

160 THE LEVI SYNDROME: CHARACTERISTICS OF EARLY HIV INFECTION WITH CABOTEGRAVIR FOR PrEP

10:13

Susan H. Eshleman, Jessica M. Fogel, Estelle Piwowar-Manning, Brett Hanscom, Alex R. Rinehart, Myron S. Cohen, Marybeth McCauley, Jennifer Farrior, Adeola Adeyeye, Mina Hosseinipour, Beatriz Grinsztejn, Mark A. Marzinke, Sinead Delany-Moretlwe, Raphael J. Landovitz,
Research Group: for the HPTN 083 and 084 Study Teams

161 CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN

10:21

Hyman Scott, Brett Hanscom, Craig Hutchinson, Jonathan Lucas, Aditya Gaur, Colleen Kelley, Debora Dubar, Paul Richardson, Jim Rooney, Alex R. Rinehart, Adeola Adeyeye, Beatriz Grinsztejn, Raphael J. Landovitz, Sheldon Fields
Research Group: HPTN 083 Study Team

162 CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01)

10:29

LB

Sybil Hosek, Erica L. Hamilton, Julie Ngo, Yuqing Jiao, Brett Hanscom, Sinead Delany-Moretlwe, Nyaradzo M. Mgodli, Bekezela Siziba, Ishana Naidoo, BRENDA G. MIREMBE, Betty Kamira, Mark A. Marzinke, Cynthia McCoig, Hans Spiegel, Lynda Stranix-Chibanda
Research Group: HPTN 08-01 Study Team

163 8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP

11:00

Jeanne Marrazzo, Marissa Becker, Linda-Gail Bekker, Connie Celum, Michael Kiragu, Ashley Leech, Allan Taylor, Faith Ussery, Juan Yang, Melanie de Boer, Christoph Carter, Moupali Das, Jared M. Baeten, Li Tao

164 SAFETY AND PK/PD OF A TENOFOVIR ALAFENAMIDE/ ELVITEGRAVIR INSERT ADMINISTERED RECTALLY

11:08

Sharon A. Riddler, Clifton Kelly, Craig Hoesley, Ken Ho, Jeanna Piper, Stacey Edick, Faye Heard, Yuqing Jiao, Gustavo F. Doncel, Sherri Johnson, Ratiya Pamela Kunjara Na Ayudhya, José Bauermeister, Craig Hendrix
Research Group: MTN-039 Protocol Team

165 ULTRA-LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV

11:16

LB

Fernanda Pons-Faudoa, Nicola Di Trani, Corrine Ying Xuan Chua, Lane Bushman, Simone Capuani, Jocelyn Nikita Campa Carranza, Kathryn Shelton, Pramod Nehete, Joan Nichols, Jason Kimata, Peter L. Anderson, Roberto C. Arduino, **Alessandro Grattoni**

Oral Abstract Session-09 LATE-BREAKING CLINICAL STUDIES ON COVID-19 AND MPOX**Flex C (Level 2)****10:00 AM - 12:00 PM****Moderators****Joseph J. Eron, Jr.**, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA***Anne F. Luetkemeyer**, *University of California San Francisco, San Francisco, CA, USA***166** **ENSITRELVIR FOR MILD-TO-MODERATE COVID-19: PHASE 3 PART OF PHASE 2/3 STUDY**

10:05

Genki Ichihashi, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato, Takumi Imamura, Takuhiro Sonoyama, Takao Sanaki, Yuko Tsuge, **Takeki Uehara**, Hiroshi Mukae**167** **EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA FOR COVID-19**

10:13

NP

Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Vitoria Helena de Souza Campos, Thiago Santiago Ferreira, Castilho Vitor Quirino dos Santos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimaraes Almeida, Leonardo Cancado Monteiro Savassi, Adhemar Dias de Figueiredo Neto, Ana Carolina Fialho Dias Rocha, Carina Bitaraes, Lindsay Wilson, Edward Mills, **Jeffrey S. Glenn****Research Group:** The TOGETHER Investigators**168** **CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MAB AGAINST SARS-CoV-2**

10:21

Manish C. Choudhary, Rinki Deo, Teresa H. Evering, Kara W. Chew, Mark Giganti, Carlee Moser, Justin Ritz, David A. Wohl, Joseph J. Eron, David A. Margolis, Yun Ji, Michael D. Hughes, Davey M. Smith, Eric S. Daar, Jonathan Z. Li**Research Group:** ACTIV-2/A5401 Study Team**169** **SAFETY AND EFFICACY OF INHALED INTERFERON-B1A (SNG001) IN OUTPATIENTS WITH COVID-19**

10:29

Prasanna Jagannathan, Kara W. Chew, Mark Giganti, Michael D. Hughes, Mark Main, Phillip Monk, Arzhang C. Javan, Jonathan Z. Li, David A. Wohl, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Upinder Singh, Davey M. Smith, **William Fischer****Research Group:** ACTG A5401 Study Team**170** **METFORMIN REDUCED SARS-CoV-2 VIRAL LOAD IN A PHASE 3 RANDOMIZED CLINICAL TRIAL**

11:00

David R. Boulware, **Carolyn Bramante**, Matthew Pullen, John Buse, David Odde, Tanvi Mehta, Christopher Tignanelli, Kenneth Beckman, Amy Karger, David Liebovitz, Hrishikesh Belani, Jacinda Nicklas, Michael Puskarich, Spencer Erickson, Thomas A. Murray**171** **SYMPTOM AND VIRAL REBOUND IN UNTREATED COVID-19 INFECTION**

11:08

Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li**Research Group:** ACTIV-2/A5401 Study Team

172 COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT
 11:16
Heather Henderson, David A. Wohl, William Fischer, Luther Bartelt, David van Duin, Joseph J. Eron, Sonia Napravnik

173 MPOX IN PEOPLE LIVING WITH HIV AND CD4 COUNTS <350 CELLS/MM³ - A GLOBAL CASE SERIES
 11:24
 Oriol Mitjà, Andrea Alemany, Jezer Ivan Lezama Mora, Juan Carlos Rodríguez-Aldama, Ever Arturo Corral Herrera, Beatriz Grinsztejn, Nicolo Girometti, Valentina Mazzotta, Aniruddha Hazra, Jade Ghosn, María Fernanda Peña Vázquez, Juan J. Montenegro Idrogo, Cristina Galvan-Casas, Michael Marks, **Chloe Orkin**
Research Group: SHARE-net writing group

Themed Discussion-06 DYNAMICS OF PROVIRAL INTEGRATION Flex A (Level 2) 1:30 PM - 2:30 PM

Moderator

Lillian Cohn, Fred Hutchinson Cancer Research Center, Seattle, WA, USA



453 DISTINCT INTEGRATION SITES OF INTACT HIV-1 PROVIRUSES IN POST-TREATMENT CONTROLLERS
 1:35

NIS **Isabelle C. Roseto**, Xiaodong Lian, Kyra Seiger, Elizabeth Parsons, Gregory Gladkov, Ce Gao, Karam Mounzer, Emmanouil Papisavvas, Pablo Tebas, Tae-Wook Chun, Luis J. Montaner, Xu G. Yu, Mathias Lichterfeld

451 CTL SELECTION ENRICHES FOR HIV INTEGRATION SITE FEATURES AND EXPANDED CLONES IN VIVO
 1:40

NIS **Noemi L. Linden**, Alexander McFarland, Ali Danesh, John Everett, Chanson J. Brumme, Paul Zumbo, Doron Betel, Dennis C. Copertino, Zabrina Brumme, Friederike Dündar, Frederic D. Bushman, R. Brad Jones

452 IMPACT OF HIV RESERVOIR IN THE LOSS OF NATURAL ELITE CONTROL OF HIV-1 INFECTION
 1:45

NIS **Carmen Gasca-Capote**, Xiaodong Lian, Ce Gao, Isabelle C. Roseto, María de los Reyes Jiménez-León, Gregory Gladkov, Alberto Pérez-Gómez, Nuria Espinosa, Francesc Vidal, Antonio Rivero, Luis Fernando López-Cortes, Xu G. Yu, Mathias Lichterfeld, Ezequiel Ruiz-Mateos

455 EFFECT OF HIV-1 INFECTION AND VIRUS PRODUCTION ON CD4+ T CELL PROLIFERATION
 1:50

Joshua T. Kufera, Ciara Armstrong, Fengting Wu, Anushka Singhal, Jun Lai, Hao Zhang, Hannah Wilkins, Francesco R. Simonetti, Janet M. Siliciano, Robert F. Siliciano

456 A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE
 1:55

NIS **Sam Weissman**, Marilia Pinzone, Alfonso Ocegüera, Ashley Ginda, Liam Swiggard, LaMont Cannon, Ryan Zurakowski, Una O'Doherty

Themed Discussion-07 A VIRUS ON MY MIND: UNRAVELING LINKS BETWEEN HIV AND MENTAL HEALTH SYMPTOMS

Ballroom 1 (Level 5)

1:30 PM - 2:30 PM

Moderator

Sean Rourke, *University of Toronto, Toronto, ON, Canada*



469 EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV

1:35

NIS

Luis Parra-Rodriguez, Jane O'Halloran, Yuezhe Wang, Raha M. Dastgheyb, Amanda B. Spence, Anjali Sharma, Deborah Gustafson, Joel Milam, Kathleen Weber, Adaora Adimora, Igho Ofotokun, Margaret Fischl, Deborah Konkle-Parker, Yanxun Xu, Leah H. Rubin

476 (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION

1:40

Arish Mudra Rakshasa-Loots, Nicholas Bakewell, David Sharp, Magnus Gisslén, Henrik Zetterberg, Jasmini Alagaratnam, Ferdinand Wit, Neeltje Kootstra, Alan Winston, Peter Reiss, Caroline Sabin, **Jaime Vera**
Research Group: COmorBidity in Relation to AIDS (COBRA) cohort

472 PSYCHIATRIC SYMPTOMS IN PLHIV: PREVALENCES, INTERACTIONS AND CONSEQUENCES

1:45

Elise M.G. Meeder, Marc J.T. Blaauw, Louise E. van Eekeren, Albert L. Groenendijk, Willem A.J.W. Vos, Quirijn De Mast, Willem L. Blok, Annelies Verbon, Marvin A.H. Berrevoets, Jan van Lunzen, Leo A. B. Joosten, Mihai G. Netea, Vasiliki Matzaraki, Andre J.A.M. van der Ven, Arnt F.A. Schellekens
Research Group: 2000HIV

474 BIOPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT

1:50

Bin Tang, **Ronald J. Ellis**, Florin Vaida, Anya Umlauf, Donald Franklin, Raha M. Dastgheyb, Leah H. Rubin, Robert K. Heaton, Scott L. Letendre

473 SLEEP DISTURBANCES ARE ASSOCIATED WITH COGNITIVE FUNCTION IN WOMEN LIVING WITH HIV

1:55

Raha M. Dastgheyb, Kathleen Weber, Elizabeth Daubert, Anjali Sharma, Deborah Gustafson, Deborah Jones Weiss, Catalina Ramirez, Deborah Konkle-Parker, Sushma Cribbs, Bradley Aouizerat, Christine Alden, Seble Kassaye, Audrey French, Leah H. Rubin

Themed Discussion-08 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?
Flex C (Level 2)

1:30 PM - 2:30 PM

Moderator

Babafemi Taiwo, *Northwestern University, Chicago, IL, USA*



516 PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE

1:35

Stephanie Kenney, Nimish Patel, Lucas Hill

518 HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION

1:40

NIS

Monica Gandhi, Jorge Salazar, Matthew D. Hickey, Katerina Christopoulos, Jon Oskarsson, Mary Shiels, John Szumowski, Janet Grochowski, Francis Munoz-Mayorga, John Saucedo, Elizabeth Imbert, Janet Nguyen, David V. Glidden, Diane V. Havlir

517 PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART

1:45

Wanyi Chen, Monica Gandhi, Paul Sax, Anne Neilan, Justine Scott, Timothy Wilkin, Andrea L. Ciaranello, Joseph J. Eron, Kenneth A. Freedberg, Emily P. Hyle

Themed Discussion-09 ADVANCES IN PrEP DELIVERY IN SUB-SAHARAN AFRICA

Ballroom 2 (Level 5)

1:30 PM - 2:30 PM

Moderator

Andrew Mujugira, *Makerere University, Auburn, WA, USA*



999 A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA

1:35

Ingrid Bassett, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile Ngcobo, Taing N. Aung, Jana Jarolimova, Danielle Zions, Christina Psaros, Nduduzo Dube, Robert Parker

978 PHARMACY-BASED PrEP DELIVERY IN KENYA: FINDINGS FROM A PILOT STUDY EXTENSION

1:40

Stephanie Roche, Victor Omollo, Peter Mogere, Magdaline Asewe, Stephen Gakuo, Preetika Banerjee, Kendall Harkey, Josephine Odoyo, Jared M. Baeten, Patricia Ongwen, Daniel Were, Elizabeth A. Bukusi, Kenneth Ngunjiri, Katrina F. Ortblad

977 EFFECTS OF 6-MONTH PrEP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA

1:45

NIS

Ashley R. Bardon, Kenneth Ngunjiri, Peter Mogere, Katherine Thomas, Stephen Gakuo, Catherine Kiptinness, Sarah Mbaire, Dorothy Mangale, Jacinta Nyokabi, Nelly Mugo, Jared M. Baeten, Katrina F. Ortblad

976 INCREASED UPTAKE OF BIOMEDICAL HIV PREVENTION BY YOUTH THROUGH COMMUNITY-BASED SRH

1:50

Maryam Shahmanesh, Glory Chidumwa, Natsayi Chimbindi, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Kobus Herbst, Jana Jarolimova, Thandeka Khoza, Deenan Pillay, Theresa Smit, Osee Behuhuma, Jean-Michel Molina

975 RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT OUTPATIENT DEPARTMENT IN EAST AFRICA

1:55

Catherine Koss, James Ayieko, Jane Kabami, Laura Balzer, Elijah Kakande, Helen Sunday, Marilyn Nyabuti, Erick Wafula Mugoma, Melanie Bacon, Elizabeth A. Bukusi, Gabriel Chamie, Maya Petersen, Moses Kanya, Diane V. Havlir

Research Group: SEARCH Study Team

WEDNESDAY FEBRUARY 22, 2023

Oral Abstract Session-10 IMMUNOPATHOGENESIS AND VACCINES

Ballroom 3 (Level 5)

10:00 AM - 12:00 PM

Moderators

Richard A. Koup, *National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA*

Cynthia Derdeyn, *University of Washington, Seattle, WA, USA*



174 **CD8+ T CELLS INDUCE HIV LATENCY IN CD4+ T CELLS THROUGH THE DOWNMODULATION OF NF-κB**

10:05

Simona Mutascio, Hong Wang, Mirko Paiardini, Guido Silvestri, Deanna A. Kulpa

175 **BLOCKING CD4+T CELL MIGRATION DELAYS VIRAL SPREAD FOLLOWING VAGINAL SIV CHALLENGE**

10:13

Christine M. Fennessey, David R. Morcock, Jorden L. Welker, James A. Thomas, Charles M. Trubey, Caroline Widmaier, Kristin Killoran, Jeffrey D. Lifson, Brandon F. Keele, **Claire Deleage**

176 **DEPLETION OF SIV-SPECIFIC CD8+ T CELLS DOES NOT ALTER VIRAL LOAD DURING SIV INFECTION**

10:21

Jennifer Simpson, Carly Starke, Alexandra Ortiz, Amy Ransier, Sam Darko, Daniel C. Douek, Sian Llewellyn-Lacey, David Price, Jason Brenchley

177 **PROTECTION AGAINST HTLV-1 CHALLENGE BY VACCINATION INDUCING ANTIBODIES IN MACAQUES**

10:29

Midori Nakamura-Hoshi, **Hiroshi Ishii**, Takushi Nomura, Midori Okazaki, Yuriko Suzuki, Kenzo Yonemitsu, Yasushi Ami, Tetsuro Matano

178 **SHIFTS IN SYSTEMIC INFLAMMATION AFTER FECAL MICROBIOTA TRANSPLANT IN PEOPLE WITH HIV**

11:00

NIS

Claudio Díaz-García, Elena Moreno, Alba Talavera, José A. Pérez-Molina, Fernando Dronda, María José Gosalbes, Jorge Díaz-Álvarez, Javier Martínez-Sanz, Raquel Ron, María Jesús Vivancos, Santiago Moreno, Sergio Serrano-Villar

179 **AUTOLOGOUS NEUTRALIZING ANTIBODY RESPONSES IN bNAb-TREATED RHESUS MACAQUES**

11:08

Elise Viox, Ryan Krause, Emily Lindemuth, Jin Wang, Sadia Samer, Kevin Nguyen, Steffen Docken, Suvadip Mallick, Brandon F. Keele, Michael R. Betts, Miles Davenport, Mirko Paiardini, Katharine Bar

180 **ANALYSIS OF EPITOPE-SPECIFIC T CELLS IN SARS-CoV-2 INFECTION AND VACCINATION**

11:16

Kristin L. Boswell, Lauren A. Bowman, Amy Ransier, Jesmine Roberts-Torres, Jakob T. Samsel, David R. Ambrozak, Phillip A. Swanson, Giune Padilla, Sam Darko, Ingelise Gordon, Irini Sereti, Adrian B. McDermott, Martin Gaudinski, Daniel C. Douek, Richard A. Koup

181 **ANTI-PD-1 THERAPY INDUCED RAPID INNATE INTERFERON RESPONSES DRIVE HIV RESERVOIR DECAY**

11:24

LB

Ashish Arunkumar Sharma, Aarthi Talla, Ana B. Enriquez, Gabriela Sanchez, Adam Pelletier, Leonard D'Amico, Nicolas Chomont, Sharon Lewin, Steven G. Deeks, Kathryn Lurain, Elad Sharon, Steven Fling, Martin Cheever, Thomas Uldrick, Rafick P. Sékaly

182 SINGLE INFUSION OF STEM LIKE CCR5-MODIFIED CD4 T CELLS PROVIDE LONG-TERM HIV CONTROL

11:32

LB

Ana B. Enriquez, Ashish Arunkumar Sharma, Joumana Zeidan, Gary Lee, Slim Fourati, Khader Ghneim, Gabriela Sanchez, Francesco Procopio, Robert Balderas, Nicolas Chomont, Dale Ando, Steven G. Deeks, Rafick P. Sékaly, Rémi Fromentin

Oral Abstract Session-11 NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-CoV-2

Ballroom 2 (Level 5)

10:00 AM - 12:00 PM

Moderators

Serena S. Spudich, *Yale University, New Haven, CT, USA*

Michael Corley, *Weill Cornell Medicine, New York, NY, USA*



183 SEX MODIFIES THE ASSOCIATION OF AGE AND VIREMIA WITH STROKE RISK IN HIV

10:05

Felicia C. Chow, Robin Nance, Emily Ho, Andrew Huffer, Rizwan Kalani, Christina Marra, Joseph Zunt, Laura Bamford, Greer Burkholder, Edward Cachay, Mari Kitahata, Sonia Napravnik, David Tirschwell, Joseph Delaney, Heidi Crane

Research Group: CFAR Network of Integrated Clinical Systems (CNICS) Network

184 INCREASED IMMUNE ACTIVATION IN HIV+ MSM ON ART, BUT NOT WHEN COMPARED TO MSM ON PrEP

10:13

Josefina Robertson, Arvid Eden, Aylin Yilmaz, Lars Hagberg, Lars-Magnus Andersson, Johanna Gostner, Dietmar Fuchs, Henrik Zetterberg, **Magnus Gisslén**

185 CEREBROSPINAL FLUID HIV RNA AND VIRAL NUCLEIC ACID DETECTION IN PERSONS WITH HIV

10:21

NIS

Merle Henderson, Nuala Pepper, Manraj Bawa, David Muir, Alex Everitt, Nicola Mackie, Alan Winston

186 HIV CLINICAL, COMORBID, AND SOCIAL DETERMINANTS OF HEALTH ARE LINKED WITH BRAIN AGING

10:29

Kalen J. Petersen, Tina Lu, Julie Wisch, June Roman, Nicolas Metcalf, Sarah Cooley, Beau Ances

187 CHANGES TO MICROGLIAL GENOME STRUCTURE AND FUNCTION IN THE HIV-INFECTED HUMAN BRAIN

11:00

NIS

Amara Plaza-Jennings, Aditi Valada, Benjamin K. Chen, Susan Morgello, Hyejung Won, Schahram Akbarian

188 BRAIN AND BEHAVIOR PREDICTORS OF SARS-CoV-2 INFECTION AMONG PEOPLE WITH HIV

11:08

Robert Paul, Jacob Bolzenius, Somchai Sriplienchan, Carlo Sacdalan, Napapon Sailasuta, Julie A. Ake, Donn Colby, Phillip Chan, Ferron F. Ocampo, Denise Hsu, Lishomwa Ndhlovu, Adam W. Carrico, Sandhya Vasani, Victor Valcour, Serena Spudich

189 NO CSF BIOMARKER EVIDENCE OF PERSISTING CNS INFECTION AFTER SARS-CoV-2 INFECTION

11:16

Arvid Eden, Anna Grahn, Nelly Kanberg, Erika Stentoft, Staffan Nilsson, Aylin Yilmaz, Daniel Bremell, Marie Studahl, Daniel Romero, Mingyue Wang, Martin Stengelin, George Sigal, Michael Schöll, Henrik Zetterberg, Magnus Gisslén

Research Group: SEARCH 010/RV254 Study Team

190 CSF & PLASMA SOLUBLE BIOMARKERS IN NEURO-PASC: PRELIMINARY RESULTS FROM COVID MIND

11:24

Shelli Farhadian, **Lindsay S. McAlpine**, Hailey Reiser, Jennifer Yoon, Jennifer Chiarella, Priya Kosana, PeiXi Chen, Kaj Blennow, Debanjana Chakravarty, Samuel Pleasure, Michael Wilson, Magnus Gisslén, Henrik Zetterberg, Serena Spudich

Oral Abstract Session-12 ANTIVIRAL STRATEGIES FOR TREATMENT AND PREVENTIONS

Ballroom 1 (Level 5)

10:00 AM - 12:00 PM

Moderators

Angela Kashuba, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

Anton L. Pozniak, *Chelsea and Westminster Hospital, London, England, United Kingdom*



191 SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF

10:05

Moti N. Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Diaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Kenneth Sutton, Denise Sutherland-Phillips, Alessandro Berni, Christine Latham, Feifan Zhang, Ronald D'Amico, Kimberly Smith, Jean Van Wyk

192 EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNT

10:13

Kathleen E. Squires, Todd A. Correll, Michael N. Robertson, Stephanie O. Klopfer, Peggy May Tan Hwang, Yun-Ping Zhou, Elizabeth Martin, Elizabeth G. Rhee

193 LENACAPAVIR WITH bNABs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV

10:21

Joseph J. Eron, Susan R. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyantha Jayaweera, Edwin DeJesus, Sarah E. Waldman, Megha L. Mehrotra, Laurie A. VanderVeen, Hailin Huang, Sean E. Collins, Jared M. Baeten, Marina Caskey

194 TARGET3D: GLECAPREVIR-PIBRENTASVIR FOR FOUR WEEKS IN PEOPLE WITH RECENT HCV INFECTION

10:29

Marianne Martinello, Sanjay Bhagani, David Shaw, Chloe Orkin, Graham Cooke, Edward Gane, Margaret Hellard, Andrew Ustianowski, Ranjababu Kulasegaram, Catherine Stedman, Elise Tu, Jason Grebely, Gregory Dore, Mark Nelson, Gail Matthews

195 LOW CONCENTRATIONS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN PATIENTS WITH HIV

11:00

Emma Rubenstein, Myriam Diemer, Lauriane Goldwirt, Caroline Lascoux, Matthieu Lafaurie, Jeremy Zeggagh, Mariagrazia Tateo, Diane Ponscarne, Julien Gras, Blandine Denis, Agathe Rami, Pierre Sellier, Marie-Laure Chaix, Constance Delaugerre, Jean-Michel Molina

196 SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL

11:08

LB

Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani Saud, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Isaias Noel Gendrano, Karen Eves, Jason Kim, Todd A. Correll

197 SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL

11:16

LB

Anthony M. Mills, Giuliano Rizzardini, Moti Ramgopal, Olayemi Osiyemi, Johannes R. Bogner, Debbie Hagins, Roger Paredes, Jacques Reynes, Jürgen Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O. Klopfer, Rebeca M. Plank, Michelle C. Fox, Todd A. Correll



Continuing Medical Education



Late-Breaking



New Investigator Scholarship



Nonauthor Presenter

198 D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE HIV THERAPY

11:24

LB

Gail Matthews, Margaret Borok, Nnekelu Eriobou, Richard Kaplan, N Kumarasamy, Anchalee Avihingsanon, Marcelo H. Losso, Iskander Shah Azwa, Muhammad Karyana, Sounkalo Dao, Mohamed Cisse, Emmanuelle Papot, Simone Jacoby, Jolie Hutchison, Matthew G. Law,
Research Group: D2EFT Study Group

Oral Abstract Session-13 OPTIMIZING THE HIV TREATMENT CASCADE Flex A (Level 2)

10:00 AM - 12:00 PM

Moderators

Landon Myer, *University of Cape Town, Cape Town, Western Cape, South Africa*

Euphemia Sibanda, *Centre for Sexual Health & HIV/AIDS Research, Harare, Zimbabwe*



199 HIV REGENCY TESTING WITH INDEX TESTING CAN IDENTIFY NEW INFECTIONS EARLIER IN RWANDA

10:05

LB

Suzue Saito, Giles Reid, Eugenie Poirot, Jean-Claude Irabona, Collins Kamanzi, Veronicah Mugisha, Beata Sangwayire, Eric Remera, Tom Oluoch, Richard Mwesigwa, Elysee Tuyishime, Kemba Lee, David A. Miller, Amitabh B Suthar, Gallican N. Rwebasira
Research Group: Rwanda HIV Recency Evaluation Study Team

200 RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV CARE FOR HIGHLY MOBILE PERSONS IN EAST AFRICA

10:13

James Ayieko, Colette Inviolata, Elijah Kakande, Fred Opel, Erick Wafula Mugoma, Laura Balzer, Jane Kabami, Elizabeth A. Bukusi, Carol Camlin, Edwin Charlebois, Melanie Bacon, Maya Petersen, Diane V. Havlir, Moses Kanya, Gabriel Chamie
Research Group: SEARCH Study Team

201 THE IMPACT OF PATIENT-CENTRED CARE ON HIV TREATMENT IN ZAMBIA: A STEPPED-WEDGE TRIAL

10:21

Kombatende Sikombe, Aaloke Mody, Charles Goss, Ingrid Eshun-Wilson, Sandra Simbeza, Anjali Sharma, Laura K Beres, Jake M. Pry, Njekwa Mukamba, Brian Rice, Jacob Mutale, Carolyn Bolton Moore, Charles B Holmes, Izukanji Sikazwe, Elvin Geng

202 A RANDOMIZED CONTROL TRIAL OF MHEALTH TOOL EFFECT ON VIRAL SUPPRESSION IN YOUTHS

10:29

NIS

Agnes Bwanika Naggirinya, Maria S. Nabaggala, David B. Meya, Joseph Rujumba, Peter Waiswa, Rosalind Parkes-Ratanshi

203 SUPPRESSING VIRAL LOAD IN PEOPLE WITH HIV WHO INJECT DRUGS IN RUSSIA: LINC-II RCT

11:00

Jeffrey H. Samet, Elena Blokhina, Debbie M Cheng, Sydney Rosen, Dmitry Lioznov, Karsten Lunze, Ve Truong, Natalia Gnatienko, Emily Quinn, Natalia Bushara, Anita Raj, Evgeny Krupitsky

204 URINE TENOFOVIR LEVELS PREDICT VIRAL SUPPRESSION IN PATIENTS ON TENOFOVIR ALAFENAMIDE

11:08

Kelly A. Johnson, Okochi Hideaki, Mireya Arreguin, Joseph Watabe, David V. Glidden, Anindita Chattopadhyay, Elizabeth Imbert, Matthew D. Hickey, Monica Gandhi, Matthew A. Spinelli

205 TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS AND HIV-1 RESISTANCE IN SOUTH AFRICA

11:16

Yashna Singh, Jose Castillo-Mancilla, Lauren Jennings, Richard Madimabe, Christopher Ferraris, Reuben N. Robbins, Peter L. Anderson, Robert H. Remien, **Catherine Orrell**

206 ART SHARING IS COMMON AND ASSOCIATED WITH VIREMIA: A POPULATION-BASED STUDY IN UGANDA

11:24

Caitlin E. Kennedy, Xinyi Feng, Joseph G. Rosen, Joseph Ssekasanvu, Robert Ssekubugu, Godfrey Kigozi, David M. Serwadda, Joseph Kabanda, Ping Teresa Yeh, Joseph Kagaayi, Steven J. Reynolds, Larry William W. Chang, Fred Nalugoda, Mary K. Grabowski
Research Group: The Rakai Health Sciences Program

Oral Abstract Session-14 EPIDEMIOLOGY AND PREVENTION OF MPOX AND SARS-CoV-2 Flex C (Level 2)

10:00 AM - 12:00 PM

Moderators

Adaora Adimora, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

François Dabis, *University of Bordeaux, Bordeaux, Aquitaine, France*



207 EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL

10:05

Boghuma K. Titanji, Angelia Eick-Cost, Lauren Epstein, Natalie Wells, Jeremy Smith, Shauna L. Stahlman, Abirami Balajee, Saiju Pyarajan, Chris W. Woods, Mark Holodniy, Elizabeth J. Partan, Victoria J. Davey, Robert A. Bonomo, Yinong Young-Xu, Vincent C. Marconi

208 IMPACT OF VACCINATION ON MPOX INCIDENCE IN MSM ON PrEP IN THE ANRS 174 DOXYVAC TRIAL

10:13

Jade Ghosn, Lambert Assoumou, Moussa Ouattara, Michele Algarte-Genin, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Claudine Duvivier, Juliette Pavie, Jean-Paul Viard, Severine Gibowski, Manon Ollivier, Dominique Costagliola, Jean-Michel Molina

209 HOUSEHOLD TRANSMISSION OF MONKEYPOX TO CHILDREN AND ADOLESCENTS

10:21

Darpun Sachdev, Rilene Ng, Cameron Stainken, Meredith Haddix, Erin Peterson, Kristen Wendorf

210 ASSOCIATION BETWEEN OBSERVED MASKING AND SARS-CoV-2 PRESENCE IN SCHOOL WASTEWATER

10:29

Rebecca Fielding-Miller, Tommi Gaines, Ashkan Hassani, Vinton Omaleki, Marlene Flores, Araz Majnoonian, Carrissa Wijaya, Richard Garfein

211 VARIABLE REDUCTIONS IN SARS-CoV-2 VARIANT IMPORTATIONS FOLLOWING TRAVEL RESTRICTIONS

11:00

Angela McLaughlin, Jeffrey B Joy

212 INTERVENTION EFFICACY ON COVID-19 TESTING AND VACCINATION IN PEOPLE WHO INJECT DRUGS

11:08

Angela R. Bazzi, Daniela Abramovitz, Alicia Harvey-Vera, Tara Stamos-Buesig, Carlos F. Vera, Irina Artamonova, Janna Logan, Thomas L. Patterson, Steffanie A. Strathdee

213 CLUSTER-RANDOMIZED TRIAL COMPARING TWO SARS-CoV-2 TESTING MODELS IN AFRICA

11:16

Nilesh Bhatt, Aida Yemaneberhan, Boris K. Tchounga, Leonie Simo, Djikeussi Katcho. Tatiana, James Ndimbii, Stephen Siamba, Magoma Kwasa, Emilienne Epee, Anne Cecile Zoung-Kanyi Bissek, Sharee Pearson, Rhoderick Machekano, Appolinaire Tiam, Laura Guay, Rose Masaba

214 COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION

11:24


Jing Sun, Yifan Zhang, Alfred J. Anzalone, Amy L. Olex, Eric Hurwitz, Jomol Mathew, Nasia Safdar, Jessica Y. Islam, Roslyn Mannon, Amanda J. Vinson, Christopher Chute, Melissa A. Haendel, Rena Patel, Greg Kirk
Research Group: National COVID Cohort Collaborative

Themed Discussion-10 CELLULAR IMMUNE CONTROL OF HIV Ballroom 2 (Level 5)

1:30 PM - 2:30 PM

Moderator

Marcus Altfeld, *Leibniz Institute for Virology, Hamburg, Germany*



315 ELITE CONTROLLERS WITH DISTINCT VIRAL RESERVOIR HAVE ROBUST CTL TO NETWORKED EPITOPES

1:35

David Collins, Clarety Kaseke, Umar Urshad, Xiaodong Lian, Bridget Coffey, Daniel Worrall, Alicja Piechocka-Trocha, Micayla George, Benjamin R. Bone, Mathias Lichterfeld, Xu G. Yu, Bruce D. Walker, Gaurav Gaiha

311 IL-15 DEPENDENT NK CELLS AND DENDRITIC CELLS CROSS-TALK IN HIV-1 ELITE CONTROLLERS

1:40

NIS

Ciputra A. Hartana, Ce Gao, Yelizaveta Rassadkina, Mathias Lichterfeld, Xu G. Yu

337 NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI

1:45

NIS

Ashley F. George, Tongcui Ma, Min-Gyoung Shin, Reuben Thomas, Mauricio Montano, Satish Pillai, Martin Tolstrup, Ole S. Sogaard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Katherine S. Pollard, Warner C. Greene, Nadia R. Roan

312 DISTINCT NK CELL RESPONSES DEFINE DURABLE CONTROL IN ELITE CONTROLLERS

1:50

NIS

Nerea Sánchez Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José Miguel Benito, Ezequiel Ruiz-Mateos, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
Research Group: HIV Translational Research Group

313 MONOCYTES OF HIV-1 ELITE CONTROLLERS AND RELATIVES SHOW ENHANCED TRAINED IMMUNITY

1:55

Albert L. Groenendijk, Emiliano Dalla, Jelmer H. Van Puffelen, Willem A.J.W. Vos, Marc J.T. Blaauw, Louise E. van Eekeren, Richard M. Dunham, Casper Rokx, Annelies Verbon, Musa M. Mhlanga, Jan van Lunzen, Leo A. B. Joosten, Andre J.A.M. van der Ven, Mihai G. Netea, **Jéssica C. Dos Santos**
Research Group: 2000HIV

Themed Discussion-11 WEIGHT GAIN: DOES WHAT GOES UP ALWAYS COME DOWN?

Ballroom 1 (Level 5)

1:30 PM - 2:30 PM

Moderator

Peter Hunt, *University of California San Francisco, San Francisco, CA, USA*



671 WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG

1:35

Bronwyn E. Bosch, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Many Mirchandani, Francois Venter

672 FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC

1:40

Sophie Degroote, Sophie Vanherrewege, Els Tobback, Els Caluwe, Lara Vincke, Wim Trypsteen, Mareva Delporte, Evy Blomme, **Linos Vandekerckhove**, Marie-Angélique De Scheerder

673 REVERSIBILITY OF TAF- AND/OR INSTI-ASSOCIATED WEIGHT GAIN

1:45

Myrthe L. Verburgh, Ferdinand Wit, Anders Boyd, Peter Reiss, Marc van Der Valk
Research Group: the ATHENA national observational cohort

674 WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A DOLUTEGRAVIR-BASED HIV REGIMEN IN KENYA

1:50

Kassem Bourgi, Susan Ofner, Beverly Musick, Kara Wools-Kaloustian, Lameck Diero, Constantin Yiannoutsos, Samir Gupta

Themed Discussion-12 HIV SERVICES IN TIMES OF CRISIS

Flex A (Level 2)

1:30 PM - 2:30 PM

Moderator

Siobhan Crowley, *The Global Fund, Geneva, Switzerland*



1077 A MODEL OF SUCCESSFUL ART INITIATION IN THE CONTEXT OF MASSIVE CIVIL UNREST IN HAITI

1:35

Jean Bernard Marc, Samuel Pierre, Vanessa Rivera, Zion Abigail, David Montreuil, Fabienne Homeus, David Andre, Carl Frederic Duchatellier, Elizabeth Fox, Vanessa Rouzier, Bernard Liautaud, Patrice Severe, Collette Guiteau, Jean William Pape, Serena Koenig

1076 CONDUCTING RESEARCH IN A SETTING OF SEVERE POLITICAL INSTABILITY: THE GHESKIO MODEL

1:40

Samuel Pierre, Carl Frederic Duchatellier, Vanessa Rivera, Nancy Dorvil, Marie Flore Pierre, Joseph Marie Bajo Joseph, Alexandra Apollon, Sean E. Collins, Denis Israelski, Stephano St Preux, Sanjana Sundaresan, Hongjue Wang, Patrice Severe, Jean William Pape, Serena Koenig

1078 EMERGENCY RESPONSE TO RESTORE HIV TREATMENT SERVICES IN AMHARA REGION, ETHIOPIA, 2022

1:45

Chanie Temesgen Bayieh, Minesh Shah, Solomon Ahmed, Tekeste Kebede, Ismael Ahmed, Dereje Habte, Adugna Tesfaye, Mirte Getachew Meselu, Gashu Kindu Akale, Hiwot Debebe, Abdulkerim Mengistu Yimam, Jemal Aliy, Zenebe Melaku, Caroline A Ryan, Melkamu Abte
Research Group: National and Amhara Regional Emergency Response Team

Themed Discussion-13 PRECLINICAL STUDIES OF NEW PREVENTION INTERVENTIONS

Ballroom 3 (Level 5)

1:30 PM - 2:30 PM

Moderator

Ariane van der Straten, *University of California San Francisco, Kensington, CA, USA*



992 **LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL**

1:35

Elena Bekerman, Stephen Yant, Laurie A. VanderVeen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut

990 **EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS**

1:40

Natalia Makarova, Tyana Singletary, Missy Peet, James Mitchell, Angela Holder, Chuong Dinh, Yi Pan, Maria Corazon Bueno Mendoza, Meredith Clark, Walid Heneine, James Smith, Gerardo Garcia-Lerma, Gustavo F. Doncel

989 **VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES**

1:45

Michele B. Daly, Daniel Kim, Linying Li, Archana Krovi, Chasity Norton, Catalina Forero, Marie Brake, Chuong Dinh, Tiancheng Edwards, Mackenzie Cottrell, Walid Heneine, Gerardo Garcia-Lerma, Charles Dobard, James Mitchell, Leah Johnson

991 **PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT**

1:50

NIS

Isabella Young, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Craig Sykes, Mackenzie Cottrell, Angela DM. Kashuba, S. Rahima Benhabbour

Please Note: The bolding of presenting authors in the Poster Sessions By Day may be inconsistent and incorrect. Please refer to the Abstract eBook and CROI 2023 Conference Platform for the correct notation of presenting authors.

POSTER SESSIONS BY DAY

MONDAY FEBRUARY 20, 2023

Poster Session-A1 EARLY EVENTS

2:30 PM - 4:00 PM

- 215** **LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE**
Chenglei Li, Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak
- 216** **SINGLE-VIRUS IMAGING OF HIV-1 NUCLEAR IMPORT**
 Anayat Bhat, Ivan Nombela, Barbara V. Remoortel, **Frauke Christ**, Zeger Debyser
Research Group: Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven
- 217** **RESTRICTION OF LENTIVIRAL CAPSIDS BY PRIMATE TRIM34**
Joy Twentyman, Abby Felton, Michael Emerman, Molly Ohainle

Poster Session-B1 GENETICS, EARLY HIV INFECTION, NATURAL CONTROL

2:30 PM - 4:00 PM

- 240** **EARLY EVOLUTION OF HIV-1 FROM TRANSMITTED FOUNDERS DURING ACUTE INFECTION**
Valerie F. Boltz, Wei Shao, Clarissa Halpern, Adam A. Capoferri, Morgane Rolland, Nittaya Phanuphak, Denise Hsu, Carlo Sacdalan, John W. Mellors, John M. Coffin, Mary F. Kearney
Research Group: RV254/SEARCH 0101 Study Team
- 241** **ASSOCIATION OF MBL2 GENE POLYMORPHISMS WITH HIV-1 INFECTION IN MOROCCO**
Meryem Bouqdayr, Hanâ Baba, Asmae Saih, Anass Abbad, Salsabil Hamdi, Anass Kettani, Lahcen Wakrim
- 242** **DIFFERENTIAL INFECTION OF ECTO- AND ENDOCERVIX BY TRANSMITTED/FOUNDER HIV-1 EX VIVO**
Teresia A. Muhomah, Robert Langat, Michael McRaven, Ramon Redondo, Ann Marie Carias, Marianne Mureithi, Omu Anzala, Thomas J. Hope
- 243** **PD-1 IS AN INSENSITIVE MARKER FOR HIV/SIV RNA+ LYMPH NODE TFH IN UNTREATED INFECTION**
Joy Folkvord, Matthew Ollerton, Andria Albert, Eva Rakasz, Pamela Skinner, Elizabeth Connick
- 244** **IDENTIFICATION OF HIV-2 EXTREME ELITE CONTROLLERS OFFERS INSIGHT TO FUNCTIONAL CURE**
Zsófia I. Szojka, Emil Johansson, Angelica Palm, Jacob Lindman, Sara Karlson, Lydia Scharf, Fredrik Månsson, Antonio Biague, Marcus Buggert, Annika C. Karlsson, Hans Norrgren, Joakim Esbjörnsson, Patrik Medstrand, Marianne Jansson
Research Group: SWEGUB CORE group
- 245** **T CELLS HOMEOSTASIS DISTURBANCES IN A COHORT OF LONG-TERM ELITE CONTROLLERS**
 Norma Rallón, Daniel Jiménez-Carretero, Maria A. Navarrete-Muñoz, José M. Ligos, Jaime Valentín-Quiroga, Clara Restrepo, Alfonso Cabello, Miguel Górgolas, Eduardo López-Collazo, Fátima Sánchez-Cabo, **José M. Benito**

- 246** **LOW TRYPTOPHAN CATABOLISM MARKS IMMUNE PRESERVATION IN HIV+ VIREMIC NON-PROGRESSORS**
NIS
Angel Bayon-Gil, Aaron Goldman, Judith Dalmau, Kai Ying Hong, Jane Koshy, Leila Giron, Mohamed Abdel-Mohsen, Javier Martinez Picado, Maria C. Puertas
- 247** **PHENOTYPE OF SIV-INFECTED CELLS IN BLOOD AND TISSUES USING A NEW SINGLE-CELL APPROACH**
César A. Trifone, Manon Nayrac, Michael Nekorchuk, Kathleen Busman-Sahay, Rémi Fromentin, Daniel Kaufmann, Jacob Estes, **Nicolas Chomont**

Poster Session-B6 SARS-CoV-2 PATHOGENESIS**2:30 PM - 4:00 PM**

- 271** **PLASMA LIPIDS AND AMINO ACIDS LINKED TO LOW SARS-CoV-2 SUSCEPTIBILITY**
Elena Moreno, Oihane E Albóniga, Javier Martínez-Sanz, Pilar Vizcarra, Raquel Ron, Jorge Díaz-Álvarez, Matilde Sanchez-Conde, Claudio Díaz-García, Juan Carlos Galán, Santiago Moreno, Coral Barbas, Sergio Serrano-Villar
- 272** **EARLY INFLAMMATORY PROFILES PREDICT MAXIMAL DISEASE SEVERITY IN COVID-19**
Grace Kenny, Gurvin Saini, Colette Marie Gaillard, Riya Negi, Dana Alalwan, Alejandro Garcia Leon, Willard Tinago, Eoin R. Feeney, Aoife Cotter, Eoghan Debarra, Mary Horgan, Obada Yousif, Cecilia O'Kane, Danny McAuley, Patrick Mallon
Research Group: All Ireland Infectious Diseases Study Group
- 273** **DIFFERENTIAL ASSOCIATION OF CYTOMEGALOVIRUS WITH ACUTE AND POST-ACUTE COVID-19**
Michael J. Peluso, Harry Pickering, Fay Chan, Gabrielle C. Ambayec, Gabriele Beck-Engeser, Katherine Wick, Michael Matthay, Carolyn Calfee, Jeffrey Martin, Steven G. Deeks, Smita Iyer, Holden Maecker, Timothy Henrich, Elaine F. Reed, Peter W. Hunt
Research Group: IMPACC, COMET, and LIINC study teams
- 274** **BASELINE AND TEMPORAL DIFFERENCES IN PROTEOMICS FOLLOWING SARS-CoV-2 INFECTION IN PWH**
Márton Kolossváry, Christopher Defilippi, Sara McCallum, Kathleen V. Fitch, Heather J. Ribaud, Carl J. Fichtenbaum, Judith A. Aberg, Carlos Malvestutto, Judith S. Currier, Jose L. Casado, Félix Gutiérrez, Irini Sereti, Pam S. Douglas, Markella V. Zanni, Steven K. Grinspoon
- 275** **SARS-CoV-2 BA.5 CAUSES HIGHER REPLICATION AND LETHAL INFECTION IN K18-hACE2 MICE**
Rahul K. Suryawanshi, Maria McCavitt-Malvido, Melanie Ott
- 276** **AUTOPHAGY AND Acyl-CoA-BINDING PROTEIN INFLUENCE COVID-19 SEVERITY**
Stephane Isnard, Léna Royston, Tsoarello Mabanga, Simeng Bu, Carolina Berini, John Lin, Brandon Fombuena, Cecilia Costiniuk, Bertrand Lebouché, Nicole Bernard, Guido Kroemer, Madeleine Durand, Jean-Pierre Routy
Research Group: BQC-19 Biobank
- 277** **INFLAMMATORY PATHWAYS ASSOCIATED WITH COVID-19 SEVERITY DIFFER BASED ON OBESITY STATUS**
Stefano Savinelli, Grace Kenny, Colm O'Brien, Kathleen McCann, Alejandro Garcia Leon, Gurvin Saini, Colette Marie Gaillard, Rya Negi, Dana Alalwan, Alan Landay, Cecilia O'Kane, Aoife Cotter, Patrick Mallon, Eoin R. Feeney, Eoghan de Barra, Obada Yousify
Research Group: All Ireland Infectious Diseases Cohort

- 278 SARS-CoV-2 VARIANTS-DEPENDENT INFLAMMASOME ACTIVATION**
Elisa Teyssou, Stephane Marot, Adeline Gothland, Isabelle Malet, Karen Zafilaza, Valentin Leducq, Theophile Cocherie, Cathia Soulié, Anne-Geneviève Marcelin, Vincent Calvez
- 279 HIGH FAT AND SUGAR DIET INDUCES GUT LEUKOCYTE DISRUPTIONS EXACERBATED BY SARS-CoV-2**
Kelsie Brooks, Quentin Le Hingrat, Anna Jasinska, Lilas Tarnus, Makheni Jean Pierre, Ankur Sharma, Christine Nelson, Mark Lewis, Daniel Barber, Cristian Apetrei, Jason Brenchley, Ivona Pandrea
- 280 ACE2 SUBSTRATE CLEAVAGE EFFECT ASSOCIATED WITH COVID-19 PATIENT PLASMA IMMUNOGLOBULIN**
 Yufeng Song, Regan Myers, Lila Murphy, Bailey Brooks, Alexandra Kadl, Judith Woodfolk, **Steven Zeichner**
- 281 SARS-CoV-2 VARIANTS' TEMPORAL AND VL DISTRIBUTIONS IN IMMUNOCOMPROMISED PATIENTS**
Karen Zafilaza, Valentin Leducq, Romain Coppée, Eve Todesco, Cathia Soulié, Anna-Maria Franco Yusti, Antoine Fauchois, Charlotte Charpentier, Antoine Bridier-Nahmias, Diane Descamps, Anne-Geneviève Marcelin, Vincent Calvez, Valentine M. Ferré, Stephane Marot
Research Group: ANRS MIE - EMERGEN Consortium

Poster Session-D1 ANTIBODY AND BROADLY NEUTRALIZING RESPONSES

2:30 PM - 4:00 PM

- 298 MYCOBACTERIUM TUBERCULOSIS ASSOCIATES WITH HIGHER HIV-1-SPECIFIC ANTIBODY RESPONSES**
 NP
 Bukola Adeoye, Lydia Nakiyingi, Yvetane Moreau Moreau, Ethel Nankya, Alex Olson, Mo Zhang, Karen Jacobson, Amita Gupta, Yukari C. Manabe, Mina Hosseinipour, Johnstone Kumwenda, Manish Sagar, **Joseph B. McWhirter**
Research Group: AIDS Clinical Trials Group A5274 (REMEMBER) Study Team
- 299 IMPACT OF THE INTRAUTERINE HIV EXPOSURE ON THE INFANTS VIRUS ANTIBODY REPERTOIRE**
 NIS
Rachael Gachogo, Anna-Ursula Happel, Berenice Alinde, Clive M Gray, Heather Jaspán, Sonwabile Dzanibe
- 300 VIRUS PANEL CLASSIFICATION: A STRATEGY TOWARD DELINEATION OF PLASMA bNAb ACTIVITY**
 NIS
Chloe Pasin, Peter Rusert, Nikolas Friedrich, Merle Schanz, Matthias Glögl, Andri Rauch, Matthias Cavassini, Alexandra Calmy, Hans H. Hirsch, Roger D. Kouyos, Huldrych F. F. Günthard, Alexandra Trkola
Research Group: Swiss HIV Cohort Study
- 301 INFERRING IMMUNOGENIC PROPERTIES OF ENV TRIMERS BY REACTIVITY TO bNAb INDUCER PLASMA**
 NIS
 Irene A. Abela, **Chloe Pasin**, Nikolas Friedrich, Peter Rusert, Merle Schanz, Rogier W. Sanders, Ralf Wagner, Marit J. van Gils, Winfried Weissenhorn, Peter D. Kwong, Huldrych F. F. Günthard, Roger D. Kouyos, Alexandra Trkola
Research Group: Swiss HIV Cohort Study
- 302 GLYCAN-DEFICIENT SHIVS TO ELICIT BROADLY NEUTRALIZING ANTIBODIES IN MACAQUES**
 NIS
Daniel Morris, Hui Li, Shuyi Wang, Jinery Lora, Craig Lauer, Kirsten Sowers, Tongqing Zhou, Peter D. Kwong, George Shaw

303 IDENTIFICATION OF HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES TARGETING MPER

Lauren N. Smith, Gina Donofrio, Rajeshwer Sankhala, Vincent Dussupt, Letzibeth Mendez-Rivera, Bonnie Slike, Nicole Doria-Rose, Victoria Polonis, Sandhya Vasan, Julie A. Ake, Merlin L. Robb, Gordon Joyce, Shelly Krebs

304 NASCENT HIV-1 ENV-REACTIVE bNAb INDUCTION IN SHIV-INFECTED NEONATAL RHESUS MACAQUES

Bhavna Hora, Hui Li, Shaunna Shen, Mitchell Martin, Yue Chen, Madison Berry, Thomas Denny, M. Anthony Moody, Mark Lewis, Kevin Wiehe, Derek Cain, David Montefiori, George Shaw, Wilton B. Williams

305 AUTOLOGOUS NEUTRALIZING ANTIBODIES DEVELOP AFTER EARLY BUT NOT ACUTE ART INITIATION

LB

Greg Whitehill, Ryan Krause, Francesco Marino, Jaimy Joy, Suvadip Mallick, Rebecca Hoh, Steven G. Deeks, Rebecca M. Lynch, Sulggi Lee, Katharine Bar

306 ART-DIX: A NOVEL STRATEGY TO MONITOR BROADLY NEUTRALIZING ANTIBODY ACTIVITY ON ART

NIS

Magdalena Schwarzmüller, Merle Schanz, Irene A. Abela, Selina Epp, Martina Curcio, Peter Rusert, Roger D. Kouyos, Huldrych F. Günthard, Alexandra Trkola

307 EFFICACY AND COMPLEMENTARITY OF HIV-1 SUPPRESSION BY CD4-BINDING bNABs

Sabrina Helmold Hait, Hannah Shrader, Sarah Lovelace, Emily Coates, Ro Shauna Rothwell, Eileen Donaghy, Carl J. Fichtenbaum, Jorge Santana, Rachel Presti, Jhoanna Roa, Anjali Bhatnagar, Rebecca M. Lynch, Pablo Tebas, John R. Mascola, Amarendra Pegu

Research Group: Virology Laboratory, Vaccine Research Center, NIAID, NIH

308 ASSESSING IMMUNOGENICITY BARRIERS OF THE HIV-1 ENVELOPE TRIMER

Nikolas Friedrich, Liridona Maliqi, Matthias Glögl, Peter Rusert, Maryam Zaheri, Chloe Pasin, Stefan Schmutz, Irene A. Abela, Roger D. Kouyos, Huldrych F. Günthard, Marit J. van Gils, Rogier W. Sanders, Ralf Wagner, Andreas Plückthun, Alexandra Trkola

309 ISOLATION OF PAN-SARBEVIRUS mABs THAT NEUTRALIZE SARS-COV-1 AND SARS-CoV-2 VARIANTS

Felicitas Ruiz, Jamie Guenthoer, Michelle Lilly, Vrasha Chohan, Will Foreman, Ashley Taylor, Jesse Bloom, Helen Chu, Tyler Starr, Julie M. Overbaugh

310 BROAD ANTIBODIES TO FUNCTIONALLY CONSTRAINED REGIONS OF SARS-CoV-2 SPIKE

Jamie Guenthoer, Michelle Lilly, Tyler Starr, Bernadeta Dadonaite, Klaus Lovendahl, Jacob Croft, Caitlin Stoddard, Vrasha Chohan, Shilei Ding, Felicitas Ruiz, Andrés Finzi, Jesse Bloom, Helen Chu, Kelly Lee, Julie M. Overbaugh, Mackenzie Kopp

Poster Session-D2 ELITE CONTROLLERS

2:30 PM - 4:00 PM

311 IL-15 DEPENDENT NK CELLS AND DENDRITIC CELLS CROSS-TALK IN HIV-1 ELITE CONTROLLERS

NIS

Ciputra A. Hartana, Ce Gao, Yelizaveta Rassadkina, Mathias Lichterfeld, Xu G. Yuk

312 DISTINCT NK CELL RESPONSES DEFINE DURABLE CONTROL IN ELITE CONTROLLERS

NIS

Nerea Sánchez Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José Miguel Benito, Ezequiel Ruiz-Mateos, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
Research Group: HIV Translational Research Group

313 MONOCYTES OF HIV-1 ELITE CONTROLLERS AND RELATIVES SHOW ENHANCED TRAINED IMMUNITY

Albert L. Groenendijk, Emiliano Dalla, Jelmer H. Van Puffelen, Willem A. J. W. Vos, Marc J. T. Blaauw, Louise E. van Eekeren, Richard M. Dunham, Casper Rokx, Annelies Verbon, Musa M. Mhlanga, Jan van Lunzen, Leo A. B. Joosten, Andre J.A.M. van Der Ven, Mihai G. Netea, **Jéssica C. Dos Santos**
Research Group: 2000HIV

314 TRAINED IMMUNITY FEATURES IN NK CELLS OF HIV-1 ELITE CONTROLLERS

Albert L. Groenendijk, Adriana Navas, Willem A. J. W. Vos, Marc J. T. Blaauw, Louise E. van Eekeren, Mike van Der Kolk, Casper Rokx, Annelies Verbon, Mihai G. Netea, Leo A. B. Joosten, Andre J.A.M. van Der Ven, **Jéssica C. Dos Santos**
Research Group: 2000HIV

315 ELITE CONTROLLERS WITH DISTINCT VIRAL RESERVOIR HAVE ROBUST CTL TO NETWORKED EPITOPES

David Collins, Clarety Kaseke, Umar Urshad, Xiaodong Lian, Bridget Coffey, Daniel Worrall, Alicja Piechocka-Trocha, Micayla George, Benjamin R. Bone, Mathias Lichterfeld, Xu G. Yu, Bruce D. Walker, Gaurav Gaiha

Poster Session-D5 NK CELLS, NEUTROPHILS, AND B CELLS

2:30 PM - 4:00 PM

333 AGING IMPAIRS HIV RESPONSES IN NEUTROPHILS FROM BLOOD AND THE FEMALE GENITAL TRACT

NIS

Laura Moreno de Lara, Anna Borchers, Alexandra Werner, Francisco J. Carrillo-Salinas, Christina Ochsenbauer, Charles R. Wira, Marta Rodriguez Garcia

334 RAPID EXPANSION OF MEMORY NK CELLS IN ACUTE HIV INFECTION WHICH PERSIST DESPITE ART

Anna Hearps, Jingling Zhou, Phuongnhi Ha, Silvia Lee, Patricia Price, Eugene Kroon, Nittaya Phanuphak, Denise Hsu, Paul Agius, Alexandra Schuetz, Sandhya Vasani, Jintanat Ananworanich, Anthony Jaworowski

335 HIERARCHICAL CLUSTERING SHOWS B-CELL PERTURBATIONS INDEPENDENT OF HIV-2 VIRAEMIA

Emil Johansson, Priscilla F. Kerkman, Lydia Scharf, Jacob Lindman, Zsófia I. Szojka, Fredrik Månsson, Antonio Biague, Patrik Medstrand, Hans Norrgren, Marcus Buggert, Annika C. Karlsson, Mattias Forsell, Joakim Esbjörnsson, Marianne Jansson
Research Group: SWEGUB CORE Group

336 EARLY ART TREATMENT PREVENTS B CELL LOSS AND DYSFUNCTION IN PEOPLE LIVING WITH HIV

Samantha Townsley, Yuwadee Phuang-Ngern, Ningbo Jian, David Leggat, Vincent Dussupt, Suteeraporn Pinyakorn, Merlin L. Robb, Suchada Sukhumvittaya, Julie A. Ake, Sandhya Vasani, Denise Hsu, Nittaya Phanuphak, Shelly Krebs, Alexandra Schuetz
Research Group: RV217 and RV254/RV304 study groups

- 337** **NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI**
NIS
Ashley F. George, Tongcui Ma, Min-Gyoung Shin, Reuben Thomas, Mauricio Montano, Satish Pillai, Martin Tolstrup, Ole S. Sogaard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Katherine S. Pollard, Warner C. Greene, Nadia R. Roan
- 338** **CHARACTERIZATION OF TISSUE-RESIDENT NK CELLS IN A TISSUE MODEL OF HIV INFECTION**
NIS
David Perea-Pérez, Nerea Sánchez Gaona, Ana Gallego Cortés, Stefania Landolfi, Félix Pumarola, Núria Ortiz, Juan Lorente, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
Research Group: HIV Translational Research
- 339** **LOW-DENSITY GRANULOCYTES DISPLAY IMMATURE CELLS WITH PRIMED PHENOTYPE IN PLWH**
Juwon Park, Logan Dean, Jack Heckl, Michelle Tallquist, Dominic Chow, Cecilia Shikuma
Research Group: Hawaii Center for AIDS

Poster Session-D6 SARS-CoV-2 IMMUNOPATHOGENESIS

2:30 PM - 4:00 PM

- 340** **NK CELLS ARE CRITICAL FOR IN VIVO CONTROL OF SARS-CoV-2 REPLICATION AND DISEASE**
Harikrishnan Balachandran, Rhianna Jones, Kyle Kroll, Cordelia Manickam, Brady Hueber, Matthew Mosher, Andrew Hudson, Karen Terry, Amanda Martinot, Griffin Woolley, R. Keith Reeves
- 341** **SIGLEC-9 RESTRAINS ANTIBODY-DEPENDENT NK CELL CYTOTOXICITY AGAINST SARS-CoV-2**
Pratima Saini, Samson Adeniji, Devivasha Bordoloi, Jeff Martinson, Danielle M. Parent, Abhijeet Kulkarni, Robert Balk, James N. Moy, Leila Giron, Russell P. Tracy, Ali Keshavarzian, Kar Muthumani, Alan Landay, David B. Weiner, Mohamed Abdel-Mohsen
- 342** **ICAM-1 MEDIATES PLASMACYTOID DENDRITIC CELL SENSING OF SARS-CoV-2-INFECTED CELLS**
Chenrongrong Cai, Tram N. Q. Pham, Eric Cohen
- 343** **POLYFUNCTIONAL SARS-CoV-2-SPECIFIC T CELLS PERSIST IN TISSUE OF COVID-19 CONVALESCENTS**
Kyrlia C. Young, Ashley F. George, Matthew McGregor, Xiaoyu Luo, Rebecca Marquez, Kailin Yin, Tongcui Ma, Trimble Spitzer, Nadia R. Roan
- 344** **HIGH RNAemia ASSOCIATES WITH SKEWED T-CELL RESPONSE IN PLWH HOSPITALIZED FOR COVID-19**
Matteo Augello, Valeria Bono, Roberta Rovito, Camilla Tincati, Silvia Bianchi, Lucia Taramasso, Antonio Di Biagio, Annapaola Callegaro, Franco Maggiolo, Elisa Borghi, Antonella D'Arminio Monforte, Giulia C. Marchetti
- 345** **HIGH-RESOLUTION MAPPING OF T-CELL HYBRID IMMUNITY TO THE ENTIRE SARS-CoV-2 PROTEOME**
Raúl Pérez-Caballero, Laia Bernad, Athina Kilpeläinen, Oscar Blanch-Lombarte, Luis Romero, Ruth Peña, Gabriel Felipe Rodríguez-Lozano, Josep Maria Manresa-Dominguez, Bonaventura Clotet, Alex Olvera, Christian Brander, Eva Maria Martínez Caceres, Concepció Violán, Pere Torán-Monserrat, Julia G. Prado

346 UNIQUE DIFFERENTIATION AND HOMING FEATURES OF T CELLS IN INDIVIDUALS WITH LONG COVID

Kailin Yin, Michael J. Peluso, Reuben Thomas, Jason Neidleman, Xiaoyu Luo, Rebecca Hoh, Scott Lu, Sarah A. Goldberg, Sulggi Lee, Kara Lynch, John D. Kelly, Jeffrey Martin, Steven G. Deeks, Timothy Henrich, Nadia R. Roan

347 LONGITUDINAL CORONAVIRUS ANTIBODY RESPONSES IN AFRICA BETWEEN 2013 AND 2021

Yifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, Bradley Beckman, Thembi Mdluli, Allahna L. Esber, Jonah Maswai, John Owuoth, Hannah Kibuuka, Michael Iroezindu, Emmanuel Bahemana, Kayvon Modjarrad, Sandhya Vasan, Julie A. Ake, Morgane Rolland

348 IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV

NIS

Samuel R. Schnittman, Wonyeong Jung, Kathleen V. Fitch, Markella V. Zanni, Sara McCallum, Jessica Lee, Sally Shin, Brandon J. Davis, Evelynne S. Fulda, Marissa Diggs, Judith S. Currier, Pam S. Douglas, Heather J. Ribaldo, Galit Alter, Steven K. Grinspoon

349 LYMPHOCYTE TRAJECTORIES AND OUTCOMES OF COVID-19 INFECTION IN PEOPLE WITH HIV

Jerry Liu, Richard Medford, **Roger Bedimo**, John Hanna

350 CHRONIC HIV INFECTION IMPACTS THE IMMUNE RESPONSE DURING ACUTE SARS-CoV-2

NIS

Skye Opsteen, Tim Fram, Nathan Erdmann, Dustin M. Long

351 PRIOR SARS-CoV-2 INFECTION PROTECTS AGAINST SYMPTOMATIC COMMON COLD CORONAVIRUSES

David Bean, Janet Monroe, Janice Weinberg, Manish Sagar

352 RESPIRATORY DISEASE FACTORS LINK WITH REDUCED SARS-CoV-2 SUSCEPTIBILITY IN PWH

Irene A. Abela, Anthony Hauser, Chloe Pasin, Magdalena Schwarzmüller, Huldrych F. Günthard, Alexandra Trkola, Roger Kouyos
Research Group: Swiss HIV Cohort Study

353 DELINEATING FACTORS ASSOCIATED WITH ASYMPTOMATIC PRIMARY SARS-CoV-2 INFECTION

Irene A. Abela, Chloe Pasin, Magdalena Schwarzmüller, Agne Ulyte, Radtke Thomas, Audigé Annette, Huber Michael, Berger Christoph, Barbara Hasse, Peter Rusert, Huldrych F. Günthard, Roger Kouyos, Milo Puhan, Kriemler Susi, Alexandra Trkola

354 HIGHER SPIKE GENETIC DIVERSITY OF DELTA/OMICRON VARIANTS IN IMMUNOCOMPROMISED HOSTS

NIS

Romain Coppée, Antoine Bridier-Nahmias, Valentin Leducq, Anna-Maria Franco Yusti, Karen Zafilaza, Eve Todesco, Cathia Soulié, Antoine Fauchois, Quentin Le Hingrat, Anne-Geneviève Marcelin, Vincent Calvez, Charlotte Charpentier, Diane Descamps, Stephane Marot, **Valentine M. Ferré**

Poster Session-E1 CONTROLLERS AND POSTTREATMENT CONTROLLERS
2:30 PM - 4:00 PM
380 CD103 EXPRESSION ON CD8 T CELLS PREDICTS LONGER TIME REBOUND OF HIV AFTER ATI

NIS

Tongcui Ma, Ashley F. George, Min-Gyoung Shin, Mauricio Montano, Satish Pillai, Katherine S. Pollard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Reuben Thomas, Warner C. Greene, Nadia R. Roan

- 381 THE CIRCULATING CELL-FREE DNA METHYLOME PREDICTS HIV POST-TREATMENT CONTROL**
Akshay Gala, Zain Dossani, Perna Dabral, Michael J. Peluso, Steven G. Deeks, Jonathan Z. Li, Satish K. Pillai
- 382 WHICH ENDPOINT TO CHOOSE DURING ANTIRETROVIRAL TREATMENT INTERRUPTION?**
Rodolphe Thiebaut, Marie Alexandre, Mélanie Prague, Yves Levy
Research Group: ANRS 118 ILIADE, ANRS 149 VRI02 LIGHT, ANRS VRI DALIA trials
- 383 PREEXISTING HOST EPIGENETIC STATES ASSOCIATED WITH HIV REBOUND KINETICS**
Michael Corley, Nathalia Mantovani, Leila Giron, Alina Pang, Juliana Galinskas, Danilo Dias, Paulo Ferreira, Gisele Gosuen, James Hunter, Andrea Savarino, Ricardo Diaz, Lishomwa Ndhlovu
- 384 PARTICIPANT EXPERIENCES IN A CURE-DIRECTED LONG-TERM ANALYTIC TREATMENT INTERRUPTION**
Eion Plenn, Frances K. Barg, Katharine Rendle, Andrea Bilger, William B. Carter, Andrea Lamour-Harrington, Christopher Roebuck, Beth Peterson, Pablo Tebas, Karam Mounzer, David Metzger, Luis J. Montaner, Karine Dube
- 385 PLASMA CD33 LEVEL IS A MARKER OF VIRUS CONTROL POST-KICK-AND-KILL CURE INTERVENTION**
NIS
Clara Duran Castells, Anna Prats, Bruna Oriol Tordera, Anuska Llano, Cristina Galvez, Javier Martinez Picado, Ester Ballana, Edurne García-Vidal, Bonaventura Clotet, Jose A. Muñoz Moreno, Tomas Hanke, José Moltó, Beatriz Mothe Pujades, Christian Brander, Marta Ruiz Riol
- 386 COMPREHENSIVE ANALYSIS OF VIRAL RESERVOIRS IN HIV-INFECTED ELITE CONTROLLER**
NIS
Brooke D. Kennedy, Jana Blazkova, J. Shawn Justement, Victoria Shi, M. Ali Rai, Maegan R. Manning, Lauren Praiss, Kathleen Gittens, Paul A. Wender, Sean C. Patro, Xiaolin Wu, Susan Moir, Tae-Wook Chun
- 387 PREDICTORS OF HIV REBOUND AFTER INTERRUPTION OF ART STARTED DURING PRIMARY INFECTION**
Antoine Chaillon, Caroline Ignacio, Merle Schanz, Tingting Yu, Rui Wang, Roger D. Kouyos, Gemma Caballero, Noah Gaitan, Stephen Rawlings, Celsa Spina, Herbert Kuster, Karin Metzger, Huldrych F. Günthard, Davey M. Smith, Sara Gianella Weibel

Poster Session-E2 DYNAMICS OF THE HIV RESERVOIR

2:30 PM - 4:00 PM

- 388 SHORT- AND LONG-TERM DYNAMICS OF SIV-INFECTED CELL POPULATIONS ON ART**
Emily Fray, Fengting Wu, Francesco R. Simonetti, Carolin Zitzmann, Narmada Sambaturu, John Ventura, Thomas Leitner, Ruy Ribeiro, Alan S. Perelson, Dan Barouch, Janet M. Siliciano, Robert F. Siliciano
- 389 PRESENTATION OF COGNATE ANTIGENS BY DENDRITIC CELLS CAUSES STOCHASTIC HIV EXPRESSION**
NIS
Milica Moskovljevic, Filippo Dragoni, Hao Zhang, Fengting Wu, Nathan L. Board, Jun Lai, Rebecca Hoh, Steven G. Deeks, Luis J. Montaner, Janet M. Siliciano, Robert F. Siliciano, Francesco R. Simonetti
- 390 STABILITY AND INSTABILITY OF THE CELLULAR HIV RESERVOIR AFTER REBOUND DURING ATI**
Vincent Wu, Jayme Nordin, Son Nguyen, Katharine Bar, Laura Vella, Michael R. Betts

- 391 LACK OF DETECTABLE ONGOING REPLICATION ON ART IN SIV-INFECTED RHESUS MACAQUES**
Taina T. Immonen, Christine M. Fennessey, **Brandon F. Keele**
- 392 SLOWING OR REVERSAL OF DECAY OF INTACT PROVIRUSES OVER 2 DECADES OF SUPPRESSIVE ART**
Rajesh T. Gandhi, Ronald J. Bosch, Hanna Mar, Gregory M. Laird, Elias K. Halvas, Laura Hovind, Ann C. Collier, Sharon A. Riddler, Kristen Ritter, Deborah K. McMahon, Joseph J. Eron, Joshua C. Cyktor, John W. Mellors
Research Group: AIDS Clinical Trials Group A5321 Team
- 393 DIFFERENTIAL TRANSCRIPTION LEVELS OF HIV-1 FULL-LENGTH AND HIGHLY DELETED PROVIRUSES**
Thuy Thi Thu Nguyen, Lindsey Adams, Mary-Elizabeth Zipparo, Annie Glassey, Erin Madeen, Ulisses Santamaria, Catherine Rehm, Jessica Earhart, Wei Shao, Chuen-Yen Lau, Frank Maldarelli
- 394 HUMAN GALECTIN-9 PROMOTES THE EXPANSION OF HIV RESERVOIRS IN VIVO IN HUMANIZED MICE**
Zhe Yuan, Leila Giron, Colin Hart, Kwasi Gyampoh, Jane Koshy, Kai Ying Hong, Toshiro Niki, Thomas Premeaux, Lishomwa Ndhlovu, Luis J. Montaner, Mohamed Abdel-Mohsen
- 395 HIV-1 CLADE C RESERVOIR CHARACTERISTICS IN EARLY AND CHRONIC TREATED INFECTION**
Kavidha Reddy, Guinevere Q. Lee, Nicole Reddy, Tatenda J. Chikowore, Krista Dong, Bruce D. Walker, Xu G. Yu, Mathias Lichterfeld, Thumbi Ndung'u
- 396 PERSISTENCE OF INDUCIBLE REPLICATION-COMPETENT HIV-1 AFTER LONG-TERM ART**
NIS
Natalie F. McMyn, Joseph Varriale, Jun Lai, Anushka Singhal, Mauro A. Garcia, Vivek Hariharan, Brianna Lopez, Robert F. Siliciano, Janet M. Siliciano
- 397 IN-DEPTH TRANSCRIPTOMIC ANALYSIS OF THE TRANSLATION-COMPETENT HIV-1 RESERVOIR**
NIS
Marion Pardons, Basiel Cole, Laurens Lambrechts, Willem van Snippenberg, Sofie Rutsaert, Ytse Noppe, Nele De Langhe, Annemieke Dhondt, Jerel Vega, Erik Nijs, Ellen Van Gulck, Daniel Boden, Linos Vandekerckhove

Poster Session-E7 MECHANISMS OF HIV LATENCY**2:30 PM - 4:00 PM**

- 438 DIFFERENTIATION ENHANCES REACTIVATION OF HIV-1 IN CD4+ T CELLS AFTER LONG-TERM ART**
Yury V. Kuzmichev, Krupa Subramanian, Sonia Bakkour, Carol Lackman-Smith, Mars Stone, Christina H. Mallarino-Haeger, Roger G. Ptak, Michael P. Busch, Elizabeth R. Wonderlich, Deanna A. Kulpa
- 439 A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV**
Zichong Li, Melanie Ott, Warner C. Green
Research Group: The HOPE Collaboratory
- 440 CCNT1 IS A NONESSENTIAL GENE IN JURKAT T CELLS REQUIRED FOR HIV RELEASE FROM LATENCY**
Terry L. Hafer, Emily Hsieh, Carley Gray, Michael Emerman

- 441 ncRNA PROFILE IN EXTRACELLULAR VESICLES REVEALS A POTENTIAL MECHANISM OF HIV-CONTROL**
 Maria A. Navarrete-Muñoz, Ignacio Maillou, Héctor Peinado, Ricardo Ramos, María L. García-Gil, Alfonso Cabello, Miguel Górgolas, José M. Benito, **Norma Rallón**
- 442 c-Myc AND NR4A REGULATE STOCHASTIC REACTIVATION OF LATENT HIV-1**
NIS
Rajiv Pathak, Annalena La Porte, Carolina Eliscovich, Estah L. Bock, Laura J. Martins, Adam Spivak, Masako Suzuki, Vicente Planelles, Robert H. Singer, Ganjam V. Kalpana
- 443 HIV TEM-SEQ: TARGETED ENZYMATIC METHYLATION SEQUENCING OF HIV-1 PROVIRUSES**
Alina Pang, Lishomwa Ndhlovu, Michael Corley
- 444 EX-VIVO IMPACT OF LRAs AND SPECIFIC LIGANDS ON ESTROGEN RECEPTOR IN CD4+ T CELLS**
NIS
Cristina Ceriani, Anthony Abeyta-Lopez, Kena J. Lemu, Brigitte Allard, Katherine S. James, David Margolis, Nancie Archin
- 445 ENHANCED HIV-INDUCED LINEAGE TRACING REPORTER SYSTEM REVEALS EARLY LATENCY PHENOTYPE**
Don Nguyen, Namita Satija, Tia Robinson, Gerrit Schmidt, Foramben Patel, Benjamin K. Chen
- 446 TARGETING 2 NEUTRAL SPHINGOMYELINASE 2 PROMOTES DEATH OF HIV-INFECTED CELLS**
 Seung-Wan Yoo, Abdul A. Waheed, Pragny Deme, Rana Rais, Ajit Thomas, Matthew D. Smith, Peter A. Calabresi, Eric O. Freed, Barbara S. Slusher, **Norman J. Haughey**
- 447 DPP9 INHIBITION ENHANCES NNRTI-MEDIATED CLEARANCE OF HIV-1 LATENT RESERVOIRS**
NIS
Kolin Clark, Josh Kim, Qiankun Wang, Liang Shan
- 448 INTERLEUKIN-2-INDUCIBLE T-CELL KINASE (ITK) INHIBITION PREVENTS HIV LATENCY REVERSAL**
NIS
Prerna Dabral, Li Du, Mohamed Bouzidi, Richard Miller, Steven G. Deeks, Satish K. Pillai

Poster Session-F1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV **2:30 PM - 4:00 PM**

- 460 COGNITIVE TRAJECTORIES AMONG PEOPLE WITH HIV MODELED BEFORE AND AFTER SUSTAINED ART**
Robert Paul, Jacob Bolzenius, Peter Brandes, Eduardo Ruiz, Cecilia Correa, Kevin Robertson, Ann Duerr
- 461 THE COURSE OF NEUROCOGNITIVE PERFORMANCE OVER FOUR YEARS IN WELL-TREATED PLWH**
LB
José Damas, Bruno Ledergerber, Mélanie Bieler-Aeschlimann, Philip Tarr, Marcel Stöckle, Hachfeld Anna, Alexandra Calmy, Frédéric Assal, Patrick Schmid, Thomas Hundsberger, Caroline Di Benedetto, Barbara Hasse, Renaud Du Pasquier, Katherine Darling, Matthias Cavassini
Research Group: Swiss HIV Cohort Study
- 462 NEUROCOGNITIVE IMPAIRMENT NEGATIVELY AFFECTS VIRAL CONTROL IN ART-TREATED PWH**
Mattia Trunfio, Elisa Vuaran, Daniela Vai, Alessandro Di Stefano, Daniele Imperiale, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno

463 ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS

Nicholas Bakewell, Caroline Sabin, Patrick Mallon, Memory Sachikonye, Nicki Doyle, **Alan Winston**, Ken M. Kunisaki

Poster Session-F2 INTERPLAY BETWEEN VASCULAR AND NERVOUS SYSTEM FUNCTION IN HIV**2:30 PM - 4:00 PM****464 VASCULAR AGE AND COGNITIVE OUTCOMES IN AN ACUTE HIV COHORT AFTER 6 YEARS OF ART**

Kathryn Holroyd, Carlo Sacdalan, Suteeraporn Pinyakorn, Varaporn Unsombut, Somchai Sriplienchan, Robert Paul, Nittaya Phanuphak, Denise Hsu, Sandhya Vasan, Serena Spudich, **Phillip Chan**

Research Group: RV254/SEARCH 010 Study Team

465 NON-CLASSICAL MONOCYTES CORRELATE NEGATIVELY WITH HIV-ASSOCIATED COGNITIVE IMPAIRMENT

Meera Singh, Md Nasir Uddin, Mae Covacevich, Zachary Boodoo, Karli Sutton, Angelique Johnson, Madalina Tivarus, Henry Wang, Bogachan Sahin, Jianhui Zhong, Miriam Weber, Xing Qiu, Sanjay Maggirwar, Giovanni Schifitto

466 COCAINE USE INDEPENDENTLY PREDICTS WHITE MATTER LESION BURDEN IN HIV DISEASE

Christina Meade, Ryan Bell, Sheri Towe, Christopher Lascola

467 EXTRACELLULAR VESICLES IN ALWH PROMOTE CEREBRAL ENDOTHELIAL PROFILES LINKED TO STROKE

NIS

Hannah Fandl, Vinicius Garcia, Kelly Stockelman, William Hollenbach, John Treuth, Auburn Berry, Hannah Cardenas, Noah Desouza, Cynthia Firnhaber, Jared Greiner, Brian Stauffer, Elizabeth Connick, Christopher Desouza

468 NEUROFILAMENT LIGHT IS ASSOCIATED WITH CARDIORESPIRATORY AND METABOLIC HEALTH IN HIV

Sarah Cooley, Beau Ances

Poster Session-F3 ANTIRETROVIRAL EFFECTS ON CENTRAL NERVOUS SYSTEM OUTCOMES**2:30 PM - 4:00 PM****469 EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV**

NIS

Luis Parra-Rodriguez, Jane O'Halloran, Yuezhe Wang, Raha M. Dastgheyb, Amanda B. Spence, Anjali Sharma, Deborah Gustafson, Joel Milam, Kathleen Weber, Adaora Adimora, Igho Ofofokun, Margaret Fischl, Deborah Konkle-Parker, Yanxun Xu, Leah H. Rubin

470 DTG IMPACTS ZEBRAFISH BEHAVIOUR THROUGH DOPAMINERGIC PATHWAYS: RESCUE BY FOLATE

NIS

Daniela Zizioli, Sara Ferretti, Luca Mignani, **Samuele Storti**, Isabella Zanella, Francesco Castelli, Eugenia Quiros-Roldan

471 DOLUTEGRAVIR IS ASSOCIATED WITH MORE DEPRESSIVE SYMPTOMS IN OLDER PEOPLE WITH HIV

Upal Roy, Asante R. Kamkwala, Avery. Matthews, Ankita Garg, David B. Clifford, Benjamin Gelman, Susan Morgello, Payal Patel, Leah H. Rubin, Donald Franklin, Erin Sundermann, Robert K. Heaton, Ronald J. Ellis, Scott L. Letendre

Poster Session-F8 POST-ACUTE NERVOUS SYSTEM SEQUELAE OF COVID-19 IN PEOPLE WITH AND WITHOUT HIV

2:30 PM - 4:00 PM

- 492 POST-COVID COGNITIVE IMPAIRMENT MRI BRAIN SCAN ABNORMALITIES: A POTENTIAL BIOMARKER**
 Joga Chaganti, Lucette Cysique, Xin Zhang, Benjamin Heng, David Darley, Anthony Byrne, Chansavath Phetsouphanh, Anthony D. Kelleher, Gregory Dore, Gail Matthews, Gilles Guillemin, **Bruce Brew**
Research Group: St Vincent's Centre for Applied Medical Research
- 493 COGNITIVE, MOTOR, & NEGATIVE VALENCE SYSTEMS IN NEUROLOGIC PASC: A PRELIMINARY STUDY**
Lindsay S. McAlpine, Raha M. Dastgheyb, Jennifer Chiarella, Robert K. Fulbright, Todd Constable, Cheryl Lacadie, Jennifer Yoon, Hailey Reisert, Shelli Farhadian, Serena Spudich, Leah H. Rubin
Research Group: The COVID Mind Study
- 494 CHARACTERISTICS AND OUTCOMES OF COVID-19 IN AN EARLY-TREATED HIV COHORT IN THAILAND**
Ferron F. Ocampo, Misti Paudel, Carlo Sacdalan, Suteeraporn Pinyakorn, Suwanna Puttamaswin, Somchai Sriplienchan, Robert Paul, Nittaya Phanuphak, Phillip Chan, Denise Hsu, Serena Spudich
Research Group: RV254/SEARCH010 Study Team
- 495 TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV**
Alisha Dziarski, Nuria Gallego Marquez, Armaan Jamal, Samantha N. Walch, Arianna Romero, Mariana Araújo-Pereira, Artur T L Queiroz, Christina Bunch, Ashley Zelaya, Enam Akasreku, Bruno B. Andrade, Michael J. Peluso, Alan Landay, Tracy Vannorsdall, Annukka A R. Antar
- 496 INFLAMMATORY AND BLOOD-BRAIN BARRIER MARKERS AFTER COVID-19 AMONG PEOPLE WITH HIV**
Daniel Adesse, Maria L. Alcaide, Deborah Jones Weiss, Michal Toborek

Poster Session-G1 IMPORTANT ISSUES IN CLINICAL PHARMACOLOGY

2:30 PM - 4:00 PM

- 497 MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPPRESSED PWH**
Ryan Vargo, Seth Robey, Xiaowei Zang, Lihong Du, Bhargava Kandala, Jessica Roberts, Stephanie O. Klopfer, Kathleen E. Squires
- 498 ESTRADIOL CONCENTRATIONS IN TRANS WOMEN ON InSTIs COMPARED TO THOSE WITHOUT HIV**
Mona Loutfy, Ashley Lacombe-Duncan, Yasmeen Persad, Ian Armstrong, Raymond Fung, Kimberly K. Scarsi, Alice Tseng, Louie Chan, Quang Nguyen, Thea Weisdorf, Sue Hranilovic, Roberta Halpenny, Nirubini Jeyarajah, George Kovchazov, Harshita Iyer
- 499 N6LS WITH rHuPH20 ENABLES SAFE HIGH-DOSE MONOCLONAL ANTIBODY SUBCUTAENOUS DELIVERY**
Richard Wu, Katherine Houser, Myra Happe, Martin Gaudinski, Seemal Awan, Alicia Widge, Lasonji Holman, Jamie Saunders, Christian Buettner, Bob Lin, Mike Castro, Edmund Capparelli, Robert Seder, Richard A. Koup, Lesia Dropulic
Research Group: VRC 609 Study Team
- 500 TFV-DP & FTC-TP IN BLOOD CELL SUBSETS OF PERSONS WITH HIV**
Vincent A. Mainella, Jose R. Castillo Mancilla, Brian Branchford, Travis Nemkov, Seth Hosford, Bethany Johnson, Ye Ji Choi, Pang Xiong, Martin Williams, Jia-Hua Zheng, Lucas Ellison, Lane Bushman, Jennifer Kiser, Peter L. Anderson, Kristina M. Brooks

- 501 IN SILICO PHARMACOKINETICS EVALUATION OF FORGIVENESS FOR DORAVIRINE & RILPIVIRINE**
Yeleen Fromage, Najwa Jamal, Cyrielle Codde, Jean-François Faucher, **Jean-Baptiste Woillard**
- 502 SCREENING APPROACHES AND CLINICAL DESCRIPTION OF THE ANTICHOLINERGIC BURDEN IN PWH**
Maria Mazzitelli, Mattia Trunfio, Alessandra Coin, Lolita Sasset, Jacopo Farina, Monica Brundu, Vincenzo Scaglione, Giuseppe Sergi, Anna Maria Cattelan
- 503 PHARMACOKINETICS & SAFETY OF SUSTAINED-RELEASE FLUCYTOSINE PELLETT FORMULATION**
Edrich Krantz, Francois Simon, Jean-Yves Gillon, Amaria Saayman, Anouk Neven, Stephen Robinson, Johanna Eriksson, Sarika Victor, Carol Ruffell, Aljosa Celebic, Henri Caplain, Mathieu Louis, **Vishal Goyal**, Isabela Ribeiro
Research Group: 5FC-HIV-CRYPTO Consortium
- 504 POPULATION PK ANALYSIS TO GUIDE DOSING WINDOW FOLLOWING LENACAPAVIR SC ADMINISTRATION**
Naveed A. Shaik, Francesco Bellanti, Craig Comisar, Martin S. Rhee, Sandhya Girish, Ramesh Palaparthy, Renu Singh

Poster Session-H3 ANTIRETROVIRAL THERAPY: OBSERVATIONS FROM COUNTRIES, CLINICS, AND PWH

2:30 PM - 4:00 PM

- 528 HIGH SUPPRESSION AMONG PLHIV ON DOLUTEGRAVIR WITH VIROLOGICAL FAILURE IN UGANDA**
Grace Namayanja, Juliana de Fatuma Da Silva, Elur Bill, Pamela Nasirumbi Muniina, Elliot Raizes, Julius Ssempira, Esther Nazziwa, Miriam Nabukenya, Jennifer Balaba, Ntale Jonathan, Jackie Calnan, Estella Birabwa, Juliet Akao, Christina Mwangi, Emilio Dirlikov
- 529 EARLY VIROLOGICAL OUTCOME OF DTG-BASED REGIMEN IN ADULT ARV-NAIVE PLHIV IN RWANDA**
Simeon Tuyishime, Bienvenu Niyongabo, Michel Gasana, Madeleine M. Uwungutse, Damascene J. Nirere, Benjamin Bizimana, Gallican N. Rwibasira, Samuel Malamba
- 531 TRENDS IN TDR TO FIRST-LINE ANTIRETROVIRALS IN SPAIN: 2007-2021**
Laura Viñuela, Adolfo de Salazar, Ana Fuentes, Adriana Pinto, José Antonio Iribarren, Mar Masiá, **Marta Montero**, Iker Falces-Romero, Nuria Espinosa, Begoña Baza, Antonio Aguilera, Joaquim Peraire, Rebeca de Miguel, Federico Garcia
Research Group: CoRIS group
- 532 WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE?**
Paul Sax, Joseph J. Eron, Janna Radtchenko, Megan Dunbar, Joshua Gruber, Moshe Fridman, Moti Ramgopal, Karam Mounzer, Gregory Huhn, Steven Santiago, Richard A. Elion
- 533 ASSOCIATION OF WEIGHT GAIN ON DOLUTEGRAVIR WITH CHANGES IN ADHERENCE AND VIRAL LOAD**
Matthew L. Romo, Ajay Parikh, Allahna L. Esber, Joseph S. Cavanaugh, Susannah Colt, Emma Duff, Trevor A. Crowell, Valentine Sing'Oei, John Owuoth, Jonah Maswai, Michael Iroezindu, Emmanuel Bahemana, Hannah Kibuuka, Neha Shah, Julie A. Ake
- 534 PREDICTIVE VALIDITY OF A MEASURE OF BARRIERS TO ART ADHERENCE FOR HIV CARE (I-SCORE)**
Kim Engler, Serge Vicente, David Lessard, Karine Lacombe, Dominic Chu, Hayette Rougier, Lucas Delvallez, Jean-Pierre Routy, Alexandra De Pokomandy, Marina Klein, **Bertrand Lebouché**

- 535 US PATIENT PREFERENCES FOR LONG-ACTING HIV TREATMENT: A DISCRETE CHOICE EXPERIMENT**
Susan M. Graham, Douglas Barthold, Brett Hauber, Aaron Brah, Enrique Saldarriaga, Ann C. Collier, Rodney Ho, Vincent C. Marconi, Jane Simoni
Research Group: Emory PREFER Team
- 536 ANTIRETROVIRAL THERAPY CONCEALMENT, ADHERENCE, AND PREFERENCES IN PEOPLE WITH HIV**
Christina E. Parisi, Rebecca Fisk-Hoffman, Nanyangwe Siuluta, Delaney D. Ding, Maya Widmeyer, Charurut Somboonwit, Robert L. Cook
Research Group: Southern HIV and Alcohol Research Consortium
- 530 VIROLOGIC FAILURE AFTER ROUTINE SWITCHING TO DTG-BASED FIRST-LINE ART**
LB
Veronika Whitesell, Jaqueline Huwa, Geldert Chiwaya, Shameem Buleya, Joseph Chintedza, Thokozani Kalua, Guy Muula, Esau Banda, Belinda Chihota, Carolyn Bolton Moore, Stefanie Hossmann, Roger D. Kouyos, Richard Lessells, Gilles Wandeler, Matthias Egger

Poster Session-H5 NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES
2:30 PM - 4:00 PM

- 542 ZINC ADJUVANT TREATMENT IN SARS-CoV-2: A RANDOMIZED CLINICAL TRIAL**
Silvia Gómez-Zorrilla, Juan Du, Elena Sendra, Merce Espona, Ana Siverio, Alicia Rodríguez-Alarcon, Claudia Navarro-Valls, Oriol Rins-Lozano, Esperanza Cañas-Ruano, Itziar Arrieta-Aldea, Alejandro Fierro-Villegas, Cristina Plata, Natalia Garcia-Giralt, Ruben Vicente,
Robert Guerri-Fernandez
- 543 RETHINKING REMDESIVIR: ENHANCING ANTI-SARS-CoV-2 ACTIVITY OF ORAL LIPID RVn PRODRUGS**
Aaron Carlin, James Beadle, Alex Clark, Kendra Gully, Fernando Moreira, Ralph Baric, Rachel Graham, Nadejda Valiaeva, Sandra Leibel, William Bray, Rachel McMillan, Xing-Quan Zhang, Joyce Murphy, Robert Schooley, Karl Hostetler
- 544 SARS-CoV-2 ANTIVIRAL ACTIVITY OF ZOTATIFIN, A HOST-TARGETING EIF4A INHIBITOR**
Sam Sperry, Peggy Thompson, Craig Stumpf, Gary Chiang, Stephen Worland, **Amy Patick**
- 545 A PHASE 1B STUDY OF ZOTATIFIN FOR THE TREATMENT OF MILD TO MODERATE COVID (PROpel)**
Harry Malech, Almena Free, Enola Okonkwo, Patricia Littel, Nicole Rooths, Priscilla Quackenbush, Martha Marquesen, Michael Hodges, Amy Patick, Sam Sperry, Bin Yao, Nawaid Rana,
Doug Warner

546

WITHDRAWN

- 547 SMALL MOLECULE INHIBITOR FOR BLOCKING SARS-CoV-2 ENTRY**
Enming Xing, Yuexiu Zhang, Rajni Kant Shukla, Jianrong Li, Valarmathy Murugaiah, Xiaolin Cheng, Pui Kai Li, Amit Shama
Research Group: The Ohio State University
- 548 PLITIDEPSIN IS A BROAD-SPECTRUM ANTIVIRAL SHAPING THE CELL PROTEOSTATIC BALANCE**
Daniel Perez-Zsolt, Elisa Molina Molina, Joan Josep Bech-Serra, Roger Badia, Eva Riveira-Muñoz, Sachse Martin, Sandra Franco, Pablo Avilés, Miguel A. Martinez, Roger Paredes, Bonaventura Clotet, Cristina Risco, Ester Ballana, Carolina De la Torre, Nuria Izquierdo-Useros
Research Group: Broad-Spectrum Antivirals Study Group

- 549 TARGETING THE HOST-VIRUS INTERFACE TO BLOCK SARS-CoV-2 ASSEMBLY IN AIRWAY CELLS**
Li Du, Fred Deiter, Mohamed Bouzidi, Jean-Noël Billaud, Graham Simmons, Prerna Dabral, Suganya Selvarajah, Anuradh Lingappa, Maya Michon, Shaofeng Yu, Kumar Paulvannan, Vishwanath Lingappa, Homer Boushey, John Greenland, Satish K. Pillai
- 550 SAFETY AND PHARMACOKINETICS OF A NOVEL DOUBLE PRODRUG ASC10 IN HEALTHY SUBJECTS**
 Yunqing Qiu, Jian Liu, You Zhai, Qingwei Zhao, Yuemei Yan, Handan He, **Jinzi J. Wu**
- 551 MECHANISM AND RESISTANCE STUDIES OF SARS-CoV-2 MPRO INHIBITOR POMOTRELVIR (PBI-0451)**
Xiao Tong, Laura Stevens, Walter Keung, Lee Arnold, Uri Lopatin, Mark Denison, Ann Kwong
- 552 SARS-CoV-2 E-PROTEIN VIROPORIN INHIBITOR BIT225 ACTIVE IN hACE2 TRANSGENIC MICE**
Michelle Miller, Gary Ewart, Michael Bobardt, Bo Bentzen, Audrey Thomson, Klaus Klumpp, Stephen Becker, Mette Rosenkilde, Gallay Philippe

Poster Session-H6 CAN ANTIVIRAL AGENTS PREVENT SARS-CoV-2 TRANSMISSION?

2:30 PM - 4:00 PM

- 553 NAFAMOSTAT AS NASAL CHEMOPROPHYLAXIS FOR SARS-CoV-2 IN HAMSTERS**
Megan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, Joanne Herriott, Edyta Kijak, Chloe Bramwell, Helen Cox, Lee Tatham, Paul Curley, James Hobson, Steve Rannard, Anja Kipar, James Stewart, Andrew Owen
Research Group: CELT Pharmacology
- 554 PHASE 1 CLINICAL TRIALS OF A Q-GRIFFITHSIN NASAL SPRAY FOR SARS-CoV-2 PROPHYLAXIS**
Henry W. Nabeta, Maryam Zahin, Amanda Lasnik, Elizabeth D. Cash, Xiaoyong Wu, Shesh Rai, Kathleen Kitterman, Lin Wang, Sravan Patel, Lisa Rohan, Sharon L. Hillier, Nobuyuki Matoba, Kevin L. Potts, Gerald Dryden, Kenneth E. Palmer
- 555 NIRMATRELVIR AND MOLNUPIRAVIR COADMINISTRATION MODIFIES PRECLINICAL VIRAL EXPOSURE**
Lee Tatham, Henry Pertinez, Megan Neary, Joanne Sharp, Edyta Kijak, Joanne Herriott, Anthony Valentijn, Chloe Bramwell, Helen Cox, Paul Curley, Usman Arshad, Rajith Rajoli, Richard Pleass, James Stewart, Andrew Owen
Research Group: Drugs for Neglected Diseases initiative (DNDi) Study Group

Poster Session-I2 HIV RESISTANCE TO NEUTRALIZING ANTIBODIES

2:30 PM - 4:00 PM

- 580 SUSCEPTIBILITY SCREENING TO bNAbs GS-5423 AND GS-2872 IN ART-SUPPRESSED PARTICIPANTS**
Lisa Selzer, Laurie A. Vanderveen, Aiyappa Parvangada, Ross Martin, Sean E. Collins, Megha L. Mehrotra, Christian Callebaudy

- 581 PHENOTYPIC SUSCEPTIBILITY TO VRC07-523LS AND ITS CORRELATES IN THE ACTG A5357 STUDY**
Babafemi Taiwo, Jackie Reeves, Yu (Evelyn) Zheng, Yolanda Lie, Leah Burke, Lucio Garma, Christos J. Petropoulos, Pablo F. Belaunzaran-Zamudio, Richard A. Koup, Parita Rathod, Jennifer Tiu, Jenifer Baer, Jennifer Kiser, Michael Dorosh, Katherine Bar, Pablo Tebas
Research Group: AIDS Clinical Trials Group
- 582 HIGH PREDICTED bNAb RESISTANCE AMONG ADULTS WITH HIV-1 SEROCONVERSION IN BOTSWANA**
Natasha O. Moraka, Wonderful T. Choga, Irene Gobe, Margaret Mokomane, Moses K. Chawawa, Nametso Kelentse, Ontlametse T. Bareng, Molly Pretorius Holme, Terence Mohammed, Roger L. Shapiro, Joseph Makhema, Shahin Lockman, Vladimir Novitsky, Sikhulile Moyo, Simani Gaseitsiwe

Poster Session-J5 STEATOSIS AND STEATOHEPATITIS

2:30 PM - 4:00 PM

- 609 PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV**
Louise E. van Eekeren, Marc J. T. Blaauw, Nadira Vadaq, Vasiliki Matzaraki, Wilhelm A. J. W. Vos, Albert L. Groenendijk, Adriana Navas, Gert Weijers, Mike van Der Kolk, Andre J.A.M. van Der Ven, Quirijn De Mast, Leo Joosten, Eric Tjwa
Research Group: 2000HIV
- 610 LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE**
Cecile D. Lahiri, Michael Yu, Logan Gerig, Cyra C. Mehta, Joffi Musonge-Effoe, Jennifer C. Price, Phyllis C. Tien, Amanda B. Spence, Svenja Albrecht, Maria L. Alcaide, Adaora Adimora, Audrey French, Michael H. Augenbraun, Kathryn Anastos, Jessica A. Alvarez
- 611 NIS SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE**
Dana Kablawi, Thierry Fotsing Tadjio, Jovana Milic, Wesal Elgretli, Claudia Goe, Bertrand Lebouché, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola, Giada Sebastiani
- 612 NIS NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV**
Win Min Han, Tanakorn Apornpong, Jedsadakorn Bonrungrisirap, Thanathip Wichiangsan, Hay Mar Su Lwin, Sivaporn Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsanon
- 613 AUTOMATED LIVER ATTENUATION ASSESSMENT FOR STEATOSIS IN CLINICAL IMAGES BY HIV STATUS**
Jessie Torgersen, Scott Akers, Yuankai Huo, James G. Terry, John J. Carr, Alexander T. Ruutiainen, Joseph K. Lim, Kaku So-Armah, Debika Bhattacharya, Li Shen, Rotonya M. Carr, Russell M. Shinohara, Michele McClain, Matthew Freiberg, Amy C. Justice
Research Group: Veterans Aging Cohort Study
- 614 CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD**
Wesal Elgretli, Nathalie Paisible, Cecilia Costiniuk, Joseph Cox, Dana Kablawi, Marina Klein, Nadine Kronfli, Jean-Pierre Routy, Julian Falutz, Giovanni Guaraldi, Bertrand Lebouché, **Giada Sebastiani**

615 CAP AND METABOLIC PROFILE WORSENING POST-SVR IN HCV/HIV PEOPLE AS A SIGN OF STEATOSIS

NIS

Alessia Siribelli, Daniele Ceccarelli, Laura Galli, Giulia Morsica, Riccardo Lolatto, Costanza Bertoni, Antonella Castagna, Caterina Uberti Foppa, Hamid Hasson

616 PERFORMANCE OF SEROLOGICAL SCORES FOR LIVER STEATOSIS AMONG PEOPLE LIVING WITH HIV

NIS

Carlotta Riebensahm, Julia Brocker, Annalisa Berzigotti, Bernard Surial, Huldrych F. F. Günthard, Philip Tarr, Hansjakob Furrer, Andri Rauch, Gilles Wandeler

Poster Session-K3 KAPOSI SARCOMA AND KHSV-RELATED DISEASES: PATHOGENESIS AND TREATMENT

2:30 PM - 4:00 PM

630 RATIONALE FOR THE USE OF PACRITINIB IN KSHV-MULTICENTRIC CASTLEMAN DISEASE

Yiquan Wu, Victoria Wang, Robert Yarchoan

631 IFN-IL18 AXIS CYTOKINES DISCERN MYCOBACTERIAL AND KSHV INFLAMMATORY SYNDROMES IN PWH

NIS

Joseph Rocco, Ramya Ramaswami, Kathryn Lurain, Elizabeth Laidlaw, Andrea Lisco, Frances Galindo, Adam Rupert, Denise Whitby, Maura Manion, Robert Yarchoan, Irini Sereti

632 STUDY OF CHARACTERISTICS AND OUTCOMES OF KSHV INFLAMMATORY CYTOKINE SYNDROME (KICS)

Ramya Ramaswami, Kathryn Lurain, Mark Polizzotto, Anaida Widell, Ralph Mangusan, Irene Ekweide, Tishiya Carey, Crystal Lu, Jomy George, Denise Whitby, Thomas Uldrick, Robert Yarchoan

633 KAPOSI SARCOMA IN ART-TREATED PLWH: DISTINCT VIRAL AND IMMUNE CHARACTERISTICS

NIS

Léna Royston, Stephane Isnard, Aude Jarry, Carolina Berini, Tsoarello Mabanga, John Lin, Valentin Leducq, Vincent Calvez, Anne-Geneviève Marcelin, Jean-Pierre Routy

Poster Session-K4 CERVICAL CANCER: SCREENING AND TREATMENT

2:30 PM - 4:00 PM

634 IMPLICATIONS OF CERVICAL CANCER SCREENING AND TREATMENT PROGRAM ROLL OUT IN UGANDA

Josephine C. Ninsiima, Julius Namonyo Kalamya, Ibrahim Lutalo, Joseph Kabanda, Evelyn Akello, Alice Namale, Mina Ssali, Simon Muhumuza, Rhoda Wanyenze, Emilio Dirlikov, Sarah Alger

635 INTEGRATING POINT-OF-CARE HPV TESTING INTO HIV CARE FOR KENYAN WOMEN LIVING WITH HIV

James Kangethe, John Kinuthia, Kenneth Mutai, Jillian Pintye

636 PROGRESS TOWARDS THE ELIMINATION OF CERVICAL CANCER AMONG WOMEN LIVING WITH HIV

Laura J. McCormick Viens, Catherine Godfrey, Oluwatosin Adeoye, Ismael Ahmed, Fana Tefera, Michele Montandon, Elizabeth Carter, Michelle Chevalier, Daniel Magesa, Timothy A. Efuntoyey, Emily Coard, Catherine Motswere Chirwa, Julius Namonyo Kalamya, Jessica Setswalo Mafa, Brigitte Zemburuka

637 HUMAN PAPILLOMA VIRUS INFECTION PREVALENCE AMONG WOMEN LIVING WITH HIV IN ETHIOPIA

Fana Tefera, Ismael Ahmed, Yared Tedla, Hiwot Berhanu, Daniel Atnafu, Agraw Abdulkadir, Addis Zewdie, Dessie Adugna, Takelech Moges, Daniel M. Desalegn, Hezekiel Petros

Poster Session-L1 PLAQUE**2:30 PM - 4:00 PM****646 CORONARY ARTERY PLAQUE COMPOSITION AND SEVERITY RELATE TO THE INFLAMMASOME IN HIV**

NIS

Samuel R. Schnittman, Douglas Kitch, Talia H. Swartz, Tricia H. Burdo, Kathleen V. Fitch, Jack T. Stapleton, Jose L. Casado, Markella V. Zanni, Carlos Malvestutto, Carl J. Fichtenbaum, Judith A. Aberg, Heather J. Ribaldo, Pam S. Douglas, Michael T. Lu, Steven K. Grinspoon

647 BURDEN OF CORONARY DISEASE IN TRANSGENDER WOMEN WITH AND WITHOUT HIV

Jordan E. Lake, Han Feng, Hongyu Miao, Paula Debroy, Adrian Dobs, Sabina Haberlen, Lawrence Kingsley, Joseph B. Margolick, Katherine McGowan, Frank Palella, Wendy Post, Mallory Witt, Shalender Bhasin, Matthew Budoff, Todd T. Brown

648 MUSCLE QUALITY IS ASSOCIATED WITH CORONARY ARTERY PLAQUE & PHYSICAL FUNCTION IN PWH

Kristine Erlandson, Triin Umbleja, Edgar T. Overton, Michael T. Lu, Jana Taron, Heather J. Ribaldo, David W. Haas, Rachel Presti, Paul Sax, Michael T. Yin, Markella V. Zanni, Kathleen V. Fitch, Pamela S. Douglas, Steven K. Grinspoon, Todd T. Brown
Research Group: REPRIEVE Study Team

649 PERICORONARY ADIPOSE TISSUE DENSITY AND SUBCLINICAL CORONARY ARTERY DISEASE IN HIV

Borek Foldyna, Thomas Mayrhofer, Markella V. Zanni, Asya Lyass, Tricia H. Burdo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Udo Hoffmann, Heather J. Ribaldo, Joseph Massaro, Michael T. Lu, Pam S. Douglas, Steven K. Grinspoon
Research Group: REPRIEVE Study Team

650 SPATIAL PROFILING OF CORONARY PLAQUE SUGGESTS UNIQUE IMMUNE PATHWAYS IN HIV

Celestine N. Wanjalla, Kenji Kawai, Saikat Kumar B. Ghosh, Alope Finn, Renu Virmani, Meghan Hogan, Rama Gangula, Samuel S. Bailin, Mona Mashayekhi, Curtis L. Gabriel, Davey M. Smith, Sara Gianella, David G. Harrison, Simon A. Mallal, John R. Koethe

Poster Session-L2 LIPID METABOLISM**2:30 PM - 4:00 PM****651 HIGH PLASMA APOE IN PEOPLE WITH HIV COMPARED WITH UNINFECTED CONTROLS**

NIS

Anne Marie Reimer Jensen, Ruth Frikke-Schmidt, Marco Gelpi, Thomas Lars Benfield, Børge G. Nordestgaard, Tor Biering-Sørensen, Susanne Dam Poulsen

652 PERFORMANCE OF LDL CHOLESTEROL POLYGENIC RISK SCORE IN INDIVIDUALS WITH HIV INFECTION

Roger S. Zou, Yunfeng Ruan, Buu Truong, Romit Bhattacharya, Michael T. Lu, Heather J. Ribaldo, Hilary C. Martin, David A. van Heel, Kathleen V. Fitch, Markella V. Zanni, Pam S. Douglas, Steven K. Grinspoon, Aniruddh P. Patel, Pradeep Natarajan

653 CHOLESTEROL EFFLUX IS REDUCED IN ART TREATED PWH BUT ASSOCIATED WITH SUBCLINICAL CAD

Padraig McGettrick, Aoife Lacey, Willard Tinago, Julie O'Brien, Leo Lawler, Alejandro Garcia Leon, Niall Mahon, John Lambert, Gerard Sheehan, Alan Landay, Caroline Sabin, Aoife Cotter, Jane O'Halloran, Patrick Mallon

Poster Session-M4 BIOMARKERS OF MORBIDITY AND MORTALITY**2:30 PM - 4:00 PM****689 ANY LEVEL OF DETECTABLE VIREMIA IS ASSOCIATED WITH SERIOUS NON-AIDS EVENTS**

Anuradha Ganesan, Hsing-Chuan Hsieh, Xiuping Chu, Rhonda Colombo, Catherine Berjohn, Tahaniyat Lalani, Jason Blaylock, Karl Kronmann, Jason Okulicz, Brian Agan

Research Group: Infectious Disease Clinical Research Program

690 CD4/CD8 AT 2 YEARS OF ANTIRETROVIRAL THERAPY AND INCIDENCE OF SERIOUS NON-AIDS EVENTS

NIS

Javier Martínez-Sanz, Jorge Díaz-Álvarez, Marta Rosas, Raquel Ron, Cristina Roca-Oporto, Carmen Busca, María José Galindo, Miguel Cervero, Roberto Muga, Santiago Moreno, Sergio Serrano-Villar

Research Group: CoRIS

691 SOLUBLE IMMUNOREGULATORY PROTEINS PREDICTIVE FOR COMORBID EVENTS IN PEOPLE WITH HIV

NIS

Thomas Premeaux, Scott Bowler, Courtney Friday, Carlee Moser, Alan Landay, Sara Gianella, Lishomwa Ndhlovu

Research Group: AIDS Clinical Trials Group NWCS 411 study team

692 TELOMERE LENGTH IN AVIREMIC PWH: HOW DIFFERENT IS IT FROM PERSONS WITHOUT HIV?

NIS

Julen Cadiñanos, **Javier Rodríguez-Centeno**, Rocio Montejano, Andrés Esteban-Cantos, Beatriz Mena-Garay, María Jiménez-González, Gabriel Saiz-Medrano, Rosa de Miguel, Fernando Rodríguez-Artalejo, José Ignacio Bernardino, Cristina Marcelo-Calvo, Lucía Gutiérrez-García, Patricia Martínez-Martín, Berta Rodes, José R. Arribas, Mario Mayoral-Muñoz

693 BLOOD TELOMERE LENGTH GAIN IN PLWH SWITCHING TO DTG+3TC VS CONTINUING TRIPLE REGIMEN

Francesca Lombardi, Alessia Sanfilippo, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Iolanda Mozzetta, Enrica Tamburrini, Simona Di Giambenedetto

694 COMPARISON OF TELOMERE LENGTH CHANGES OVER 48 WEEKS IN SALSA STUDY: DTG/3TC VS CAR

Mark Underwood, James Oyee, Joseph Horton, Tatini Chakraborty, Chris Parry, Ruolan Wang, Jue Lin, Myooran Sithampanathan, Bryn Jones, Brian Wynne, Choy Man, Andrew Zolopa

695 SEVERAL INSTI AFFECT IMMUNE CELL MITOCHONDRIA, PROLIFERATION, AND APOPTOSIS EX VIVO

NIS

Renying Cai, Anthony Hsieh, Aya Zakaria, Helene C. F. Côté

Poster Session-N1 PASC (LONG COVID)**2:30 PM - 4:00 PM****710 INFLAMMATORY PROFILES ARE ASSOCIATED WITH LONG COVID 6 MONTHS AFTER ILLNESS ONSET**

Elke Wynberg, Alvin X. Han, Lisa van Pul, Irma Maurer, Ester van Leeuwen, Anouk Verveen, Hugo van Willigen, Menno D. de Jong, Maria Prins, Neeltje Kootstra, **Godelieve de Bree**

Research Group: The RECOVERED Study Group

- 711 CYTOKINE PROFILE IN DIFFERENT POST-COVID-19 CONDITION PHENOTYPES**
Maria Nevot, Francisco Muñoz-López, Marina Martinez-Velasco, Macedonia Trigueros, Sergio España-Cueto, Gemma Lladós, Cora Lose, Cristina Lopez, Jose Ramon Santos, Ruth Toledo, Bonaventura Clotet, Roger Paredes, Lourdes Mateu, Marta Massanella
- 712 NEW ONSET AUTOIMMUNE DISEASE MORE COMMON AFTER COVID-19**
Corrilynn O. Hileman, Nirav T. Patil, Grace A. McComsey
- 713 INCIDENT NEW ONSET DIABETES AFTER COVID-19 INFECTION: A NATIONAL MULTICENTER COHORT**
Sokratis N. Zisis, Jared C. Durieux, Jamie A. Perez, Christian Mouchati, Mary Chong, Betul Hatipoglu, Grace A. McComsey
- 714 WORSE ARTERIAL STIFFNESS, AND NOT ENDOTHELIAL DYSFUNCTION, IS ASSOCIATED WITH PASC**
Sokratis N. Zisis, Jared C. Durieux, Christian Mouchati, Mary Chong, Danielle Labbato, Grace A. McComsey
- 715 OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS**
 Lucette Cysique, Faye Yang, Amy Regan, Valerie Bramah, Benjamin Heng, Sharron Chow, David Darley, Anthony Byrne, Anthony D. Kelleher, Gregory Dore, Gail Matthews, Gilles Guillemin, **Bruce Brew**
- 716 OLFACTORY FUNCTION AND BRAIN STRUCTURAL EFFECTS FOLLOWING SARS-CoV-2 INFECTION**
 NP
 Erin E. O'Connor, Nikita Rednam, Andrea Levine, Thomas Zeffiro, **James Becker**
- 717 SEX MODIFIES THE EFFECT OF COVID-19 AND PASC STATUS ON ARTERIAL STIFFNESS**
Jared C. Durieux, Sokratis N. Zisis, Christian Mouchati, Mary Chong, Jamie C. Perez, Grace A. McComsey
- 718 INCIDENCE OF LONG COVID SYMPTOMS IN PATIENTS PREVIOUSLY HOSPITALIZED FOR COVID-19**
Mark Berry, Amanda Kong, Julie Paone, Rohan Shah, Rebecca Taylor, Essy Mozaffari, Rikisha Gupta, Jason Goldman, Anand Chokkalingam
- 719 FACTORS ASSOCIATED WITH LONG COVID-19 IN ZAMBIA, 2020 TO 2022**
Warren Malambo, Lily Besa, Duncan Chanda, Danielle Engamba, Linos Mwiinga, Mundia Mwitumwa, Jonas Hines, Sombo Fwoloshi
- 720 15-MONTH ATTRIBUTES OF POST-COVID SYNDROME IN THERAPEUTICALLY VACCINATED OUTPATIENTS**
Max Augustin, Melanie Stecher, Hauke Wuestenberg, Veronica Di Cristanziano, Elisabeth Pracht, Dominic Rauschnig, Henning Gruell, Florian Klein, Michael Hallek, Philipp Schommers, Clara Lehmann
- 721 POST-ACUTE COVID OUTCOMES: AMUBARVIMAB/ROMLUSEVIMAB VS PLACEBO IN THE ACTIV-2 TRIAL**
Teresa H. Evering, Carlee Moser, Nikolaus Jilg, Justin Ritz, David A. Wohl, Jonathan Z. Li, David A. Margolis, Arzhang C. Javan, Joseph J. Eron, Judith S. Currier, Eric S. Daar, Davey M. Smith, Michael D. Hughes, Kara W. Chew
Research Group: ACTIV-2/A5401 Study Team

722 SYMPTOMS AND BIOMARKERS OF LONG COVID IN PEOPLE LIVING WITH AND WITHOUT HIV
Annukka A R. Antar, Nuria Gallego Marquez, Armaan Jamal, Alisha Dziarski, Jia Fu, Samantha N. Walch, Arianna Romero, Artur T L Queiroz, Mariana Araújo-Pereira, Ashley Zelaya, Enam Akasreku, Bruno B. Andrade, Michael J. Peluso, Alan Landay

723 SEVERITY CLUSTERS AND LIKELIHOOD OF RECOVERY FROM POST-COVID-19 CONDITION
Lourdes Mateu, Christian Tebe, Cora Loste, Cristina López, Sergio España, José Ramón Santos, Gemma Lladós, Maria Nevot, Francisco Muñoz-López, Bonaventura Clotet, Roger Paredes, Marta Massanella

Poster Session-01 PREDICTORS OF TB TREATMENT OUTCOMES
2:30 PM - 4:00 PM

741 ADVERSE DRUG REACTIONS ON TB TREATMENT: A PREDICTION MODEL INCLUDING HIV AND HBA1C
NIS
Felipe Ridolfi, Lauren Peetluk, Gustavo Amorim, Mariana Araújo-Pereira, Marcelo Cordeiro-Santos, Afranio Kritski, Marina Figueiredo, Bruno B. Andrade, Valeria Rolla, Timothy R. Sterling
Research Group: Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil consortium

743 ISONIAZID TOXICITY AMONG PWH WITH LATENT TB WHO CONSUME ALCOHOL: A SINGLE ARM TRIAL
Judith A. Hahn, Christine Ngabirano, Robin Fatch, Nneka Emenyonu, Debbie M. Cheng, Julian Adong, Adah Tumwegamire, Karen Jacobson, Benjamin Linas, Kendall Bryant, Winnie Muyindike

744 RISK FACTORS FOR ADRS RELATED TO IPT AMONG PLHIV ON DOLUTEGRAVIR-BASED ART IN UGANDA
Stella Z. Muyanja, Joseph Musaaazi, Esther Nalugga, Eva Laker, Nelson Kalema, Barbara Castelnuovo, Mary G. Mudioppe, Grace Namayanja, Deus Lukoye, Yukari C. Manabe

740 TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS
NIS
Rob van Wijk, Vincent Chang, Marjorie Imperial, Patrick Phillips, Susan Swindells, Richard Chaisson, Payam Nahid, Rodney Dawson, Ian Sanne, Ziyaad Waja, Susan Dorman, Ekaterina Kurbatova, Rada Savic
Research Group: Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team

742 PREDICTORS OF POOR OUTCOMES IN PATIENTS WITH TUBERCULOSIS SYMPTOMS AT HIV DIAGNOSIS
Nancy Dorvil, Vanessa Rivera, Cynthia Riviere, Patrice Severe, Heejung Bang, Kerlyne Lavoile, Giovanni Saintyl, Samuel Pierre, Margaret McNairy, Richard B. Berman, Pierre Cremieux, Jean William Pape, Serena Koenig

745 TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT
Salome Charalambous, Noriah Maraba, Lauren Jennings, Kavindhran Velen, Piotr Hippner, Israel Rabothata, Rachel Mukora, Stemberidge Mpemba, Lihle McHunu, Dolphina Cogill, Pren Naidoo, Catherine Orrell, **Catherine Orrell**, Katherine Fielding

Poster Session-02 OUTCOMES ASSOCIATED WITH OPPORTUNISTIC INFECTIONS IN THE CURRENT ERA
2:30 PM - 4:00 PM

746 HIGH MORTALITY IN HOSPITALISED VIRALLY SUPPRESSED ADULTS WITH HIV IN SOUTH AFRICA
Firdaus Nabeemeeah, Kennedy Otwomeh, Khuthadzo Hlongwane, Nadia Sabet, Pattamukkil Abraham, Alex Van Blydenstein, Phetho Mangena, Ebrahim Variava, Neil Martinson

- 747 LONG-TERM OUTCOMES OF PNEUMOCYSTIS JIROVECI PNEUMONIA IN THE ANTIRETROVIRAL ERA**
Brian Epling, Maura Manion, Arlene Sirajuddin, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Anela Kellogg, Irini Sereti
- 748 RISK FACTORS ASSOCIATED WITH NEURO-COGNITIVE IMPAIRMENT IN CRYPTOCOCCAL MENINGITIS**
Laura J. Nsangi, Mahsa Abassi, David B. Meya, David R. Boulware, Biyue Dai, Darlisha A. Williams, Kenneth Ssebambulidde, Lillian Tugume, Edwin Nuwagira, Abdu Musubire
- 749 CEREBROSPINAL FLUID PROTEIN CLINICAL IMPACT IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS**
 John Kasibante, Eesha Irfanullah, Abduljaweed Wele, Kenneth Ssebambulidde, Timothy Mugabi, Abdu Musubire, Samuel Jjunju, Laura J. Nsangi, Enock Kagimu, Morris K. Rutakingirwa, **Mahsa Abassi**, Conrad Muzoora, David B. Meya, David R. Boulware
Research Group: ASTRO-cm group

Poster Session-P5 NOVEL UNDERSTANDINGS OF BIRTH OUTCOMES WITH ART

2:30 PM - 4:00 PM

- 787 ANGIOGENIC BIOMARKERS OF POOR OUTCOMES IN PREGNANT WOMEN WITH HIV IN BOTSWANA**
Caroline E. Dunk, Kathleen M. Powis, Justine Legbedze, Shan Sun, Keolebogile Mmasa, Samuel W. Kgole, Gosego Masasa, Sikhulile Moyo, Terence Mohammed, Lynn Yee, Mompoti O. Mmalane, Joseph Makhema, Jennifer Jao, Lena Serghides
- 788 DOLUTEGRAVIR EXPOSURE AND CONGENITAL ANOMALIES IN SUB-SAHARAN AFRICA**
Rena Patel, Ushma Mehta, John Humphrey, Emma Kalk, Alexa Heekes, Audrey Chepkemoi, Steve Brown, Beverly Musick, Constantin Yiannoutsos, Edwin Were, Andrew Boule, Mary-Ann Davies, Kara Wools-Kaloustian
Research Group: leDEA Multiregional MANGO Collaboration
- 789 ALLOSTATIC LOAD AND SPONTANEOUS PRETERM BIRTH AMONG WOMEN WITH HIV IN LUSAKA, ZAMBIA**
 Joan T. Price, Yuri Sebastião, Katelyn Rittenhouse, Humphrey Mwape, Bellington Vwalika, Mwansa Ketty Lubeya, Margaret Kasaro, **Kristina De Paris**, Jeffrey Stringer
- 790 NEURAL TUBE AND OTHER BIRTH DEFECTS BY HIV STATUS AND ART REGIMEN IN ESWATINI**
Michelle M. Gill, Philisiwe Khumalo, Caspian Chouraya, Mthokozisi Kunene, Futhi Dlamini, Heather J. Hoffman, Angela E. Scheuerle, Bonisile Nhlabatsi, Wiseman Mngometulu, Lynne Mofenson
- 791 VAGINAL INFLAMMATORY MARKERS ASSOCIATED WITH PRETERM BIRTH IN ZAMBIAN WOMEN WITH HIV**
Dominique Davis, Hazel Milla, Humphrey Mwabe, Yuri Sebastiao, Margaret Kasara, Bellington Vwalika, Joan T. Price, Kristina De Paris, Jeffrey Stringer
- 792 MATERNAL ART USE AND PRETERM DELIVERY: THE IMPACT OF DATA SOURCES AND DATA QUALITY**
Hthokozile R. Malaba, Emma Kalk, Amy L. Slogrove, Ushma Mehta, Hlengiwe P. Madlala, Dorothy C. Nyemba, Jonathan Euvrard, Mary-Ann Davies, Andrew Boule, Landon Myer

793 PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES

Kathleen M. Powis, Caroline E. Dunk, Keolebogile Mmasa, Gosego Masasa, Samuel W. Kgole, Justine Legbedze, Shan Sun, Sikhulile Moyo, Nyaladze C. Maphorisa, Terence Mohammed, Mompoti O. Mmalane, Joseph Makhema, Jennifer Jao, Lena Serghides

Poster Session-Q1 OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN**2:30 PM - 4:00 PM****797 HIV-EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES**

Li Yin, Bernard Fischer, Guglielmo Venturi, Upasana Nepal, Shivangi Choudhary, Jerry Shen, Kai-Fen Chang, Isaac Raplee, Samiksha Borkar, Julie Kim-Chang, Kristina De Paris, Maureen Goodenow, John Sleasman

798 NO EVIDENCE OF PERTURBATIONS OF THE BREAST MILK MICROBIOME BY ANTIRETROVIRAL THERAPY

Nicole H. Tobin, Fan Li, Sean Brummel, Patricia Flynn, Sufia Dadabhai, Dhayendre Moodley, Lameck Chinula, Mandisa Nyati, Mary Glenn Fowler, Grace Aldrovandi
Research Group: 1077BF/1077FF PROMISE (Promoting Maternal and Infant Survival Everywhere) Team

799 RBC FOLATE CONCENTRATIONS IN MOTHERS/INFANTS RANDOMIZED IN PREGNANCY: DTG VS EFV

Denise L. Jacobson, Krista Crider, Patricia Demarrais, Sean Brummel, Mindy Zhang, Christine Pfeiffer, Cynthia Moore, Katie McCarthy, Sikhulile Moyo, Tichaona Vhembo, Enid Kabughho, Gerald Muzorah Agaba, Nahida Chakhtoura, Lameck Chinula, Shahin Lockman

800 EFFECT OF IN-UTERO HIV AND ANTIRETROVIRAL THERAPY EXPOSURE ON GROWTH DURING INFANCY

Ashenafi S. Cherkos, Sylvia M. Lacourse, John Kinuthia, Jerphason Mecha, Daniel A. Enquobahrie, Jaclyn Escudero, Grace John-Stewart

801 IPT DURING INFANCY HAS NO ADVERSE EFFECT ON GROWTH AMONG HEU CHILDREN

Ashenafi S. Cherkos, Sylvia M. Lacourse, Daniel A. Enquobahrie, Jaclyn Escudero, Jerphason Mecha, Daniel Matemo, John Kinuthia, Grace John-Stewart

802 IMPACT OF IN-UTERO EXPOSURE TO HIV AND LATENT TB ON INFANT HUMORAL RESPONSES

NIS

Kimberly Shankwitz, Lesley de Armas, Grace Montepiedra, Suresh Pallikkuth, Lynda Stranix-Chibanda, Gaerolwe Masheto, Philippa Musoke, Enid Kabughho, Jyoti Mathad, Renee Browning, Rajendra Pahwa, Galit Alter, Adriana Weinberg, Amita Gupta, Savita Pahwa
Research Group: for the IMPAACT P1078/TB APPRISE Study Team

803 LOWER ACADEMIC PERFORMANCE AMONG CHILDREN WITH PERINATAL HIV EXPOSURE IN BOTSWANA

Kathleen M. Powis, Lesedi Lebanna, Sara Schenkel, Gosego Masasa, Samuel W. Kgole, Martha Ngwaca, Paige L. Williams, Amy L. Slogrove, Roger L. Shapiro, Shahin Lockman, Mompoti O. Mmalane, Joseph Makhema, Jennifer Jao, Adam R. Cassidy

804 PSYCHIATRIC DISORDERS IN HIV-EXPOSED UNINFECTED VS NON-HIV-EXPOSED CHILDREN

Ellen Moseholm, Sammy Ameri, Merete Storgaard, Gitte Pedersen, Isik S. Johansen, Terese L. Katzenstein, Nina Weis

805 EVALUATING ASSOCIATIONS BETWEEN IN UTERO HIV/ART EXPOSURE AND PUBERTAL STATUS

Lena Serghides, Denise L. Jacobson, Jessica Lee, Mitchell E. Geffner, Elizabeth J. McFarland, Linda Dimeglio, Kathleen M. Powis, Paige L. Williams, Jennifer Jao

Research Group: Pediatric HIV/AIDS Cohort Study

Poster Session-Q5 ARVs AND bNAbS FOR CHILDREN AND ADOLESCENTS
 2:30 PM - 4:00 PM
826 PK & SAFETY OF ABC/3TC DISPERSIBLE TABLETS & LPV/r GRANULES IN NEONATES: PETITE STUDY

Adrie Bekker, Helena Rabie, Nicolas Salvadori, Samantha Du Toit, Kanchana Than-In-At, Maria Groenewald, Edmund Capparelli, Ratchada Cressey, Marc Lallemand, Mark Cotton, **Tim R. Cressey**

Research Group: PETITE Study Team

827 TWICE DAILY 50 MG DOLUTEGRAVIR IN TUBERCULOSIS-HIV COINFECTED CHILDREN 20-35 KG

LB

Anushka Naidoo, Kogieleum Naidoo, Gabriella Cromhout, Marothi Letsoalo, Mounier Almett, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner, Kelly E. Dooley, Moherdran Archary

828 CAREGIVERS OF CHILDREN WITH HIV IN BOTSWANA PREFER MONTHLY IV bNAbS TO DAILY ORAL ART

NIS

Maureen Moselehi, Gbolahan Ajibola, Roxanna Haghighat, Oganne Batlang, Kenneth Maswabi, Molly Pretorius Holme, Kathleen M. Powis, Shahin Lockman, Joseph Makhema, Mathias Lichterfeld, Daniel Kuritzkes, Roger L. Shapiro

829 SIX-MONTH OUTCOME OF F/TAF COBICISTAT-BOOSTED DARUNAVIR IN CHILDREN 14 TO < 25KG

Hilda A. Mujuru, Renate Strehlau, Natella Rakhmanina, Kulkanya Chokeyhaibulkit, Pope Kosalaraksa, **Vinicius Vieira**, Kathryn Kersey, Rory Leisegang, Shaolan Xiang

830 BIC/FTC/TAF IN FRENCH CHILDREN: FREQUENT VIRAL FAILURE BUT RARE ACQUIRED RESISTANCE

Pierre Frange, Florence Veber, Stephane Blanche, Veronique Avettand-Fenoel

831 ADEQUATE DTG EXPOSURE IN INFANTS ON RIFAMPICIN TREATMENT RECEIVING TWICE-DAILY DTG

NIS

Tom G. Jacobs, Vivian Mumbiro, Uneisse Cassia, Damalie Nalwanga, Kevin Zimba, Sara Dominguez, Constantine Mutata, W. Chris Buck, Chishala Chabala, Victor Musiime, Mutsa Bwakura-Dangarembizi, Cinta Moraleta, David Burger, Pablo Rojo, Angela Colbers, Hilda A. Mujuru
Research Group: EMPIRICAL clinical trial group

832 MODEL-INFORMED DOLUTEGRAVIR DOSE SELECTION IN PEDS WITH 1ST GENERATION InSTI-R

Hardik Chandasana, Ann Buchanan, Michael McKenna, Cindy Vavro, Linda Lewis, Mary Paul, Ana Puga, Lionel Tan, Cindy Brothers, Theodore Ruel

833 IMPACT OF MALNUTRITION ON DOLUTEGRAVIR EXPOSURE AND ALTERNATIVE DOSING

Alexander J. Floren, Belen Perez Solans, Kendra K. Radtke, Rada Savic

Poster Session-R1 MOLECULAR HIV EPIDEMIOLOGY

2:30 PM - 4:00 PM

- 843** **STUDY ON THE FREQUENCY OF DUAL INFECTIONS IN NEW HIV-1 DIAGNOSES IN SPAIN**
NIS
Ana Donoso, Javier Enrique Cañada-García, Elena Delgado, Sara Monzón, Horacio Gil, María Moreno-Lorenzo, Mónica Sánchez, Isabel Cuesta, Ángel Zaballo, Pilar Jiménez, Michael M. Thomson
Research Group: the Spanish Group for the Study of New HIV Diagnoses
- 844** **EPIDEMIOLOGICAL AND MOLECULAR EVOLUTION OF THE HIV-1 CRF94: BIRTH OF CRF132**
 Marc Wirden, Fabienne De Oliveira, Marie-Laure Chaix, Stephanie Marque Juliet, Sidonie Lambert-Niclot, Basma Abdi, Benedicte Roquebert, Charlotte Charpentier, Jean-Christophe Plantier, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, **Benoit Viseaux**
Research Group: ANRS-MIE AC43 Medical Virology Network
- 845** **ACCURACY OF MOLECULAR EPIDEMIOLOGICAL INFERENCES IN A SIMULATED EPIDEMIC**
 Fabricia Nacimiento, **Sanjay Mehta**, Susan R. Little, Erik Volz
- 846** **PRESENCE OF CXCR4-USING HIV-1 VIRUS IN NEWLY DIAGNOSED INDIVIDUALS IN NORTH CAROLINA**
Shuntai Zhou, Nathan Long, Matt Moeser, Erika Samoff, Scott Shone, Collin Hill, Michael Clark, Ronald Swanstrom, Ann Dennis

Poster Session-R2 RECENT HIV INFECTIONS

2:30 PM - 4:00 PM

- 847 HOTSPOTS OF RECENT HIV INFECTIONS AMONG ADULT PEOPLE LIVING WITH HIV IN NIGERIA**
Amobi A. Onovo, Pamela Gado, Angela Agweye, Abiye Kalaiwo, Ughweroghene Omo-Emmanuel, Konrad Bradley, Kristina Bishop, Helina Meri, Rachel Goldstein
- 848 PROGRAMMATIC IMPLICATIONS OF NATIONAL RECENT HIV INFECTION SURVEILLANCE IN CAMBODIA**
Vichea Ouk, Sovannarith Samreth, Bora Ngauv, Bunthoeun Eng, Rommel Bain, Chhaily Hy, Alexandra Ernst, George W. Rutherford, Chunfu Yang, Vanthy Ly, Amitabh B. Suthar, Rachel Albalak
- 849 AN ANALYSIS OF HIV RECENT INFECTION SURVEILLANCE DATA AMONG YOUNG PEOPLE IN MALAWI**
 Alinune N. Kabaghe, **Reno Stephens**, Danielle Payne, Joe Theu, Misheck Luhanga, Davie D. Chalira, Melissa Arons, Gabrielle O'Malley, Kerry A. Thomson, Mtemwa Nyangulu, Trudy Dobbs, Vedapuri Shanmugam, Rose Nyirenda, Pragna Patel, Nellie Wandonda-Kabondo
- 850 HIV RECENT INFECTION IN SEXUAL AND GENDER MINORITIES IN BRAZIL AND PERU: ImPrEP STUDY**
Thiago S. Torres, Sylvia L. M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Derrico, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Silver K. Vargas, Cristina Pimenta, Beatriz Grinsztejn, Celia Landmann Szwarcwald, Carlos Caceres, Valdilea Veloso
Research Group: ImPrEP Seroincidence Study Group
- 851 HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES, 2018-2021**
Camden J. Hallmark, Laurie Linley, Agha Ajmal, Olivia O. Russell, Mary Plaster, Sheryl B. Lyss, Nivedha Panneer, Rashida Hassan, Anne Marie France, Alexandra M. Oster

Poster Session-R3 HIV INFECTION CLUSTERS

2:30 PM - 4:00 PM

- 852 EVOLUTION OF CLUSTERS TRANSMISSION PATTERNS IN FRANCE DURING THE LAST DECADE**
Benoit Visseaux, Mathilde Roussel, Stéphanie Teixeira, Eric Hedbaut, Laura Verdurme, Sabine Trombert, Stéphanie Haim-Boukobza, Benedicte Roquebert
- 853 BEYOND FAST-TRACK CITIES: DYNAMIC OF HIV CLUSTERS IN A FRENCH REGION NEAR PARIS**
Nived Collercandy, Antoine Chaillon, Marc-Florent Tassi, Leslie Grammatico-Guillon, Emeline Laurent, Laurent Hocqueloux, Jerome Guinard, Clémence Guillaume, Adrien Lemaigen, Guillaume Gras, Karl Stefic
- 854 NOT ALL CLUSTERS ARE EQUAL: STATEWIDE MOLECULAR HIV CLUSTER DYNAMICS IN RHODE ISLAND**
Vlad Novitsky, Jon A. Steingrimsson, Mark Howison, Casey Dunn, Fizza Gillani, John Fulton, Thomas Bertrand, Katharine Howe, Lila Bhattarai, Guillermo Ronquillo, Meghan MacAskill, Utpala Bandy, Joseph W. Hogan, Rami Kantor
- 855 HIV SEQUENCING AT DIAGNOSIS ENHANCES DETECTION OF CLUSTERS AND POTENTIAL CARE GAPS**
Cara Bayer, Shuntai Zhou, Annalea Greifinger, Nathan Long, Erika Samoff, Victoria Mobley, Simon Frost, Scott Shone, Joseph J. Eron, Myron S. Cohen, Ronald Swanstrom, Ann Dennis

856 MOLECULAR CLUSTER TYPES SUSTAINING HIV SPREAD AMONG MSM IN QUEBEC: 2014-2020

Bluma G. Brenner, Vladimir Novitsky, Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Michel Roger, **Jean-Pierre Routy**, Rami Kantor

Research Group: Montreal PHI Cohort Study Group

857 CHANGING RISK OF HIV BEHAVIORAL AND DEMOGRAPHIC CLUSTERS IN RAKAI, UGANDA

Victor O. Popoola, **Mary K. Grabowski**, Joseph Kagaayi, Joseph Ssekasanvu, Robert Ssekubugu, Anthony Ndyanabo, Fred Nalugoda, Larry William W. Chang, Godfrey Kigozi, Stella Alamo, Maria Wawer, Steven J. Reynolds, David M. Serwadda, Justin Lessler

Poster Session-R6 HIV MORTALITY**2:30 PM - 4:00 PM****870 TRENDS IN MORTALITY IN PEOPLE LIVING WITH HIV IN AN INTERNATIONAL COHORT (RESPOND)**

NIS

Erich Tusch

Research Group: The RESPOND Study Group

871 NON-AIDS DEFINING MALIGNANCY MORTALITY IN PEOPLE LIVING WITH HIV

NIS

Marta Rava, Félix Gutierrez, José A. Pérez-Molina, Inés Suarez-García, Francisco J. Vera Méndez, Fernando Baigorria Feltrin, Mar Masiá, Juan Macías, Gemma Navarro, Santiago Moreno, Inmaculada Jarrín

Research Group: Cohorte de la Red de Investigación en Sida (CoRIS)

872 PROPORTION OF DEATHS OCCURRING OUTSIDE OF HEALTH FACILITIES ATTRIBUTABLE TO HIV/AIDS

Newton L. Kalata, Alinune N. Kabaghe, George Mtonga, Emmanuel Mkambankhani, Masauso Mussa, Amos Nyaka, Kondwani Nkanaunena, Verita Buie, Ramesh Sethi, Rodrick Langwe, Kelsey Mirkovic, Nellie Wandonda-Kabondo

873 MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT

Shannon M. Farley, Giles Reid, Katharine Yuengling, Connor Wright, George Bello, James M. Juma, Stephane Helleringer, Jessica Justman

874 ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION

Nicholas Bakewell, **Caroline Sabin**, Tanmay Kanitkar, Maggie Symonds, Oshani Dissanayake, Stephanie Rimmer, Amit Adlakha, Marc Lipman, Sanjay Bhagani, Banwari Agarwal, Robert Miller

875 REGISTRY LINKAGE IMPROVES SURVIVAL ESTIMATION AMONG PEOPLE WITH HIV IN LATIN AMERICA

Gabriela Carriquiry, Yanink Caro-Vega, Paula Luz, Ahra Kim, Karu Jayathilake, Eduardo Gotuzzo, Lara E. Coelho, Antonio G. Pacheco, Claudia M. Cortes, Regina Succi, Lorena Guerrero-Torres, Bryan E. Shepherd, Stephany Duda, **Peter F. Rebeiro**

Research Group: Caribbean, Central and South America network for HIV epidemiology (CCASAnet)

Poster Session-S1 COVID-19 CHARACTERISTICS AND OUTCOMES**2:30 PM - 4:00 PM****884 12-MONTH CONSEQUENCES IN PEOPLE WITH HIV/SARS-CoV-2 COINFECTION: NATIONAL EHR COHORT**

Yuanzhen Yue, **Chen Liang**, Sharon Weissman, Tianchu Lyu, Bankole Olatosi, Xiaoming Li

Research Group: National COVID Cohort Collaborative Consortium

- 885 TRENDS IN COVID-19 ADMISSIONS AND DEATHS AMONG PEOPLE WITH HIV IN SOUTH AFRICA**
 Waasila Jassat, Lovelyn Ozougwu, Caroline Mudara, Richard Welch, Tracy Arendse, Maureen Masha, Lucille Blumberg, Tendesayi Kufa, Adrian Puren, Michelle Groome, Pedro Pisa, Ian Sanne, **Heena Brahmhatt**, Lauren Parmley, Cheryl Cohen, Sharlene Govender, Pappie Majuba, Petro Rousseau, Milani Wolmarans
Research Group: DATCOV author group
- 886 A MULTICENTER STUDY OF COVID-19 INFECTION IN PEDIATRIC INTENSIVE CARE UNITS IN THE US**
German A. Contreras, Gabriela Delbianco, Michael Chang, Gilhen Rodriguez, Elizabeth Aguilera, James Murphy, Gloria Heresi
- 887 IDENTIFICATION OF CLINICAL FEATURES ASSOCIATED WITH SARS-CoV-2 REINFECTIONS**
Francisco Muñoz-López, Antoni E. Bordoy, Ignacio Blanco, Elisa Matró, Pere-Joan Cardona, Roger Paredes, Bonaventura Clotet, Marc Noguera Julian, José Ramón Santos, Marta Massanella, Lourdes Mateu, Cristina Casañ, Ana Blanco-Suárez
Research Group: Translational Research in Immunology and Ageing (TRIA)
- 888 ANEMIA AS A PREDICTOR OF POOR CLINICAL OUTCOME IN PATIENTS ADMITTED FOR COVID-19**
 Francesco Di Gennaro, Francesco Vladimiro Segala, Luca Carruba, Anna La Carrubba, Diletta Agnello, Davide Fiore Bavaro, Mario Barbagallo, Nicola Veronese, **Annalisa Saracino**
- 889 CLINICAL OUTCOMES BY SARS-CoV-2 VARIANT AT A SINGLE ACADEMIC MEDICAL CENTER**
 Pankaja Desai, Juan Rojas, Yi-Shuan Chen, Susan Gawel, Hannah Barbian, Anthony Orzechowski, **Gavin Cloherty**, Alan Landay
- 890 EXCESS OF MORTALITY IN OLDER PEOPLE DURING THE COVID-19 PANDEMIC IN MOZAMBIQUE**
Inacio Mandomando, Richard Sheppard, Arsenia Massinga, Rita Ernesto, Auria de Jesus, Augusto Messa Jr, Ariel Nhacolo, Arsenio Nhacolo, Charfudin Sacoor, Patrick Walker, Alfredo Mayor

Poster Session-S2 IMPACT OF COVID-19 ON HIV AND MALARIA SERVICES AND OUTCOMES

2:30 PM - 4:00 PM

- 891 HIV VIRAL LOAD SUPPRESSION AND RACIAL DISPARITIES DURING THE COVID-19 PANDEMIC IN NYC**
Emma Tucker, Harry Reyes Nieva, Kayla Schiffer, Lindsay Grant, Michael T. Yin, Delivette Castor, Peter Gordon, Noémie Elhadad, Jason Zucker
- 892 HIV AND CHRONIC COMORBIDITIES: MEDICATION ADHERENCE AND CLINICAL ENDPOINT COVARIATION**
LB
Michael J. Miller, Celeena R. Jefferson, Lindsay G. Eberhart, Michael A. Horberg
- 893 HIGH PANDEMIC-RELATED MORTALITY AMONGST PEOPLE WITH HIV IN SASKATCHEWAN, CANADA**
Kirsten Hall, Molly Trecker, Sarah Craddock, Raynell Lang, Danielle Myrah, Kumudhini Karunakaran, Lanre Medu, Alexander Wong
- 894 IMPACT OF THE COVID-19 PANDEMIC ON MALARIA SERVICES IN UGANDA: A TIME SERIES ANALYSIS**
 Francesco Di Gennaro, Francesco Vladimiro Segala, Jerry Ictho, Mariangela L'Episcopia, Emmanuel Onapa, Davide Fiore Bavaro, Samuel Okori, Giovanni Dall'Oglio, Giovanni Putoto, Carlo Severini, Peter Lochoro, **Annalisa Saracino**

928

WITHDRAWN

929 HIGH PERFORMANCE OF BLOOD-BASED HIV SELF-TESTS AT PRIVATE PHARMACIES IN KENYA

Katrina F. Ortblad, Benn Kwach, Shengruo Zhang, Magdaline Asewe, Kendall Harkey, Rachel Malen, Josephine Odoyo, Daniel Were, Kenneth Nguni, Victor Omollo, Elizabeth A. Bukusi

930 REMOVAL OF A SUBSIDY FOR HIV SELF-TESTING KITS REDUCES ONLINE KIT SALES IN KENYA

NIS

Obinna I. Ekwunife, Carlos Culquichicon, Maeve Rafferty, Paulami Naik, Nicky Nyamasyo, Tony Wood, Daniel Were, Kenneth Nguni, Melissa Mugambi, Annie Haakenstand, Katrina F. Ortblad

931 VIRTUAL SUPPORT IMPROVES CLIENT EXPERIENCES WITH AN ONLINE HIV SELF-TESTING SERVICE

Allison M. McFall, Jalpa Thakker, Talia A. Loeb, Jade Bell, Aditya Singh, Rose Pollard, Mahender Taduri, Anthony Reddy, Jagadish Patil, Subash Ghosh, Ajay Enugu, Shruti H. Mehta, Sunil S. Solomon

932 PEOPLE WHO INJECT DRUGS' WILLINGNESS TO USE AND DELIVER HIV SELF-TEST KITS TO PEERS

Heather A. Pines, William H. Eger, Britt Skaathun, Claire C. Bristow, Carlos F. Vera, Alicia Harvey-Vera, Steffanie A. Strathdee, Irina Artamonova, Angela R. Bazzi

933 OVERCOMING ACCESS BARRIERS TO VIRAL SUPPRESSION TESTING BY SELF-MICROCOLLECTED BLOOD

Amanda J. Smith, Wei Luo, M. Leanne Ward, Silvina Masciotra, Tashyra Burnside, Pollyanna Chavez, Erin Rogers, Ruth Dana, Robin MacGowan, Patrick S. Sullivan, Jeffrey A. Johnson

Poster Session-U1 MPOX TESTING

2:30 PM - 4:00 PM

948 **CLINICAL DIAGNOSIS IS HIGHLY PREDICTIVE OF LAB-CONFIRMED MPOX IN A SEXUAL HEALTH CLINIC**

Chase Cannon, Ellora Karmarkar, Meena Ramchandani, Julia C. Dombrowski, Matthew Golden

949

WITHDRAWN

950 **MPOX TESTING AMONG MEN WHO HAVE SEX WITH MEN WHO REPORTED RECENT HIV OR STI TESTING**

Yasmin Ogale, Alison Ridpath, Travis H. Sanchez, Marissa Hannah, Kevin Delaney, Stefan Baral, Patrick S. Sullivan, Thomas Carpino, Kaitlyn Atkins, Eboni Galloway, Bruce Furness, **Laura H. Bachmann**, Winston Abara

951 **FACTORS ASSOCIATED WITH MPOX SYMPTOMS AND TESTING AMONG MSM IN THE US, AUGUST 2022**

NIS

Kaitlyn Atkins, Thomas Carpino, Amrita Rao, Travis H. Sanchez, O. Winslow Edwards, Marissa Hannah, Patrick S. Sullivan, Yasmin Ogale, Winston E. Abara, Kevin Delaney, Stefan Baral

952 **UTILITY OF A VIRAL VESICULAR PANEL MULTIPLEX PCR ASSAY FOR THE DIAGNOSIS OF MPOX**

Eli Wilber, Paulina A. Rebolledo, Vyjayanti Kasinathan, Stephanie Merritt, **Boghuma K. Titanji**, Bruce Aldred, Sheetal Kandiah, Susan Ray, Anandi N. Sheth, Jonathan Colasanti, Yun Wang

953 **MPOX VIRAL LOAD BY SPECIMEN TYPE AND DIAGNOSTIC TESTING IN A CLINICAL LABORATORY**

Nancy Matic, Matthew Young, Gordon Ritchie, Christopher F. Lowe, Marc G. Romney

954 **MPOX VIRUS (MPXV) OUTBREAK IN BERLIN: IMPLEMENTATION OF MOLECULAR DIAGNOSTICS**

Martin J. Obermeier, Ivanka Krznaric, Stefan Breuer, Kudor Harb, Robert Ehret

955 **PERFORMANCE OF A DUAL TARGET MPOX VIRUS REAL-TIME PCR ASSAY**

Ron M. Kagan, Susan E. Realegeno, Gwynngelle A. Borillo, Amy A. Rogers, Taekkyun Kim, Lamela Umaru, Clemente I. Montero, Hollis J. Batterman, Elizabeth M. Marlowe

Poster Session-V1 COST EFFECTIVENESS OF PEP AND PrEP

2:30 PM - 4:00 PM

967 **COST-EFFECTIVENESS OF THE DUAL PREVENTION PILL FOR CONTRACEPTION AND HIV PROPHYLAXIS**

Masabho Milali, David Kaftan, Ingrida Platais, Hae-Young Kim, Danielle Resar, Danny Edwards, Jenny Campbell, Sarah Jenkins, Anna Bershteyn

968 **POTENTIAL IMPACT & COST-EFFECTIVENESS OF WIDELY ACCESSIBLE TLD IN SUB-SAHARAN AFRICA**

Andrew Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, James Hargreaves, Paul Revill, Euphemia Sibanda, Jens Lundgren, Catherine Godfrey, Frances M. Cowan, Valentina Cambiano
Research Group: The HIV Modelling Consortium

969 POPULATION IMPACT OF EXPANDING PrEP USAGE IN SOUTH AFRICA: MODEL COMPARISON ANALYSIS

NIS

Sarah E. Stansfield, Jesse Heitner, Lise Jamieson, Gesine Meyer-Rath, Leigh Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansal-Matharu, Andrew Phillips, Mia Moore, Ruanne Barnabas, Marie-Claude Boily, Dobromir Dimitrov

Poster Session-V2 PrEP AND PEP: ADHERENCE MEASURES AND STIS

2:30 PM - 4:00 PM

970 RANDOMIZED EVALUATION OF THE IMPACT OF STI POINT-OF-CARE TESTING ON PrEP INITIATION

Alex de Voux, Miriam Silliman, Rufaro Mvududu, Nyiko Mashele, Landon Myer, Dvora Joseph Davey

971 SEXUAL BEHAVIOR AND STI INCIDENCE DURING THE FIRST 4 YEARS OF PrEP USE AMONG MSM

NIS

Mark van den Elshout, Eline Wijstma, Vita Jongen, Liza Coyer, Anders Boyd, Udi Davidovich, Henry de Vries, Maria Prins, Maarten Schim Van Der Loeff, Elske Hoornenborg

Research Group: Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative

972 PEP-IN-POCKET (PIP): LONG-TERM FOLLOW-UP OF ON DEMAND HIV POST-EXPOSURE PROPHYLAXIS

Maxime J. Billick, **Karla N. Fisher**, Samantha Myers, Darrell H. S. Tan, Isaac I. Bogoch

973 ACCEPTABILITY AND FEASIBILITY OF A NEW URINE-BASED TENOFOVIR ADHERENCE TEST IN KENYA

Kenneth Ngiro, Phelix Okello, Vallery Ogello, Peter Mogere, Stephen Gakuo, Deepalika Chakravarty, Charlene Biwott, Purba Chatterjee, Jennifer Vellozo, Nelly Mugo, Monica Gandhi

974

WITHDRAWN

Poster Session-W1 MPOX PREVENTION

2:30 PM - 4:00 PM

1000 DISPARITIES IN MPOX VACCINATION UPTAKE IN SAN FRANCISCO AMONG PLWH AND PEOPLE ON PrEP

Elise S. Mara, Ling Hsu, Julia Janssen, Melissa Ongpin, Michelle Kirian, Melissa A. Sanchez, Stephanie Cohen

1001 ESTABLISHING AN OBSERVATIONAL MPOX VACCINATION STUDY WHILE THE OUTBREAK EVOLVES

NP

Angelica C. Kottkamp, Marie Samanovic, Ellie Carmody, Lalitha Parameswaran, Heekoung Allison Youn, Olivia Frank, Stephanie Rettig, Lisa Zhao, Julia Wagner, Celia Engelson, Miguel Rodriguez, Trishala Karmacharya, Jane R. Zucker, Jennifer B. Rosen, Mark J. Mulligan,

Aaron Oom

Research Group: NYC OSMI Study Group

- 1002 EVALUATING THE USE OF DOSE-SPARING VACCINATION STRATEGIES FOR MPOX**
Dobromir Dimitrov, Blythe Adamson, Laura Matrajt
- 1003 IDENTIFYING DISPARITIES IN MPOX VACCINATION IN A SOUTHEASTERN ACADEMIC HIV CLINIC**
Edwin Wilbur. Woodhouse, Ahmad Mourad, Emily Niehaus, Hayley Cunningham, Naseem Alavian, Sofia Zavala, Patricia Kohler, Steven Pappas, Michael Yarrington, Nwora Lance Okeke, Cameron R. Wolfe, Gary Cox, Kristen V. Dicks, Jason E. Stout
- 1004 MPOX AWARENESS, RISK REDUCTION, AND VACCINE ACCEPTANCE AMONG PWH IN WASHINGTON, DC**
Amanda D. Castel, Elisabeth Andersen, Anne Monroe, Jose Lucar, Rachel Lee, Debra Benator, Alan Greenberg
Research Group: The DC Cohort Executive Committee

Poster Session-X1 SPECIAL TOPICS IN SRH AND HIV

2:30 PM - 4:00 PM

- 1021 COMPARISON BETWEEN HIV+ WOMEN TRANSITIONING THROUGH MENOPAUSE AND MEN OF SIMILAR AG**
 Hachfeld Anna, **Andrew Atkinson**, Catrina Mugglin, Petra Stute, Alexandra Calmy, Philip Tarr, Katherine Darling, Baharak Babouee-Flury, Christian Polli, Leila Sultan-Beyer, Irene Abela, Chloe Pasin, Andri Rauch, Karoline Aebi-Popp
Research Group: Swiss HIV Cohort Study (SHCS)
- 1022 DISTINCT EFFECT OF SEX HORMONE INTAKE ON IMMUNITY IN CIS AND TRANS WOMEN WITH HIV**
 NIS **Chloe Pasin**, David Garcia Nuñez, Katharina Kusejko, Hachfeld Anna, Karoline Aebi-Popp, H el ene Buvelot, Matthias Cavassini, Lauro Damonti, Christoph Fux, Bego na Martinez de Tejada, Julia Notter, Alexandra Trkola, Huldrych F. F. G unthard, Roger D. Kouyos, Irene A. Abela
Research Group: Swiss HIV Cohort Study
- 1023 ACCEPTABILITY OF EMERGENCY CONTRACEPTION IN ACTG A5375**
Elizabeth Barr, Laura Smeaton, Maxine Olefsky, Susan E. Cohn, Rosie Mngqibisa, Kimberly K. Scarsi, Catherine Godfrey
Research Group: A5375 Protocol Team
- 1024 THE EFFECT OF FP EDUCATION ON KNOWLEDGE AND USE OF FP IN UGANDAN FISHING COMMUNITIES**
Annet Nanvubya, Rhoda Wanyenze, Andrew Abaasa, Teddy Nakaweesa, Juliet Mpendo, Barbarah Kawoozo, Francis Matovu, Sarah Nabukalu, Geoffrey Omoding, Jed Kaweesi, John Ndugga, Bernard Bagaya, Kundai Chinyenze, Matt A. Price, Jean Pierre Van Geertruyden

Poster Session-Y01 ACCESS TO ART

2:30 PM - 4:00 PM

1036

NIS

WITHDRAWN

- 1037 INEQUITIES IN TRAVEL-TIME TO HIV TREATMENT IN AFRICA: A 3- COUNTRY COMPARISON**
 Justin T. Okano, Andrea Low, Luckson Dullie, Wongani Mzumara,
Sally Blower

1038 EVALUATION OF MEDICAL DRONES FOR ANTIRETROVIRAL DELIVERY IN AN ISLAND POPULATION

LB

Rosalind Parkes-Ratanshi, Patrick Mr. Ssesaazi, **Agnes Bwanika Naggirinya**, Jackie Lydia N. Ssemata, Joan Akullo, Dickson Masoni, Agnes Kiragga, Theresa Pattery, Robert Kimbui, Andrew Kambugu, Tom Kakaire

Poster Session-Y02 MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION

2:30 PM - 4:00 PM

1038.5 A LOW-COST, RAPID URINE TEST FOR TFV INCREASES ART ADHERENCE AND VIRAL SUPPRESSION

Leonard Bikinesi, Matthew A. Spinelli, Ntombizodwa Nyoni, Jesaya Hifindwako, Assegid Mengistu, Jacques Kamangu, Gram Mutandi, Daniella Mouton, Fekir Negussie, Guohong Wang, Rachel Suzanne Beard, Monica Gandhi, Steven Y. Hong

1039 DOES TYPE OF PICK-UP POINT INFLUENCE 12-MONTH VIROLOGIC SUPPRESSION IN SOUTH AFRICA?

Ingrid Bassett, Joyce Yan, Sabina Govere, Anele Khumalo, Zinhle Shazi, Mpilonhle Nzuzi, Taing N. Aung, Danielle Zions, Nduduzo Dube, Laura Bogart, Robert Parker

1040 AN ADAPTIVE INTERVENTION TRIAL TO SUPPORT VIRAL SUPPRESSION AMONG FEMALE SEX WORKERS

NIS

Sheree Schwartz, Carly Comins, Mfezi McInzana, Siyanda Makama, Lillian Shipp, Ntambue Mulumba, Rene Phetthu, Vijay Guddera, Katherine Young, Pravi Moodley, Kerusha Govender, **Harry P. Hausler**, Stefan Baral
Research Group: Siyaphambili study team

1041 TRENDS IN PERSISTENT HIV VIREMIA DURING UNIVERSAL TEST-AND-TREAT SCALE-UP IN UGANDA

Joseph G. Rosen, Larry William W. Chang, Ronald M. Galiwango, Robert Ssekubugu, Anthony Ndyanabo, Gertrude Nakigozi, Katherine B. Rucinski, Caitlin E. Kennedy, Fred Nalugoda, Godfrey Kigozi, Joseph Kagaayi, Thomas C. Quinn, Lisa A. Mills, Steven J. Reynolds, Mary K. Grabowski

Poster Session-Y03 ACHIEVING TARGETS

2:30 PM - 4:00 PM

1042 USAGE PATTERNS AND OUTCOMES IN A LARGE COMMUNITY ART PROGRAMME IN SOUTH AFRICA

Lara Lewis, Yukteshwar Sookrajh, Johan van Der Molen, Munthra Devi Maraj, Thokozani Khubone, Rosemary Van Heerden, Francesca Little, Reshma Kassarjee, Nigel Garrett, Jienchi Dorward

1043 HIGH COVERAGE OF HIV TREATMENT, LOW COVERAGE OF PREVENTION SERVICES AMONG KP IN INDIA

Allison M. McFall, Viswanathan Arumugam, Jade Bell, Saya Okram, Aditya Singh, Rose Pollard, Ajay Enugu, Shruti H. Mehta, Sunil S. Solomon

1044 ACHIEVING THE EHE INCIDENCE REDUCTION GOALS AMONG AT-RISK POPULATIONS IN THE SOUTH

Deven T. Hamilton, Karen Hoover, Dawn Smith, Kevin Delaney, Li Yan Wang, Jingjing Li, Tamika Hoyte, Samuel Jenness, Steven M. Goodreau

1045 PROGRESS ON UNAIDS 95-95-95 TARGETS AMONG KEY POPULATIONS IN 3 TANZANIA REGIONS

Tara Pinto, Werner Maokola, Gulam Abdulkarim, George Mgomella, Mucho Mizinduko, Joyce Neal, Prince Mutalemwa, Samwel Sumba, Mark Breda, Ananthy Thambinayagam, Nyambura Moremi, Jessica Greene, Mahesh Swaminathan, Shannon M. Farley, Elias Bukundi

1046 INCREASING IN LIFE EXPECTANCY OF THAI LIVING WITH HIV IN THE ERA OF TREAT ALL

Sirinya Teeraananchai, Stephen J. Kerr, Cheewanan Lertpiriyasuwat, Rattaphon Triamwichanon, Patchara Benjarattanaporn, Win Min Han, Matthew G. Law, Anchalee Avihingsanon, Kiat Ruxrungtham

1047 REACHING THE THIRD 95 IN UGANDA AFTER LOWERING HIV VIRAL LOAD SUPPRESSION CUTPOINTS

NIS

Joseph G. Rosen, Steven J. Reynolds, Ronald M. Galiwango, Godfrey Kigozi, Thomas C. Quinn, Oliver Ratmann, Lisa J. Nelson, Gertrude Nakigozi, Margaret Nalugemwa, Katherine B. Rucinski, Caitlin E. Kennedy, Larry William W. Chang, Joseph Kagaayi, David M. Serwadda, Mary K. Grabowski

1048 GETTING TO ZERO: ACHIEVEMENT OF 95-95-95 AND DECLINING HIV INCIDENCE IN ESWATINI

LB

Harriet Nuwagaba-Biribonwoha, Sindisiwe Dlamini, Neena Philip, Choice Ginindza, Michelle Li, Kristin Brown, Nokuthula Mahlalela, Yvonne Mavengere, Daniel Catano, Kelsie Decker-Pulice, Jessica Justman, Ruben Sahabo, Rejoice Nkambule, David Hoos, Wafaa El-Sadr

Research Group: SHIMS3 Team

Poster Session-Y04 HIV TESTING

2:30 PM - 4:00 PM

1049 EARLY CASE-FINDING IS STILL NEEDED IN THE HIV TEST-AND-TREAT ERA TO PREVENT MORTALITY

Sasi Jonnalagadda, Jacques Muthusi, Anthony Waruru, Wanjiru Waruiru, Kevin Kintungu, Margaret Ndisha, Mary Mwangome, Kenneth Masamaro, Abraham Katana, Appolonia Aoko, Lucy Nganga, Rachael Joseph

1050 RE-NORMING OF HIV TESTING IN TB CONTACT INVESTIGATION: A RANDOMIZED CONTROLLED TRIAL

Mari Armstrong-Hough, Joseph Ggita, Amanda Gupta, Joanita Nangendo, Achilles Katamba, J. Lucian Davis

Research Group: Uganda TB Implementation Research Consortium (U-TIRC)

1051 MODELED IMPACT OF HIV SELF-TESTING FOR PrEP SCALE-UP ON DRUG RESISTANCE IN KENYA

NIS

Sarah N. Cox, Linxuan Wu, Rachel Wittenauer, Ifechukwu Benedict Nwogu, Samantha Clark, D. Allen Roberts, Olga Vitruk, Cheryl Johnson, Muhammad S. Jamil, Anita Sands, Robin Schaeffer, Rachel Baggaley, Joanne D. Stekler, Adam Akullian, Monisha Sharma

TUESDAY FEBRUARY 21, 2023

Poster Session-A2 IFN AND ANTIVIRAL FACTORS

2:30 PM - 4:00 PM

- 218 HIV INFECTION OF TFH: INTERROGATING THE SAMHD1 CONTRIBUTION THROUGH HIV-2**
NP André Pires, Rita Moura, Guilherme B. Farias, Carolina M. Conceição, Ana V. Antão, Tiago Ferreira, Bárbara Tavares, Amelia C. Trombetta, Ana Godinho-Santos, Ana E. Sousa, **Robert Badura**
- 219 NEF FROM PRIMARY HIV INFECTION COUNTERACTS IFITM3 AND RESTORES VIRION INFECTIVITY**
Maresh Agarwal, Saliha Majdoul, Abigail A. Jolley, Alex A. Compton
- 220 Vpu OF AN SIV ISOLATE CAN TARGET HUMAN BST-2**
 Weitong Yao, Akhil Chennuru, Preston Moore, Klaus Strelbel, Tetsuro Matano, Taisuke Izumi, **Takeshi Yoshida**
- 221 STINGING CD4+ T CELLS TO RENDER THEM REFRACTORY TO HIV INFECTION**
 Naseem Sadek, Sarah Welbourn, David Gordon, Rafick P. Sékaly, **Jeffrey A. Tomalka**
- 222 PAN-CASPASE INHIBITION PREVENTS HIV REPLICATION BY THE INDUCTION OF THE IFN I PATHWAY**
 Jordi Senserrich, Sònia Pedreño, Elisabet García, Elisabet Gómez, Bonaventura Clotet, **Cecilia Cabrera**
- 223 THE SPIKE OF SARS-CoV-2 VARIANTS ALLOWS FOR MORE EFFICIENT COUNTERACTION OF BST2**
Yuhang Shi, Yuxuan Chen, Ruth Serra-Moreno
- 224 cGAS-STING PATHWAY LIMITS SARS-CoV-2 REPLICATION IN ACE2+ AIRWAY CELL LINES**
Maritza N. Puray-Chavez, Kyle M. Lepak, Ria Jasuja, Shawn Mohammed, Dana Q. Lawson, M. Ben Major, Dennis Goldfarb, Sebla B. Kutluay
- 225 LONG NON-CODING RNA REGULATES IFN-I RESPONSE AND SARS-CoV-2 REPLICATION**
Smita Kulkarni

Poster Session-B3 HIV NON IMMUNO PATHOGENESIS, COINFECTION

2:30 PM - 4:00 PM

- 253 BODY MASS INDEX AND INFLAMMATION IN PEOPLE LIVING WITH HIV AND UNINFECTED CONTROLS**
Marco Gelpi, Rebekka Faber Thudium, Malene Hove-Skovsgaard, Thomas Lars Benfield, Sisse Rye Ostrowski, Susanne Dam Poulsen
- 254 IRON METABOLISM IN CHRONIC HIV: IMPAIRED HEPcidIN-SOLUBLE TRANSFERRIN RECEPTOR AXIS**
NIS **Vanesa Garrido-Rodríguez**, Ana Isabel Alvarez-Rios, Israel Olivas-Martínez, María Del Mar Pozo-Balado, Ángel Bulnes-Ramos, Manuel Leal, Yolanda Pacheco
- 255 ENDOTHELIAL GM-CSF IN PLWH CONTRIBUTES TO PROINFLAMMATORY VASCULAR MICROENVIRONMENT**
NIS **Soumya Panigrahi**, Elizabeth Mayne, Nicholas Funderburg, Archeesha Chakraborty, Michael M. Lederman, Michael L. Freeman, Scott F. Sieg

- 256 EFFECT OF *P. FRAGILE* COINFECTION ON ART AND IMMUNITY IN SIV-INFECTED RHESUS MACAQUES**
Sydney Nemphos, Hannah Green, Kelly Goff, Matilda Moström, Coty Tatum, Chad Massey, Robert Blair, Carolina Allers, Monica Embers, Nicholas Maness, Preston Marx, Brooke Gasperge, Amitinder Kaur, Jennifer Manuzak
- 257 INNATE IMPAIRMENT DURING SIV INFECTION ALTERS ZIKV VIRAL PATHOGENESIS**
 Jennifer Tisoncik-Go, Thomas B. Lewis, Skyler Niemeyer, Andrew Gustin, Rene A. Ruiz, Paul Kim, Kai Hubbell, Naoto Iwayama, Solomon Wangari, Chul Ahrens, Robert Murnane, Kathryn A. Guerriero, Michael Gale, Deborah H. Fuller, **Megan A. O'Connor**
- 258 LYMPHOID TISSUE VOLUMES AND GLUCOSE METABOLISM IN EARLY SIV INFECTION OF AGM AND RM**
LB
Hyukjin Jang, Dongzhu Ma, Sharat Srinivasula, Brad Long, Heather Brown, Cui Ling Xu, Cristian Apetrei, Ivona Pandrea, Michele Di Mascio
- 259 THE BREADTH AND POLYFUNCTIONALITY OF T CELL RESPONSES TO CMV DIFFER BY HIV STATUS**
Weiyang Zhang, Tricia L. Nilles, Jay H. Bream, Huifen Li, Sean X. Leng, Joseph B. Margolick

Poster Session-B5 HIV IMMUNOPATHOGENESIS
2:30 PM - 4:00 PM

- 265 GERMINAL CENTER B CELLS INDUCE TFH ACTIVATION AND HIV REPLICATION**
NIS
Matthew Ollerton, Joy Folkvord, David Parry, Elizabeth Connick
- 266 SIALIDASE INHIBITION PREVENTS HIV-MEDIATED INFLAMMATION AND IMMUNE ACTIVATION IN VIVO**
Leila Giron, Shalini Singh, Kai Ying Hong, Joshua Glover, Eric Balboa, Derrick Dopkin, Michelle Burrows, Anthony Secreto, Nicolas Skuli, Todd T. Brown, Alan Landay, Ali Keshavarzian, Ivona Pandrea, Paul Denton, Mohamed Abdel-Mohsen
- 267 EXPRESSION OF UNSPLICED HIV-1 RNA INDUCES INFLAMMASOME ACTIVATION IN MYELOID CELLS**
Sallieu Jalloh, Ivy Hughes, Chelsey Skeete, Hisashi Akiyama, Aldana Gojanovich, Gustavo Mostoslavsky, Rahm Gummuluru
- 268 IMPACT OF EARLY ART ON TISSUE RESIDENT MEMORY T CELLS IN THE GASTROINTESTINAL TRACT**
 Aloysious Ssemaganda, Yuwadee Phuang-Ngern, Chayada Sajjaveerawan, Phil Ehrenberg, Henok Gebrebrhan, Sandra Choi, Michael Corley, Giulia Severini, Nittaya Phanuphak, Carlo Sacdalan, Denise Hsu, Rasmi Thomas, Lyle McKinnon, **Alexandra Schuetz**
Research Group: RV254/SEARCH010 and SEARCH013/RV304 study groups
- 269 MULTOMIC BIOMARKERS ACROSS ART INITIATION TIMEPOINTS REVEAL INTERFEROME ENRICHMENT**
 Harrison B. Lindley, Cheryl Cameron, Brian Richardson, Jillian Petroski, Wendy Lin, Jared M. Baeten, Connie Celum, Florian Hladik, Jairam Lingappa, Romel Mackelprang, **Mark Cameron**
- 270 HIV SUPPRESSION IS LINKED TO SHIFTING EPIGENETIC/ TRANSCRIPTOME FEATURES IN MONOCYTES**
 Guido Massaccesi, Brittany White, Eric S. Rosenberg, Todd Allen, **Eileen P. Scully**

Poster Session-B7 LONG COVID

2:30 PM - 4:00 PM

- 282 PLASMA-BASED ANTIGEN PERSISTENCE IN THE POST-ACUTE PHASE OF SARS-CoV-2 INFECTION**
Michael J. Peluso, Zoe Swank, Sarah A. Goldberg, Yasmeen Senussi, Scott Lu, Rebecca Hoh, Khamal Anglin, Beatrice Huang, Matthew S. Durstenfeld, John D. Kelly, Timothy Henrich, Steven G. Deeks, David V. Glidden, David Walt, Jeffrey Martin
Research Group: LIINC study team
- 283 PLASMA ANTIBODY AND N ANTIGEN STATUS PREDICT OUTCOMES IN OUTPATIENTS WITH COVID-19**
Nikolaus Jilg, Mark Giganti, Kara W. Chew, Katy Shaw-Saliba, Justin Ritz, Carlee Moser, Teresa H. Evering, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Henry C. Lane, Robin Dewar, Davey M. Smith, Jonathan Z. Li
- 284 VIRAL DYNAMICS AND FACTORS FAVOURING THE DURATION OF COVID-19 POSITIVITY IN CAMEROON**
Aurelie Minelle Kengni Ngueko, Fokam Joseph, Alex Durand Nka, Collins Ambe Chenwi, Ngoufack Jagni Ezechiel Semengue, Takou Désiré, Aude Christelle Ka'E, Davy-Hyacinthe Gouissi Anguecha, John Otshudiema Otokoye, Francesca Ceccherini-Silberstein, Yap Boum Ii, Alfred K. Njamshi, Nicaise Ndembu, Carlo-Federico Perno, Ndjolo Alexis
Research Group: Chantal Biya International Reference Center COVID-19 team
- 285 MITOCHONDRIAL DYSFUNCTION IS ASSOCIATED WITH POST-ACUTE SEQUELAE OF COVID-19**
Sahera Dirajjal-Fargo, Jared C. Durieux, Anastasia Andrukhiv, David Maison, Mariana Gerschenson, Grace A. McComsey
- 286 SINGLE-CELL ANALYSIS REVEALS CHARACTERISTICS OF MYELOID CELLS IN PULMONARY PASC**
Hyundong Yoon, Boonyanudh Jiyarom, Logan Dean, Dominic Chow, Cecilia Shikuma, Gehan Devendra, Youngil Koh, **Juwon Park**
- 287 ADAPTIVE IMMUNITY DYSREGULATION IS ASSOCIATED TO THE DEVELOPMENT OF LONG COVID**
Roberta Rovito, Valeria Bono, Matteo Augello, Francesca Bai, Camilla Tincati, Guillaume Beaudoin-Bussièrès, Alexandra Tauzin, Silvia Bianchi, Joanna Mikulak, Elisa Borghi, Antonella D'Arminio Monforte, Silvia Della Bella, Andrés Finzi, Domenico Mavilio, **Giulia C. Marchetti**
- 288 INCREASED GUT PERMEABILITY AND OXIDIZED LIPIDS IN PASC**
Christian Mouchati, Jared C. Durieux, Sokratis N. Zisis, Mary Chong, Danielle Labbato, Grace A. McComsey
- 289 NONHUMAN PRIMATE MODEL OF LONG COVID: IMMUNE INSIGHTS OF GLYCOMETABOLIC DYSFUNCTIONS**
Clovis C. Palmer, Chrysostomos Perdios, Mohamed Abdel-Mohsen, Nicholas Maness, Gabrielle Lehmicke, Joseph Mudd, Kasi Russell-Lodrigue, Angela Birnbaum, Rudolf Bohm, Jason Dufour, Robert Blair, Ahmed Saied, Jay Rappaport, Cecily Midkiff, Carol Coyne, Nadia Golden
- 290 PROLONGED SARS-CoV-2 VIRAL BURDEN IN SIV/SARS-CoV-2 COINFECTED MACAQUES**
Megan N. Fredericks, Hillary C. Tunggal, Cecily C. Midkiff, Jeana E. Barrow, Anthony L. Cook, Robert Blair, Ankur Sharma, Deborah H. Fuller, Megan A. O'Connor

Poster Session-C1 BASIC SCIENCE OF TUMOR VIRUSES: HTLV, HBV, EBV, AND ENDOGENOUS RETROVIRUSES

2:30 PM - 4:00 PM

294 INNATE IMMUNITY IN HTLV-1 INFECTION: IFN-GAMMA LEVELS ARE UP-REGULATED IN EARLY HAM

Marta S. Porto, Sandy V. Teixeira, **Gabriela S. Prates**, George Gonçalves, Jorge Casseb

295 HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH HIF-1 α

Min Xu, Charlotte Warner, Xiaoqiong Duan, Andre Jeyarajan, Zhimeng Cheng, Zachary Manickas-Hill, Tuo Shao, **Shadi Salloum**, Xu G. Yu, Raymond Chung, Wenyu Lin

296

NIS

WITHDRAWN

297 ENDOGENOUS RETROVIRAL DYSREGULATED EXPRESSION IN PEDIATRIC CROHN'S DISEASE

Konstantina Kitsou, Vana Spoulou, Pagona Lagiou, Gkikas Magiorkinis

Poster Session-D3 IMMUNE MODULATION AND VACCINES

2:30 PM - 4:00 PM

316 DNA LAUNCHED BROADLY NEUTRALIZING KILLERS: A DOUBLE-EDGED THERAPEUTIC AGAINST HIV-1

Sukanya Ghosh, Mansi Purwar, Samson Adeniji, Abhijeet Kulkarni, Zhe Yuan, Pratik Bhojnagarwala, Giselle Lopez Fernandez, Luis J. Montaner, Mohamed Abdel-Mohsen, David B. Weiner

317 LAIR-1: NEGATIVE REGULATOR OF SIV- SPECIFIC CD8 T CELLS DURING CHRONIC SIV INFECTION

Sakthivel Govindaraj, Ashish Arunkumar Sharma, Syed Ali, Hemalatha Babu, Kathleen Busman-Sahay, Deepa Machiah, Steven Bosinger, Jacob Estes, Rafick P. Sékaly, Francois Villinger, Rama R. Amara, **Vijayakumar Velu**

318 TIGIT/CD155 BLOCKADE BOOSTS T-CELL IMMUNITY AND HIV-SPECIFIC DEGRANULATION IN PLWH

NIS

Miguel Marin, Julieta Carabelli, Eudald Vehi, Ruth Peña, Gabriel Felipe Rodríguez-Lozano, Natalia Isabel Rodrigo, Carlo Carolis, Luis Álvarez-Vallina, Jorge Carrillo, Bonaventura Clotet, Julia G. Prado

Research Group: VIRAL IMMUNE EVASION AND VACCINES (VIRIEVAC)

319 EVALUATION OF HIV-SPECIFIC T CELL RESPONSE IN BEAT2 CLINICAL TRIAL

M. Betina Pampena, Pablo Tebas, Livio Azzoni, Emmanouil Pappasavvas, Matthew Fair, Karam Mounzer, Luis J. Montaner, Michael R. Betts

320 ONE-YEAR TREATMENT WITH PONATINIB INDUCES SUSTAINED CYTOTOXIC ACTIVITY AGAINST HIV

NIS

Fernando Ramos-Martín, Mario Manzanares, Montserrat Torres, Elena Mateos, Lorena Vigón, Guiomar Casado Fernández, Sara Rodríguez Mora, Vicente Planelles, Valentín García-Gutiérrez, Mayte Coiras

321 DECREASED HIV-SPECIFIC POLYFUNCTIONAL RESPONSES FOLLOWING DIPYRIDAMOLE TREATMENT

Benjamin C. Morris, Emily Hixson, Cynthia Klamar-Blain, Edwin Jackson, Kaleab Abebe, Lori Caruso, John W. Mellors, Charles Rinaldo, Sharon A. Riddler, Bernard Macatangay

- 322 URACIL TREATMENT DOES NOT INCREASE SUSCEPTIBILITY TO RECTAL SIV INFECTION**
Alexandra Ortiz, Charlotte Langner, Jason Brenchley
- 323 HETEROLOGOUS ChAd/samRNA SIV VACCINE INDUCES ROBUST T CELL RESPONSES IN MACAQUES**
Amy Rappaport, Elena Bekerman, Greg Boucher, Janette Sung, Brian Carr, Cesar Corzo, Sue-Jean Hong, Heather Larson, Ciaran Scallan, Bill Wang, Romas Geleziunas, Devi Sengupta, Karin Jooss
- 324 CD40.HIVRI.Env VACCINE INDUCES STRONG AND DURABLE IMMUNE RESPONSES: ANRS VRI06 TRIAL**
LB
Jean-Daniel Lelievre, Christiane Moog, Aurélie Wiedemann, Christine Lacabartz, Fabio Candotti, Melany Durand, Véronique Rieux, Lucile Hardel, Alpha OB. Diallo, Song Ding, Mireille Centlivre, Rodolphe Thiebaut, Giuseppe Pantaleo, Laura Richert, Yves Levy
- 325 THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS IN STI-MEDIATED ENHANCED HIV INFECTION**
NIS
Daan K.J. Pieren, Núria Massanasa, Vicente Descalzo, Maider Arando, Jorge García-Pérez, Patricia Álvarez, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Desideria Martínez, Josep Castellvi, Clara Ramírez Serra, Daniel Álvarez-de la Sierra, Vicenç Falcó, Maria J Buzon, Meritxell Genescà
- 326 BEAT2: PEG-IFN-ALPHA + 3BNC117 & 10-1074 REBOUND VIRUS PHENOTYPE AND EVOLUTION**
Jaimy Joy, Francesco Marino, Ryan Krause, Christos J. Petropoulos, Emmanouil Pappasavvas, Matthew Fair, Karam Mounzer, Pablo Tebas, Luis J. Montaner, Katharine Bar
- 327 TIGIT BLOCKADE RESTORES FUNCTIONAL NKG2C+ NK CELLS AND LIMITS SPREAD OF HIV-1 IN VIVO**
LB
Ildefonso Sánchez-Cerrillo, Marta Calvet-Mirabent, Olga Popova, Ignacio De Los Santos, Jesús Sanz, Patricia Fuentes, Juan Alcain, Ilya Tsukalov, Arantzazu Alfranca, Maria J Buzon, María Luisa Toribio, Angeles Muñoz-Fernández, Francisco Sánchez-Madrid, Enrique Martin-Gayo
Research Group: CIBERINFECC
- 328 GERMLINE-TARGETING ENV TRIMER ELICITS bNAb PRECURSORS IN INFANT, NOT JUVENILE MONKEYS**
LB
Yasmine lassah, John Isaac, Xintao Hu, Shaunna Shen, Gabe Orozowski, Shiyu Zhang, Andrew Ward, David Montefiori, Rogier Sanders, Koen Van Rompay, Kristina De Paris, Sallie R. Permar

Poster Session-D7 SARS-CoV-2 VACCINES AND PREVENTION

2:30 PM - 4:00 PM

- 355 REAL-WORLD EFFECTIVENESS OF mRNA, SUBUNIT, AND VECTOR-BASED VACCINES AGAINST COVID-19**
Cheng-Yi Lee, Hung-Wei Kuo, Yu-Lun Liu, Jen-Hsiang Chuang, Jih-Haw Chou
- 356 IMMUNOGENICITY OF SARS-CoV-2 VACCINES BY VACCINE TYPE IN RANDOMISED CLINICAL TRIALS**
Sreenidhi Venkatesh, Andrea Navarro Perez, Andrew Hill
- 357 IVSV-BASED COVID VACCINE FOR THE PREVENTION OF BREAKTHROUGH SARS-CoV-2 INFECTIONS**
Ryan Troyer, Mansour Haeryfar, Stephen Barr, C. Yong Kang

- 358 HOSPITAL PROTECTION CORRELATES IN OUTPATIENT COVID-19 CONVALESCENT PLASMA RECIPIENTS**
Anna Yin, Caelan Barranta, Han-Sol Park, John Lee, Christopher Caputo, Judith S. Currier, Sonya L. Heath, Moises A. Huaman, Oliver Laeyendecker, Aaron Tobian, Andrew Pekosz, Kelly Gebo, David J. Sullivan, Sabra L. Klein, Daniel F. Hanley, Arturo Casadevall, Evan M. Bloch, Shmuel Shoham
Research Group: CSSC Group
- 359 SARS-CoV-2 INFECTIONS AMONG 275 PATIENTS WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS**
Valentine M. Ferré, Laura Kramer, Christophe Rioux, Tiphaine Goulenok, Nathan Peiffer-Smadja, Mathilde Salpin, Quentin Le Hingrat, Eric Daugas, Michael Thy, Richard Dorent, Sébastien Ottaviani, Yazdan Yazdanpanah, Diane Descamps, Jade Ghosn, Véronique A. Joly
- 360 CD8+ T CELL CLONES FROM PRIOR SARS-CoV-2 INFECTION PREDOMINATE AFTER MRNA VACCINATION**
 Emily Ford, **Koshlan Mayer-Blackwell**, Lichen Jing, Anton Sholukh, Russell St Germain, Thomas Pulliam, Saumya Jani, Stacy Selke, Anna Wald, Rebecca Elyanow, Harlan Robins, Elise C. Wilcox, Aude G. Chapuis, Andrew Fiore-Gartland, David M. Koelle, Emily L. Bossard
- 361 LIMITED INDUCTION OF LUNG-RESIDENT MEMORY T CELLS BY SARS-CoV-2 mRNA VACCINATION**
Daan K.J. Pieren, Sebastián Kuguel, Joel Rosado, Alba González Robles, Joan Rey-Cano, Cristina Mancebo Pérez, Juliana Esperalba, Vicenç Falcó, Maria J Buzon, Meritxell Genescà
- 362 CD40.SARS.CoV2 VACCINE, BUT NOT mRNA, INDUCES SPECIFIC CD8+ T MEMORY STEM CELLS**
 Laury Nguema, Marwa El Hajj, Florence Picard, Craig Fenwick, Sylvain Cardinaud, Aurélie Wiedemann, Giuseppe Pantaleo, Sandy Zurawski, Mireille Centlivre, Gerard Zurawski, Yves Lévy, **Veronique Godot**
- 363 SARS-CoV-2 VACCINE-INDUCED T CELL RESPONSES IN CANCER PATIENTS UNDERGOING TREATMENT**
Chad Poloni, Xiaojiao Wang, Andrew Sze, Stephen Chia, Laura Cook, Ted Steiner
- 364 NEUTRALIZING ACTIVITY AND T CELL RESPONSE AFTER BIVALENT THIRD BOOSTER DOSE IN PLWH**
 Alessandra Vergori, **Giulia Matusali**, Alessandro Cozzi Lepri, Eleonora Cimini, Marisa Fusto, Francesca Colavita, Stefania Cicalini, Stefania Notari, Valentina Mazzotta, Davide Mariotti, Roberta Gagliardini, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Silvia Meschi, Gianluca Prota, Massimo Francalancia, Marika Rubino, Giuseppina Giannico
Research Group: HIV-VAC Study Group
- 365 12-MONTH HUMORAL RESPONSE AFTER mRNA COVID-19 VACCINATION IN PEOPLE LIVING WITH HIV**
Paul Loubet, Linda Wittkop, Alexis Francois, Karine Lacombe, Valérie Pourcher, Alain Makinson, Pierre-Olivier Girodet, David Chirio, Philippe Vanhems, Maeva Lefebvre, Catherine Schmidt-Mutter, Xavier de Lamballerie, Julie Longobardi, Jean-Daniel Lelievre, Odile Launay
Research Group: ANRS0001S COV-POPART cohort study group
- 366 SARS-CoV-2 LIVE VIRUS NEUTRALIZATION AFTER FOUR COVID-19 VACCINE DOSES IN PWH ON ART**
 Peter K. Cheung, Hope Lapointe, Yurou Sang, Siobhan Ennis, Francis Mwimanzi, Sarah Speckmaier, Evan Barad, Winnie Dong, Janet Simons, Christopher F. Lowe, Marc G. Romney, Chanson J. Brumme, Masahiro Niikura, Mark Brockman, **Zabrina Brumme**
Research Group: COVID-19 vaccine immunity study team

- 367** **IMMUNOGENICITY OF SARS-CoV-2 mRNA VACCINATION IN IDIOPATHIC CD4 LYMPHOPENIA**
NIS **Joseph Rocco**, Kristin L. Boswell, Elizabeth Laidlaw, Megan Anderson, Leonid Serebryanny, Sandeep Narpala, Sarah O'Connell, Heather Kalish, Adrian B. McDermott, Susan Moir, Maura Manion, Andrea Lisco, Richard A. Koup, Irini Sereti
- 368** **RESTORATION OF HUMORAL RESPONSE TO COVID-19 VACCINATION IN RITUXIMAB-TREATED PATIENTS**
Wang-Da Liu, Tai-Chung Huang, Jann-Tay Wang, Hsin-Yun Sun, Shang-Ju Wu, Huai-Hsuan Huang, Chia-Yi Lin, Guei-Chi Li, Sui-Yuan Chang, Chien-Ching Hung
- 369** **THREE DOSES OF COVID-19 VACCINES IN PWH: IMMUNOGENICITY AND EFFECTS ON HIV RESERVOIR**
Vitaliy Matveev, Erika Benko, Erik Mihelic, Terry Lee, Karen Colwill, Robert Reinhard, Sebastian Grocott, Patrick Budykowski, Lela Kardava, Susan Moir, Jennifer Gommerman, Anne-Claude Gingras, Colin Kovacs, Mario Ostrowski
- 370** **EFFECTS OF COVID-19 mRNA VACCINATION ON HIV VIREMIA AND RESERVOIR SIZE IN PWH ON ART**
Maggie Duncan, F Harrison Omondi, Natalie Kinloch, Hope Lapointe, Sarah Speckmaier, Nadia Moran-Garcia, Tanya Lawson, Mari Demarco, Janet Simons, Daniel Holmes, Christopher F. Lowe, Marc G. Romney, Marianne Harris, Mark Brockman, Zabrina Brumme
- 371** **COVID-19 VACCINATION IMPACTS FUNCTIONAL IMMUNE RESPONSES AND PLASMA PROTEOME IN PLWH**
Twan JW. Otten, Nadira Vadaq, Albert L. Groenendijk, Marc J. T. Blaauw, Willem A. J. W. Vos, Louise E. van Eekeren, Elise M. G. Meeder, Janneke E. Stalenhoef, Casper Rokx, Marvin A. H. Berrevoets, Leo A. B. Joosten, Mihai G. Netea, Andre J.A.M. van Der Ven
Research Group: 2000HIV Functional Genomics Partnership Program
- 372** **IMPACT OF GUT MICROBIOTA ON IMMUNOGENICITY TO COVID-19 VACCINES IN PLWH**
Shilpa Ray, Aswathy Narayanan, Jan Vesterbacka, Giorgio Gabarrini, Yu Gao, Hans-Gustaf Ljunggren, Marcus Buggert, Soo Aleman, Anders Sönnnerborg, Margaret Sällberg Chen, **Piotr Nowak**
- 373** **SEQUENTIAL IMMUNIZATION OF UPDATED COVID-19 DNA AND RNA VACCINES IN NONHUMAN PRIMATES**
Sandra Dross, Megan N. Fredericks, Mathias D. Maughan, Justin T. Ulrich-Lewis, Thomas B. Lewis, Yuqi Dong, James T. Fuller, Solomon Wangari, Alexander Cohen, Pamela J. Bjorkman, Arlene I. Ramsingh, Janice Pata, Jesse Erasmus, Kenneth C. Bagley, Deborah H. Fuller

Poster Session-E4 HIV RESERVOIRS IN CELLS AND TISSUES

2:30 PM - 4:00 PM

- 415** **UNRAVELING ONGOING INFLAMMATION AFTER EARLY ART BY IN-DEPTH ANALYSIS OF LYMPH NODES**
NIS **Jozefien De Clercq**, Kathleen Busman-Sahay, Laurens Lambrechts, Sofie Rutsaert, Sol Taylor-Brill, Stephen Bondoc, Marie-Angélique De Scheerder, Jacob Estes, Sarah Gerlo, Linos Vandekerckhove
Research Group: HIV Cure Research Center
- 416** **UNEQUAL DISTRIBUTION OF INTACT HIV PROVIRUSES IN CELLS EXPRESSING PD-1 AND/OR CTLA-4**
NIS **Katie Fisher**, Timothy Schlub, Zoe Boyer, Thomas Rasmussen, Ajantha Rhodes, Rebecca Hoh, Frederick Hecht, Steven G. Deeks, Sharon Lewin, Sarah Palmer

- 417** **DECIPHERING THE SOURCE OF VIRAL REBOUND IN SIV-INFECTED RHESUS MACAQUES**
NIS
Antonio Solis-Leal, Nongthombam Bobby, Suvadip Mallick, Yilun Cheng, Fei Wu, Grey De La Torre, Jason Dufour, Xabier Alvarez, Vinay Shivanna, Jeffrey D. Lifson, Qingsheng Li, Brandon F. Keele, Binhua Ling
- 418** **AN INTESTINAL TISSUE MODEL FOR TARGETED STRATEGIES DIRECTED TO TISSUE RESERVOIRS**
NIS
Ana Gallego Cortés, Nerea Sánchez Gaona, Cristina Mancebo Pérez, Stefania Landolfi, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
- 419** **MONOCYTE-DERIVED MACROPHAGES CONTAIN LONG-LIVED LATENT HIV RESERVOIRS**
Rebecca Veenhuis, Celina Abreu, Pedro Costa, Edna Ferreira, Janaysha Ratliff, Lily Pohlenz, Erin Shirk, Joel N. Blankson, Lucio Gama, Janice Clements
- 420** **SYSTEMIC INFLAMMATION, GUT DYSBIOSIS AND GUT MICROBIOME IMPACT HIV MIGRATION DYNAMICS**
Ravi Goyal, Sara Gianella, Christophe Vanpouille, Wendy Fitzgerald, Gemma Caballero, Caroline Ignacio, Magali Porrachia, Victor De Gruttola, Davey M. Smith, Antoine Chaillon
- 421** **T-TRACE ENABLES SINGLE-CELL MULTI-OMICS ANALYSIS OF HIV RESERVOIR CELLS FROM TISSUES**
NIS
Julie Frouard, Xiaoyu Luo, Jason Neidleman, Kailin Yin, Sushama Telwatte, Steven Yukl, Jennifer Cohen, Anastasia Polos, Carol Thuman, Rebecca Hoh, Steven G. Deeks, Pavitra Roychoudhur, Sulggi Lee, Phyllis C. Tien, Nadia R. Roan
- 422** **HIV VIRION PROFILING SUGGEST THAT CXCR3+CD4 T CELLS ARE THE MAIN HIV-PRODUCING CELLS**
LB
Olivia Muñoz, Riddhima Banga, Alessandra Noto, David Vinals, Francesco Procopio, Andrea Mastrangelo, Rachel Schelling, Craig Fenwick, Christine Lacabaratz, Yves Levy, Laurent Perez, Matthias Cavassini, Giuseppe Pantaleo, Matthieu Perreau

Poster Session-E6 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND

2:30 PM - 4:00 PM

- 428** **REDUCTION IN HIV RESERVOIR MARKERS WITH GAG/POL/IL-12 DNA THERAPEUTIC VACCINATION**
Kara W. Chew, David V. Glidden, Rémi Fromentin, Jana Jacobs, Amélie Pagliuzza, Gregory M. Laird, Nicolas Chomont, Mansi Purwar, Laurent Humeau, John W. Mellors, David B. Weiner, Rafick P. Sékaly, Steven G. Deeks, Rachel L. Rutishauser
- 429** **DOUBLING DOLUTEGRAVIR DOSAGE REDUCES HIV PERSISTENCE MARKERS IN ART-TREATED ADULTS**
NIS
Céline Fombellida-Lopez, Alexander Pasternak, Aurelija Cicilionytė, Nathalie Maes, Céline Vanwinge, Aurélie Ladang, Etienne Cavalier, Lee Winchester, Courtney V. Fletcher, Fabrice Susin, Dolores Vaira, Marie-Pierre Hayette, Catherine Reenaers, Michel Moutschen, Gilles Darcis
- 430** **RANDOMIZED CONTROLLED TRIAL OF VRCO1 MONOCLONAL ANTIBODY DURING ACUTE HIV INFECTION**
Julie A. Ake, Somchai Sriplienchan, Josphat Kosgei, Hannah Kibuuka, Joel Mwakisisile, Caroline Subra, Christine Orndahl, Leigh Anne Eller, Nelson L. Michael, Sheila A. Peel, Randall Tressler, Richard A. Koup, Morgane Rolland, Merlin L. Robb
Research Group: RV398 Study Team

- 431 BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN- α 2B +3BNC117 & 10-1074 IN CHRONIC HIV INFECTION**
Pablo Tebas, Livio Azzoni, Emmanouil Papasavvas, Grace H. Choi, Susan Ellenberg, Marina Caskey, Bonnie Howell, Larry Fox, Christos J. Petropoulos, Kenneth Lynn, Linden Lalley-Charecko, Jay R. Kostman, William Short, Karam Mounzer, Emily Hiserodt, **Luis J. Montaner**
- 432 LONG-TERM PROTECTION OF CD4+ T CELLS AGAINST HIV BY ONE-YEAR TREATMENT WITH PONATINIB**
NIS
Mario Manzanera, Fernando Ramos-Martín, Guiomar Casado-Fernández, Montserrat Torres, Elena Mateos, Lorena Vigón, Vicente Planelles, Sara Rodríguez Mora, Valentín García-Gutiérrez, Mayte Coiras
- 433 A PLACEBO-CONTROLLED RANDOMIZED TRIAL OF THE HTI IMMUNOGEN VACCINE AND VESATOLIMOD**
LB
Beatriz Mothe Pujades, Adrià Curran, Juan Carlos López, Julen Cadiñanos, Ignacio De Los Santos, Juan Ambrosioni, Arkaitz Imaz, Santiago Moreno, Pere Domingo, Yanhui Cai, Romas Geleziunas, Devi Sengupta, Ian McGowan, Christian Brander, Jose R. Arribas, Álvaro Aranguren, Margarida Garcia-Garcia, Isabel Leal, Heinz Lubenau
Research Group: The AELIX-003 Study Team
- 434 HIV-1 VIRAL RESERVOIR REACTIVATION AFTER CCR5 DELTA 32/32 STEM CELL TRANSPLANTATION**
LB
Paul Rubinstein, Liliana Perez, Damiano Rondelli, Hannah Shepard, Karen Sweiss, Shrihari Kadkol, Habiba Sultana, Christine M. Fennessey, Brandon F. Keele, Robert Gorelick, Peter Burbelo, Frank Maldarelli, Eli Boritz, Richard Novak
- 435 REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR9 AGONIST, AND bNAB**
LB
Michael J. Peluso, Amelia Deitchman, Gesham Magombedze, Meghan Williams, Nitasha Kumar, James Mullins, Barbara K. Felber, George Pavlakis, Rowena Johnston, Jackie Reeves, Lucio Gama, Michel C. Nussenzweig, Timothy Henrich, Rachel L. Rutishauser, Steven G. Deeks
Research Group: UCSF-amfAR Clinical Trial Team
- 436 HIV GAG X CD3 SOLUBLE TCR BISPECIFIC: SAFETY AND ACTIVITY IN A FIRST IN HUMAN TRIAL**
LB
Linos Vandekerckhove, Julie Fox, Borja Mora-Peris, Jordi Navarro, Sabine D. Allard, Alison Uriel, Santiago Moreno, Marta Boffito, Frank Post, Vicente Estrada, Beatriz Mothe Pujades, Yuan Yuan, Adel Benlahrech, Lucy Dorrell, Sarah Fidler
- 437 VESATOLIMOD PHARMACODYNAMIC RESPONSE IS ASSOCIATED WITH TIME TO HIV REBOUND**
LB
Liao Zhang, Mary Wire, Yanan Zheng, Susie SY. Huang, Lisa Selzer, Donovan Verrill, Christiaan R. de Vries, Devi Sengupta, Jeffrey J. Wallin, Yanhui Cai

Poster Session-E8 DYNAMICS OF PROVIRAL INTEGRATION SITES

2:30 PM - 4:00 PM

- 449 IN-DEPTH ASSESSMENT OF THE HIV-1 VIRAL RESERVOIR IN EARLY TREATED INDIVIDUALS**
NIS
Tine Struyve, Marion Pardons, Liesbet Termote, Jozefien De Clercq, Laurens Lambrechts, Jerel Vega, Daniel Boden, Mathias Lichterfeld, Sofie Rutsaert, Linos Vandekerckhove
- 450 HIV-1 RESERVOIRS IN YOUNG ADULTS AFTER LONG-TERM ART FOR CONGENITAL INFECTION**
NIS
Benjamin R. Bone, Nicola Cotugno, Ce Gao, Catherine Koofhethile, Xiaodong Lian, Isabelle C. Roseto, Libera Sessa, Seoyhun Hong, Xu G. Yu, Paolo Palma, Mathias Lichterfeld

- 451** **CTL SELECTION ENRICHES FOR HIV INTEGRATION SITE FEATURES AND EXPANDED CLONES IN VIVO**
NIS
Noemi L. Linden, Alexander McFarland, Ali Danesh, John Everett, Chanson J. Brumme, Paul Zumbo, Doron Betel, Dennis C. Copertino, Zabrina Brumme, Friederike Dünder, Frederic D. Bushman, R. Brad Jones
- 452** **IMPACT OF HIV RESERVOIR IN THE LOSS OF NATURAL ELITE CONTROL OF HIV-1 INFECTION**
NIS
Carmen Gasca-Capote, Xiaodong Lian, Ce Gao, Isabelle C. Roseto, María de los Reyes Jiménez-León, Gregory Gladkov, Alberto Pérez-Gómez, Nuria Espinosa, Francesc Vidal, Antonio Rivero, Luis Fernando López-Cortes, Xu G. Yu, Mathias Lichterfeld, Ezequiel Ruiz-Mateos
- 453** **DISTINCT INTEGRATION SITES OF INTACT HIV-1 PROVIRUSES IN POST-TREATMENT CONTROLLERS**
NIS
Isabelle C. Roseto, Xiaodong Lian, Kyra Seiger, Elizabeth Parsons, Gregory Gladkov, Ce Gao, Karam Mounzer, Emmanouil Pappasavvas, Pablo Tebas, Tae-Wook Chun, Luis J. Montaner, Xu G. Yu, Mathias Lichterfeld
- 454** **EFFECTS OF CHEMORADIATION ON EXPANDED PROVIRAL CLONES IN AN ELITE CONTROLLER**
NIS
Filippo Dragoni, Abena K. Kwaa, Caroline C. Garliss, Bezawit A. Woldemeskel, Angelica Camilo-Contreras, Rebecca Veenhuis, Haley Raymond, Eileen P. Scully, Amanda M. Rosecrans, Frederic D. Bushman, Francesco R. Simonetti, Joel N. Blankson
- 455** **EFFECT OF HIV-1 INFECTION AND VIRUS PRODUCTION ON CD4+ T CELL PROLIFERATION**
Joshua T. Kufera, Ciara Armstrong, Fengting Wu, Anushka Singhal, Jun Lai, Hao Zhang, Hannah Wilkins, Francesco R. Simonetti, Janet M. Siliciano, Robert F. Siliciano
- 456** **A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE**
NIS
Sam Weissman, Marilia Pinzone, Alfonso Ocegüera, Ashley Ginda, Liam Swiggard, Lamont Cannon, Ryan Zurakowski, Una O'Doherty

Poster Session-E9 HIV RESERVOIRS IN CHILDREN AND YOUTH

2:30 PM - 4:00 PM

- 457** **ACUTE/RECENT HIV INFECTION IN YOUTH: HIV RESERVOIRS AND ANTIBODY FOLLOWING EARLY ART**
Karin Nielsen-Saines, Ruth Cortado, Myung Shin-Sim, Tara Kerin, Manuel Ocasio, Sue Ellen Abdalian, Risa Flynn, Robert Bolan, Dallas Swendeman, Sophia Paiola, Yetunde Adebambo, Bonnie Ank, Yvonne Bryson, Maria Isabel Fernandez
Research Group: CARES ATN Team
- 458** **LEUKAPHERESIS: A FEASIBLE TOOL TO INFORM ATI THROUGH HIV RESERVOIR STUDY IN CHILDREN**
NIS
Nicola Cotugno, Giuseppe Rubens Pascucci, Elena Morrocchi, Benjamin R. Bone, Chiara Pighi, Chiara Medri, Marco Sanna, Nicole Colantoni, Simona Tedde, Giovanna Leone, Giovanna Del Principe, Stefania Bernardi, Paolo Rossi, Mathias Lichterfeld, Paola Palma
- 459** **SIV CLEARANCE FROM NEONATAL MACAQUES FOLLOWING TRANSIENT CCR5 DEPLETION**
LB
Jesse Deere, David Merriam, Kawthar Leggat, Wen-Lan William Chang, Gema Méndez-Lagares, Joseph Dutra, Ning Chin, Corey Miller, Steven G. Deeks, Kathleen Engelman, Diogo Magnani, Keith Reimann, Jeffrey D. Lifson, Mario Stevenson, Dennis Hartigan-O'Connor, Connie Chen, Justin Fontaine, Hung Kieu, Wenze Lu, Jessica Salinas

Poster Session-F4 PSYCHIATRIC SYMPTOMS, SLEEP DISTURBANCE, AND ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV

2:30 PM - 4:00 PM

- 472 PSYCHIATRIC SYMPTOMS IN PLHIV: PREVALENCES, INTERACTIONS, AND CONSEQUENCES**
Elise M. G. Meeder, Marc J. T. Blaauw, Louise E. van Eekeren, Albert L. Groenendijk, Willem A. J. W. Vos, Quijrin De Mast, Willem L. Blok, Annelies Verbon, Marvin A. H. Berrevoets, Jan van Lunzen, Leo A. B. Joosten, Mihai G. Netea, Vasiliki Matzaraki, Andre J.A.M. van Der Ven, Arnt F. A. Schellekens
Research Group: 2000HIV
- 473 SLEEP DISTURBANCES ARE ASSOCIATED WITH COGNITIVE FUNCTION IN WOMEN LIVING WITH HIV**
Raha M. Dastgheyb, Kathleen Weber, Elizabeth Daubert, Anjali Sharma, Deborah Gustafson, Deborah Jones Weiss, Catalina Ramirez, Deborah Konkle-Parker, Sushma Cribbs, Bradley Aouizerat, Christine Alden, Seble Kassaye, Audrey French, Leah H. Rubin
- 474 BIOPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT**
 Bin Tang, **Ronald J. Ellis**, Florin Vaida, Anya Umlauf, Donald Franklin, Raha M. Dastgheyb, Leah H. Rubin, Robert K. Heaton, Scott L. Letendre
- 475 SEX-SPECIFIC ASSOCIATION BETWEEN IL-6 AND DEPRESSION IN PERSONS WITH AND WITHOUT HIV**
Kalen J. Petersen, Xiaoying Yu, Judith Lobo, Mary Clare Masters, Tina Lu, Scott L. Letendre, Ronald J. Ellis, Erin Sundermann
- 476 (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION**
 Arish Mudra Rakshasa-Loots, Nicholas Bakewell, David Sharp, Magnus Gisslen, Henrik Zetterberg, Jasmini Alagaratnam, Ferdinand Wit, Neeltje Kootstra, Alan Winston, Peter Reiss, Caroline Sabin, **Jaime Vera**
Research Group: COmorBidity in Relation to AIDS (COBRA) cohort

Poster Session-F5 CNS HIV INFECTION, PERSISTENCE, AND CURE STUDIES

2:30 PM - 4:00 PM

- 477 ESTABLISHMENT OF HIV LATENCY AND MICROGLIOSIS IN PRIMARY HUMAN MICROGLIA CELLS**
NIS
Eun Hye Grace. Kim, Roy Missall, Lubbertus C. Mulder, Lotje De Witte, Viviana Simon
- 478 REBOUND HIV-1 IN CSF AFTER TI IS DOMINATED BY CLONALLY AMPLIFIED T CELL-TROPIC VIRUS**
Laura P. Kincer, Sarah Joseph, Maria Gilleece, Blake Hauser, Sabrina Sizemore, Shuntai Zhou, Clara Di Germanio, Henrik Zetterberg, Dietmar Fuchs, Steven G. Deeks, Serena Spudich, Magnus Gisslen, Richard Price, Ronald Swanstrom
- 479 IMPACT OF IL-15 NEUTRALIZATION ON CNS PATHOGENESIS IN ACUTE HIV/SIV INFECTION**
LB
 Raja Gopalakrishnan, Daniel Ram, Malika Boudries, Caitlin Davis, Gikundiro Eunice, Rhianna Jones, Valerie Varner, Elizabeth McAuley, Lifton Michelle, Steven Bosinger, Dan Barouch, Brandon F. Keele, **R. Keith Reeves**, C. Sabrina Tan
- 480 A FRESH SINGLE-CELL STUDY DETECTS MULTI-COMPARTMENT PERSISTENT HIV RNA DESPITE ART**
Michael Corley, Supranee Buranapraditkun, Alina Pang, Alexandra Schuetz, Sodsai Tovanabuttra, Shelli Farhadian, Morgane Rolland, Nittaya Phanuphak, Jennifer Chiarella, Carlo Sacdalan, Denise Hsu, Sandhya Vasan, Serena Spudich, Lishomwa Ndhlovu
Research Group: SEARCH013/RV304 study group
- 481 INTERACTIONS BETWEEN GUT MICROBIOTA SIGNATURES AND CNS STATUS IN A HIV CURE STRATEGY**
NIS
Alessandra Borgognone, Anna Prats, Bonaventura Clotet, José Moltó, Beatriz Mothe Pujades, Roger Paredes, Jose A. Muñoz-Moreno

- 482 ASTROCYTES-MICROGLIA CROSSTALK: HOMEOSTATIC MODULATION OF HIV EXPRESSION IN MICROGLIA**
Yoelvis Garcia-Mesa, Fengchun Ye, Sheetal Sreeram, Ahmed El Sayed, Konstantin Leskov, Jonathan Karn

Poster Session-G2 DRUG-DRUG INTERACTIONS: A FOCUS ON TB, EFAVIRENZ SWITCHING

2:30 PM - 4:00 PM

- 505 GENETICS OF HIV AND TB DRUG INTERACTIONS WITH LEVONORGESTREL EMERGENCY CONTRACEPTION**
NIS **Nana Agyemang**, Kimberly K. Scarsi, Paxton Baker, Laura Smeaton, Anthony T. Podany, Maxine Olefsky, Sajeeda Mawlana, Khuanchai Supparatpinyo, Sivaporn Gatechompol, Emilia M. Jalil, Pablo F. Belaunzaran-Zamudio, Catherine Godfrey, Susan E. Cohn, Rosie Mngqibisa, David W. Haas
Research Group: AIDS Clinical Trials Group A5375 Study Team
- 506 IMPACT OF OBESITY ON THE DRUG-DRUG INTERACTION BETWEEN DOLUTEGRAVIR AND RIFAMPICIN**
NIS **Mattia Berton**, Sara Bettonte, Felix Stader, Manuel Battegay, Catia Marzolini
- 507 PHARMACOKINETICS OF STANDARD VS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCH FROM EFAVIRENZ**
Rulan Griesel, Clifford Banda, Ying Zhao, Phumla Sinxadi, Zaayid Omar, Graeme Meintjes, Gary Maartens
- 508 INTRAMUSCULAR CABOTEGRAVIR/RILPIVIRINE CONCENTRATIONS AFTER SWITCHING FROM EFAVIRENZ**
NIS **Sara Bettonte**, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini
- 509 SWITCHING OFF EFAVIRENZ TO NON-EFAVIRENZ ART LOWERS NICOTINE METABOLITE RATIO IN PWH**
Robert Gross, Warren Bilker, Xiaoyan Han, Jessica Merlin, Michael Plankey, Jeffrey Martin, Heidi Crane, Leila Hojat, Laura Bamford, Robert Schnoll, Rachel Tyndale, Rebecca Ashare
Research Group: CNICS

Poster Session-H1 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?

2:30 PM - 4:00 PM

- 516 PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE**
NIS **Stephanie Kenney**, Nimish Patel, Lucas Hill
- 517 PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART**
Wanyi Chen, Monica Gandhi, Paul Sax, Anne Neilan, Justine Scott, Timothy Wilkin, Andrea L. Ciaranello, Joseph J. Eron, Kenneth A. Freedberg, Emily P. Hyle
- 518 HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION**
Monica Gandhi, Jorge Salazar, Matthew D. Hickey, Katerina Christopoulos, Jon Oskarsson, Mary Shiels, John Szumowski, Janet Grochowski, Francis Munoz-Mayorga, John Saucedo, Elizabeth Imbert, Janet Nguyen, David V. Glidden, Diane V. Havlir
- 519 THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1**
LB **Franco Felizarta**, Ronald D'Amico, Kehui Wang, Herta Crauwels, Mar Masiá, Miguel Garcia Deltoro, Olaf Degen, Jonathan Angel, Chiu-Bin Hsiao, Vasiliki Chounta, Kelong Han, Conn Harrington, Kelly Rimler, William R. Spreen, Susan Ford

Poster Session-H7 SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESIVIR

2:30 PM - 4:00 PM

- 556 REMDESIVIR REDUCES MORTALITY IN HOSPITALIZED COVID-19 PATIENTS ACROSS VARIANT ERAS**
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Chidinma Chima-Melton, Stephanie H. Read, Heng Jiang, Celine Der-Torossian, Eunyong Lee, Lauren Dau, Mark Thrun, Mark Berry, Richard Haubrich, Andre C. Kalil
- 557 REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19**
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Andre C. Kalil, Stephanie H. Read, Heng Jiang, Mel Chiang, Eunyong Lee, Rikisha Gupta, Mark Thrun, Chidinma Chima-Melton
- 558 REMDESIVIR IS ASSOCIATED WITH REDUCED READMISSION AFTER COVID-19 HOSPITALIZATION**
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Andre C. Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas Oppelt, Lauren Dau, Mark Berry, Chidinma Chima-Melton
- 559 RISK OF DEATH IN REMDESIVIR TREATED AND UNTREATED PATIENTS WITH COVID-19 INFECTION**
Adeel Butt, Victor Talisa, Peng Yan, Obaid Shaikh, Florian G. Mayr
- 560 REMDESIVIR IN HOSPITALIZED COVID-19 PATIENTS: INDIVIDUAL PATIENT DATA META-ANALYSIS**
Alain Amstutz, Benjamin Speich, France Mentré, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel
- 561 REMDESIVIR RESISTANCE ANALYSES FROM THE PINETREE STUDY IN OUTPATIENTS WITH COVID-19**
Lauren Rodriguez, Hery W. Lee, Jiani Li, Ross Martin, Dong Han, Simin Xu, Gregory Camus, Jason K. Perry, Robert Hyland, Danielle P. Porter, Mazin Abdelghany, Matthias Götte, Charlotte Hedskog
- 562 REMDESIVIR RETAINS POTENT ACTIVITY AGAINST SARS-CoV-2 VARIANTS OF CONCERN**
 Lauren Rodriguez, Tien-Ying Hsiang, Jiani Li, Dong Han, Xianghan Lu, Ross Martin, Nicholas C. Riola, Jared Pitts, Jason K. Perry, John P. Bilello, Michael Gale, Danielle P. Porter, **Charlotte Hedskog**

Poster Session-I1 HIV RESISTANCE EMERGENCE AND OUTCOMES

2:30 PM - 4:00 PM

- 573 FACTORS ASSOCIATED WITH HIV-1 RESISTANCE TO INTEGRASE STRAND TRANSFER INHIBITORS**
 Horacio Gil, Elena Delgado, Sonia Benito, María Moreno-Lorenzo, **Michael M. Thomson**
Research Group: Spanish Group for the Study of Antiretroviral Drug Resistance
- 574 EFFICACY OF 3TC+DTG VS 3-DRUG REGIMENS IN VIROLOGICALLY-SUPPRESSED PLWH**
Alberto Borghetti, Arturo Ciccullo, Francesca Lombardi, Rosanna Passerotto, Francesco Lamanna, Damiano Farinacci, Alex Dusina, Gianmaria Baldin, Maurizio Zazzi, Simona Di Giambenedetto
- 575 INFREQUENT DETECTION OF EMERGENT HIV DRUG RESISTANCE IN LOW VIRAL LOAD SPECIMENS**
Hanwei Sudderuddin, Walter Scott, Charlotte Beelen, Anh Le, Tetyana Kalynyak, Rob Hollebakken, Amanda Granados, Sakshi Khanna, Weiyan Dong, Viviane D. Lima, Julio Montaner, Chanson J. Brumme

- 576** **DRUG RESISTANCE IN PEOPLE FAILING DOLUTEGRAVIR-BASED ART: HIV COHORT COLLABORATION**
NIS
Tom Loosli, Stefanie Hossmann, Suzanne M. Ingle, Hajra Okhai, Ard van Sighem, Melanie Stecher, Antonella D'Arminio Monforte, M. John Gill, Caroline Sabin, Gary Maartens, Huldrych F. Günthard, Jonathan A.C. Sterne, Richard Lessells, Matthias Egger, Roger D. Kouyos
- 577** **LOW-FREQUENCY NNRTI MUTATIONS CORRELATE WITH HIV ART FAILURE IN PREGNANT WOMEN**
Rachel M. Burdorf, Nathan Long, Claire Amon, Collin Hill, Lily Adams, Gerald Tegha, Maganizo Chagomerana, Allan Jumbe, Madalitso Maliwichi, Shaphil Wallie, Sarah Joseph, Ronald Swanstrom, Shuntai Zhou, Mina Hosseinipour
- 578** **EMERGING INTEGRASE INHIBITOR HIV DRUG RESISTANCE MUTATIONS: TANZANIAN NATIONAL SURVEY**
Doreen D. Kamori, Godfrey Barabona, Werner Maokola, Joan Rugemalila, Salim Masoud, Mucho Mizinduko, Amon Sabasaba, George Mgomella, Macdonald R. Mahiti, Anath Rwebembera, Takamasa Ueno, Prosper Njau, Bruno F. Sunguya
- 579** **INCIDENCE OF ACQUIRED INTEGRASE RESISTANCE AFTER TRANSITION TO DOLUTEGRAVIR IN UGANDA**
LB
Suzanne M. McCluskey, Winnie Muyindike, Richard Lessells, Jennifer Giandhari, Victoria Nanfuka, Daniel Omoding, Taing N. Aung, Bethany Hedt-Gauthier, Vincent C. Marconi, Mahomed-Yunus Moosa, Deenan Pillay, Ravindra Gupta, Mark Siedner

Poster Session-J1 HBV PREVENTION AND TREATMENT

2:30 PM - 4:00 PM

- 586** **KINETICS OF HBV RNA AND CORE-RELATED ANTIGEN LEVELS IN PLWH WITH FUNCTIONAL HBV CURE**
NIS
Lorin Bagné, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Franziska Suter-Riniker, Charles Béguelin, Jürgen K. Rockstroh, Huldrych F. Günthard, Alexandra Calmy, Matthias Cavassini, Hans H. Hirsch, Massimo Levrero, Gilles Wandeler, Fabien Zoulim, Andri Rauch
Research Group: Swiss HIV Cohort Study
- 587** **LONG-TERM HEPATITIS B OUTCOMES IN ZAMBIA WITH TENOFOVIR-TREATED HBV/HIV COINFECTION**
Michael Vinikoor, Kalongo Hamusonde, Guy Muula, Mah Asombang, Debika Bhattacharya, Edford Sinkala, Georg Lauer, Raymond Chung, Wilson Mbewe, Matthias Egger, Samuel Bosompah, **Gilles Wandeler**
Research Group: leDEA Southern Africa
- 588** **"MICRO-INFECTION" OF HBV CAN OCCUR IN MSM WITH VACCINATION OR TENOFOVIR-BASED PrEP**
Daisuke Mizushima, Misao Takano, Takahiro Aoki, Koji Watanabe, Haruka Uemura, Hiroyuki Gatanaga, Shinichi Oka
- 589** **BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV COINFECTED PATIENTS IN REAL-LIFE SETTINGS**
LB
Victor de Ledinghen, Anne Gervais, Marie-Noelle Hilleret, Karine Lacombe, Patrick Mialhes, Bruno Roche, Louis D'Alteroche, Jean-Pierre Arpurt, Isabelle Rosa, Antonia Le Gruyer, Marc-Antoine Valantin, Helene Regnault, Christiane Stern, Tarik Asselah, Stanislas Pol
Research Group: cATU

Poster Session-J2 NEW DEVELOPMENTS IN HCV EPIDEMIOLOGY AND TREATMENT

2:30 PM - 4:00 PM

- 590** **HCV INCIDENCE AMONG MSM ON PrEP AND MSM WITH HIV IN NEW YORK CITY OVER 2 DECADES**
Richard J. Silvera, Antonio Urbina, Keith Sigel, Daniel Fierer

591 HEPATITIS C BURDEN IN GREECE, ITALY, PORTUGAL, AND SPAIN: 2000-2019

NIS

Claudia Palladino, **Ifeanyi Jude Ezeonwumelu**, Nuno Taveira, Verónica Briz**592 USABILITY AND ACCEPTABILITY OF HCV SELF-TESTING IN THE GENERAL POPULATION FROM BRAZIL****Hugo Perazzo**, Cristiane Villela-Nogueira, Maria Kátia Gomes, Andre Daher, Cristiane Valle, Ana Cristina G. Ferreira, Elton C. Almeida, Sandra Cardoso, Beatriz Grinsztejn, Valdilea Veloso**Research Group:** Grupo de Pesquisa Clínica em Hepatologia (GPC-HEPATOL)**593 UPTAKE AND LINKAGE TO CARE FOR HCV SELF-TESTING: RESULTS FROM A MULTI-COUNTRY RCT**Sonjelle Shilton, Saeed Hamid, Muhammad Radzi Abu Hassan, Ketevan Stvilia, Aliya Hasnain, Xiaohui Sem, Maia Japaridze, Miranda Jghenti, Nino Tsereteli, Dali Usharidze, Anushiya Karunanithy, Niklas Luhmann, **Brooke Nichols**, Jessica Markby, Elena Replold**594 MOBILIZING PRIMARY CARE PROVIDERS TO TREAT HEPATITIS C IN RURAL WEST VIRGINIA****Judith Feinberg**, Adam Baus, Garret Cooper, Joy Juskowich, Andrea Calkins, John Guilfoose**595 OPTIMAL FREQUENCY OF HCV RNA TESTING FOR PLWH AT RISK FOR ACUTE HCV INFECTION**Hsin-Yun Sun, Po-Liang Lu, Shu-Hsing Chen, Nan-Yao Lee, Chien-Yu Cheng, Sung-Hsi Huang, Tun-Chieh Chen, Bo-Huang Liou, Chun-Yuan Lee, **Chia-Jui Yang**, Cheng-Pin Chen, Mao-Song Tsai, Hung-Jen Tang, Yuan-Ti Lee, Chien-Ching Hung**596 SVR12 OUTCOMES FOR NOVEL HCV GENOTYPE/SUBTYPES WITH SOF/VEL IN MINMON STUDY**

NIS

Win Min Han, Sunil S. Solomon, Sandra Wagner-Cardoso, Jiani Li, Aiyappa Parvangada, Mark S. Sulkowski, Susanna Naggie, Ross Martin, Hongmei Mo, Evguenia Maiorova, David Wyles**597 SOFOSBUVIR/VELPATASVIR PHARMACOKINETICS IN PREGNANT WOMEN WITH HEPATITIS C VIRUS**

LB

Catherine Chappell, Jennifer Kiser, Riley Randolph, Ingrid Macio, Leslie Meyn, Sam Mawhinney, Anne-Marie Rick, Gysella Muniz, Kyung-Min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Sharon L. Hillier**Poster Session-L3 HYPERTENSION, VASCULAR DISEASE, AND PLATELET FUNCTION**

2:30 PM - 4:00 PM

654 SMOKING CESSATION AND SHORT-TERM VASCULAR IMPROVEMENT IN A COHORT OF PEOPLE WITH HIV**Rodrigo Moreira**, Angela Rodrigues, Carla Renata, Beatriz Leonardo, Daniel Arabe, Sandra Wagner Cardoso, Beatriz Grinsztejn, Valdilea Veloso, Antonio G. Pacheco**655 AORTIC ANEURYSMS AND MARKERS OF ENDOTHELIAL AND PLATELET ACTIVATION IN PLWH**Sylvester Gronbaek, Julie Hogh, Michael Pham, **Andreas D. Knudsen**, Andreas Fuchs, Sisse Ostrowski, Thomas Lars Benfield, Klaus Kofoed, Susanne Dam Poulsen**Research Group:** COCOMO study**656 BMI MEDIATES THE LINK BETWEEN HIV-RELATED FACTORS AND HYPERTENSION BUT NOT DIABETES****Peter-Vanes Ebasone**, Anastase Dzudie, Nasheeta Peer, Andre Pascal Kengne

- 657 RACIAL AND HIV DISPARITIES IN HYPERTENSION TREATMENT CASCADE AMONG WOMEN**
Jessica Blair, Mirjam Colette-Kempf, Jodie Dionne-Odom, Zenoria Causey-Pruitt, Jenni Wise, Elizabeth Jackson, Paul Muntner, David B. Hanna, Jorge R. Kizer, Margaret Fischl, Igho Ofotokun, Adaora Adimora, Stephen Gange, Emily B. Levitan
- 658 DOLUTEGRAVIR EXPOSURE, BUT NOT BICTEGRAVIR, INCREASES IN VITRO PLATELET AGGREGATION**
Renos Keniyopoulos, Akif A. Khawaja, Mike Emerson
- 659 MARIJUANA USE AND THE RISK OF INCIDENT VENOUS THROMBOEMBOLISM IN PEOPLE WITH HIV**
Lara Haidar, Robin Nance, Stephanie Ruderman, Alekhya Lavu, Laila Aboulatta, Payam Peymani, Andrew Hahn, Amanda Willig, Katerina Christopoulos, Jeannie Keruly, Kristina Crothers, Joseph Delaney, Heidi Crane, Sherif Eltonsy

Poster Session-M2 METABOLIC COMPLICATIONS

2:30 PM - 4:00 PM

- 675 RANDOMIZED CLINICAL TRIAL OF TRANSGENDER WOMEN SWITCHING TO BIC/F/TAF (MOBETTA TRIAL)**
Ana Hyatt, Han Feng, Paula Debroy, Aaren Kettelhut, Hongyu Miao, Liming Peng, Shalender Bhasin, Todd T. Brown, Nicholas Funderburg, Jordan E. Lake
- 676 METABOLOMIC PROFILING SHOWS MORE LIPID ABNORMALITIES IN NNRTI COMPARED TO INSTI USERS**
Wilhelm A. J. W. Vos, Nadira Vadaq, Albert L. Groenendijk, Marc J. T. Blaauw, Louise E. van Eekeren, Vasiliki Matzaraki, Kees Brinkman, Quirijn De Mast, Mike van Der Kolk, Jan van Lunzen, Janneke E. Stalenhoef, Willem L. Blok, Andre J.A.M. van Der Ven
Research Group: 2000HIV
- 677 INSULIN RESISTANCE, DM 2, AND POTENTIAL IMPACT OF FIRST ART IN NAIVE HIV-SUBJECTS**
Maria Luisa Montes, Carmen Busca, Maria Lagarde, Inés Suárez-García, Maria Rivero, Arkaitz Imaz, Julián Olalla, Cristina Hernández-Gutierrez, Félix Gutierrez, José Antonio Iribarren, Miguel Górgolas, Miguel de Zárraga, José Ignacio Bernardino, Luz Martín-Carbonero, Juan González-García
Research Group: RIS, Red Investigación en SIDA
- 678 MITOCHONDRIAL HAPLOGROUPS, ANTIRETROVIRAL DRUGS, AND DIABETES RISK AMONG MEN WITH HIV**
Jing Sun, Todd T. Brown, David Samuel, Weiqun Tong, Sudipa Sarker, Alison Abraham, Jeremy Martinson, Shehnaz Hussain, Steven Wolinsky, Todd Hulgan
Research Group: MWCCS
- 679 ASSOCIATION OF SEX HORMONES WITH INCIDENT DIABETES IN WOMEN WITH AND WITHOUT HIV**
Rebecca A. Abelman, Michael Schneider, Christopher Cox, Jennifer C. Price, Mardge Cohen, Deborah Gustafson, Michael Plankey, Anjali Sharma, Phyllis C. Tien
- 680 IMMUNE CHECKPOINTS AND PANCREATIC BETA CELL DYSFUNCTION IN HIV**
Luke Pryke, Ziyue Liu, Alka Khaitan, Emily Sims, Samir Gupta
- 681 AGREEMENT BETWEEN HBA1C AND INTERSTITIAL GLUCOSE IN PEOPLE LIVING WITH HIV**
Harriet Daultrey, Belinda Chihota, Nick Oliver, Matthias Egger, Gilles Wandeler, Carolyn Bolton Moore, Guy Muula, Juliet Wright, Tom Levett, Jaime Vera, Ali Chakera

682 A RANDOMIZED CONTROLLED TRIAL OF BERBERINE EFFICACY ON METABOLIC SYNDROME PLUS HIV

Luz A. González-Hernández, Shaúl Navarro-Lara, Jaime F. Andrade-Villanueva, Vida V. Ruiz-Herrera, Monserrat Alvarez-Zavala, Karina Sánchez-Reyes, Pedro Martínez-Ayala, Nathaly Carrillo-Iñiguez, Jocelyn G. Torres-Arias, Aldo Valenzuela-Ramírez

Poster Session-M3 BONE, RENAL, PULMONARY, AND HEMATOLOGIC DISEASE**2:30 PM - 4:00 PM****683 HIV, GENOTYPE, AND CKD: DOES TENOFOVIR EXPOSURE MATTER IN AFRICAN AMERICAN PWH?**

NIS

Skye Opsteen, Ashutosh Tamhane, Chris Mathews, Cheryl Winkler, Christina Wyatt, Mari Kitahata, Heidi Crane, Richard Moore, Jeffrey Jacobson, Katerina Christopoulos, Kenneth Mayer, Michael S. Saag, Michael J. Mugavero, Thibaut Davy Mendez, Ellen Eaton

Research Group: Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)

684 VITAMIN C DYSREGULATION IN HIV: CROSS-SECTIONAL STUDY OF RENAL LEAK IN HIV+ WOMEN

Ifechukwude C. Ebenuwa, Pierre-Christian Violet, Kate Michel, Hongbin Tu, Kenneth Wilkins, Seble Kassaye, Daniel Merenstein, Mark Levine

685 RECOVERY OF BONE MASS IN WOMEN ON DEPO-PROVERA AND TDF-BASED ART SWITCHED TO B/F/TAF

Flavia Matovu Kiweewa, Mags E. Beksinska, Martin Nabwana, Juliet Allen Babirye, Esther Isingel, Noah Kiwanula, John Pettifor, Todd T. Brown

Research Group: BONE:STAR STUDY TEAM

686 QUARTERLY VITAMIN D3 SUPPLEMENTATION TO MITIGATE TENOFOVIR-ASSOCIATED BONE LOSS

Evelyn Hsieh, Wei Cao, Hongxin Zhao, Wen Wang, Wei Pan, Xiaojing Song, Yang Han, Wenmin Guan, Yunshan Xu, Michael T. Yin, Karl Insogna, Liana Fraenkel, Wei Yu, Weibo Xia, Taisheng Li, fuping Guo, Ting Zhu

687 IL-1 β AND IL-10 ARE ASSOCIATED WITH FASTER LUNG FUNCTION DECLINE IN PEOPLE WITH HIV

Rebekka Faber Thudium, **Nicoline Stender Arentoft**, Hedda Hoel, Jakob Hjorth Von Stemann, Julie Lyng Forman, Jon Torgny Wilcke, Thomas Lars Benfield, Marius Trøseid, Álvaro Humberto Borges, Sisse Rye Ostrowski, Jørgen Vestbo, Ken M. Kunisaki, Jens-Ulrik Stæhr Jensen, Susanne Dam Poulsen

688 ASSOCIATION OF ANEMIA ON SURVIVAL AMONG PEOPLE WITH HIV AFTER ART INITIATION

Raynell Lang, Sally B. Coburn, M. John Gill, Ronald J. Bosch, Michael A. Horberg, Amy C. Justice, Mona Loutfy, Angel Mayor, Richard Moore, Charles Rabkin, Michael J. Silverberg, Kelly Gebo, Keri Althoff

Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

Poster Session-M5 FRAILITY, FUNCTIONAL STATUS, AND HEALTH**2:30 PM - 4:00 PM****696 SARCOPENIA, FRAILITY, NUTRITION, AND HCV INFECTION AMONG OLDER PEOPLE WITH HIV**

Hay Mar Su Lwin, Win Min Han, Tanakorn Apornpong, Thanathip Wichiangsan, Jedsadakorn Bonrungsirisap, Chanya Chatjitakornkul, Matthew Sirisuksakulchai, Papitchaya Sukruen, Sivaporn Gatechompol, Stephen J. Kerr, Anchalee Avihingsanon

Research Group: HIV-NAT

- 697** **CMV IgG IS ASSOCIATED WITH MUSCLE FUNCTION BUT NOT QUALITY OR MASS IN PEOPLE WITH HIV**
Kristine Erlandson, Triin Umbleja, Edgar T. Overton, Tricia H. Burdo, Jacqueline M. Flynn, Michael T. Lu, Jana Taron, Samuel R. Schnittman, Evelynne S. Fulda, Carl J. Fichtenbaum, Carlos Malvestutto, Heather J. Ribaldo, Pamela S. Douglas, Steven K. Grinspoon, Todd T. Brown
Research Group: REPRIEVE Study Team
- 698** **VALIDITY OF A SELF-REPORTED MODIFIED FRAILTY PHENOTYPE AMONG PEOPLE WITH HIV**
Stephanie Ruderman, Allison Weibel, Amanda Willig, Lydia Drumright, Annette Fitzpatrick, Michelle Odden, John Cleveland, Christine Davey, Julia Fleming, Thomas Buford, Raymond Jones, Meredith Greene, Charles Kamen, Chintan Pandya, Heidi Crane
- 699** **COMORBIDITIES AND SYMPTOMS ASSOCIATED WITH FALLS: 2020-2021**
 Lydia Drumright, **Stephanie Ruderman**, Amanda Willig, Bridget Whitney, Robin Nance, Andrew Hahn, Sarah Mixson, Jimmy Ma, Rob Fredericksen, Jeff Jacobson, Katerina Christopoulos, Sonia Napravnik, Edward Cachay, Allison Weibel, Heidi Crane
- 700** **PREVALENCE, INCIDENCE, AND RISK FACTORS FOR FALLS IN OLDER PEOPLE WITH AND WITHOUT HIV**
 Emanuele Focà, **Stefania Arsuffi**, Jovana Milic, Chiara Mussi, Alessandra Marengoni, Micol Ferrara, Benedetto Maurizio Cesia, Giordano Madeddu, Anna Maria Cattelan, Stefano Calza, Andrea Calcagno, Giovanni Guaraldi
- 701** **A 12-WEEK MULTICOMPONENT EXERCISE PROGRAM REVERSES FRAILTY IN OLDER ADULTS WITH HIV**
Fátima Brañas, Jorge Díaz-Álvarez, Jesús Fernández-Luna, Brian Vásquez, Rafael García-Molina, Elena Moreno, Pablo Ryan, Javier Martínez-Sanz, Laura Luna, Marta Martínez, Fernando Dronza, Matilde Sánchez-Conde
- 702** **SMOKING CESSATION AND ASSOCIATED FACTORS IN THE HIV OUTPATIENT STUDY: 2007-2021**
Jun Li, Carl Armon, Alexander Ewing, Jonathan Mahnken, Ellen Tedaldi, Frank Palella, Richard Novak, Cynthia Firnhaber, Stockton Mayer, Andrea Wendrow, Gina Simoncini, Linda Battalora, Kimberly Carlson, Marcus Durham, Kate Buchacz
Research Group: HIV Outpatient Study (HOPS) Investigators

Poster Session-N2 COVID-19 IN THOSE WITH HIV AND IMMUNOCOMPROMISING CONDITIONS

2:30 PM - 4:00 PM

- 724** **HIV INFECTION INCREASES RISK OF PASC WHILE COVID-19 VACCINATION IS PROTECTIVE**
George A. Yendewa, Jamie A. Perez, Nirav T. Patil, Grace A. McComsey
- 725** **IMMUNE STATUS AND SARS-CoV-2 VIRAL DYNAMICS**
Yijia Li, Carlee Moser, Evgenia Aga, Judith S. Currier, David A. Wohl, Eric S. Daar, Justin Ritz, Robert Coombs, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Kara W. Chew, Jonathan Z. Li
Research Group: ACTIV-2/A5401
- 726** **PROLONGED VIABLE VIRAL SHEDDING IN IMMUNOCOMPROMISED PATIENTS WITH COVID-19**
 Sung-Woon Kang, Jun-Won Kim, Ji Yeun Kim, So Yun Lim, Choi-Young Jang, Euijin Chang, Jeong-Sun Yang, Kyung-Chang Kim, Hee-Chang Jang, Dasol Kim, Younmin Shin, Joo-Yeon Lee, **Sung-Han Kim**
- 727** **SUICIDAL RISK AMONG PEOPLE WITH HIV AFTER LOCKDOWN DUE TO COVID-19 PANDEMIC**
 Yanink Caro-Vega, Jessica Mejía- Castrejón, Atenea Alvarez, Alvaro López Iñiguez, Juan Sierra-Madero, **Brenda E. Crabtree-Ramirez**

Poster Session-N3 COVID-19: CLINICAL AND PROGNOSTIC FEATURES AND EFFECTS OF THERAPEUTIC INTERVENTIONS

2:30 PM - 4:00 PM

- 728 SIGNIFICANCE OF ELEVATED SARS-CoV-2 ANTIGEN LEVELS DURING EARLY HOSPITALIZATION**
Mamta K. Jain
Research Group: ACTIV-3/TICO Study Group
- 729 IMMEDIATE AND CONTRIBUTORY CAUSES OF DEATH IN PATIENTS HOSPITALIZED WITH COVID-19**
Adeel Butt, Mylai D. Guerrero, Elenor B. Canlas, Husni Al-Dwairi, Aseel Hatem Subhi Alzibdeh, Thasneem Odaippurath, Ali Ahmed Sheikh Saleh Alkeldi, Mohammad Fawaz Saber Mohammad, Anil G. Thomas, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Abdullatif Al-Khal, Muna Al-Maslamani, Abdul-Badi Abou-Samra
- 730 ANTI-S-RBD TITER AND RISK OF CLINICAL PROGRESSION IN PATIENTS WITH COVID-19 PNEUMONIA**
Giuseppe Lapadula, Luca Mezzadri, Giustina Lo Cascio, Sergio Malandrini, Alice Ranzani, Silvia Limonta, Annalisa Cavallero, Paolo Bonfanti
- 731 AI-BASED PREDICTION OF LUNG TISSUE INVOLVEMENT IS PREDICTIVE OF COVID-19 SEVERITY**
Miłosz Parczewski, Bogusz Aksak-Wąs, Daniel Chober, Laura Lesiewska, Malwina Karasińska-Cieślak, Krystian Awgul, Adam Majchrzak, Karol Serwin
- 732 A JOINT ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS ON ENOXAPARIN FOR COVID-19**
Giovanni Dolci, Cinzia Del Giovane, Massimo Arquati, Valeria Coluccio, Erica Franceschini, Roberto D'Amico, Roberto Vicini, Pasquale Mighali, Riccardo Colombo, Alba Taino, Pietro Facchinetti, Lucia Trombetta, Francesca Tonelli, Marco Marietta, Maddalena Alessandra Wu
- 733 THE IMPACT OF EARLY OUTPATIENT TREATMENTS FOR COVID-19: A RETROSPECTIVE STUDY**
 Silvia Amadasi, Paola Bertuccio, **Melania Degli Antoni**, Francesca Viola, Davide Minisci, Francesco Rossini, Alex Francesco Bolandrini, Francesco Castelli, Anna Odone, Eugenia Quiros-Roldan

Poster Session-O3 STRATEGIES FOR OPTIMIZING TB TREATMENT AND PREVENTIVE THERAPY

2:30 PM - 4:00 PM

- 750 HIGH-DOSE ISONIAZID EARLY BACTERICIDAL ACTIVITY AGAINST DRUG-RESISTANT TUBERCULOSIS**
Kamunhwala Gausi, Soyeon Kim, Ryan Wu, Xin Sun, Elisa Ignatius, Laura Moran, Veronique De Jager, Yvetot Joseph, Samuel Pierre, Susan Rosenkranz, Susan Swindells, Eric Nuermberger, Andreas Diacon, Paolo Denti, Kelly E. Dooley
Research Group: ACTG A5312 study team
- 751 TWICE-DAILY DOSING OF ATAZANAVIR SAFELY OVERCOMES THE INTERACTION WITH RIFAMPICIN**
L.B.
Kamunhwala Gausi, Henry Mugerwa, Marco Siccardi, Maiara Montanha, Antonio D'Avolio, Lubbe Wiesner, Letisha Najjemba, Gary Maartens, Shamim Nakubaye, Cissy Kityo, Helen McIlhleron, Saye Khoo, Mohammed Lamorde, Paolo Denti, Catriona Waitt
- 752 LINEZOLID REACHES TARGET SITE IN PATIENTS WITH TB MENINGITIS AND HIV COINFECTION**
NIS
Rob van Wijk, Freddie Kibengo, Paddy Kafeero, Anita Kabarambi, Patrick Muhumuza, Maria Nakimbugwe, Anthony Ssemaganda, Colman Tayebwa, Matthew Zimmerman, Fiona Cresswell, Veronique Dartois, Payam Nahid, Rada Savic, Felicia C. Chow

- 753** **PREDICTIVE VALIDITY OF POPULATION MODELS FOR LINEZOLID EXPOSURE AND TOXICITY IN ZeNIX**
NIS Marjorie Imperial, **Belen Perez Solans**, Jerry Nedelman, Rada Savic
- 754** **HARD-TO-TREAT PHENOTYPES INCREASE TIME TO CULTURE CONVERSION IN DRUG-RESISTANT TB**
NIS **Belen Perez Solans**, Marjorie Imperial, Morounfolu Olugbosi, Rada Savic
- 755** **EFFECTIVENESS OF DOLUTEGRAVIR IN PEOPLE ON RIFAMPIN-BASED TUBERCULOSIS TREATMENT**
LB **N. Sarita Shah**, Cissy Kityo, Michael D. Hughes, Caitlyn McCarthy, Carole Wallis, Mina Hosseini-pour, Deborah Langat, Mulinda Nyirenda, Mohammed Rassool, Rodney Dawson, Elizabeth Woolley, Catherine Godfrey, John W. Mellors, Charles Flexner, Gary Maartens
Research Group: AIDS Clinical Trials Group A5381/Hakim Study Team
- 756** **DIFFERENTIATED SERVICE DELIVERY FOR PEOPLE COINFECTED WITH DRUG RESISTANT TB AND HIV**
NIS **Karl Reis**, Jennifer Zelnick, Allison Wolf, Rubeshan Perumal, Kogieleum Naidoo, Boitumelo Seepamore, Kevin Guzman, Jesse Ross, Ken Cheung, K. Rivet Amico, Gerald Friedland, Amrita Daftary, Max O'Donnell
Research Group: PRospective study of Adherence in M/XDR-TB Implementation Science (PRAXIS) Research Group
- 757** **ACCELERATING TUBERCULOSIS PREVENTIVE TREATMENT AMONG TANZANIANS LIVING WITH HIV**
Alexander Kailembo, Jaiving Kazitanga, Daniel Magesa, Peter Neema, Diana Forno Rodriguez, Anand Date, Eva Matiko, Nicolas Schaad, Jonathan Grund, Brian Baker, Mahesh Swaminathan, Mohamed Jalloh
- 758** **LOWER TB INCIDENCE AMONG PWH AFTER PREVENTIVE TREATMENT IN HIGH-BURDEN MDR TB SETTING**
LB **Olutomi Sodeke**, Juliana de Fatuma Da Silva, Snigdha Vallabhaneni, Sherri L. Pals, N. Sarita Shah

Poster Session-P2 OBESITY, INFLAMMATION, AND HIV IN PREGNANCY
2:30 PM - 4:00 PM

- 774** **ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES: A MEDIATION ANALYSIS**
LB Risa Hoffman, Lauren Ziembra, Lameck Chinula, Esau Joao, Jeffrey Stringer, Lee Fairlie, Avy Violari, Linda Aupibul, Victoria Ndyanabangi, Chelsea Krotje, Katie McCarthy, Nahida Chakhtoura, Patrick Jean-Philippe, Shahin Lockman, **Sean Brummel**
Research Group: IMPAACT 2010
- 775** **UNIQUE EICOSANOID/LIPID PROFILES IN PREGNANT WOMEN LIVING WITH HIV IN BOTSWANA**
Jennifer Jao, Lauren Bonner, Shan Sun, Justine Legbedze, Keolebogile Mmasa, Gosego Masasa, Samuel W. Kgole, Sikhulile Moyo, Joseph Makhema, Mitchell E. Geffner, Elaine J. Abrams, Mariana Gerschenson, Yunping Qiu, Kathleen M. Powis, Irwin Kurland
- 776** **CARDIOMETABOLIC RISK IN SOUTH AFRICAN POSTPARTUM WOMEN LIVING WITH HIV**
Hlengiwe P. Madlala, Landon Myer, Azetta Fisher, Mushi Matjila, Gregory Petro, Zandile Maqwatini, Angela Bengtson
- 777** **IMMUNE MARKERS IN PREGNANT WOMEN LIVING WITH HIV ON ART THERAPY BY MATERNAL BMI**
NIS **Jessica More**, Thokozile R. Malaba, Elton Mukonda, Shameem Jaumdally, Hlengiwe P. Madlala, Landon Myer, Marie-Louise Newell

Poster Session-P4 USING ANTIRETROVIRALS IN PREGNANCY
2:30 PM - 4:00 PM

- 782** **PBPK MODEL PREDICTION OF LONG-ACTING CAB AND RPV CONCENTRATIONS IN PREGNANCY**
Yifan Yu, Adrie Bekker, Xinnong Li, Robert Bies, Rachel Scott

- 783 PHARMACOKINETICS AND VIROLOGIC OUTCOMES OF BICTEGRAVIR IN PREGNANCY AND POSTPARTUM**
Kathleen M. Powis, Mauricio Pinilla, Lauren Bergam, Alice Stek, Kristina M. Brooks, David Shapiro, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Priyanka Arora, Brookie M. Best, Mark Mirochnick, Jeremiah D. Momper
Research Group: IMPAACT 2026 Protocol Team
- 784 LONG-ACTING NANOFORMULATIONS REDUCE DOLUTEGRAVIR EXPOSURE TO EMBRYO BRAIN**
Emma G. Foster, Benson Edagwa, Howard E. Gendelman, Aditya Bade
- 785 DAPIVIRINE RING SAFETY AND DRUG DETECTION IN BREASTFEEDING MOTHER-INFANT PAIRS**
Maxensia Owor, Lisa Noguchi, Elizea Horne, Moleen Matimbira, Phionah Kibalama Ssemambo, Vitumbiko Madhlopa-Mandiwa, Rachel Scheckter, Holly M. Gundacker, Barbra Richardson, Mark A. Marzinke, Peter L. Anderson, Katherine E. Bunge, Nahida Chakhtoura, Jeanna Piper, **Jennifer Balkus**
Research Group: MTN-043/B-PROTECTED Study Team
- 786 PREGNANCY AND BIRTH OUTCOMES FOLLOWING ORAL PrEP USE BY OBJECTIVE LEVELS OF TDF/FTC**
Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashela, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer
Research Group: PrEP-PP Study Group

Poster Session-P6 COVID-19 IN PREGNANCY: EVOLVING INSIGHTS

2:30 PM - 4:00 PM

- 794 SARS-CoV-2 ANTIBODY RESPONSES POST-INFECTION IN PREGNANCY BY VACCINATION STATUS**
Sylvia M. Lacourse, Erica Wetzler, Morgan C. Aurelio, Jaclyn Escudero, Stacy Selke, Alexander L. Greninger, Alisa B. Kachikis, Janet A. Englund, Alison L. Drake
- 795 SARS-CoV-2 SEROPREVALENCE TREND AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022**
Elizabeth Heilmann, Taniya Tembo, Felix Chilambe, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Warren Malambo, Victoria Seffren, Ruchi Yadav, Theodora Savory, Andrew Auld, Jonas Hines, Lloyd B. Mulenga, Izukanji Sikazwe
- 795.5 SARS-CoV-2 SEROPREVALENCE BY HIV STATUS AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022**
Elizabeth Heilmann, Taniya Tembo, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Julie Gutman, Victoria Seffren, Ruchi Yadav, Theodora Savory, Izukanji Sikazwe, Jonas Hines
- 796 COVID-19 VACCINATED MATERNAL/CORD BLOOD DON'T HAVE NEUTRALIZATION FOR OMICRON VARIANTS**
Sakthivel Govindaraj, Narayanaiah Cheedarla, Suneetha Cheedarla, Les'Shon S Irby, Andrew Neish, John Roback, Alicia K. Smith, Vijayakumar Velu

Poster Session-Q2 INFLAMMATION AND IMMUNITY IN CHILDREN

2:30 PM - 4:00 PM

- 806 MORTALITY LINKED TO HIGHER INFLAMMATION IN PERINATALLY-INFECTED HIV+ KIDS**
Elena Morrocchi, Giuseppe Rubens Pascucci, Nicola Cotugno, Chiara Medri, Chiara Pighi, Sara Dominguez, Alfredo Tagarro, Lesley de Armas, Savita Pahwa, Maria Raffaella Petrara, Anita De Rossi, Ofer Levy, Paolo Rossi, Carlo Giaquinto, Paolo Palma
Research Group: EPIICAL Consortium

- 807** **INFECTED NAIVE CD4+ T CELLS IN CHILDREN WITH HIV CAN PROLIFERATE AND PERSIST ON ART**
NIS
Mary Grace Katusiime, Shuang Guo, Victoria Neer, Sean C. Patro, Xiaolin Wu, Anna Horner, Ann Chahroudi, Maud Mavigner, Mary F. Kearney
- 808** **LONGITUDINAL T CELL IMMUNE PROFILING IN HIV-EXPOSED INFECTED AND UNINFECTED INFANTS**
Lesley de Armas, Suresh Pallikkuth, Stefano Rinaldi, Vinh Dinh, Paula Vaz, Nadia Siteo, Nicola Cotugno, Rajendra Pahwa, Paolo Palma, Maria Grazia Lain, Savita Pahwa
- 809** **TORQUETENOVIRUS: MARKER OF IMMUNE RECONSTITUTION IN PERINATALLY HIV-INFECTED PATIENTS**
 Laura Tarancon-Diez, Itziar Carrasco, Laura Montes, Iker Falces, Santiago Jimenez de Ory, Marta Dapena, Luis López-Cortés, Elena Colino, Ana Isabel Menasalvas, Jose Antonio Iribarren, Cristina Díez, José Ignacio Bernardino, M^a Ángeles Muñoz-Fernández, Marisa Navarro, **Talía Sainz**

Poster Session-Q3 REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV

2:30 PM - 4:00 PM

- 810** **HIGH MORTALITY IN AFRICAN INFANTS HOSPITALIZED WITH SEVERE PNEUMONIA AND ADVANCED HIV**
Alfeu Passanduca, W. Chris Buck, Alfredo Tagarro, Victor Musiime, Hilda A. Mujuru, Chishala Chabala, Lola Madrid, Sara Dominguez, Pui-Ying Iroh Tam, Tisungane Mvalo, Justina Magalhaes-Bramugy, Raoul Moh, Álvaro Ballesteros, Cinta Moraleta, Pablo Rojo
Research Group: EMPIRICAL Clinical Trial Group
- 811** **MORTALITY RISK AMONG CHILDREN < 5 YEARS OLD LIVING WITH HIV ON ART**
Nickolas T. Agathis, Iyiola Faturiyeye, Kiva Fisher, Stephanie Hackett, Elfriede Agyemang, Susan Hrapcak, George Siberry, Catherine Godfrey
- 812** **RELATIVE GAP IN HIV VIRAL LOAD SUPPRESSION IN YOUNGER CHILDREN IN ETHIOPIA**
Dereje Habte, Alemayehu Mekonnen, Tekeste Kebede, Wondimu Teferi, Daniel M. Desalegn, Caroline A Ryan
- 813** **FANMI: A RANDOMIZED TRIAL OF COMMUNITY COHORT HIV CARE FOR ADOLESCENT GIRLS, HAITI**
Vanessa Rouzier, Lindsey Reif, Joseph Marie Bajo Joseph, Rose Riche, Heejung Bang, Elaine J. Abrams, Jean William Pape, Daniel W. Fitzgerald, Margaret McNairy
Research Group: The FANMI Clinical Trial Team
- 814** **ECONOMIC STRENGTHENING INTERVENTION TO IMPROVE ART ADHERENCE IN HIV-INFECTED YOUTH**
Samuel Kizito, Flavia Namuwonge, Proscovia Nabunya, Josephine Nabayinda, Fred Ssewamala

Poster Session-R4 SEX, GENDER, AND VIOLENCE AND ASSOCIATION WITH OUTCOMES

2:30 PM - 4:00 PM

- 858** **SEX DIFFERENCES IN NON-FATAL OVERDOSES: A POPULATION-BASED COHORT STUDY**
NIS
Megan E. Marziali, Katherine W. Kooij, Jason Trigg, Michael O. Budu, Monica Ye, Viviane D. Lima, Julio Montaner, Robert S. Hogg
- 859** **TRANSGENDER WOMEN BASELINE PROFILE IN transCITAR: TRANS-SPECIFIC COHORT IN ARGENTINA**
Claudia E. Frola, Romina Caballero, Carina César, Emilia Frontini, Maria I. Figueroa, Carolina F. Pérez, Nicolás Doudtchitzky, Nadir Cardozo, Virginia Zalazar, Ana Gun, Pedro E. Cahn, Valeria Fink, Inés Arístegui
Research Group: TransCITAR Study Group

- 860 INTIMATE PARTNER VIOLENCE IN A COHORT OF PERSONS WITH HIV IN CARE**
Rob Fredericksen, Lydia Drumright, Sarah Mixson, Robin Nance, Bridget Whitney, Stephanie Ruderman, Jimmy Ma, Andrew Hahn, Sonia Napravnik, Amanda Willig, Jeff Jacobson, Katerina Christopoulos, Edward Cachay, Mari Kitahata, Heidi Crane
- 861 SYNERGISM BETWEEN VIOLENCE & HIV STATUS ON SUICIDAL IDEATION AMONG TRANSGENDER WOMEN**
 Evelyn Olansky, Kathryn Lee, Ruthanne Marcus, Susan Cha, **Patrick C. Eustaquio**
Research Group: NHBS-Trans Study Group
- 862 PREVALENCE AND CORRELATES OF VIOLENCE AMONG PARTNERS OF PWID LIVING WITH HIV IN KENYA**
NIS
Sai W. Aung, Hanley Kingston, Brandon L. Guthrie, Loice W. Mbogo, Betsy Sambai, Pyone Yadanar Paing, Nicholus Zaw, Aliza Monroe-Wise, Natasha T. Ludwig-Barron, Bhavna H. Chohan, Sarah Masyuko, William Sinkele, David Bukusi, Joshua Herbeck, Carey Farquhar

Poster Session-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION

2:30 PM - 4:00 PM

- 863 PERSISTENTLY HIGH HIV INCIDENCE AMONG MSM AND PWID ATTENDING CARE CENTRES IN INDIA**
Allison M. McFall, Mihili P. Gunaratne, Aylur K. Srikrishnan, C. K. Vasudevan, Santhanam Anand, David D. Celentano, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas
- 864 NOT GETTING TO ZERO HIV FOR PEOPLE WHO INJECT DRUGS, SAN FRANCISCO**
LB
Moranda Tate, Bow Suprasert, Danyion Reagan, Katherine Gao, Katherine McNaughton, Raul Ruiz, Cassandra Miller, Alexander Marr, Kelly D. Taylor, Willi McFarland, Erin C. Wilson
- 865 RACIAL DISPARITIES IN HIV PRE-EXPOSURE PROPHYLAXIS-RELATED OUTCOMES IN MALE VETERANS**
Dagan Coppock, Benjamin Viernes, Michael Kauth, Robert Gross, Kristine Lynch
- 866 BEHAVIOR CHANGE AMONG HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN NOT USING PrEP IN THE US**
Steven M. Goodreau, Michael P. Barry, Deven T. Hamilton, Travis H. Sanchez, Kevin Delaney
- 867 REASONS FOR MIGRATION AND ASSOCIATIONS WITH HIV RISK AMONG SEXUAL MINORITY MEN**
Jane J. Lee, Roxanne P. Kerani, Gabriel Robles, Travis H. Sanchez, David A. Katz
- 868 SEXUAL RISK AND ROLE OF LOW-LEVEL VIREMIA TO HIV TRANSMISSION IN SUB-SAHARAN AFRICA**
Olanrewaju Edun, Lucy Okell, Helen M. Chun, Kyle Milligan, Emilio Dirlikov, Ray W. Shiraishi, Jeffrey W. Eaton
Research Group: Viremia HIV Transmission Investigation Group
- 869 REDUCTION OF HIV INCIDENCE AFTER ELIMINATION OF LYMPHATIC FILARIASIS**
Inge Kroidl, Lucas Maganga, Agatha Urjo, Jacklina Mhidze, Jonathan Mnkai, Maureen Mosoba, Thomas Marandu, Antelmo Haule, Sacha Horn, Basel Habboub, Elmar Saathoff, Friedrich Riess, Nhamo Chiwarengo, Michael Hoelscher, Mkunde Chachage

Poster Session-S3 MPOX EPIDEMIOLOGY, IMPACT ON SEXUAL BEHAVIORS, AND STIGMA

2:30 PM - 4:00 PM

- 895 NEW HIV DIAGNOSES IDENTIFIED FROM LINKAGE TO CARE AFTER MPOX INFECTION, TEXAS 2022**
Analise Monterosso, Kristyn Krolikowski, Kenneth Davis, Rania Milleron, Stephen White
- 896 MPOX VIRUS IN THE PHARYNX OF MEN HAVING SEX WITH MEN: A CASE SERIES**
 Silvia Limonta, Laura Corsico, **Giuseppe Lapadula**, Francesca Rovida, Alice Ranzani, Fausto Baldanti, Paolo Bonfanti
- 897 MPOX AMONG MSM IN THE NETHERLANDS PRIOR TO MAY 2022, A RETROSPECTIVE STUDY**
Elske Hoornenborg, Henry de Vries, Hannelore Götz, Sylvia Bruisten, Annemiek van Der Eijk, Maria Prins, Bas Oude Munnik, Matthijs Welkers, Marcel Jonges, Richard Molenkamp, Benda Westerhuis, Daphne Mulders, Leonard Schule, Mariken van Der Liubben, Marion Koopmans, Arjen Stam
- 898 CHANGES IN SEXUAL BEHAVIORS DUE TO MPOX: A CROSS-SECTIONAL STUDY OF SGM IN ILLINOIS**
Gregory Phillips, Michael Curtis, Dylan Felt, Shahin Davoudpour, Anthony Rodriguez-Ortiz, Alfred Cortez, Audrey French, Sybil Hosek, Pedro Serrano
- 899 SEXUAL BEHAVIOR REDUCTION DO NOT EXPLAIN DECREASED MPOX INCIDENCE AMONG PrEP USERS.**
Roberto Rossotti, Daniele Calzavara, Massimo Cernuschi, Anna De Bona, Alessandro Tavelli, Simona Bossolasco, Camilla Muccini, Daniele Tesoro, Davide Moschese, Giovanni Mulé, Antonella D'Arminio Monforte
- 900 STIGMA RELATED TO HUMAN MPOX VIRUS AMONG MSM IN THE US, AUGUST 2022**
Thomas Carpino, Kaitlyn Atkins, Kevin Delaney, O. Winslow Edwards, Evan Eschliman, Amrita Rao, Saskia Vos, Sarah Murray, John Mark Wiginton, Travis H. Sanchez, Stefan Baral
- 901 HIGH LEVEL OF MPOX KNOWLEDGE AND STIGMA AMONG LGBTQIA+ COMMUNITIES IN BRAZIL**
Thiago S. Torres, Mayara S. T. Silva, Carolina Coutinho, Brenda Hoagland, Sandra Wagner-Cardoso, Julio Moreira, Paula M. Luz, Valdilea G. Veloso, Beatriz Grinsztejn
Research Group: The INI-Fiocruz MpoX Study Group

Poster Session-S4 MPOX CHARACTERISTICS AND OUTCOMES

2:30 PM - 4:00 PM

- 902 CHARACTERISTICS AND DISPARITIES AMONG HOSPITALIZED PERSONS WITH MPOX IN CALIFORNIA**
Akanksha Vaidya, Jon Brock, Linda Lewis, Philip J. Peters, Linda Crebbin, Kayla Saadeh, Elana Silver, Eric Chapman, Eric C. Tang, David Bui, Lauren Finn, Azarnoush Maroufi, Amy Garlin, Amanda Kamali, Robert E. Snyder
- 903 CD4 COUNT < 350 CELLS/MM³ INCREASES RISK OF HOSPITALIZATION WITH MPOX IN PWH**
David CE. Philpott, Robert Bonacci, Paul J. Weidle, Kathryn G. Curran, John Brooks, George Khalil, Lauren Barrineau-Vejjajiva, Amanda Feldpausch, Jessica Pavlick, Pascale Wortley, Jesse O'Shea
Research Group: CDC MpoX Special Studies Team
- 904 MPOX VIRUS INFECTION IS MORE SEVERE IN PATIENTS WITH UNCONTROLLED HIV INFECTION**
Anaïs Corma-Gómez, Marta Santos, Alfonso Cabello, Miguel Morante-Ruiz, Aws Waleed Al-Hayani, Irene Carrillo Acosta, Lucio García-Fraile, Cristina Gómez-Ayerbe, David Rodrigo-Domínguez, Sergio Reus, Ana C. Silva Klug, Sandra De la Rosa-Riestra, Ana Ferrer-Ribera, Juan A. Pineda, Juan Macías

- 905 IMPACT OF HIV INFECTION ON MPOX-RELATED HOSPITALIZATIONS IN BRAZIL**
Mayara S. T. Silva, Carolina Coutinho, Thiago S. Torres, Eduardo Peixoto, Isabel C. F. Tavares, Estevão P Nunes, Ronaldo I Moreira, Flavia C. S. Lessa, Hugo B. Andrade, Maira B. Mesquita, Matheus O Bastos, Sandra Wagner Cardoso, Valdilea Veloso, Beatriz Grinsztejn
Research Group: INI-Fiocruz Mpx Study Group
- 906 CHARACTERISTICS OF THE 2022 MPOX OUTBREAK IN A SOUTHEASTERN US CITY**
Bruce Aldred, Colleen Kelley, Jonathan Colasanti, Vincent C. Marconi, Anandi N. Sheth, Minh Nguyen, Jane Yoon Scott, Sheetal Kandiah, Aley G. Kalapila, Daniel Gromer, Amalia Aldredge, Brittany Szabo, Betsy Hall, Valeria D. Cantos
Research Group: Emory MAPS Study Group
- 907 CLINICAL OUTCOMES AMONG IN- AND OUTPATIENTS WITH MPOX IN AN URBAN HEALTH SYSTEM**
William M. Garneau, Joyce L. Jones, Gabriella Dashler, Nathan Kwon, Matthew Hamill, Elizabeth Gilliams, David Rudolph, Jeannie Keruly, Eili Klein, Bhakti Hansoti, Kelly Gebo
- 908 HIV CARE AND PREVENTION CHARACTERISTICS AMONG PERSONS WITH MPOX AND HIV, TEXAS 2022**
Kristyn Krolikowski, Kenneth Davis, Rania Milleron, Stephen White
- 909 MPOX OUTBREAK IN PLWHA AND PrEP USERS IN A BRAZILIAN STI CENTER: DIFFERENT CHALLENGES**
Alvaro Costa, Simone Queiroz Rocha, Mylva Fonsi, Roberta Schiavon Nogueira, Arthur Olhovetchi Kalichman, Jose V. Madruga, Maria Clara Gianna, Rosa Alencar, Rosangela Rodrigues, Angela Tayra, Lucas Ramos, Marisa Vono Tancredi
Research Group: MONKEYPOX GROUP - CRT CASA DA PESQUISA
- 910 MPOX IN THE CONTEXT OF POPULATION-LEVEL HIV TREATMENT AND HIV PrEP PROGRAMS IN BC**
K. Junine Toy, **Raquel M. Espinoza**, Paul Sereda, Erin Ready, Wendy W. Zhang, Viviane D. Lima, Kate Salters, Rolando Barrios, Julio Montaner
- 911 MPOX IN AMSTERDAM: CROSS-SECTIONAL STUDY AMONG MSM AT THE CENTRE FOR SEXUAL HEALTH**
Elske Hoornenborg, Matthijs Siegenbeek Van Heukelom, Vita Jongen, Jason Schouten, Sylvia Bruisten, Benda Westerhuis, Matthijs Welkers, Maria Prins, Maarten Schim Van Der Loeff, Henry de Vries
- 912 CHARACTERISTICS OF PATIENTS HOSPITALIZED WITH MPOX DURING THE 2022 US OUTBREAK**
Preetam A. Cholli, Maureen J. Miller, Pritiza Paromita, Karen K. Wong, James T. Lee, Jennifer Cope, Dana Meaney Delman, Shama Cash-Goldwasser, Grace E. Marx, Jeremy A W. Gold, Sapnah Bamrah Morris
Research Group: Centers for Disease Control Severe Mpx Investigations Team
- 913 EQUITY FOCUSED EVALUATION OF MPOX CARE METRICS IN KING COUNTY, WA**
Ellora Karmarkar, Chase Cannon, Matthew Golden, Sargis Pogojans, Eric Chow, Meena Ramchandani, Kaitlin Zinsli, Julia C. Dombrowski
- 914 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MPOX WITHIN A NEW YORK CITY HEALTH SYSTEM**
Christopher A. Vo, Rustin Zomorodi, Richard J. Silvera, Logan Bartram, Amarilis Lugo, Erna Kojic, Antonio Urbina, Judith A. Aberg, Keith Sigel, Rachel Chasan, Gopi Patel
- 915 MPOX INFECTION IN WOMEN: A CASE SERIES FROM BRAZIL**
Carolina Coutinho, Luciane Velasque, Mayara Silva, Thiago S. Torres, Eduardo Peixoto, Sandra Wagner Cardoso, Gabriella Nazário, Maira Mendonça, Marianna Menezes, Paula Maria Almeida, Shenon Bia Bedin, Aline Maria Almeida, Silvia Carvalho, Valdilea Veloso, Beatriz Grinsztejn
Research Group: The INI-Fiocruz Mpx Study Group

Poster Session-T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING
2:30 PM - 4:00 PM

- 934 RACIAL/ETHNIC DISPARITIES IN HIV TESTING EXPERIENCE BEFORE HIV DIAGNOSIS: 2014-2019**
Sonia Singh, Xueyuan Dong, Laurie Linley
- 935 CDC-FUNDED HIV TESTING AND UNDIAGNOSED HIV INFECTION IN ENDING THE HIV EPIDEMIC AREAS**
Deesha Patel, Weston O. Williams, Carolyn Wright, Aba Essuon, Guoshen Wang, Mesfin Mulatu
- 936 FACTORS ASSOCIATED WITH HIV POSITIVITY UNAWARENESS AMONG TANZANIANS LIVING WITH HIV**
Alexander Kailembo, Oscar Rwabiyago, George Mgomella, Kokuhumbya Kazaura, Eva Matiko, Prosper Njau, Brian Baker, Mahesh Swaminathan, Mohamed Jalloh
- 937 OVER- AND UNDER-REPORTING IN HIV TESTING, STATUS, AND TREATMENT IN RURAL SOUTH AFRICA**
Hannah H. Leslie, Chodziwadziwa Kabudula, Rebecca West, Mi-Suk Kang Dufour, Aimée Julien, Nkosinathi Masilela, Stephen Tollman, Audrey Pettifor, Kathleen Kahn, Sheri Lippman
- 938 SIGNS OF LATE HIV DIAGNOSIS AND OUTBREAKS IN TRANSMISSION NETWORKS IN JAPAN**
Teiichiro Shiino, Machiko Otani, Tadashi Kikuchi, Kazuhisa Yoshimura, Wataru Sugiura
Research Group: Japanese Drug Resistance HIV-1 Surveillance Network
- 939 PATTERNS OF HIV-1 RECENT INFECTIONS AMONG GENERAL AND KEY POPULATIONS IN NIGERIA**
Adebola Sunday Adekogbe, Blessing Salako, Ray-Desmond Umechinedu, David Barnabas, Fadeke Abuwonronye, Abimbola Phillips, Livinus Ibiang, Oluseyi Adegbulugbe, Collins Imarhiagbe, **Bolanle Oyeledun**
- 940 NO INCREASED VIOLENCE VICTIMIZATION AFTER RETURN OF REGENCY TEST RESULTS IN RWANDA**
Eugenie Poirot, Giles Reid, Suzue Saito, Jean-Claude Irabona, Collins Kamanzi, Vusumuzi Mwalia, Veronicah Mugisha, Beata Sangwayire, Eric Remera, Eugenie Kayirangwa, Samuel Malamba, Meagan Cain, Jennifer Hegle, Stephanie Behel, Gallican N. Rwibasira
Research Group: Rwanda HIV Recency Evaluation Study Team

Poster Session-U2 SARS-CoV-2 SELF-TESTING
2:30 PM - 4:00 PM

- 956 COVID-19 SELF-TESTING AMONG HEALTHCARE WORKERS AND GENERAL POPULATION IN MALAWI**
Madalo Mukoka, Euphemia Sibanda, Constanca Watadzaushe, Moses Kumwenda, Florence Abok, Elizabeth Corbett, Elena Replod, Augustine Choko, Marriott Nliwasa
- 957 INTEGRATION OF SARS-CoV-2 RAPID ANTIGEN TEST IN HEALTH SERVICES IN KENYA AND CAMEROON**
Boris K. Tchounga, Nelia Hoffman, Rose Masaba, Elvis Moma, Virginia Gitau, Shabbir Ismail, Calvine Lwaka Lwaka, Evelyne Sikuku, Patrice Tchendjou, Stephen Siamba, Njoki Kimani, Anne Cecile Zoung-Kanyi Bissek, Aida Yemaneberhan, Nilesh Bhatt, Rhoderick Machezano, Saint-Just Petnga, Emilienne Epee
- 958 IMPACT AND COST-EFFECTIVENESS OF COVID-19 RAPID SELF-TESTING STRATEGIES IN SCHOOLS**
Joshua M. Chevalier, Alvin X. Han, Megan A. Hansen, Ethan Klock, Hiromi Pandithakorlage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, **Colin A. Russell**, Brooke Nichols

959 COST-EFFECTIVENESS OF WORKPLACE COVID-19 SELF-TESTING: A MATHEMATICAL MODELING STUDY

Ethan Klock, Alvin X. Han, Joshua M. Chevalier, Megan A. Hansen, Hiromi Pandithakorralage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell, Brooke Nichols

960 HOME VERSUS FACILITY SARS-CoV-2 TESTING AMONG OLDER ADULTS IN NEW YORK CITY

Abigail R. Greenleaf, **Shannon M. Farley**, David Hoos, Melissa Reyes, Takura Kupamupindi, Kimberly Geoffrey, Wafaa El-Sadr

Poster Session-V3 OPTIMIZING PrEP ROLLOUT**2:30 PM - 4:00 PM****975 RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT OUTPATIENT DEPARTMENT IN EAST AFRICA**

Catherine Koss, James Ayieko, Jane Kabami, Laura Balzer, Elijah Kakande, Helen Sunday, Marilyn Nyabuti, Erick Wafula Mugoma, Melanie Bacon, Elizabeth A. Bukusi, Gabriel Chamie, Maya Petersen, Moses Kamyra, Diane V. Havlir

Research Group: SEARCH Study Team

976 INCREASED UPTAKE OF BIOMEDICAL HIV PREVENTION BY YOUTH THROUGH COMMUNITY-BASED SRH

Maryam Shahmanesh, Glory Chidumwa, Natsayi Chimbindi, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Kobus Herbst, Jana Jarolimova, Thandeka Khoza, Deenan Pillay, Theresa Smit, Osee Behuhuma, Jean-Michel Molina

Research Group: Isisekelo Sempilo Research Group

977 EFFECTS OF 6-MONTH PrEP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA

NIS

Ashley R. Bardon, Kenneth Ngure, Peter Mogere, Katherine Thomas, Stephen Gakuo, Catherine Kiptinness, Sarah Mbaire, Dorothy Mangale, Jacinta Nyokabi, Nelly Mugo, Jared M. Baeten, Katrina F. Ortblad

978 PHARMACY-BASED PrEP DELIVERY IN KENYA: FINDINGS FROM A PILOT STUDY EXTENSION

Stephanie Roche, Victor Omollo, Peter Mogere, Magdaline Asewe, Stephen Gakuo, Preetika Banerjee, Kendall Harkey, Josephine Odoyo, Jared M. Baeten, Patricia Ongwen, Daniel Were, Elizabeth A. Bukusi, Kenneth Ngure, Katrina F. Ortblad

979 PREDICTIVE VALUES OF URINE PrEP (TFV) TEST SHOW STRONG CLINICAL AND RESEARCH UTILITY

Brian Mustanski, Richard D'Aquila, Monica Gandhi, Daniel Ryan, Matthew A. Spinelli, Michael Newcomb

Research Group: RADAR Study Investigators

980 ORAL AND INJECTABLE PrEP USE IN THE UNITED STATES, 2013 TO 2022

LB

Weiming Zhu, Ya-Lin Huang, Athena P. Kourtis, Karen W. Hoover

981 BREAKTHROUGH HIV-1 INFECTION IN SETTING OF LONG-ACTING CABOTEGRAVIR FOR PrEP

LB

Aniruddha Hazra, Connor Quinby, Cathy Creticos

Poster Session-V6 PrEP PRODUCT UPDATE AND EFFECTIVENESS**2:30 PM - 4:00 PM****993 EFFECTIVENESS OF HIV PRE-EXPOSURE PROPHYLAXIS AMONG FEMALE SEX WORKERS IN RWANDA**

Eric Remera, Gallican N. Rwibasira

- 994 PRE-EXPOSURE PROPHYLAXIS PRODUCT CHOICE IN US PARTICIPANTS IN HPTN 083**
Meredith E. Clement, Zhe Wang, Carl J. Fichtenbaum, Schuyler Thomas, Jose A. Bazan, Paul Richardson, Matthew A. Spinelli, Brett Hanscom, Alex R. Rinehart, Jim Rooney, Adeola Adeyeye, Marybeth McCauley, Myron S. Cohen, Beatriz Grinsztejn, Raphael J. Landovitz
Research Group: HPTN 083 Study Team
- 995 OPTIMIZING PRE-EXPOSURE PROPHYLAXIS WITH TDF-FTC AND TAF-FTC FOR INSERTIVE SEX**
NIS
Carolina Herrera, Laura J. Else, Emily Webb, Azure-Dee Pillay, Thabiso B. Seiphetlo, Limakatso Lebina, Jennifer Serwanga, Andrew Sentoogo Ssemata, Patricia Namubiru, Geoffrey Odoch, Clive M Gray, Francesca Chiodi, Saye Khoo, Neil Martinson, Julie Fox
Research Group: CHAPS study team
- 996 INTERACTION BETWEEN TAF-BASED PREP AND HORMONE THERAPY IN TRANSGENDER WOMEN: iFACT 3**
NIS
Akarin Hirsansuthikul, Narukjaporn Thammajarak, Stephen J. Kerr, Rena Janamnuysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressey, Nittaya Phanuphak
Research Group: the iFACT3 study team
- 997 PREP USE AMONG US VETERANS USING VETERAN HEALTH ADMINISTRATION SERVICES: 2017-2021**
Ya-Lin A. Huang, Elliot Lowy, Lei Yu, Weiming Zhu, Wei Wei, Karen Hoover, Lauren A. Beste
- 998 ALIGNMENT OF PrEP USE WITH HIV RISK IN YOUNG WOMEN AND MEN IN UGANDA**
NIS
Linxuan Wu, Andrew Mujugira, Timothy Muwonge, Timothy Ssebubila, Felix Bambia, Olivia Nampewo, Renee Heffron
- 999 A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA**
Ingrid Bassett, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile Ngcobo, Taing N. Aung, Jana Jarolimova, Danielle Zions, Christina Psaros, Nduduzo Dube, Robert Parker

Poster Session-W2 SARS-CoV-2 VACCINE STRATEGIES

2:30 PM - 4:00 PM

- 1005 LONG-TERM COVID-19 BOOSTER EFFECTIVENESS AND IMMUNE IMPRINTING**
 Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, **Laith J. Abu-Raddad**
- 1006 RESIDENTIAL SEGREGATION AS A BARRIER TO COVID-19 BOOSTER COVERAGE IN DEEP SOUTH**
 Chengbo Zeng, Jiajia Zhang, Zhenlong Li, Xiaowen Sun, Huan Ning, Xueying Yang, Sharon Weissman, Bankole Olatosi, Xiaoming Li, **Chen Liang**
- 1007 SARS-CoV-2 VACCINE EFFECTIVENESS IN A COHORT OF ACTIVE-DUTY US MILITARY PERSONNEL**
Jessica J. Cowden, Vanessa Cox, Diane Epperson, Elissa Thomas, Genice Jacques, Sonya Arzola, Kelly McKee, Jason Okulicz
Research Group: VIRAMP Study Group
- 1008 EFFECTS OF PUBLIC HEALTH INTERVENTIONS AGAINST COVID-19 IN FRANCE**
 Iris Ganser, David L. Buckeridge, Mélanie Prague, **Rodolphe Thiebaut**
- 1009 EQUITY-BASED OPTIMIZATION FOR COVID-19 VACCINE ALLOCATION**
 Erin Stafford, Dobromir Dimitrov, Rachel Ceballos, **Laura Matrajt**

- 1010 VACCINE UPTAKE IN A PREDOMINANTLY BLACK AND LATINX COHORT HOSPITALIZED FOR COVID-19**
Michelle Chang, Jennifer Chang, Simian Huang, Joan Bosco, Meredith McNairy, Sade Tukur, Yi Hao Wu, Jonathan Kunkel-Jure, Jessica Weidler, Carlie Dorr, Renee Roberts, Brett Gray, Jason Zucker, Delivette Castor, Magdalena E. Sobieszczyk
- 1011 PREVALENCE AND CORRELATES OF SARS-CoV-2 VACCINE HESITANCY AMONG US PEOPLE WITH HIV**
Matthew A. Spinelli, Mallory O. Johnson, Nadra E. Lisha, Jennifer P. Jain, Carlos Moreira, David V. Glidden, Greer Burkholder, Heidi Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard Moore, Monica Gandhi, Katerina Christopoulos
- 1012 SAFETY OF HETEROLOGOUS MRNA-1273 BOOST AFTER AD26. CoV2.S PRIME IN SOUTH AFRICA**
Nigel Garrett, Ameena Goga, Tarylee Reddy, Azwidihi Takalani, Kubashni Woeber, Phumeza Jonas, Imke Engelbrecht, Ishen Seocharan, Jacqueline Odhiambo, Kentse Khuto, Nonhlanhla Yende-Zuma, Kate Anteyi, Brett Leav, Linda-Gail Bekker, Glenda E. Gray
Research Group: SHERPA Study Team
- 1013 REACTOGENICITY AMONG PEOPLE LIVING WITH HIV AFTER MRNA-1273 VACCINE IN UBUNTU STUDY**
Asa Tapley, Jessica Andriesen, Yunda Huang, Azwidihi Takalani, Bongile Mabilane, Manuel V. Villaran, Taraz Samandari, Sofia Dadabhai, Linda-Gail Bekker, Margaret Yacovone, Aaron Hudson, Lawrence Corey, Glenda E. Gray, Philip Kotze, Nigel Garrett
Research Group: CoVPN 3008 Ubuntu Study Team
- 1014 COVID-19 VACCINATION IN PERSONS WITH AND WITHOUT HIV: VETERANS AGING COHORT STUDY**
Emily J. Cartwright, Kathleen McGinnis, Janet P. Tate, Christopher T. Rentsch, Kendall Bryant, Emily C. Williams, Sheldon T. Brown, Evelyn Hsieh, Amy C. Justice, Lesley S. Park
- 1015 THE CHANGING IMPACT OF VACCINES IN THE COVID-19 PANDEMIC: A MODELING STUDY**
Robyn Stuart, Jamie Cohen, Jasmina Panovska-Griffiths, Edinah Mudimu, Romesh Abeysuriya, Cliff Kerr, Michael Famulare, Daniel Klein
- 1016 HIV VIRAL LOAD AND TIME-TO-COVID-19 VACCINATION AMONG PEOPLE WHO INJECT DRUGS**
Pieter Baker, Javier Cepeda, Becky Genberg, Greg Kirk, Shruti H. Mehta, Kenneth Feder, Jacqueline E. Rudolph, Jing Sun
- 1017 COVID-19 VACCINE COVERAGE AMONG PEOPLE WITH HIV IN THE VACCINE SAFETY DATALINK**
Rulin Hechter, Lei Qian, In-Lu Amy Liu, Lina Sy, Denison Ryan, Joshua Williams, Laura Hurley, Nicola Klein, Robyn Kaiser, Elizabeth Liles, Hung Fu Tseng
- 1018 CORRELATES OF COVID-19 VACCINE UPTAKE IN MALAWIAN ADULTS**
Hannah Whitehead, John Songo, Pericles Kalande, Khumbo Phiri, Eric Lungu, Sam Phiri, Joep J Van Oosterhout, Agnes Moses, **Risa Hoffman**, Corrina Moucheraud
- 1019 SAFETY OF AD26.CoV2.S AND AZD1222 COVID-19 VACCINES AMONG ADULTS IN MALAWI**
NP
Lucky D. Makonokaya, Lester Kapanda, Thulani Maphosa, Louiser Kalitera, Harrid Nkhoma, Rachel Chamanga, Cathy Golowa, Suzgo Zimba, Godfrey Woelk, Malocho Phoso, **Nilesh Bhatt**
- 1020 COMPARISON OF THE EFFECTIVENESS OF DIFFERENT COVID-19 VACCINES AMONG PLWH**
Wang-Da Liu, Pei-Ying Wu, Ling-Ya Chen, Hsin-Yun Sun, Yu-Shan Huang, Kuan-Yin Lin, Guei-Chi Li, Wen-Chun Liu, Yi-Ching Su, Yi-Chen Yeh, Yi-Ting Chen, Hsi-Yen Chang, Yu-Zhen Luo, Sui-Yuan Chang, Chien-Ching Hung

Poster Session-X2 STI EPIDEMIOLOGY IN POPULATIONS AFFECTED BY HIV

2:30 PM - 4:00 PM

- 1025 INCREASED HIV, HCV & STIs AMONG ADULTS REPORTING SEX WORK IN ALABAMA: 2008-2022**
NIS
Kaitlyn Atkins, Josh Bruce, Emma Kay, Karen Musgrove, Polly Kellar, Sarah MacCarthy
- 1026 PREVALENCE OF CHLAMYDIA AND GONORRHEA AMONG ADOLESCENTS IN KISUMU, KENYA**
Hong-Ha M. Truong, Elsa Heylen, Kevin Kadede, Sayo Amboka, Damaris Odeny, Maurice Opiyo, Marion Hewa, Fidel Opondo, Beatrice Otieno, Hannington Odhiambo, David Ogolla, Mary Guzé, Lara E. Miller, Craig R. Cohen, Elizabeth A. Bukusi
Research Group: Maneno Yetu Study Team
- 1027 PATTERNS OF STI AMONG TRANSGENDER WOMEN LIVING WITH AND WITHOUT HIV IN THE US**
NIS
Erin E. Brown, Eshan U. Patel, Erin E. Cooney, Tonia Poteat, Asa Radix, Jowanna Malone, Dee Adams, Christopher M. Cannon, Megan Stevenson, Jason S. Schneider, Chris Beyrer, Andrew Wawrzyniak, Kenneth Mayer, Oliver Laeyendecker, Sari L. Reisner, Andrea L. Wirtz, Keri Althoff
Research Group: American Cohort To Study HIV Acquisition Among Transgender Women (LITE) Study Group
- 1028 SEXUALLY TRANSMITTED INFECTIONS AMONG YOUNG ADULTS AFFECTED BY PREINATAL HIV**
Anna-Barbara Moscicki, Yanling Huo, Lisa B. Haddad, Deborah Kacaneck, Claude A. Mellins, Sharon Nichols, Kunjal Patel, Katherine K. Tassiopoulos, Tzy-Jyun Yao
Research Group: Pediatric HIV AIDS Cohort Study Network

Poster Session-X4 INTERTWINED: MPOX and STI EPIDEMIOLOGY

2:30 PM - 4:00 PM

- 1033 MPOX AND SEXUALLY TRANSMITTED INFECTION AMONG MEN WHO HAVE SEX WITH MEN**
Jesse J. Carlson, Karen Wendel, Kellie Hawkins, Oluyomi Obafemi, Edward M. Gardner, Michael Breyer, Laura Podewils
- 1034 HIV AND SEXUALLY TRANSMITTED INFECTIONS AMONG MPOX CASES, TEXAS 2022**
 Analise Monterosso, Kacey Russell, Enyinnaya Merengwa, **Kristyn Krolikowski**, Abigail Jordan, Kenneth Davis, Rania Milleron, Stephen White
- 1035 CONCURRENT STI TESTING AMONG PATIENTS TESTED FOR MPOX AT DUKE UNIVERSITY HEALTH**
Emily Niehaus, Ahmad Mourad, Edwin Wilbur. Woodhouse, Hayley Cunningham, Naseem Alavian, Sofia Zavala, Patricia Kohler, Steven Pappas, Michael Yarrington, Nwora Lance Okeke, Cameron R. Wolfe, Gary Cox, Kristen V. Dicks, Jason E. Stout

Poster Session-Y05 PRESENTATION TO CARE

2:30 PM - 4:00 PM

- 1052 PREDICTORS OF PLWH NEWLY PRESENTING TO CARE WITH VIRAL SUPPRESSION IN LUSAKA, ZAMBIA**
Jake M. Pry, Chilambwe Mwila, Herbert Kapesa, Musunge Mulabe, Christiana Frimpong, Theodora Savory, Carolyn Bolton Moore, Michael E. Herce, Shilpa S. Iyer
- 1053 LATE PRESENTATION IN OLDER PWH IS ASSOCIATED WITH MORTALITY AND POOR IMMUNE RESPONSE**
NIS
Win Min Han, Sirinya Teeraananchai, Cheewanan Lertpiriyasuwat, Rattaphon Triamwichanon, Anchalee Avihingsanon, Stephen J. Kerr, Kiat Ruxruntham

Poster Session-Y06 LONG-ACTING ART

2:30 PM - 4:00 PM

- 1054 POTENTIAL IMPACT OF LONG-ACTING ANTIRETROVIRAL THERAPY ON LOCAL HIV INCIDENCE**
Preetham Bachina, Parastu Kasaie, Melissa Schnure, David Dowdy, Maunank Shah, Anthony Fojo
- 1055 IDENTIFYING PREFERRED PROGRAM DELIVERY ATTRIBUTES FOR LONG-ACTING INJECTABLE ART**
Jose Gutierrez, Elizabeth Montgomery, Moira McNulty, Jonathan Colasanti, Mallory O. Johnson, Torsten Neilands, Kimberly Koester, John Saucedo, Samantha E. Dilworth, Xavier Erguera, Kaylin Dance, Manami Diaz Tsuzuki, John Schneider, Elvin Geng, Katerina Christopoulos

Poster Session-Y07 ART REGIMENS

2:30 PM - 4:00 PM

- 1056 UPTAKE AND OUTCOMES OF FIRST-LINE DOLUTEGRAVIR IN A LARGE SOUTH AFRICAN COHORT**
 Jienchi Dorward, Yuktेशwar Sookrajh, Thokozani Khubone, Johan van Der Molen, Riona Govender, Sifiso Phakathi, Lara Lewis, Christian Bottomley, Munthra Maraj, Richard Lessells, Kogieleum Naidoo, Christopher Butler, Rosemary Van Heerden, **Nigel Garrett**
- 1057 SEX DISPARITIES IN THE ROLLOUT OF DOLUTEGRAVIR IN LATIN AMERICA AND THE CARIBBEAN**
Fernanda F. Fonseca, Paridhi Ranadive, Bryan E. Shepherd, Beatriz Grinsztejn, Sandra Wagner Cardoso, Valdilea Veloso, Flávia Ferreira, Maria Fernanda Rodriguez, Daisy Maria Machado, Vanessa Rouzier, Diana Varela, Emilia M. Jalil, Jessica L. Castilho
Research Group: CCASAnet
- 1058 MONITORING HIV DUAL-THERAPY IMPLEMENTATION AS REGIMEN SIMPLIFICATION POLICY IN BRAZIL**
 Nazle Veras, Rosana Pinho, Alexandre Ferreira, Ana Cristina G. Ferreira, Beatriz Kamiensky, Ana Francisca Kolling, Gerson Fernando M. Pereira, **Ana Roberta Pascom**
- 1059 A NATIONWIDE OPTIMIZATION STRATEGY USING SECOND-GENERATION INSTIs IN MEXICO**
Alicia Piñeirúa-Menéndez, Yanink Caro-Vega, Juan Luis Mosqueda-Gómez, Santiago Ávila-Ríos, Florentino Badial-Hernández, Andrea González-Rodríguez, Gustavo Reyes-Terán, Juan Sierra-Madero, Alethse De La Torre-Rosas
- 1060 PEOPLE FAILING FIRST-LINE REGIMENS REMAIN AT RISK FOR ADVERSE SECOND-LINE OUTCOMES**
NIS **Pupe Sudsila**, Sirinya Teeraanachai, Sasisopin Kiertiburanakul, Cheewanan Lertpiriyasuwat, Rattaphon Triamwichanon, Sivaporn Gatechompol, Opas Putcharoen, Ploenchon Chetchotisakd, Anchalee Avihingsanon, Stephen J. Kerr, Kiat Ruxrungtham
- 1061 PREDICTORS OF TRANSITIONING TO A FIRST-LINE DOLUTEGRAVIR REGIMEN IN WEST AFRICA**
Thierry Tiendrebeogo, Karen Malateste, Armel Poda, Albert K. Minga, Eugène Messou, Henri Chenal, Ephrem Mensah, Oliver Ezechi, Didier K. Ekouevi, Igbo Ofotokun, Antoine Jaquet
Research Group: leDEA West Africa Collaboration
- 1062 TRANSITION TO DOLUTEGRAVIR-BASED ART IN LOW- AND MIDDLE-INCOME COUNTRIES IN leDEA**
Elizabeth Zaniewski, Veronika Whitesell, Matthias Egger, Aggrey Semeere, Cordelia Kunzekwenyika, Sanjay Mundhe, Peter-Vanes Ebasone, Thierry Tiendrebeogo, Lara E. Coelho, Kara Wools-Kaloustian, Jonathan Euvrard, Vohith Khol, Dominique Mahambou-Nsonde, Stefanie Hossmann, Marie Ballif
Research Group: the International epidemiology Databases to Evaluate AIDS (leDEA) consortium

1063 NATIONAL TRENDS IN ART REGIMENS FILLED FOR PEOPLE WITH HIV ON MEDICARE: 2013-2019Jose Figueroa, Jessica Phelan, Luke Ang, **Emily P. Hyle****Poster Session-Y12 ADVANCED HIV DISEASE****2:30 PM - 4:00 PM****1085 COST DRIVERS OF PROVIDING ADVANCED HIV DISEASE CARE THROUGH HUB/SPOKE MODEL IN MALAWI****Mario Songane**, Sushant Mukherjee, Rachel Chamanga, Barry Longwe, Joseph Namathanga, Thulani Maphosa, Allan Ahimbisibwe, Rebecca Bailey, Appolinaire Tiam**1086 ADVANCED HIV DISEASE CARE PACKAGE IMPLEMENTATION IN LESOTHO AND SOUTH AFRICA****Tinne Gils**, Lutgarde Lynen, Kamele Mashaete, Josephine Muhairwe, Thulani Ngubane, Philip Joseph, Klaus Reither, Moniek Bresser, Alastair van Heerden**Poster Session-Y13 PREVENTION AND PrEP MODELS****2:30 PM - 4:00 PM****1087 ARE VENUE-BASED STRATEGIES THE TICKET TO THE LAST MILE IN HIV PREVENTION IN MALAWI?****Emmanuel Singogo**, Sharon Weir, Evaristar Kudowa, Maganizo Chagomerana, Jessie Edwards, John Chapola, Confidence Banda, Gift Kawalizira, Andreas Jahn, Yohane Kamgwira, Lucy Platt, Brian Rice, James Hargreaves, Mina Hosseinipour, Sarah Bourdin, Thomas Hartney
Research Group: CLOVE Study**1088 COMMUNITY-ENGAGED PrEP DEMONSTRATION PROJECT FOR MSM IN CHINA**Bin Yu, Cao Fang, Zhuoheng Yin, Chunyan Li, Haojie Huang, Kun Wang, Quanmin Li, Linghua Li, Ke Liang, Ivy Jiang, Joseph Tucker, Renslow Sherer, Jonathan Lio, Aniruddha Hazra, **Weiming Tang****1089 RANDOMIZED TRIAL LEVERAGING ELECTRONIC HEALTH RECORD DATA TO INCREASE HIV PrEP UPTAKE****Michael J. Silverberg**, Wendy A. Leyden, Catherine Lee, Alexandra N. Lea, Julia L. Marcus, Douglas S. Krakower, Vincent X. Liu, Michelle Donnelly, Kristine L. Lee, Jonathan E. Volk**1090 COSTS OF PROVIDING PHARMACY-INITIATED PrEP IN KENYA: FINDINGS FROM A PILOT STUDY**

NIS

Alexandra Kuo, Obinna I. Ekwunife, Peter Mogere, Victor Omollo, Josephine Odoyo, Yilin Chen, Jared M. Baeten, Elizabeth A. Bukusi, Kenneth Ngure, Katrina F. Ortblad, Monisha Sharma**1091 CLIENT PREFERENCES FOR PrEP REFILLS AT FACILITIES VS PHARMACIES: A PILOT IN KENYA**Peter Mogere, **Alexandra Kuo**, Stephen Gakuo, Njeri Wairimu, Stephanie Roche, Mary Mugambi, Jared M. Baeten, Kenneth Ngure, Katrina F. Ortblad**1092 MALE CIRCUMCISION IN BOTSWANA: EFFECT OF QUALITY IMPROVEMENT ON ADVERSE EVENT RATES**Ludo S. Monene, Mooketsi Molefi, Keikantse Matlhagela, **Billy M. Tsim****Poster Session-Y14 COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES****2:30 PM - 4:00 PM****1093 HIV OUTCOMES AFTER EXTENDED 12-MONTH SCRIPTS FOR ART DURING COVID-19 IN SOUTH AFRICA****Lara Lewis**, Yuktेशwar Sookrajh, Johan van Der Molen, Thokozani Khubone, Phelelani Sosibo, Riona Govender, Sifiso Phakathi, Munthra Maraj, Rosemary Van Heerden, Francesca Little, Reshma Kassanje, Nigel Garrett, Jienchi Dorward

- 1094 VIRAL SUPPRESSION TRAJECTORIES DESTABILIZED AFTER COVID-19 AMONG US PEOPLE WITH HIV**
Matthew A. Spinelli, Katerina Christopoulos, Nadra E. Lisha, Jennifer P. Jain, Carlos Moreira, David V. Glidden, Greer Burkholder, Heidi Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard Moore, Monica Gandhi, Mallory O. Johnson
- 1095 HIV CARE DURING THE SARS-CoV-2 PANDEMIC IN BLACK PEOPLE WITH HIV IN THE UK**
 Zoe Ottaway, Lucy Campbell, Laura Cechin, Julie Fox, Fiona Burns, Lisa Hamzah, Stephen Kegg, Melanie Rosenvinge, Sarah Schoeman, David Price, Rachael Jones, Denis Onyango, Robert Miller, Shema Tariq, **Frank Post Research Group**: CoV-AFRICA study group
- 1096 DISRUPTIONS IN HEALTH CARE AMONG MWCCS PARTICIPANTS DURING THE COVID-19 PANDEMIC**
Jenni Wise, Lorie Benning, Mackey Friedman, Tracey Wilson, Catalina Ramirez, Adaora Adimora, Bradley Aouizerat, Anjali Sharma, Matthew Mimiaga, Anandi N. Sheth, Michael Plankey, Mardge Cohen, Deborah Jones Weiss, Gypsyamber D'Souza, Mirjam Colette-Kempf
Research Group: Multicenter AIDS Cohort Study and the Women's Interagency HIV Study Combined Cohort Study (MWCCS) Research Group
- 1097 UTILITY OF DIGITAL SOLUTIONS IN SUSTAINING ACCESS AND IMPROVING EFFICIENCY OF HIV VL**
Ughweroghene Omo-Emmanuel, Victor Obianeri, Omosalewa Oyelaran, Helina Meri, Abiye Kalaiwo, Dolapo Ogundehin, Rachel Goldstein, Jason Williams, Timothy Yakubu
- 1098 MITIGATING THE IMPACT OF COVID-19 ON HIV VIRAL LOAD ACCESS AMONG KEY POPULATIONS**
Ughweroghene Omo-Emmanuel, Victor Obianeri, Abiye Kalaiwo, Omosalewa Oyelaran, Jason Williams, Timothy Yakubu, Mark Akhigbe, Usman Haliru
- 1099 IMPACT OF COVID-19-INDUCED PROGRAM ADAPTATIONS ON HIV SUPPRESSION IN THREE COUNTRIES**
Vamsi Vasireddy, Neha Shah, Allahna L. Esber, Trevor A. Crowell, Joseph S. Cavanaugh, Hannah Kibuuka, Ajay Parikh, Jonah Maswai, Valentine Sing'Oei, Emmanuel Bahemana, Michael Iroezindu, Julie A. Ake
Research Group: African Cohort Study (AFRICOS) group
- 1100 CHANGES IN SERVICE ACCESS AMONG PEOPLE WHO INJECT DRUGS IN PHILADELPHIA, 2018-2022**
Tanner B. Nassau, Kathleen A. Brady

WEDNESDAY FEBRUARY 22, 2023

Poster Session-A3 VIRUS REPRODUCTION

2:30 PM - 4:00 PM

- 226** **ELEVATED HIV VIRAL LOAD IS ASSOCIATED WITH HIGHER VIRAL RECOMBINATION RATE IN VIVO**
NIS Elena V. Romero, Alison F. Feder
- 227** **Vpr ENHANCES HIV REPLICATION BY INHIBITING T CELL PROLIFERATION**
 Rodrigo A. Matus Nicodemos, David R. Ambrozak, Daniel C. Douek, Richard A. Koup
- 228** **A HUMAN-SPECIFIC CARD8 MUTATION AFFECTS INFLAMMASOME ACTIVATION AFTER HIV-1 INFECTION**
NIS Jessie Kulsuptrakul, Elizabeth Turcotte, Michael Emerman, Patrick Mitchell
- 229** **CARD8 INFLAMMASOME MODULATES HIV-1 INFECTION IN CD4+ T CELLS**
NIS Qiankun Wang, Liang Shan
- 230** **VHH DIMER P559-R45L NEUTRALIZES SARS-CoV-2 BY STABILIZING SPIKE IN UP CONFORMATION**
 Kayoko Nagata, Junso Fujita, Ryota Maeda, Kotaro Shirakawa, Tsuyoshi Inoue, Keiichi Namba, Akihiro Imura, **Akifumi Takaori-Kondo**, Akihide Ryo, Kei Sato
- 231** **FC RECEPTOR-MEDIATED INFECTION OF MYELOID CELLS BY SARS-CoV-2**
 Suzanne Pickering, Harry D. Wilson, Enrico Bravo, Marianne R. Perera, Nathalia Almeida Dos Santos, Katie J. Doores, Michael H. Malim, Stuart Neil
- 232** **OMICRON SPIKE ENDOWS SARS-CoV-2 WITH ENHANCED INFECTIVITY IN NASAL EPITHELIA**
 Guoli Shi, Tiansheng Li, Kinkui Lai, Jonathan Yewdell, Alex A. Compton
- 233** **SARS-CoV-2 REPLICONS REVEAL SPIKE-INDEPENDENT ATTENUATION OF THEOMICRON VARIANT**
 Taha Y. Taha, Irene Chen, Melanie Ott
- 234** **SARS-CoV-2 USES ENDOSOMAL MEMBRANES TO BUILD REPLICATION ORGANELLES**
 Yuexuan Chen, Ruth Serra-Moreno
- 235**

WITHDRAWN

Poster Session-A4 VIRUS DIVERSITY IN POPULATIONS

2:30 PM - 4:00 PM

- 236** **MPOX VIRUS SEQUENCES DIVERSITY IN PARIS AREA DURING THE 2022 OUTBREAK**
 Géraldine Piorkowski, **Jade Ghosn**, Valentine M. Ferré, Morgane Mailhe, Romain Coppée, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Quentin Le Hingrat, Hervé Raoul, Charlotte Charpentier, Diane Descamps, Xavier de Lamballerie

237

WITHDRAWN

238

WITHDRAWN

239 **GENOMIC SURVEILLANCE OF SARS-CoV-2 REVEALS SEVERITY OF DELTA VARIANT IN CAMEROON**

Fokam Joseph, Rene Ghislain Essomba, Richard Njouom, Okomo Assoumou Marie-Claire, Sara Eyango, Celestin Godwe, Bryan Tegomoh, Judith Shang, Linda Ezzo, Tulio de Oliveira, Moussa Moïse Diagne, Yap Boum Ii, Etoundi Mballa George Alain, Louis R. Njock, Alex Durand Nka

Poster Session-B2 HIV AND THE MICROBIOME

2:30 PM - 4:00 PM

248 **CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF**

Sandra Pinto-Cardoso, Monserrat Chávez-Torres, Adriana Aguilar, Santiago Ávila-Ríos

249 **PROTEOMIC ANALYSIS OF TRANSLOCATING BACTERIAL TAXA REVEALS NOVEL THERAPEUTIC TARGET**

Jacob K. Flynn, Alexandra Ortiz, Marlon Deleon, Samantha Knodel, Kenzie Birse, Laura Noel-Romas, Adam Burgener, Jason Brenchley

250 **THE EFFECTS OF CD4+ LYMPHOPENIA ON THE HUMAN SKIN MICROBIOME**

Irini Sereti, Jungmin Han, Andrea Lisco, Julia A. Segre, Heidi H. Kong

251 **COMMENSAL BACTERIA WITHIN THE FAMILY LACHNOSPIRACEAE ROBUSTLY INHIBIT HIV INFECTION**

NIS

Danting Jiang, Sedem Dankwa, Amir Ardeshir, Koen Van Rompay, Kristina De Paris, Sallie R. Permar, Ria Goswami, Neeraj K. Surana

252 **BACTERIAL DYSBIOSIS PERSISTS IN WOMEN LIVING WITH HIV-1 AFTER ART**

NIS

Katherine M. Bricker, Andrea Lisco, Alessandra Borgognone, Maura Manion, Andrew Redd, Frances Galindo, Sarah Kalibbala, Aggrey Anok, Stephen Tomusange, Steven J. Reynolds, Marc Noguera Julian, Irini Sereti

Poster Session-B4 HIV AND AGING

2:30 PM - 4:00 PM

260 **GLYCOMIC BIOMARKERS OF BIOLOGICAL AGING ARE ALTERED DURING SUPPRESSED HIV INFECTION**

Leila Giron, Xiangfan Yin, Susan Langan, Jinbing Zhang, Jane Koshy, Igho Ofotokun, Jason M. Lazar, Margaret Fischl, Sabina Haberlen, Lawrence Kingsley, Alan Landay, Wendy Post, Qin Liu, Todd T. Brown, Mohamed Abdel-Mohsen

Research Group: MACS/WIHS Combined Cohort Study

261 **SEX DIFFERENCES IN CYTOKINE DYNAMICS IN PEOPLE WITH HIV ON ART DURING AGING**

NIS

Alan B. Wells, Christophe Vanpouille, Victor De Gruttola, Miranda Lynch, Xinyi Huang, Jinyuan Liu, Wendy Fitzgerald, Xin Tu, Antoine Chaillon, Alan Landay, Eileen P. Scully, Leonid Margolis, Jonathan Karn, Sara Gianella

- 262 AGING IN WOMEN WITH HIV: SINGLE-CELL TRANSCRIPTOME ANALYSIS OF THE IMMUNE SYSTEM**
NIS **Konstantin Leskov**, Sara Gianella, Eileen P. Scully, Alan Landay, Antoine Chaillon, Jennifer Kinslow, Kathleen Weber, Saba Valadkhan, Victor De Gruttola, Alan B. Wells, Mary Ann Checkley, Benjamin Luttge, Jonathan Karn
- 263 MULTIPARAMETRIC CHARACTERIZATION OF TELOMERE LENGTH IN T CELLS FROM PLWH BY Flow-FISH**
NIS **Macedonia Trigueros**, Cora Loste, Maria Nevot, Francisco Muñoz-López, Diana Hernández, Ana Martínez, Marco A. Fernández, Yacine Kharraz, Julià Blanco, Eugenia Negredo, Marta Massanella
Research Group: TRANSLATIONAL RESEARCH IN IMMUNOLOGY AND AGEING (TRIA)
- 264 DURABLE ART SUPPRESSION IN AGED RHESUS MACAQUES IS ASSOCIATED WITH MHC-I ALLELES**
Alejandra Marenco, Candice Nkoy, Benjamin Varco-Merth, Aparna N. Govindan, He Li, Devin N. Fachko, Anne Lewis, Brandy Dozier, Caralyn Labriola, Michael Axthelm, Jeremy Smedley, Rebecca L. Skalsky, Scott W. Wong, **Afam A. Okoye**

Poster Session-B8 MPOX PATHOGENESIS

2:30 PM - 4:00 PM

- 291 DELAYED POSITIVIZATION OF NON-LESION SPECIMENS AMONG INDIVIDUALS WITH MPOX**
Angelo Roberto Raccagni, Davide Mileto, Alberto Rizzo, Nicola Gianotti, **Vincenzo Spagnuolo**, Caterina Candela, Elena Bruzzesi, Riccardo Lolatto, Benedetta Trentacapilli, Emanuela Messina, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza
- 292 LONGITUDINAL ASSESSMENT OF VIRAL SHEDDING AMONG PATIENTS WITH MPOX IN TORONTO, CANADA**
Darrell H. S. Tan, Robert Kozak, Jacklyn Hurst, Maedeh Naghibosadat, Hui Ting Ma, Oscar Pico Espinosa, Shreya Shah, Natasha Christie-Holmes, Jessica Lam, Angel Ly, Reva Persaud, Charlie Tan, Matthew Muller, Sharmistha Mishra
- 293 MPOX DNA CLEARANCE IN SEMEN OVER SIX MONTHS FOLLOW-UP**
Caterina Candela, Alberto Rizzo, Laura Galli, Davide Mileto, Diana Canetti, Nicola Gianotti, Maria Francesca Lucente, Costanza Bertoni, Angelo Roberto Raccagni, Maria Rita Gismondo, **Antonella Castagna**, Silvia Nozza

Poster Session-D4 LYMPH NODES

2:30 PM - 4:00 PM

- 329 DYNAMICS AND ROLE OF TOX+ TCF1+ CD39+ CD8 T CELLS IN LYMPHOID TISSUE IN SIV INFECTION**
Zachary Strongin, Claire Deleage, Gregory Tharp, Kevin Nguyen, Andrew Rahmberg, Jason Brenchley, Steven Bosinger, Haydn Kissick, **Mirko Paiardini**
- 330 SPATIAL MAPPING OF SIV-INFECTED RHESUS MACAQUE LYMPH NODE ENVIRONMENT DURING REBOUND**
NIS **Kristen Olivera**, Muhammad Shoaib Arif, Yanique Thomas, Christopher Thuruthiyil, Michael McRaven, Yanxiang Deng, Yang Liu, Graham Su, Archibald Enniful, Jack Collora, Rong Fan, Thomas J. Hope, Ya-Chi Ho
- 331 LYMPH NODE IMMUNE MICROENVIRONMENT FOLLOWING ART INITIATED DURING ACUTE HIV INFECTION**
Andrea Papadopoulos, Trevor Nkaba, Thandeka Nkosi, Krista Dong, **Thumbi Ndung'U**, Zaza Ndhlovu

332 DEVELOPMENT OF A LYMPHOID ORGAN-CHIP TO EVALUATE COVID VACCINE BOOSTING STRATEGIES

Raphaël Jeger-Madiot, Jérôme Kervevan, Isabelle Staropoli, Delphine Planas, Héloïse Mary, Cassandre Garnier, Rémy Robinot, Stacy Gellenoncourt, Olivier Schwartz, Michael Bscheider, Céline Marban-Doran, Lorna Ewart, Samy Gobaa, Lisa A. Chakrabarti

Poster Session-D8 MPOX VACCINES AND IMMUNOPATHOGENESIS**2:30 PM - 4:00 PM****374 NEUTRALIZING AND T-CELL RESPONSE AGAINST MPOX VIRUS AFTER MVA-BN VACCINE**

Valentina Mazzotta, Giulia Matusali, Alessandro Cozzi Lepri, Eleonora Cimini, Simone Lanini, Francesca Colavita, Stefania Notari, Roberta Gagliardini, Silvia Meschi, Serena Vita, Emanuele Nicastrì, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Priscilla Caputi, Flavia Cristofanelli, Francesca Faraglia, Daniele Lapa, Giorgia Natalini
Research Group: MPOX Vaccine Lazio Study Group

375 COMPARISON OF SUBCUTANEOUS VERSUS INTRADERMAL ROUTE OF ADMINISTRATION OF MVA VACCINE

Valentina Mazzotta, Pierluca Piselli, Alessandro Cozzi Lepri, Giulia Matusali, Eleonora Cimini, Roberta Gagliardini, Silvia Di Bari, Laura Scorzoloni, Emanuele Nicastrì, Andrea Siddu, Alessandra Barca, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Claudia Cimaglia, Francesca Colavita, Simona Gili, Alessandra Oliva, Gianluca Prota
Research Group: MPOX Vaccine Lazio Study Group

376 HUMORAL AND CELLULAR IMMUNE RESPONSE AFTER 3 MONTHS FROM MPOX VIRUS INFECTION

Valentina Mazzotta, Giulia Matusali, Eleonora Cimini, Francesca Colavita, Rita Casetti, Carmela Pinnetti, Annalisa Mondì, Aurora Bettini, Germana Grassi, Serena Vita, Emanuele Nicastrì, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Marta Camici, Silvia Di Bari, Silvia Meschi, Gianluca Prota, Eleonora Tartaglia
Research Group: MPOX Vaccine Lazio Study Group

377 IMMUNOGENICITY OF MVA-BN VACCINATION WITH HYBRID ADMINISTRATION ROUTE

Davide Moschese, Micol Bianchi, Maria Vittoria Cossu, Federica Salari, Andrea Giacomelli, Alberto Rizzo, Samuel Lazzarin, Federico Sabaini, Silvia Nozza, Davide Mileto, Andrea Gori, Spinello Antinori, Maria Rita Gismondo, Giuliano Rizzardini

378 IMMUNE RESPONSES AND VIRAL DYNAMICS AFTER MPOX INFECTION IN THE 2022 OUTBREAK

Susana Benet, Julieta Carabelli, Clara Suñer, Adrià Mendoza, Angel Rivero, Vicente Descalzo, Aurélien Marc, Michael Marks, Christian Brander, Alex Olvera, Nuria Izquierdo-Useros, José Moltó, Jorge Carrillo, Oriol Mitjà, Beatriz Mothe Pujades
Research Group: MoViE-Immune Study Group

379 NOVEL SEROASSAYS DETECT MPOX-SPECIFIC AND VACCINE-INDUCED ORTHOPOXVIRUS IMMUNITY

Jonah Kupritz, Savita Pahwa, Suresh Pallikkuth

Poster Session-E3 IMMUNE PRESSURE ON THE HIV RESERVOIR**2:30 PM - 4:00 PM****398 CTL RESPONSES ARE NOT ASSOCIATED WITH DECAY OF INTACT PROVIRUSES OR HIV RNA ON ART**

NIS

Adam R. Ward, Dennis C. Copertino, Eva M. Stevenson, Evan McNeil, Uchenna Chukwukere, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Bernard Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, R. Brad Jones
Research Group: ACTG A5321 Team

399 TSCM/TCM-ENRICHED ANTI-HIV duoCAR-T CELLS EXERT POTENT HIV CONTROL

Kim Anthony-Gonda, Alex Ray, Hang Su, Vanessa Chilunda, Danica Lee, Jessica Weiselberg, Lily Zemelko, Yen Wang, Jane Reese, **Rimas Orentas**, Steven G. Deeks, Rachel L. Rutishauser, Joan W. Berman, Harris Goldstein, Boro Dropulic

400 bNAb ESCAPE HIV-ENV VARIANTS IN ORALLY SHIV-INFECTED, ART-TREATED INFANT MACAQUES

Ria Goswami, Stella J. Berendam, Sedem Dankwa, Elena E. Giorgi, Joshua Eudailey, Caroline Phan, Diane G. Carnathan, Bhругu Yagnik, Chiamaka A. Enemu, Veronica Obregon-Perko, Rama R. Amara, Ann Chahroudi, Sallie R. Permar, Genevieve G. Fouda

401 BISPECIFIC ANTIBODIES PROMOTE NK CELL-MEDIATED ELIMINATION OF THE HIV-1 RESERVOIR

NIS

Nathan L. Board, Meghana Ravi, Fengting Wu, Milica Moskovljevic, Srona Sengupta, Francesco R. Simonetti, Kenneth Lynn, Luis J. Montaner, Rebecca Hoh, Steven G. Deeks, Janet M. Siliciano, Robert F. Siliciano

402 DONOR-DERIVED ENV MUTATION SCANNING REVEALS anAb AND bNAb VULNERABILITIES

Joseph Varriale, **Brianna Lopez**, Kshitij Wagh, Elena E. Giorgi, Robert F. Siliciano, Janet M. Siliciano

403 HIV-RESISTANT CAR T CELLS BY CRISPR/Cas-MEDIATED CAR INTEGRATION INTO THE CCR5 LOCUS

NIS

Frederik H. Rothemejer, Nanna Pi Lauritsen, Anna Karina Juhl, Mariane Høgsbjerg Schleimann, Saskia König, Ole Schmeltz Søgaard, Rasmus O. Bak, Martin Tolstrup

404 GENERATING BROADLY NEUTRALIZING ANTIBODY-SECRETING CAR-T-CELLS AGAINST HIV INFECTION

NIS

Hang Su, Jianhua Zheng, Scott Garforth, Kim Anthony-Gonda, Boro Dropulic, Steven Almo, Harris Goldstein

405 CIRCULATING IMMUNE PREDICTORS OF INTACT HIV RESERVOIR DECAY DURING LONG-TERM ART

Sergio Serrano-Villar, Akshay Gala, Peter Bacchetti, Clara Di Germanio, Lillian Cohn, Peter W. W. Hunt, Gregory M. Laird, Satish K. Pillai, Steven G. Deeks, Michael J. Peluso

406 THE LEAKY RESERVOIRS ARE ASSOCIATED WITH HIV-SPECIFIC CD4 AND CD8 T CELL RESPONSES

Mathieu Dubé, Olivier Tastet, G  r  my Sannier, Nathalie Brassard, Gloria Gabrielle Ortega-Delgado, Am  lie Pagliuzza, Alexandre Prat, Jean-Pierre Routy, R  mi Fromentin, Nicolas Chomont, Daniel Kaufmann

407 CTL EPITOPES FROM STRUCTURALLY IMPORTANT HIV PROTEINS ARE IDENTIFIED IN REBOUND HIV

NIS

Eunok Lee, Gabriel Duette, Katie Fisher, Anthony D. Kelleher, Steven G. Deeks, Sarah Palmer

408 IMMUNE FEATURES ASSOCIATED WITH HIGHER T-CELL RESPONSES TO AN HIV THERAPEUTIC VACCINE

Lily Zemelko, Naseem Sadek, Kara W. Chew, Mansi Purwar, Laurent Humeau, David V. Glidden, Matthew H. Spitzer, David B. Weiner, Steven G. Deeks, Rafick P. S  kaly, Jeffrey A. Tomalka, Rachel L. Rutishauser

409 ANTIRETROVIRAL THERAPY REPAIRS CD4 T-CELL DYSREGULATION IN PEOPLE LIVING WITH HIV

Alexis Sponaugle, Ann Marie Weideman, Jolene Ranek, Gatphan Atassi, Daniel Kuritzkes, Adriana Andrade, Adaora Adimora, Nancie Archin, David Margolis, Cynthia Gay, Benjamin Vincent, Natalie Stanley, Michael Hudgens, Joseph J. Eron, Nilu Goonetilleke

- 410** **REPROGRAMMING CMV-SPECIFIC CD8+ T CELLS TO TARGET HIV USING TCR GENE TRANSFER**
NIS
April Mueller, Scott Garforth, Steven Almo, Harris Goldstein
- 411** **NOVEL BISPECIFIC ENGAGER REDIRECTS CMV-SPECIFIC CTL TO ELIMINATE HIV-INFECTED CELLS**
NIS
Christopher R. Hiner, Scott Garforth, Darien Woodley, Steven Almo, Harris Goldstein
- 412** **HIV-1 RESISTANCE PROFILES AGAINST bNAb IN INTACT VS DEFECTIVE GENOMES ARE DISTINCT**
Elena E. Giorgi, Pragya Khadka, Erika Benko, Colin Kovacs, Ria Goswami, Genevieve G. Fouda, Sallie R. Permar, Marina Caskey, R. Brad Jones, **Guinevere Q. Lee**
- 413** **KIR+RA+CD8 T-CELLS EXHIBIT ANTIGEN INDEPENDENCE AND CORRELATE WITH HIV RESERVOIR SIZE**
LB
Talia Mota, Jared Weiler, Paul Zumbo, Dennis C. Copertino, Noemi L. Linden, Andrea Gramatica, Adam R. Ward, Sandra Terry, Erika Benko, Colin Kovacs, Jeffrey Safrit, Mirko Paiardini, Deanna A. Kulpa, Guido Silvestri, R. Brad Jones
- 414** **IMPACT OF SARS-CoV-2-MEDIATED CD4 T-CELL ACTIVATION AND HIV DNA PERSISTENCE IN VIVO**
Tyler-Marie Deveau, Michael J. Peluso, Amanda M. Buck, Sadie Munter, Jane Srivastava, Rebecca Hoh, Nitasha Kumar, Rachel L. Rutishauser, Steven G. Deeks, Timothy Henrich

Poster Session-E5 INNOVATIVE APPROACHES TO TARGET THE RESERVOIR

2:30 PM - 4:00 PM

- 423** **GLYCOENGINEERING ENHANCES HIV 10-1074 bNAb-DEPENDENT NATURAL KILLER CELL CYTOTOXICITY**
NIS
Angela Corrigan, Samson Adeniji, Leila Giron, Shalini Singh, Costin Tomescu, Luis J. Montaner, Mohamed Abdel-Mohsen
- 424** **SINGLE-CELL QUANTIFICATION OF HIV-1 AND LENTIVIRAL VECTOR IN GENE THERAPY STUDIES**
NIS
Amanda M. Buck, Joanna Donnatelli, Corinna Gartner, Tyler-Marie Deveau, Isaac Thomas, Julie Beegle, Kim Anthony-Gonda, Mehrdad Abedi, Joseph Anderson, Timothy Henrich
- 425** **MULTI-SEROTYPE NANOBODY-ENGINEERED AAV VECTORS FOR CD4-TARGETED GENE THERAPY**
Martin Hamann, Daniel Foth, Priti Kumar, Ulrike Lange
- 426** **AN IMMUNOCYTOCHEMISTRY METHOD TO INVESTIGATE THE TRANSLATIONALLY ACTIVE HIV RESERVOIR**
Guoxin Wu, Yuan Li, Jan Kristoff, Carol Cheney, Jill Wiler Maxwell, Tracy Lauren Diamond, Paul Zuck, Carl Balibar, Jay Grobler, Bonnie Howell, **Luca Sardo**
- 427** **DUAL ANTIRETROVIRAL-LOADED NANOPARTICLES FOR LONG-ACTING SUPPRESSIVE HIV THERAPY**
NIS
Josiane Fofana, Behnaz Eshaghi, Erik Schiferle, Chandra Roy, Zandrea Ambrose, Bjoern Reinhard, Rahm Gummuluru

Poster Session-F6 MECHANISMS OF HIV NEUROPATHOGENESIS

2:30 PM - 4:00 PM

- 483** **CSF COMPLEMENT IS CORRELATED TO IMMUNE ACTIVATION IN UNTREATED BUT NOT TREATED HIV**
Arvid Eden, Lars-Magnus Andersson, Aylin Yilmaz, Dietmar Fuchs, Lars Hagberg, Magnus Gisslen

- 484 LONGITUDINAL ASSESSMENT OF GRAPH THEORY MEASURES IN EARLY HIV INFECTION**
Yufen Chen, Guixiang Ma, James Higgins, Ann Ragin
- 485 SINGLE-COPY HIV AND NEURODEGENERATION, OXIDATIVE STRESS, AND NEUROINFLAMMATION**
Albert Anderson, Patricia K. Riggs, Anita McClernon, Daniel McClernon, Ronald J. Ellis, David B. Clifford, Benjamin Gelman, Susan Morgello, Payal Patel, Leah H. Rubin, Bin Tang, Donald Franklin, Robert K. Heaton, Scott L. Letendre
Research Group: The CHARTER group
- 486 CHARACTERIZING THE ROLE OF MONOCYTES IN HIV NEUROPATHOGENESIS**
Veronica Veksler, Rosiris Leon-Rivera, Susan Morgello, Joan W. Berman
- 487 PLASMA Aβ42:AB40 RATIOS ARE NOT REDUCED IN OLDER PERSONS WITH HIV**
Sarah Cooley, Beau Ances, Jane O'Halloran

Poster Session-F7 COINFECTIONS AND THE NERVOUS SYSTEM IN PEOPLE WITH HIV

2:30 PM - 4:00 PM

- 488 THE CEREBROSPINAL FLUID VIROME IN VIRALLY SUPPRESSED PEOPLE LIVING WITH HIV**
LB
Mattia Trunfio, Valeria Fox, Rossana Scutari, Vanessa Fini, Annarita Granaglia, Cristina Russo, Elisa Vuaran, Daniele Imperiale, Carlo Federico Perno, Stefano Bonora, Giovanni Di Perri, Claudia Alteri, Andrea Calcagno
- 489 DIVERGENT NEUROIMMUNE SIGNATURES AND HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS SURVIVAL**
NIS
Samuel Okurut, Elizabeth Okafor, David R. Boulware, David B. Meya, Edward N. Janoff, Yukari C. Manabe, Joseph O. Olobo, Joshua Rhein
Research Group: ASTRO Study Team and TIME Study Team
- 490 CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT**
NIS
Ferron F. Ocampo, Carlo Sacdalan, Suteeraporn Pinyakorn, Misti Paudel, Donn Colby, Nathornsorn Poltubtim, Somchai Sriplienchan, Robert Paul, Nittaya Phanuphak, Denise Hsu, Serena Spudich, Phillip Chan
Research Group: RV254/SEARCH 010 Study Team
- 491 CMV, SEX, AND COGNITION IN PEOPLE WITH HIV (PWH)**
NIS
Patricia K. Riggs, Gordon Honerkamp-Smith, Milenka Vargas, Gemma Caballero, Donald Franklin, Jennifer Iudicello, Leah H. Rubin, Robert K. Heaton, Ronald J. Ellis, Scott L. Letendre, Sara Gianella

Poster Session-G3 PHARMACOKINETICS/PHARMACODYNAMICS OF SARS-CoV-2 THERAPEUTICS

2:30 PM - 4:00 PM

- 510 IMMUNE-VIRAL DYNAMICS MODELING OF THE BASIS FOR INDIVIDUAL VARIATION IN COVID-19**
Youfang Cao, Akshita Chawla, Brian Maas, Ruthie Birger, Laura Liao, Matthew Rizk, Julie Stone
- 511 FACTORS INFLUENCING COVID-19 RISK: INSIGHTS FROM MOLNUPIRAVIR EXPOSURE-RESPONSE**
Akshita Chawla, Brian Maas, Ruthie Birger, Hong Wan, Youfang Cao, Matthew Johnson, Carisa De Anda, Matthew Rizk, Julie Stone
- 512 NO DOSE ADJUSTMENTS FOR CYP3A4 SUBSTRATES WHEN COADMINISTERED WITH BEMNIFOSBUVIR**
Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond

- 513 BEMNIFOSBUVIR HAS LOW POTENTIAL TO INHIBIT P-gp, BCRP, AND OATP1B1 MEDIATED TRANSPORT**
Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond
- 514 PHARMACOKINETICS INFORMS REMDESIVIR DOSING FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT**
Rita Humeniuk, Rong Deng, Inmaculada C. Sorribes, Sean Regan, Haeyoung Zhang, Richard Robson, Meghan Sise, Yiannis Koullias, Joe Llewellyn, Robert Hyland, Anu Osinusi, Sandhya Girish, Ana Ruiz-Garcia, Helen Winter
- 515 GLOBAL COLLABORATION TO PROVIDE DRUG INTERACTION GUIDANCE FOR NIRMATRELVIR/RITONAVIR**
Safia Kuriakose, Alice Tseng, Sara Gibbons, Fiona Marra, Alison Boyle, Tessa Senneker, Gregory Eschenauer, Sarita Boyd, Jomy George, Kimberly K. Scarsi, Saye Khoo, Alice K. Pau, Catia Marzolini, Page Crew, Justin Chiong, Pamela S. Belperio, Claire Lund

Poster Session-H2 ANTIRETROVIRAL THERAPY: PROSPECTIVE CLINICAL TRIALS

2:30 PM - 4:00 PM

- 520 IMPACT OF BASELINE FACTORS ON VIROLOGIC RESPONSE TO bNab VH3810109 (N6LS) IN BANNER**
Peter Leone, Margaret Gartland, Judah Abberbock, Paul Wannamaker, Beta Win, Mark Baker, Viviana Wilches, Darren Bentley, Max Lataillade, Jan Losos
- 521 RAPID ART INITIATION USING BIC/FTC/TAF AND TDF+3TC+EFV IN PEOPLE WITH HIV IN CHINA**
 Shiyun Lv, Lijun Sun, Ping Ma, Lijing Wang, Yingquan Zhou, Cuisong Wu, Renfang Chen, Rugang Wang, Fengchi Zhang, Wei Hua, **Lili Dai**
- 522 LONG-ACTING LENACAPAVIR IN A COMBINATION REGIMEN FOR TREATMENT-NAIVE PWH: WEEK 80**
Debbie Hagins, Ellen Koenig, Rachel Safran, Lizette Santiago, Michael Wohlfeiler, Chiu-Bin Hsiao, Shan-Yu Liu, Laurie A. Vanderveen, Hadas Dvory-Sobol, Martin S. Rhee, Jared M. Baeten, Samir Gupta
- 523 WEEK 52 SUBGROUP EFFICACY OF LENACAPAVIR IN HEAVILY TREATMENT-EXPERIENCED PWH**
Onyema Ogbuagu, Sorana Segal-Maurer, Antonella Castagna, Edwin Dejesus, Anchalee Avihingsanon, Christine Zurawski, Olayemi Osiyemi, Theo Hodge, Gordon Crofoot, Hui Wang, Hadas Dvory-Sobol, Martin S. Rhee, Jared M. Baeten, Jean-Michel Molina
- 524 BASELINE nRTI HIV DRUG RESISTANCE AND EFFECT ON RECYCLED nRTIs: THE VISEND TRIAL**
Suilanji Sivile, Lloyd B. Mulenga, Nyuma Mbewe, Danielle Engamba, Sombo Fwoloshi, Mundia Mwitumwa, Mpanji Siwingwa, Lameck Chirwa, Kennedy Banda, Tiza Mpata, Davison Ngandu, Kai M. Nachilima, William C. Wester, Andrew Hill, Bryony Simmons
Research Group: VISEND TRIAL GROUP
- 525 INITIAL SUPPLEMENTAL DOLUTEGRAVIR DOSE IN SECOND-LINE ART: A PHASE 2 RANDOMISED TRIAL**
NIS **Ying Zhao**, Rulan Griesel, Zaayid Omar, Bryony Simmons, Andrew Hill, Gert van Zyl, Claire Keene, Gary Maartens, Graeme Meintjes
- 526 DORAVIRINE: SAFETY, TOLERABILITY & EFFICACY IN SOUTH AFRICAN WOMEN ON CONTRACEPTION**
Nkosiphile Ndlovu, Ché K. Moshesh, Krishnaveni Reddy, Kimberly K. Scarsi, Thesla Palanee-Phillips, Nashon Yongo, Rena Patel, Shukri A. Hassan, Nazneem Cassim, Nompumelelo Sigcu
- 527 PLASMA AND URINE PK OF DOLUTEGRAVIR AND TENOFOVIR TO AID POINT-OF-CARE TESTING**
Laura J. Else, Laura Dickinson, Stacey Edick, Ashley Zyhowski, Ken Ho, Sujan Dilly-Penchala, Beth Thompson, Saye Khoo, Rhonda Brand

Poster Session-H4 ANTIRETROVIRAL THERAPY: COMPARTMENTS, HIV-2, AND NANOFORMULATIONS

2:30 PM - 4:00 PM

- 537 HIV-1 RNA DECAY IN SEMEN AND RECTUM AFTER INITIATING THERAPY WITH DTG PLUS 3TC**
Sofia C. Scevola, Jordi Niubo, Pere Domingo, Guillermo Verdejo, Adrià Curran, Vicens Diaz de Brito, Juan M. Tiraboschi, Sandra Morenilla, Benito Garcia, Irene Soriano, Daniel Podzamczar, **Arkaitz Imaz**
- 538 ANTIVIRAL ACTIVITY OF LENACAPAVIR AGAINST HIV-2 ISOLATES**
Robert A. Smith, Dana Raugi, Robbie Nixon, Moussa Seydi, Nicolas Margot, Christian Callebaut, Geoffrey Gottlieb
- 539 IMMUNO-VIROLOGICAL AND CLINICAL FOLLOW-UP OF HIV-2 PATIENTS RECEIVING BIC/FTC/TAF**
Véronique A. Joly, Valentine M. Ferré, Mélanie Cresta, Charlotte Charpentier, Marc Digumber, Florence Damond, Gilles Peytavin, Yazdan Yazdanpanah, Diane Descamps, Jade Ghosn
- 540 ULTRA-LONG-ACTING BICTEGRAVIR NANOFORMULATIONS**
NIS **Mohammad Ullah Nayan**, Srijaanee Das, Brady Sillman, Brandon Hanson, Siddappa Byrareddy, Howard E. Gendelman, Benson Edagwa

Poster Session-H8 SARS-CoV-2 TREATMENT: CLINICAL AND ANTIVIRAL ACTIVITY (OR NOT)

2:30 PM - 4:00 PM

- 563 SARS-CoV-2 VIRAL LOAD CHANGE IN A RANDOMIZED TRIAL ON THREE DIFFERENT EARLY THERAPIES**
Valentina Mazzotta, **Simone Lanini**, Giulia Matusali, Francesca Colavita, Alessandra Vergori, Emanuela Giombini, Silvia Rosati, Sabrina Minicucci, Martina Reuca, Francesca Gavaruzzi, Enrico Girardi, Emanuele Nicastrì, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Priscilla Caputi, Fabrizio Carletti, Federico De Zottis, Gruber Ernesto Cesare Maria, Maria Maddalena Plazzi
Research Group: MONET Clinical Trial Group
- 564 A RANDOMIZED TRIAL ON EARLY THERAPY IN COVID-19 HIGH-RISK OUTPATIENTS IN OMICRON ERA**
Valentina Mazzotta, **Simone Lanini**, Lavinia Fabeni, Alessandra Vergori, Alessandra D'Abramo, Maria Maddalena Plazzi, Licia Bordi, Samir Al Moghazi, Enrico Girardi, Antonella D'Arminio Monforte, Loredana Sarmati, Emanuele Nicastrì, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Federico De Zottis, Marisa Fusto, Alessandra Oliva, Silvia Rosati, Martina Rueca
Research Group: MONET Clinical Trial Group
- 565 SARS-CoV-2 OMICRON VIRAL LOAD DECREASE AFTER MONOCLONAL ANTIBODIES OR ANTIVIRALS**
Valentina Mazzotta, Alessandro Cozzi Lepri, Francesca Colavita, Simone Lanini, Giulia Matusali, Gaetano Maffongelli, Alessandra Vergori, Eleonora Lalle, Jessica Paulicelli, Pierluca Piselli, Enrico Girardi, Francesco Vaia, Emanuele Nicastrì, Fabrizio Maggi, Andrea Antinori, Emanuela Giombini, Ilaria Mastrososa, Eugenia Milozzi, Alessandra Oliva, Eliana Specchiarello
Research Group: INMI COVID-19 Outpatients Treatment Study Group
- 566 INCIDENCE AND PREDICTORS OF CLINICAL PROGRESSION IN AN EARLY TREATED COVID-19 COHORT**
Valentina Mazzotta, Alessandro Cozzi Lepri, Simone Lanini, Silvia Meschi, Alessandra Vergori, Tommaso Ascoli Bartoli, Giulia Gramigna, Giuseppina Giannico, Alessandra D'Abramo, Claudia Cimaglia, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Emanuele Nicastrì, Andrea Antinori, Carlotta Cerva, Angela Corpolongo, Massimo Francalancia, Francesca Gavaruzzi, Fabio Tucci
Research Group: INMI COVID-19 Outpatients Treatment Study Group

- 567 NIRMATRELVIR/RITONAVIR UPTAKE AMONG ADULTS WITH COVID-19, DECEMBER 2021-OCTOBER 2022**
Yanhan Shen, Mckaylee M. Robertson, Sarah G. Kulkarni, Laura Puzniak, Joann Zamparo, Kristen E. Allen, Saba A. Qasmieh, Christian Grov, Avantika Srivastava, Rebecca Zimba, John M. McLaughlin, Denis Nash
Research Group: CHASING COVID Cohort Study Team
- 568 VIRAL DYNAMIC MODELS PROVIDE AN EXPLANATION FOR SARS-CoV-2 REBOUND AFTER NIRMATRELVIR**
Alan S. Perelson, Ruy Ribeiro, Tin Phan
- 569 NIRMATRELVIR USE AND HOSPITALIZATIONS OR DEATH IN INDIVIDUALS WITH COVID-19**
Adeel Butt, Peng Yan, Obaid Shaikh, Victor Talisa, Saad Omer, Florian G. Mayr
- 570 MOLNUPAVIR IN PREVIOUSLY UNINFECTED NONHOSPITALIZED PERSONS WITH COVID-19**
Adeel Butt, Peng Yan, Obaid Shaikh, Saad Omer, Florian G. Mayr, Victor Talisa
- 571 TIXAGEVIMAB/CILGAVIMAB IM AND IV FOR COVID-19: A RANDOMIZED CONTROLLED ACTIV-2 TRIAL**
Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Carrier, Joseph J. Eron, Arzhang C. Javan, Evgenia Aga, Michael Gibbs, Herve Tchouakam Kouekam, Matthew Newell, Eric S. Daar, Jonathan Z. Li, Michael D. Hughes, Davey M. Smith, David A. Wohl, Robert Coombs, Courtney V. Fletcher, Mark Giganti, Alexander L. Greninger, Justin Ritz
Research Group: ACTIV-2/A5401 Study Team
- 572 A RANDOMIZED TRIAL OF IVERMECTIN 600 MCG/KG VS PLACEBO IN MILD/MODERATE COVID-19**
Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Matthew W. McCarthy, Russell L. Rothman, Sybil Wilson, Allison Delong, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, Elizabeth Shenkman, Adrian F. Hernandez, George J. Hanna, Rhonda Wilder, April Remaly
Research Group: for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators

Poster Session-I3 PRETREATMENT HIV DRUG RESISTANCE

2:30 PM - 4:00 PM

- 583 STATEWIDE TRENDS OF ACQUIRED HIV-1 DRUG RESISTANCE IN RHODE ISLAND: 2004-2021**
 Su Aung, **Vlad Novitsky**, Jon A. Steingrimsson, Fizza Gillani, Mark Howison, Katherine Nagel, Matthew Solomon, Thomas Bertrand, Katharine Howe, Lila Bhattarai, John Fulton, Utpala Bandy, Joseph W. Hogan, Rami Kantor
- 584 FOSTEMSAVIR RESISTANCE-ASSOCIATED MUTATIONS IN HIV-1C STRAINS FROM BOTSWANA**
NIS
Boitumelo J L. Zuze, Botshelo T. Radibe, Wonderful T. Choga, Ontlametse T. Bareng, Natasha O. Moraka, Dorcas Maruapula, Kedumetse Seru, Kaelo Seatla, Sikhulile Moyo, Simani Gaseitsiwe
- 585 NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR**
Tracy Lauren Diamond, Winnie Ngo, Shih Lin Goh, Silveria Rodriguez, Min Xu, Jay Grobler, Ernest Asante-Appiah

Poster Session-J3 VIRAL HEPATITIS IN SUB-SAHARAN AFRICA

2:30 PM - 4:00 PM

- 598 HBV TRANSMISSION IN HOUSEHOLDS OF WOMEN ENGAGED IN DR CONGO'S HIV PMTCT PROGRAM**
NIS
Camille Morgan, Patrick Ngimbi, Melchior Kashamuka Mwandagalira, Sarah Ntambua, Jolie Matondo, Martine Tabala, Nana Mbonze, Linda James, Marcel Yotebieng, Samuel Mampunza, Peyton Thompson, Jonathan Parr

- 599 PREVALENCE AND EVALUATION OF HEPATITIS B VIRAL REPLICATION IN PREGNANT WOMEN IN MALI**
Djeneba B. Fofana, Hamadi Sissoko, Sally McFall, Aminatou Coulibaly, Adama Goita, Laurence Morand-Joubert, Joel Gozlan, Mahamadou Diakite
- 600 EVOLUTIONARY HISTORY OF HEPATITIS B VIRUS SUB-GENOTYPE D3 IN BOTSWANA**
NIS
Doreen Ditshwanelo, Wonderful T. Choga, Motswedi Anderson, Bonolo Phinius, Ontlametse T. Bareng, Basetsana Phakedi, Gorata Mpebe, Tsholofelo K. Ratsoma, Kabo Baruti, Lynnette Bhebhe, Rosemary Musonda, Sikhulile Moyo, Kebaneilwe Lebani, Simani Gaseitsiwe
- 601 HEPATITIS C TREATMENT OUTCOMES AMONG PEOPLE WHO INJECT DRUGS IN KENYA**
NIS
Grace Umutesi, Joyce Boke, Aliza Monroe-Wise, Sarah Masyuko, Helgar Masyuki, David Bukusi, William Sinkele, John Scott, Carey Farquhar, Brandon L. Guthrie
- 602 HEPATOCELLULAR CARCINOMA SCREENING AMONG HIV/HBV-COINFECTED INDIVIDUALS IN ZAMBIA**
NIS
Carlotta Riebensahm, Guy Muula, Helen Chitundu, Kalongo Hamusonde, Belinda Chihota, Edford Sinkala, Veronica Sunkutu, Martin Maurer, Annalisa Berzigotti, Matthias Egger, Carolyn Bolton Moore, Michael Vinikoor, Gilles Wandeler

Poster Session-J4 LIFE AFTER SVR

2:30 PM - 4:00 PM

- 603 RISK BEHAVIOUR TRAJECTORIES AMONG PEOPLE TREATED FOR RECENT HCV INFECTION**
Joanne M. Carson, Evan Cunningham, Sebastiano Barbieri, Marc van Der Valk, Jürgen K. Rockstroh, Margaret Hellard, Arthur Kim, Sanjay Bhagani, Jordan Feld, Edward Gane, Andri Rauch, Julie Bruneau, Gail Matthews, Marianne Martinello
- 604 BEHAVIORAL RISK FOLLOWING HCV TREATMENT AMONG MEN WHO HAVE SEX WITH MEN WITH HIV**
NIS
Kris Hage, Anders Boyd, Daniëla van Santen, Kees Brinkman, Joop Arends, Fanny Lauw, Bart Rijnders, Arne van Eeden, Marc van Der Valk, Astrid Newsom, Amy Matser, Janke Schinkel, Maria Prins
- 605 LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR**
NIS
Jesica Martin Carmona, Anaïs Corma-Gómez, Francisco Tellez, Miriam Serrano-Fuentes, Luis Morano, Diana Corona Mata, Maria José Ríos, Francisco J. Vera Méndez, Isabel Barroso, Rosario Palacios, Ignacio De Los Santos, Paloma Geijo, Arkaitz Imaz, Juan A. Pineda, Juan Macías
Research Group: GEHEP-011
- 606 PREDICTION OF HEPATIC DECOMPENSATION AFTER SVR IN PATIENTS WITH HCV CHRONIC INFECTION**
NIS
Anaïs Corma-Gómez, Francisco Tellez, Luis Morano, Mario Frías, Miriam Serrano-Fuentes, Maria José Ríos, Isabel Barroso, Francisco J. Vera Méndez, Rosario Palacios, Paloma Geijo, Dolores Merino, Ignacio De Los Santos, Arkaitz Imaz, Juan A. Pineda, Juan Macías, Carlos Galera
Research Group: GEHEP-011
- 607 LONG-TERM CHANGES IN LIVER STIFFNESS POST-SVR IN PATIENTS WITH HCV CHRONIC INFECTION**
NIS
Anaïs Corma-Gómez, Francisco Tellez, Diana Corona Mata, Luis Morano, Miriam Serrano-Fuentes, Maria José Ríos, Francisco J. Vera Méndez, Isabel Barroso, Rosario Palacios, Ignacio De Los Santos, Paloma Geijo, Arkaitz Imaz, Dolores Merino, Juan A. Pineda, Juan Macías, Carlos Galera
Research Group: GEHEP-011

608 METABOLOMIC PROFILE ASSOCIATED WITH HVPG CHANGE AFTER DAAs IN HCV PTs WITH CIRRHOSIS

Ana Virseda Berdices, **Juan Berenguer**, David Rojo, Juan González-García, Oscar Brochado Kith, Amanda Fernández-Rodríguez, Daniel Sepulveda Crespo, Cristina Díez, Victor Hontañón, Leire Pérez-Latorre, Rafael Micán, Teresa Aldámiz Echevarria, Coral Barbas, Salvador Resino, María Á. Jiménez-Sousa

Poster Session-J6 PATHOGENESIS AND NATURAL HISTORY**2:30 PM - 4:00 PM****617 RISK FACTORS FOR LIVER FIBROSIS PROGRESSION IN HIV: A MULTI-CENTER LONGITUDINAL STUDY**

Giovanni Guaraldi, Jovana Milic, Stefano Renzetti, Federico Motta, Jenny Bischoff, Giulia Besutti, Giuseppe Mancini, Sara Esperti, Marianna Menozzi, Wesal Elgretli, Dana Kablawi, Stefano Calza, Cristina Mussini, Jürgen K. Rockstroh, Giada Sebastiani

618 INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS

Adeel Butt, Peng Yan, Obaid Shaikh

Research Group: ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans)

619 CONTRIBUTION OF ALCOHOL USE IN HIV/HCV COINFECTION TO ALL-CAUSE MORTALITY

Adam Trickey, Lei Zhang, Suzanne M. Ingle, Anders Boyd, Sophie Grabar, Inmaculada Jarrín, Niels Obel, M. John Gill, Robert Zangerle, Andri Rauch, Christopher T. Rentsch, Derek D. Satre, Heidi Crane, Jonathan Ac Sterne, Linda Wittkop

Research Group: Antiretroviral Therapy Cohort Collaboration (ART-CC)

620 SYNDROMIC OF CHRONIC VIRAL INFECTIONS ON THE RISK OF END-STAGE RENAL DISEASE

Dahn Jeong, Stanley Wong, Jason Wong, Jean Damascene Makuza, Geoffrey McKee, Héctor A. Velásquez García, Zahid A. Butt, Prince A. Adu, Mawuena Binka, Sofia Bartlett, Amanda Yu, Maria Alvarez, Mel Kraiden, Naveed Z. Janjua

621 LIVER NEUTROPHILS EXPRESS STRONGER PD-L1 SIGNALING IN HIV/HBV THAN IN HBV ALONE

Michael S. Wallace, Taonga Musonda, Christopher Oetheimer, Edford Sinkala, Paul Kelly, Mah Asombang, Hailey Patel, Simutanyi Mwakamui, Debika Bhattacharya, Georg Lauer, Raymond Chung, Michael Vinikoor, Nadia Alatrakchi

622 YAP-MEDIATED HEPATOCYTE DAMAGE CONTRIBUTES TO LIVER FIBROSIS WITH HIV-RELATED INJURY

NP

Brian A. Fellenstein, Volney A. Spalding, Wenyu Lin, Raymond Chung, **Shadi Salloum**

623 CHRONIC LIVER INFLAMMATION AND USE OF CONTEMPORARY ART AMONG PERSONS LIVING WITH HIV

LB

Ashley Roen

Research Group: RESPOND

624 COVID-19 OUTCOME IN PATIENTS WITH AND WITHOUT CIRRHOSIS

Obaid Shaikh, Peng Yan, **Adeel Butt**

Poster Session-K1 NON-AIDS DEFINING CANCERS: PATHOGENESIS**2:30 PM - 4:00 PM****625 ASSOCIATION OF HIV CONTROL AND IMMUNOSUPPRESSION WITH NADC RISK AMONG PATIENTS ON ART**

Brittney Dickey, Elizabeth Yanik, Zachary Thompson, Greer Burkholder, Mari Kitahata, Richard Moore, Jeffrey Jacobson, W. Christopher Mathews, Katerina Christopoulos, Julia Fleming, Chad Achenbach, Anna E. Coghill

- 626 HIV-ASSOCIATED DIFFERENCES IN THE TUMOR IMMUNE MICROENVIRONMENT OF NADCs**
Anna E. Coghil, Nathan Van Bibber, Brooke Fridley, Jordan Fenlon, Yoko Derose, Jon Mahlow, Gita Suneja
- 627 SPECIFIC EXOSOMAL PROTEOMIC PROFILE ASSOCIATED TO PLWH PRESENTING NADCs**
 José M. Benito, Maria A. Navarrete-Muñoz, Manuel Pedregal, Héctor Callata, Héctor Peinado, Sara Nistal, Alejandro Velastegui, Edinson Caviedes, María L. Hernández, María L. García-Gil, Jesús García-Foncillas, **Norma Rallón**

Poster Session-K2 CANCER (GENERAL): RISK AND MORTALITY

2:30 PM - 4:00 PM

- 628 RISK FACTORS FOR 5-YEAR MORTALITY IN PEOPLE WITH HIV AFTER CANCER DIAGNOSIS**
NIS
Sally B. Coburn, Elizabeth Humes, Raynell Lang, Michael A. Horberg, Richard Moore, Michael J. Silverberg, Gypsyamber D'Souza, Lesley S. Park, M. John Gill, Amy C. Justice, Maile Karris, Charles Rabkin, Sonia Napravnik, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
- 629 MARKERS OF IMMUNOSUPPRESSION AND MORTALITY AMONG CANCER PATIENTS WITH HIV**
 Emilia Ascanio Carerra, Qianlai Luo, Cameron Haas, Meredith Shiels, **Eric Engels**

Poster Session-K5 ANAL CANCER: PATHOGENESIS, PREVENTION, AND SCREENING

2:30 PM - 4:00 PM

638

WITHDRAWN

- 641 ASSESSING PERSPECTIVES AMONG PEOPLE WITH HIV WHO HAVE HAD HIGH RESOLUTION ANOSCOPY**
Maria C. Geba, Divya Kalluri, Benjamin Cardenas, Emma Mitchell, Tabor Flickinger, Rebecca Dillingham, Tania Thomas
- 642 RISK FACTORS FOR ANAL DYSPLASIA AND LINKAGE TO HRA IN TRANSGENDER WOMEN**
Omar Harfouch, Andrea Lisco, Rahwa Eyasu, Amelia Cover, Ashley Davis, Emade Ebah, Phyllis Bijole, Grace Garrett, Tina Liu, Michelle Spikes, Imani Fnu, Henry Masur, Shyamasundaran Kottlil, Sarah Kattakuzhy, Elana Rosenthal
- 643 IMMUNOLOGICAL BIOMARKERS ASSOCIATED WITH ANAL DYSPLASIA IN PEOPLE LIVING WITH HIV**
NIS
Cristina Mancebo Pérez, Joaquín Burgos, Núria Massanasa, Antonio Astorga Gamaza, Josep Castellvi, Stefania Landolfi, Adrià Curran, Jorge N. García, Vicenç Falcó, Maria J Buzon, Meritxell Genescà
Research Group: HIV Translational Research Group
- 644 NADIR CD4 AND ANAL CYTOLOGY PREDICT DEVELOPMENT OF INVASIVE ANAL CANCER**
Edward Cachay, Tari Gilbert, Huifang Qin, Laura Bamford, William Mathews

645 TISSUE-RESIDENT T-CELL RESPONSES IN HIV+ PATIENTS WITH HPV-DRIVEN ANAL DYSPLASIA

Rehana V. Hewavisenti, Zhong-Hong Zhang, Cecilia Chang, Tony Wang, Priyanka S. Hastak, Fengyi Jin, Mary Poynten, Fabio Luciani, Alexander Swarbrick, Andrew Grulich, Anthony D. Kelleher, Sarah C. Sasson

Poster Session-L4 INFLAMMATION AND CARDIOVASCULAR DISEASE**2:30 PM - 4:00 PM****660 LOW CD4 NADIR AT HIV DIAGNOSIS ASSOCIATES WITH INCREASED RISK OF CLONAL HEMATOPOIESIS**

Romit Bhattacharya, Aniruddh P. Patel, Md Mesbah Uddin, Abhishek Niroula, Kathleen V. Fitch, Michael T. Lu, Gerald Bloomfield, Judith A. Aberg, Carl J. Fichtenbaum, Heather J. Ribaudo, Markella V. Zanni, Benjamin Ebert, Pam S. Douglas, Steven K. Grinspoon, Pradeep Natarajan

661 CIRCULATING BIOMARKERS AND CARDIAC DYSFUNCTION IN WOMEN WITH OR AT RISK FOR HIV

David B. Hanna, Adam M. Whalen, Sanyog G. Shitole, Mahim Naveed, Jason M. Lazar, Kathryn Anastos, Mario J. Garcia, Ryung S. Kim, Phyllis C. Tien, Robert C. Kaplan, Jorge R. Kizer

662 CD2/LFA-3 AXIS COSTIMULATION OF CD57+CD28- CD8 T CELLS IN HIV AND ATHEROSCLEROSIS

NIS

Nicole Winchester, Soumya Panigrahi, Anokhi Haria, Michael M. Lederman, Michael L. Freeman

663 ANTIRETROVIRAL THERAPY AMELIORATES SIV-ASSOCIATED MYOCARDITIS IN THE HEART

NIS

Jake A. Robinson, Meng Niu, Howard Fox, Tricia H. Burdo

664 EFFECT OF NICOTINE RECEPTOR AGONISTS ON INFLAMMATION AND RISK OF CHD AND DEATH IN HIV

Hilary A. Tindle, Debbie M. Cheng, Natalia Gnatenko, Elena Blokhina, Tatiana Yaroslavtseva, Sally Bendiks, Leah Forman, Judith A. Hahn, Kaku So-Armah, Michael D. Stein, Kendall Bryant, Dmitry Lioznov, Evgeny Krupitsky, Jeffrey H Samet, **Matthew Freiberg**

665 CARDIOVASCULAR RISK AMONG PEOPLE ACCESSING DIFFERENTIATED HIV CARE IN SOUTH AFRICA

Maitreyi Sahu, Adam Szpiro, Heidi van Rooyen, Stephen Asimwe, Maryam Shahmanesh, D. Allen Roberts, Meighan Krows, Kombi Sausi, Nsika Sithole, Torin Schaafsma, Jared M. Baeten, Connie Celum, Adrienne E. Shapiro, Alastair van Heerden, Ruanne Barnabas

Research Group: Delivery Optimization of Antiretroviral Therapy (DO ART) Study Team

666 EXERCISE CAPACITY IS REDUCED IN HIV INDEPENDENT OF SARS-CoV-2 INFECTION

Matthew S. Durstenfeld, Michael J. Peluso, Matthew A. Spinelli, Danny Li, Erica Sander, Shreya Swaminathan, Victor Arechiga, Rebecca Hoh, Mandar A. Aras, Carlin S. Long, Steven G. Deeks, Priscilla Hsue

Poster Session-L5 THE GUT MICROBIOME AND COMORBIDITIES**2:30 PM - 4:00 PM****667 GUT MICROBIOTA ASSOCIATED WITH OBSTRUCTIVE CORONARY ARTERY DISEASE IN HIV INFECTION**

Marius Trøseid, Marco Gelpi, Beate Vestad, Klaus Kofoed, Andreas Fuchs, Lars Køber, Hedda Hoel, Kristian Holm, Thomas Lars Benfield, Johaness Roksund, Susanne Dam Poulsen, **Andreas D. Knudsen**

Research Group: COCOMO study

668 TRYPTOPHAN METABOLISM, THE GUT MICROBIOME, AND CAROTID ARTERY PLAQUE IN WIHS WOMEN

NP

Kai Luo, David B. Hanna, Wendy Post, Alan Landay, Howard N. Hodis, Kathleen Weber, Audrey French, Elizabeth Golub, Jason M. Lazar, Deborah Gustafson, Anjali Sharma, Kathryn Anastos, Robert C. Kaplan, Robert D. Burk, Qibin Qi, **Zheng Wang**

- 669 MULTI-OMICS ANALYSIS OF GUT MICROBIOME AND ATHEROSCLEROSIS IN WOMEN LIVING WITH HIV**
Zheng Wang, David B. Hanna, Wendy Post, Alan Landay, Kathleen Weber, Audrey French, Elizabeth Golub, Jason M. Lazar, Deborah Gustafson, Anjali Sharma, Kathryn Anastos, Robert D. Burk, Robert C. Kaplan, Rob Knight, Qibin Qi
- 670 IMPROVED GUT MICROBIOTA RECOVERY IN LATE HIV-1 PRESENTERS INITIATING DTG VS DRV/r**
NIS
Carlos Blázquez Bondia, Ferran Torres, Christian Manzardo, Eva Bonfill, Adrià Curran, Pere Domingo, Daniel Podzamczer, Lluís Force, Vicenç Falcó, Mariona Parera, Francesc Català-Moll, Maria Casadellà, José Maria Miró, Marc Noguera Julian, Roger Paredes
Research Group: ADVANZ-4 MISTRAL

Poster Session-M1 DOES WHAT GOES UP ALWAYS COME DOWN?
2:30 PM - 4:00 PM

- 671 WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG**
Bronwyn E. Bosch, Godspower Akpomemie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Many Mirchandani, Francois Venter
- 672 FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC**
 Sophie Degroote, Sophie Vanherrewege, Els Tobback, Els Caluwe, Lara Vincke, Wim Trypsteen, Mareva Delporte, Evy Blomme, **Linos Vandekerckhove**, Marie-Angélique De Scheerder
- 673 REVERSIBILITY OF TAF- AND/OR InSTI-ASSOCIATED WEIGHT GAIN**
Myrthe L. Verburgh, Ferdinand Wit, Anders Boyd, Peter Reiss, Marc van Der Valk
Research Group: ATHENA National Observational Cohort
- 674 WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A DOLUTEGRAVIR-BASED HIV REGIMEN IN KENYA**
Kassem Bourgi, Susan Ofner, Beverly Musick, Kara Wools-Kaloustian, Lameck Diero, Constantin Yiannoutsos, Samir Gupta

Poster Session-M6 WEIGHT GAIN AND ADIPOSE TISSUE
2:30 PM - 4:00 PM

- 703 MITOCHONDRIAL HAPLOGROUPS AND WEIGHT GAIN AFTER INITIATING ART IN PATIENTS WITH HIV**
Juan Berenguer, Inmaculada Jarrín, José M. Bellón, Cristina Díez, María Á. Jiménez-Sousa, Juan Carlos López, José R. Blanco, Joaquín Portilla, Alvaro Mena, María Novella, David Dalmau, Francesc Villaroya, Pere Domingo, Salvador Resino
Research Group: Cohort of the Spanish HIV Research Network (CoRIS)
- 704 WEIGHT CHANGE AFTER 48 WEEKS ON DOLUTEGRAVIR: A PROSPECTIVE STUDY OF PWH IN UGANDA**
 Jennifer Manne-Goehler, Migisha Richard, Winnie Muyindike, Geoffrey Chen, Taing N. Aung, Vincent C. Marconi, Victoria Nanfuka, Nimusiima Komukama, Mahomed-Yunus Moosa, Ravindra Gupta, Deenan Pillay, Bethany Hedt-Gauthier, Mark Siedner, **Suzanne M. McCluskey**
- 705 WEIGHT GAIN FOLLOWING SWITCH TO DOLUTEGRAVIR AMONG ADULT HIV COHORTS IN WEST AFRICA**
Thierry Tiendrebeogo, Karen Malateste, Armel Poda, Albert K. Minga, Cecile D. Lahiri, Oliver Ezechi, Didier K. Ekouevi, Igbo Ofotokun, Antoine Jaquet
Research Group: leDEA West Africa Collaboration

- 706 CHANGES IN BODY MASS INDEX WITH INTEGRASE INHIBITOR USE IN REPRIEVE**
Emma Kileel, Carlos Malvestutto, Janet Lo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Markella V. Zanni, Esteban Martinez, Nwora Lance Okeke, Princy Kumar, Esau Joao, Sara McCallum, Pam S. Douglas, Heather J. Ribaldo, Steven K. Grinspoon
- 707 DISCOVERING SUBGROUPS WITH LARGER WEIGHT GAIN WHEN TAKING DOLUTEGRAVIR**
 Jiabei Yang, Ann W. Mwangi, Rami Kantor, Issa J. Dahabreh, Monicah Nyambura, Allison Delong, **Joseph W. Hogan**, Jon A. Steingrimsson
- 708 SUBCUTANEOUS ADIPOSE TISSUE CELL COMPOSITION IS ASSOCIATED WITH VISCERAL FAT VOLUME**
Samuel S. Bailin, John J. Carr, Sangeeta Nair, Heidi J. Silver, Mona Mashayekhi, Curtis L. Gabriel, Rama Gangula, Latoya Hannah, Jonathan A. Kropski, Spyros A. Kalams, Simon A. Mallal, John R. Koethe, Celestine N. Wanjalla
- 709 VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL**
Roger Bedimo, Teresa Gonzalo, Colleen S. McGary, Taryn A. McLaughlin

Poster Session-N4 MPOX: CLINICAL FEATURES AND SEVERITY SCALES
2:30 PM - 4:00 PM

- 734 CLINICAL PREDICTORS OF MPOX SEVERITY IN AN ITALIAN MULTICENTER COHORT (MPOX-ICONA)**
 Valentina Mazzotta, Alessandro Tavelli, Francesca Colavita, Lorenzo Biasioli, Antonella Castagna, Annalisa Mondì, Fabrizio Carletti, Davide Moschese, Luca Pipitò, Daniele Tesoro, Roberta Gagliardini, Fabrizio Maggi, Andrea Antinori, Antonella D'Arminio Monforte, **Simone Lanini**, Massimiliano Fabbiani, Francesco M. Fusco, Miriam Lichtner, Claudio M. Mastroianni, Eliana Specchiarello
Research Group: MPOX-ICONA Study Group
- 735 SEVERE MPOX AMONG PEOPLE LIVING WITH HIV RECEIVING TECOVIRIMAT IN NEW YORK CITY**
Elizabeth A. Garcia, Maura K. Lash, Tristan D. McPherson, Mary Foote, Karen A. Alroy, Ellen H. Lee, Wendy Wen, Jeanne Sullivan Meissner, Amma Bosompem, Alyssa Bouscaren, Marcia Wong
- 736 MANAGEMENT OF MPOX IN PWH ATTENDING A SEXUAL HEALTH DEPARTMENT IN LONDON, UK**
Nicolo Girometti, Felicity Burton, Matthew Spencer, Simisola Agunbiade, Ruth Byrne, Margherita Bracchi, Rachael Jones, Ellen Dwyer, Gary G. Whitlock, Victoria Tittle, Anton L. Pozniak, Marta Boffito
- 737 MOSAIC CLADE 2B MPOX COHORT STUDY: CLINICAL CHARACTERISATION AND OUTCOMES**
 Xavier Lescure, Laura Merson, Cédric Laouénan, Elise Pesonel, Romain Palich, Jake Dunning, Minerva Cervantes Gonzalez, Christophe Batejat, Coralie Tardivon, Josephine Bourner, France Mentré, **Yazdan Yazdanpanah**, Diane Descamps, Alexandra Calmy, Piero Olliaro
Research Group: MOSAIC study group
- 738 DEVELOPMENT AND PILOT OF AN MPOX SEVERITY SCORING SYSTEM (MPOX-SSS)**
Jason Zucker, Jacob McLean, Simian Huang, Clare Delaurentis, Shauna Gunaratne, Kate Stoeckle, Marshall J. Glesby, Timothy Wilkin, William Fischer, Inger Damon, John Brooks
- 739 CLINICAL PRESENTATION OF MPOX IN PEOPLE WITH AND WITHOUT HIV**
 Victoria Pilkington, Killian Quinn, Lucy Campbell, Michael Brady, **Frank Post**
Research Group: King's College HIV and Sexual Health Research Group

Poster Session-04 NOVEL TB AND OI DIAGNOSTICS AND THEIR PREDICTIVE VALUE

2:30 PM - 4:00 PM

- 759 MONOCYTE-TO-LYMPHOCYTE RATIO AND HEMOGLOBIN LEVEL TO PREDICT TB AFTER ART INITIATION**
Sivaporn Gatechompol, Stephen J. Kerr, Sandra Wagner Cardoso, Wadzanai Samaneka, Srikanth Tripathy, Cecilia Kanyama, Mulinda Nyirenda, Patcharaphan Sugandhavesa, Andre Machado, Frank Van Leth, Thomas Campbell, Susan Swindells, Anchalee Avihingsanon, Frank Cobelens
Research Group: AIDS Clinical Trials Group DR067 team
- 760 IMMUNE OMIC PROFILES TO DISTINGUISH TUBERCULOSIS AMONG ADVANCED HIV ADULTS IN INDIA**
Vandana P. Kulkarni, Artur T L Queiroz, Rohidas Borse, Amita Gupta, Bruno B. Andrade, Neelu Nawani, Padmini Salgame, Vidya Mave
- 761 PERFORMANCE OF URINE XPERT ULTRA VS ALERE LAM FOR DIAGNOSING TB IN HIV IN-PATIENTS**
 David F. Stead, Sean Wasserman, Ebrahim Steenkamp, Andrew G. Parrish, **Graeme Meintjes**
- 762 CSF IMMUNE RESPONSE ASSOCIATED WITH FUNGAL BURDEN IN CRYPTOCOCCAL MENINGITIS**
Julia Stumpf, Elizabeth Okafor, Samuel Okurut, John Kasibante, Kenneth Ssebambulidde, Caleb Skipper, David B. Meya, Tyler Bold, David R. Boulware
- 763 COST-EFFECTIVENESS OF CRAG SCREENING FOR PLHIV WITH ADVANCED HIV DISEASE IN MALAWI**
Mary Feser, Amir Shroufi, Thulani Maphosa, Ajay Rangaraj, Eddie Matiya, Prakriti Shrestha, Nathan P. Ford, Justine Scott, Virginia Talbot, Appolinaire Tiam, Andrew Phillips, Kenneth A. Freedberg, Emily P. Hyle
- 764 MYCO/F LYTIC VS STANDARD BLOOD CULTURES IN FUNGAL DETECTION IN AIDS PATIENTS**
Hao T. Nguyen, Dieu Nq, Na T. Do, Lan T. Nguyen, Vinh T. Nguyen, Phuong L. Trinh, Khanh Dh, Ly Vt, Dat Q. Vu, Rogier v. Doorn, Thuy Le
- 765 MULTI-CENTER PROSPECTIVE VALIDATION STUDY OF A NOVEL ANTIGEN ASSAY FOR TALAROMYCOSIS**
Thu Nguyen, Hao T. Nguyen, Dieu Nq, Phuong TI, Khanh Dh, Men Tt, Dao Pth, Thom Vt, Chau Tth, Ly Vt, Jasper Fuk-Woo Chan, Yuen Ky, Dat Vq, Rogier Doom, Thuy Le

Poster Session-P1 HIV INCIDENCE AND PrEP IN PREGNANCY

2:30 PM - 4:00 PM

- 766 QUANTIFIED PRENATAL PrEP EXPOSURE AND PERINATAL OUTCOMES AMONG KENYAN WOMEN**
Laurén A. Gómez, John Kinuthia, Anna Larsen, Joshua Stern, Julia C. Dettinger, Mary M. Marwa, Felix Abuna, Ben Odhiambo, Nancy M. Ngumbau, Barbra Richardson, Pascal Omondi, Jared M. Baeten, Grace John-Stewart, Jillian Pintye
- 767 HIGH ACCEPTABILITY OF STI TESTING AND EPT AMONG PREGNANT KENYAN WOMEN INITIATING PrEP**
Jerusha N. Mogaka, Felix Abuna, Julia C. Dettinger, Mary M. Marwa, Ben Ochieng, Salphine Watoyi, Eunita Akim, Nancy M. Ngumbau, Celestine Adogo, Peter Owiti, Laurén A. Gómez, Grace John-Stewart, Jillian Pintye, John Kinuthia
Research Group: mWACH-PrEP Study team
- 768 INTEGRATING PrEP INTO ANTENATAL CARE FOR HIV-NEGATIVE PREGNANT WOMEN IN SOUTH AFRICA**
Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer, Dvora Joseph Davey

- 769 PrEP CONTINUATION AMONG PERI-CONCEPTION, PREGNANT, AND LACTATING WOMEN IN KENYA**
Priyanka Anand, Jared M. Baeten, Kenneth Ngunjiri, Nelly Mugo, Elizabeth A. Bukusi, Elizabeth Irungu, Josephine Oduyo, Jennifer Morton, Kenneth Mugwanya
- 770 PrEP LEVELS STRONGLY CORRELATED IN HAIR AND DBS DURING PREGNANCY AND POSTPARTUM**
NIS
Linxuan Wu, Felix Abuna, Peter L. Anderson, Jared M. Baeten, Julia C. Dettinger, Laurén A. Gómez, Monica Gandhi, Grace John-Stewart, John Kinuthia, Marwa Motongori, Ben Ochieng, Pascal Omondi, Jillian Pintye
- 771 LONGITUDINAL PrEP ADHERENCE AMONG KENYAN WOMEN WHO INITIATED PrEP DURING PREGNANCY**
Jillian Pintye, John Kinuthia, Felix Abuna, Peter L. Anderson, Julia C. Dettinger, Laurén A. Gómez, Jessica E. Haberer, Marwa Motongori, Nancy M. Ngumbau, Ben Ochieng, Joshua Stern, Salphine Watoyi, Jared M. Baeten, Grace John-Stewart, Pascal Omondi
Research Group: PrEP Implementation for Mothers in Antenatal Care (PrIMA) Study Team
- 772 INCIDENT HIV INFECTIONS IN PREGNANT/BREASTFEEDING WOMEN AND INFANTS IN MOZAMBIQUE**
NP
 Marilena Urso, William P. Killam, Judite R. Langa, Elizabeth Carter, **Laura J. McCormick Viens**
- 773 HIV RISK PERCEPTION AND PrEP USE AMONG KENYAN WOMEN DURING AND AFTER PREGNANCY**
Mary M. Marwa, Anna Larsen, Felix Abuna, Julia C. Dettinger, Ben Odhiambo, Salphine Watoyi, Pascal Omondi, Nancy M. Ngumbau, Laurén A. Gómez, Grace John-Stewart, John Kinuthia, Jillian Pintye
Research Group: PrIMA Study

Poster Session-P3 UNDERSTANDING MOTHER-TO-CHILD TRANSMISSION: FROM MOLECULES TO POPULATIONS

2:30 PM - 4:00 PM

- 777.5 MATERNAL HIV VIRAL LOAD THRESHOLD FOR GUIDING EXTENDED INFANT PROPHYLAXIS INITIATION**
 Dramane Kania, Jean-Pierre Moles, David Rutagwera, Franck Edgar Kadeba, Morgana D'Ottavi, Melany Tonga, Souleymane Tassebedo, Anaïs Mennecier, Beauty Matoka, Ajani Ousmane Taofiki, Paulin Fao, Thorkild Tylleskär, Chipepo Kankasa, Philippe Van De Perre, **Nicolas Nagot**, Leticia Sakana
Research Group: ANRS 12397 PROMISE-EPI Study group
- 778 VERTICAL TRANSMISSION IN INFANTS BORN TO WOMEN WITH HIV ON ANTIRETROVIRAL TREATMENT**
Kim Anderson, Emma Kalk, Alexa Heekes, Florence Phelanyane, Nisha Jacob, Andrew Boule, Ushma Mehta, Gayathri Sridhar, Leigh Ragone, Vani Vannappagari, Mary-Ann Davies
- 779 HIV DRUG RESISTANCE IN CASES OF PERINATAL TRANSMISSION IN IMPAACT 2010 (VESTED)**
Marley D. Bishop, Violet Korutaro, Ceejay Boyce, Ingrid A. Beck, Lauren Ziamba, Anne Coletti, Patrick Jean Philippe, Nahida Chakhtoura, Tichaona Vhembo, Haseena Cassim, Maxensia Owor, Lameck Chinula, Shahin Lockman, Lisa M. Frenkel
Research Group: IMPAACT 2010 Team
- 780 MATERNAL BROADLY NEUTRALIZING ANTIBODY ACTIVITY AND PERINATAL TRANSMISSION OF HIV-1**
Krithika P. Karthigeyan, Ria Goswami, John Isaac, Elena E. Giorgi, Justin Pollara, Joshua Eudailey, Jackie Li, Megan Connors, Carolyn Weinbaum, Joshua Tu, Feng Gao, Manish Sagar, Sallie R. Permar

781 RECONSTRUCTION OF THE ADCC ANTIBODY REPERTOIRE OF AN HIV-1 NON-TRANSMITTING MOTHER

NIS

Zak A. Yaffe, Kevin Sung, Vrasha Chohan, Laura E. Doepker, Duncan K. Ralph, Ruth Nduati, Frederick A. Matsen, Julie M. Overbaugh

Poster Session-Q4 COMORBIDITIES AND COMPLICATIONS AND IN CHILDREN AND YOUTH WITH HIV

2:30 PM - 4:00 PM

815 ORAL MICROBIOTA IN CHILDREN WHO STARTED ANTIRETROVIRAL THERAPY AT YOUNG AGES

Louise Kuhn, Tian Wang, Fan Li, Renate Strehlau, Nicole H. Tobin, Mandisa Nyati, Faezah Patel, Afaaf Liberty, Stephen Arpadi, Sunil Wadwa, Shuang Wang, Caroline Tiemessen, Grace Aldrovandi

Research Group: CHANGES Study Team

816 IMMUNE ACTIVATION AND NEUROCOGNITION IN UGANDAN ADOLESCENTS LIVING WITH HIV

Sahera Dirajjal-Fargo, Abdus Sattar, Monika Strah, Christine Karungi, Joy Gumikiriza-Onoria, Nana Asiedu, Angel Nanteza, Anthony F. Santoro, Christopher Ferraris, Daphne Tsapalas, Corey Morrison, Victor Musiime, Grace A. McComsey, Reuben N. Robbins

817 NEUROCOGNITIVE FUNCTION AMONG SCHOOL-AGED CHILDREN AFFECTED BY HIV IN BOTSWANA

Elizabeth D. Lowenthal, Tyler Moore, Ruben Gur, Ontibile Tshume, Jennifer Chapman, Boitumelo Thuto, Mogomotsi S. Matshaba, J. Cobb Scott

Research Group: Ntemoga Study

818 TRAUMATIC EVENT EXPOSURE AND MENTAL DISORDERS IN YOUTH PERINATALLY AFFECTED BY HIV

Corey Morrison, Thomas Corbeil, Luke Kluisza, Ohemaa Poku, Lucy Liotta, Naa-Djama Attoh-Okine, Curtis Dolezal, Andrew Wiznia, **Elaine J. Abrams**, Reuben N. Robbins, Claude A. Mellins

819 MULTIFACETED PREMATURE AGING IN ADOLESCENT/YOUNG ADULT WITH PERINATAL-ACQUIRED HIV

Maria Raffaella Petrara, Elena Ruffoni, Francesco Carmona, Ilaria Cavallari, Sandra Zampieri, Silvia Giunco, Paola Del Bianco, Osvalda Rampon, Paolo Palma, Paolo Rossi, Carlo Giaquinto, Anita De Rossi

Research Group: EPIICAL Consortium

820 CHILDREN WITH PERINATAL HIV EXHIBIT HIGH GDF15 LEVELS DESPITE ANTIRETROVIRAL THERAPY

Wei Li, Mussa Mwamzuka, Fatma Marshed, Aabid Ahmed, Alka Khaitan

821 48 MONTHS ANTHROPOMETRIC EVOLUTION OF ADOLESCENTS SWITCHING TO DOLUTEGRAVIR IN SPAIN

Talía Sainz, Santiago Jimenez de Ory, Luis Prieto, Luis Escosa, Claudia Fortuny, Antoni Noguera, Marie Antoinette Frick, Manuel Oltra, Lola Falcon, Matilde Bustillo, Jose Tomas Ramos, Pilar Collado, Jose Couceiro, Cesar Gavilán, Marisa Navarro

Research Group: CoRISpe (Spanish Network of pediatric HIV)

822 METABOLIC HEALTH AND BONE DENSITY IN YOUTH LIVING WITH PERINATAL HIV

Caroline Foster, Colette Smith, Merle Henderson, Moira Cheung, Sarah Fidler

Research Group: BONDY Study Research Group

823 THE BONDY STUDY: BONE DENSITY IN YOUTH LIVING WITH PERINATALLY ACQUIRED HIV

NIS

Merle Henderson, Colette Smith, Sarah Fidler, Moira Cheung, Caroline Foster

824 OUTCOMES IN CHILDREN LIVING WITH HIV WITH NON-SEVERE TUBERCULOSIS IN THE SHINE TRIAL

Chishala Chabala, Eric Wobudeya, Marieke van De Zalm, Monica Kapasa, Robert Mboizi, Megan Palmer, Aarti Kinikar, Syed Hissar, Veronica Mulenga, Philippa Musoke, Helen McIlleron, Anneke Hesselning, Anna Turkova, Diana Gibb, Angela Crook

Research Group: SHINE Trial Team

825 TUBERCULOSIS INCIDENCE AMONG ADOLESCENTS AND YOUNG ADULTS WITH HIV IN KENYA

NIS

Danae Black, Sylvia M. Lacourse, Irene Njuguna, Kristin Beima-Sofie, Caren Mburu, Cyrus Mugo, Janet Itindi, Alvin Onyango, Dalton Wamalwa, Grace John-Stewart

Poster Session-Q6 SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN AND ADOLESCENTS

2:30 PM - 4:00 PM

834 NILMATREXIVIR-RITONAVIR TREATMENT IN CHILDREN WITH SARS-CoV-2 INFECTION

Stefania Bernardi, Costanza Tripiciano, Stefania Mercadante, Anna Markowich, Giulia Lorenzetti, Francesca Calo Carducci, Lorenza Romani, Laura Cursi, Emma Concetta Manno, Federica Galaverna, Leonardo Vallesi, Massimiliano Raponi, Emanuele Nicastrì, Carlo Federico Perno, Paolo Rossi

835 COMORBIDITIES THAT INCREASE RISK FOR SEVERE ACUTE COVID-19 IN PEDIATRIC POPULATION

Alfredo Tagarro, Irati Gastesi, Andrea Ramírez Valera, María Lucia Mesa Rubio, Pablo Vásquez Hoyos, Gabriela Friedich, Melisa Naranjo Vanegas, Sonia Restrepo-Gualteros, Olga Lucía Baquero, Inés Leoz Gordillo, Cristina Calvo Rey, Siobhan Crichton, Marthe Le Prevost, Carlo Giaquinto, Cinta Moraleda

Research Group: EPICO, EPICO Colombia and ORCHESTRA

836 PERSISTENT SYMPTOMS IN CHILDREN ADMITTED WITH COVID SIMILAR TO CONTROLS 1 YEAR LATER

Alfredo Tagarro, Sara Villanueva, Ana Esteban Romero, María López Luengo, Marta Conde, Lucía de Pablo, David Aguilera-Alonso, Irati Gastesi, Sara Domínguez, Cristina Epalza, Álvaro Ballesteros, Carlota Pinto, Carlo Giaquinto, Cinta Moraleda

Research Group: EPICO, EPICO Colombia and ORCHESTRA

837 PERSISTENCE OF SYMPTOMS ONE YEAR AFTER MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN

Cinta Moraleda, Sara Villanueva, Olga Aldecoa Jiménez, Blanca Díaz Fuentes, Luis Prieto, Daniel Blázquez, Cristina Epalza, Elisa Fernández Cooke, Ángela Manzanares, Pablo Rojo, Serena Villaverde, Álvaro Ballesteros, Sara Domínguez, Alfredo Tagarro

838 PBMC IMMUNOPHENOTYPING AND PLASMA INFLAMMATORY PROFILE OF CHILDREN WITH LONG COVID

Jon Izquierdo-Pujol, Sara Moron-lopez, Judith Dalmau, Maria C. Puertas, Clara Carreras-Abad, Alba Gonzalez-Aumatell, Maria Mendez, Carlos Rodrigo, Javier Martinez Picado

839 INFLAMMASOME BUT NOT IFN-I/III RESPONSE IS ALTERED IN CHILDREN WITH LONG COVID

NP

Matteo Fracella, Leonardo Sorrentino, Federica Frasca, Mirko Scordio, Alessandra D'Auria, Giuseppe Oliveto, Carla Selvaggi, Greta Di Mattia, Maria Giulia Conti, Luigi Matera, Domenico La Regina, Gabriella D'Ettore, Guido Antonelli, Alessandra Pierangeli, Carolina Scagnolari, **Luca Maddaloni**

- 840 PROTECTION AGAINST HETEROLOGOUS CHALLENGE 1 YEAR AFTER INFANT SARS-CoV-2 IMMUNIZATION**
Emma C. Milligan, Katherine Olstad, Caitlin Williams, David Montefiori, Michael Hudgens, Darin Edwards, Andrea Carfi, Kizzmekia Corbett, Christopher Fox, Mark Tomai, Rachel Reader, Dirk Dittmer, Koen Van Rompay, Sallie R. Permar, Kristina De Paris
- 841 mRNA VACCINES INDUCE A HIGHER ANTIBODIES RESPONSE IN CHILDREN WITH PREVIOUS COVID-19**
Costanza Di Chiara, Anna Cantarutti, Francesco Bonfante, Maria Raffaella Petrara, Chiara Cosma, Matteo Pagliari, Nicola Cotugno, Alessandra Meneghel, Elisa Benetti, Luca Bosa, Paolo Palma, Anita De Rossi, Carlo Giaquinto, Daniele Dona', Andrea Padoan
Research Group: VERDI/ORCHESTRA study teams
- 842 EFFECT OF BNT162B2 ANTIGEN DOSAGE ON PROTECTION AGAINST SARS-CoV-2 OMICRON INFECTION**
Hiam Chemaitelly, Houssein H. Ayoub, Laith J. Abu-Raddad

Poster Session-R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV

2:30 PM - 4:00 PM

- 876 RACIAL/ETHNIC DISPARITIES IN TIMELY ANTIRETROVIRAL THERAPY INITIATION: 2007-2019**
Lauren Zalla, Stephen Cole, Adaora Adimora, Joseph J. Eron, Peter F. Rebeiro, Vincent C. Marconi, M. John Gill, Emily C. Williams, Jeffrey Martin, Stephen Crystal, Kelly Gebo, Kenneth H. Mayer, Heidi Crane, Jessie Edwards, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
- 877 IMPACT OF REDLINING ON TIME TO VIRAL SUPPRESSION AMONG PERSONS DIAGNOSED WITH HIV**
 Lauren J. Ostrenga, **John R. Bassler**, Dustin M. Long, Mariel Parman, Michael J. Mugavero, Ariann F. Nassel, Emily B. Levitan, Aadia Rana, D. Scott Batey
- 878 MONITORING CARE AND VIRAL SUPPRESSION AFTER HIV DIAGNOSIS IN UNITED STATES: 2017-2020**
Shacara Johnson Lyons, Xiaohong Hu, Anna Satcher Johnson
- 879 VIRAL SUPPRESSION AND COMMUNITY VIRAL LOAD AMONG MSM WITH HIV IN 23 US CITIES: 2017**
Savannah Harris, Shamaya Whitby, Silvina Masciotra, Amanda J. Smith, Jeffrey A. Johnson, Lyssa Faucher, Cyprian Wejnert, Johanna Chapin-Bardales
Research Group: NHBS-MSM5 Study Group
- 880 HOSPITAL READMISSIONS AMONG ADULTS LIVING WITH HIV IN THE US**
Xianming Zhu, Eshan U. Patel, Mary K. Grabowski, Thomas C. Quinn, Kelly Gebo, Aaron Tobian
- 881 HIV AND THE VETERANS CHOICE ACT: A GEOSPATIAL ANALYSIS IN GEORGIA, 2020-2022**
Kartavya Vyas, Vincent C. Marconi, Jodie Guest
- 882 INTERNALIZED HIV STIGMA AND MENTAL HEALTH/SUBSTANCE USE OVER TIME**
 Lydia Drumright, Duncan Short, Sonia Napravnik, Edward Cachay, Ellie Moffatt, Katerina Christopoulos, Torsten Neilands, Kenneth Mayer, Mallory O. Johnson, Jimmy Ma, Andrew Hahn, Robin Nance, Timothy Crawford, Geetanjali Chander, Rob Fredericksen, **Bridget Whitney**

883 RANDOMIZED TRIAL OF BRIEF ALCOHOL INTERVENTION FOR VIRAL SUPPRESSION AND ALCOHOL USE

Sarah Puryear, Florence Mwangwa, Fred Opel, Gabriel Chamie, Laura Balzer, Jane Kabami, James Ayieko, Elijah Kakande, John Schrom, Melanie Bacon, Sarah Woolf-King, Maya Petersen, Diane V. Havlir, Moses Kamya, Judith A. Hahn

Research Group: SEARCH Study Team

Poster Session-S5 SARS-CoV-2 SEROPREVALENCE AND SURVEILLANCE
2:30 PM - 4:00 PM
916 SARS-CoV-2 SEROPREVALENCE AMONG UGANDAN BLOOD DONORS: 2019-2022

Swetha Ashokkumar, Jodie L. White, Dorothy Kyeyune, Henry Ddungu, Ronnie Kasirye, Feben Habtehyimer, Owen Baker, Heather Hume, Andrew Redd, Steven J. Reynolds, Thomas C. Quinn, Paul Ness, Evan M. Bloch, Oliver Laeyendecker, Aaron Tobian

917 COVID-19 SEROPREVALENCE IN VACCINE-NAIVE POPULATIONS: DRC, GUINEA, LIBERIA, AND MALI

Sylvian Laverdure, Donatien Kazadi, Kadidia Kone, Renee Ridzon

Research Group: InVITE Study Team

918 SARS-CoV-2 SEROPREVALENCE AND RISKS FACTORS IN AFRICAN WLHIV ON ART AND THEIR INFANTS

Taguma Allen. Matubu, Nonhlanhla Yende-Zuma, Sean Brummel, Lynda Stranix-Chibanda, Lillian Wambudzi Ogwang, Sufia Dadabhai, Felluna Chauwa, Luis Gadama, Jim Aizire, Jackson Brooks, Taha E. Taha, Mary Glenn Fowler

919 SARS-CoV-2 INFECTION AMONG PERSONS WHO INJECT DRUGS AND THEIR PARTNERS IN KENYA

Khai Hoan Tram, Bhavna H. Chohan, Cassia Wagner, Shradha Doshi, Hanley Kingston, Brandon L. Guthrie, Betsy Sambai, Loice W. Mbogo, Aliza Monroe-Wise, William Sinkele, Kibet Shikuku, Jared Mecha, David Bukusi, Carey Farquhar, Joshua Herbeck

920 SARS-CoV-2 SEROPREVALENCE AMONG PEOPLE WHO INJECT DRUGS IN BALTIMORE

Eshan U. Patel, Shruti H. Mehta, Owen Baker, Becky Genberg, Catherine Schluth, Jacquie Astemborski, Reinaldo Fernandez, Thomas C. Quinn, Greg Kirk, Oliver Laeyendecker

921 QUANTIFYING POPULATION IMMUNITY TO COVID-19 IN WASHINGTON STATE AND OREGON

Mia Moore, Larissa Anderson, Jiaming Lin, Chloe Bracis, Eileen Burns, Dave Swan, Joshua Schiffer, Dobromir Dimitrov

922

WITHDRAWN

923

WITHDRAWN

Poster Session-S6 MODELLING MPOX AND COVID-19

2:30 PM - 4:00 PM

- 924 RETROSPECTIVE ASSESSMENT OF THE ACCURACY OF MPOX CASE PROJECTIONS IN NEW YORK CITY**
David Kaftan, Hae-Young Kim, Charles Ko, James Howard, Anna Bershteyn
- 925 MODELLING THE MPOX EPIDEMIC IN THE UK OVER MAY-AUGUST 2022**
Jasmina Panovska-Griffiths, Robert Hinch, Josie Park, Thomas Ward, Andre Charlett, Fergus Cumming, Nick Watkins, Christophe Fraser, Robyn Stuart
- 926 MODELLING THE RISK OF FUTURE MPOX OUTBREAKS IN THE NETHERLANDS**
Marc C. Shamier, Luca Zaeck, Kai Jonas, Babs Verstrepen, Corine H. Geurtsvankessel, Rory D. de Vries, Jeroen van Kampen, Marion PG. Koopmans, David van de Vijver
- 927 WHAT IMPACT WILL WORSENING AIR POLLUTION HAVE ON THE BURDEN OF COVID-19?**
Sherrie L. Kelly, Andrew J. Shattock, Martina S. Ragettli, Danielle Vienneau, Ana M. Vicedo-Cabrera, Nicole Probst-Hensch, Kees De Hoogh

Poster Session-T3 HIV TESTING IN CLINICAL SETTINGS

2:30 PM - 4:00 PM

- 941 NON-HIV ENTRY POINTS TO DELIVER HIV SERVICES TO TRANSGENDER WOMEN IN INDIA**
Simran Shaikh, Parthasarathy Mugundu Ramien, Allison M. McFall, Jade Bell, Saya Okram, Ajay Enugu, Shruti H. Mehta, Maria Salvat Ballester, Viswanathan Arumugam, Rose Pollard, Aditya Singh, Alex Keuroghlian, Kevin Ard, Kenneth Mayer, Sunil S. Solomon
- 942 DIRECTED SCREENING FOR HIV INFECTION IN EMERGENCY SERVICES: VIHGILA STUDY**
Josep Guardiola, Emilia Miro, Daniel Iturriza, Rocío De Paz, Mireia Saura, Alexis Rebollo, Cristina Ramio, Miriam Carbo, Connie Leey, Alex Smithson, Emili Gene, Oscar Miro
Research Group: VIHGILA SOCMUE Study Group
- 943 HIV TEAMS AS A TOOL TO IMPROVE HIV INDICATOR CONDITION-GUIDED TESTING**
NIS
Carlijn Jordans, Jaap Hanssen, Anna Roukens, Jeroen van Kampen, Femke Mollema, Jet Gisolf, Rachida El Moussaoui, Gonneke Hermanides, Bart Rijnders, Annelies Verbon, Casper Rokx
- 944 IMPACT OF MPOX OUTBREAK ON HIV TESTING IN A LARGE INTEGRATED HEALTHCARE SYSTEM**
Christopher Polk, Mindy Sampson, Jeremy Thomas, Robert Fairman, Tom Ludden, Hazel Tapp, Catherine Passaretti, Michael Leonard

Poster Session-T4 NEW DIAGNOSTICS AND USE OF TESTS

2:30 PM - 4:00 PM

- 945 DNA-CONFIRMATION OF HIV-1&2 COINFECTIONS AMONG DUALY-REACTIVE WEST AFRICAN PATIENTS**
Boris K. Tchounga, Mélanie Bertine, Florence Damond, Valentine M. Ferré, Andre Inwoley, Simon P. Boni, Alice Moisan, Jean-Christophe Plantier, Diane Descamps, Didier K. Ekouevi, Charlotte Charpentier
Research Group: The EDIMARK-2 Study group
- 946 EVALUATION OF A NOVEL MULTIPLEX IMMUNOASSAY: IMPROVEMENT FOR HTLV-2 DETECTION**
Victor A. Folgosi, Pedro L. Junior, Felipe D. Silva, Augusto C. Oliveira, Maan Zrein, Florent Salvador, Jorge Casseb

947 HIV DETECTION IN WASTEWATER AS A NEW EPIDEMIOLOGICAL TOOL

Austen Terwilliger, Justin Clark, Visanthi Avadhanula, Karen Feliz, Eric Murphy, Loren Hopkins, Pedro Piedra, Anthony Maresso,
Thomas P. Giordano

Poster Session-U3 SARS-CoV-2 DIAGNOSTICS**2:30 PM - 4:00 PM****961 ANTIBODIES TO SARS-CoV-2 VARY DUE TO ORDER AND FREQUENCY OF VACCINATION OR INFECTION**

Owen Baker, Evan Beck, Andrew Karaba, Eshan U. Patel, Andrea Cox, Yukari C. Manabe, Zoe Demko, Mira Prabhu, Yu-Hsiang Hsieh, Aaron Milstone, Andrew Redd, Aaron Tobian, Thomas C. Quinn, Joel N. Blankson, Oliver Laeyendecker

962 SARS-CoV-2 REPLICON SYSTEM FOR THE PHENOTYPIC EVALUATION OF NSP GENE SUBSTITUTIONS

Dong Han, Venice Du Pont, Simin Xu, Arya Vijjapurapu, Jiani Li, Bandita Parhy, Ross Martin, Gregory Camus, Jason K. Perry, Danielle P. Porter, Charlotte Hedskog, John P. Bilello, Tomas Cihlar, Hongmei Mo, Lauren Rodriguez

Research Group: Gilead Clinical Virology

963 USE OF Ag-RDTs TO REDUCE SARS-CoV-2 INFECTIONS AT RELIGIOUS GATHERINGS IN LICs & MICs

Megan A. Hansen, Alvin X. Han, Joshua M. Chevalier, Ethan Klock, Hiromi Pandithakoralage, Tom Ockhuisen, Sarah Girdwood, Nngomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell,
Brooke Nichols

964 Ag-RDT MASS TESTING IN LARGE GATHERINGS TO IDENTIFY SARS-CoV-2 INFECTIONS IN KENYA

Rose Masaba, Lise Denoeud, Stephen Siamba, Heather J. Hoffman, Mario Songane, Edyth Osire, Njoki Kimani, Magoma Kwasa

965 SARS-CoV-2 WASTEWATER SURVEILLANCE IN A US JAIL: CORRELATION, FEASIBILITY, NEXT STEPS

Lindsay Saber, Anne Spaulding, Matthew J. Akiyama, Stephen Hilton, Shanika Kennedy, Christine Moe, Victoria Phillips

Research Group: SWANSS Study Group

966 DISABILITY AND COVID-19 TESTING: A CROSS-SECTIONAL RADx-UP STUDY

Haley R. Martin, Wensong Wu, Sabrina Sales Martinez, Jose A. Bastida Rodriguez, Angeliq Johnson, Marianna K. Baum

Poster Session-V4 PrEP USE IN SPECIAL POPULATIONS**2:30 PM - 4:00 PM****982 ASSOCIATION OF METH USE AMONG GBMSM ON HIV PRE-EXPOSURE PROPHYLAXIS CARE ENGAGEMENT**

Alexander Moran, **Marjan Javanbakht**, Matthew Mimiaga, Steven Shoptaw, Pamina M. Gorbach

983 NO IMPROVEMENT IN PREEXPOSURE PROPHYLAXIS USE AMONG PWID: SAN FRANCISCO, 2018-2022**L.B.**

Bow Suprasert, Moranda Tate, Danyion Reagan, Raul Ruiz, Katherine Gao, Katherine McNaughton, Cassandra Miller, Alexander Marr, Kelly D. Taylor, Willi McFarland, Erin C. Wilson

984 EFFECT OF INTIMATE PARTNER VIOLENCE ON ART & PREP ADHERENCE IN SERODIFFERENT COUPLES**NIS**

Dorothy Thomas, Lylianne Nakabugo, Florence Nambi, Joseph Kibuuka, Timothy Muwonge, Erika Feutz, Katherine Thomas, Jane Simoni, Elizabeth Montgomery, Norma Ware, Monique Wyatt, Ingrid Katz, Herbert Kadama, Andrew Mujugira, Renee Heffron

985 DETERMINANTS OF PREEXPOSURE PROPHYLAXIS RETENTION AMONG TRANSGENDER WOMEN

Jack Andrzejewski, Heather A. Pines, Sheldon Moris, Robert Bolan, David J. Moore, Leah B. Burke, Jill Blumenthal

986 PrEP PRESCRIPTIONS AMONG PERSONS WITH MEDICAID BY RACE AND ETHNICITY: UNITED STATES

Karen Hoover, Weiming Zhu, Duygu Islek Yaras, Dawn Smith, Ya-Lin A. Huang

987 BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP IN MSM AND TGW IN HPTN 083

Todd T. Brown, Robert Arao, Nittaya Phanuphak, Esper Kallas, Tomitope Oyedele, Richard Berman, Philip Sullivan, Brett Hanscom, Adeola Adeyeye, Jim Rooney, Alex R. Rinehart, Andrea Jennings, Marybeth McCauley, Beatriz Grinsztejn, Raphael J. Landovitz
Research Group: HPTN 083 Study Team

Poster Session-V5 EARLY STUDIES OF NEW PREVENTION AGENTS**2:30 PM - 4:00 PM****988 PHASE 1 TRIAL OF CAP256V2LS AND VRC07-523LS ANTIBODIES AMONG WOMEN IN SOUTH AFRICA**

Sharana Mahomed, Nigel Garrett, Edmund Capparelli, Farzana Osman, Nonhlanhla N. Mkhize, Derseree Archary, Leonid Serebryanny, Mike Castro, Adrian B. McDermott, Kevin Carlton, Penny L. Moore, Lynn Morris, Quarraisha Abdool Karim, John R. Mascola, Salim S. Abdool Karim

989 VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES

Michele B. Daly, Daniel Kim, Linying Li, Archana Krovi, Chasity Norton, Catalina Forero, Marie Brake, Chuong Dinh, Tiancheng Edwards, Mackenzie Cottrell, Walid Heneine, Gerardo Garcia-Lerma, Charles Dobard, James Mitchell, Leah Johnson

990 EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS

Natalia Makarova, Tyana Singletary, Missy Peet, James Mitchell, Angela Holder, Chuong Dinh, Yi Pan, Maria Corazon Bueno Mendoza, Meredith Clark, Walid Heneine, James Smith, Gerardo Garcia-Lerma, Gustavo F. Doncel

991 PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT

NIS

Isabella Young, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Craig Sykes, Mackenzie Cottrell, Angela DM. Kashuba, S. Rahima Benhabbour

992 LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL

Elena Bekerman, Stephen Yant, Laurie A. Vanderveen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut

Poster Session-X3 NEW PERSPECTIVES ON HUMAN PAPILLOMAVIRUS AND HIV**2:30 PM - 4:00 PM****1029 INCREASED BURDEN OF ANAL HPV-RELATED POTENTIALLY PRECANCEROUS LESIONS IN HIV+ WOMEN**

Eugenio Nelson Cavallari, **Letizia Santinelli**, Motta Eleonora, Federica Tanzi, Luca Maddaloni, Ilaria Cuccu, Giancarlo Ceccarelli, Carolina Scagnolari, Alessandra Pierangeli, Innocenza Palaia, Claudio M. Mastroianni, Gabriella D'Etto

- 1030 EFFICACY OF LATE HPV VACCINATION IN YOUNG HIV+ MSM**
Eugenio Nelson Cavallari, **Letizia Santinelli**, Luca Maddaloni, Motta Eleonora, Mirko Scordio, Federica Frasca, Giancarlo Ceccarelli, Carolina Scagnolari, Stefano Arcieri, Alessandra Pierangeli, Claudio M. Mastroianni, Gabriella D'Ettorre
- 1031 HIGH PREVALENCE OF HPV, OTHER STIs, AND ANAL LESIONS AMONG MSM IN TOGO**
Valentine M. Ferré, Arnold Sadio, Diane Fifonsi Gbeasor-Komlanvi, Salou Mounerou, Beatrice Bercot, Cecile Bebear, Laurent Abramowitz, Meryem Zaidi, Amivi P. Amenyah-Ehlan, Ephrem Mensah, Anoumou Claver Dagna, Jade Ghosn, Diane Descamps, **Charlotte Charpentier**, Didier K. Ekouevi
- 1032 METHYLATION MARKERS ON ANAL SMEARS ARE ASSOCIATED WITH HIGHER ANAL CANCER RISK**
NIS
Valentine M. Ferré, Axelle Dupont, Mélanie Draullette, Emy Valette, Ghislain Staumont, Margot Bucau, Anas Naji, Laurent Siproudhis, Bart Hesselink, Dominique Bouchard, Lucas Spindler, Renske D. M. Steenberg, Diane Descamps, Charlotte Charpentier, Laurent Abramowitz, Carine Roy, **Research Group:** COAIN3 national cohort

Poster Session-Y08 HIV CARE CASCADE

2:30 PM - 4:00 PM

- 1064 NEW HIV DIAGNOSES IN THE SETTING OF PUBLICLY FUNDED PrEP IN BRITISH COLUMBIA, CANADA**
K. Junine Toy, Raquel M. Espinoza, Jason Trigg, Erin Ready, Cora L. Keeney, Wendy W. Zhang, Chanson J. Brumme, Paul Sereda, Rolando Barrios, Julio Montaner
- 1065 ESTIMATING THE EPIDEMIOLOGICAL IMPACT OF FLORIDA'S INTEGRATED HIV CARE PLAN IN MIAMI**
Lia Humphrey, Benjamin Enns, Micah Piske, **Xiao Zang**, Bohdan Nosyk, Emma Spencer, Mara Michniewicz, Daniel Feaster, Hansel Tookes
Research Group: Centre for Health Evaluation & Outcome Sciences (CHÉOS)
- 1066 AN RCT OF HOME-BASED CARE TO REDUCE POSTHOSPITAL MORTALITY IN SOUTH AFRICA: HOMELINK**
Christopher Hoffmann, Kate Shearer, Boitumelo Kekana, Tumelo Moloantoa, Maxine Nunu, Jonathan Golub, Ebrahim Variava, **Neil Martinson**
- 1067 IMPROVING REINITIATION IN CARE AMONG MEN WITH HIV IN MALAWI: TWO RANDOMIZED TRIALS**
Kathryn Dovel, Kelvin Balakasi, Julie Hubbard, Misheck Mphande, Isabella Robson, Elijah Chikuse, Morna Cornell, Risa Hoffman, Sam Phiri, Joep J Van Oosterhout, Agnes Moses, Thomas J. Coates, Augustine Choko
- 1068 REENGAGING PERSONS WITH HIV OUT OF CARE: RADICAL CHANGE IS NEEDED**
Thomas Martin, Laramie Smith, Susan R. Little, Christy Anderson, Kari Abulhosn
- 1069 THE IMPACT OF FINANCIAL INCENTIVES AND A DECISION-SUPPORT APP ON THE HIV CARE CASCADE**
NIS
Maxime Inghels, Hae-Young Kim, Thulile Mathenjwa, Maryam Shahmanesh, Janet Seeley, Adrian Dobra, Manisha H. Yapa, Sally Wyke, Nuala McGrath, Till Baernighausen, Frank Tanser
- 1070 THE HIV CARE CONTINUUM AMONG TRANSGENDER WOMEN IN 2010-2020 IN THE NETHERLANDS**
Vita Jongen, Ceranza Daans, Ard van Sighem, Maarten Schim Van Der Loeff, Kris Hage, Camiel Welling, Alex Von Vaupel-Klein, Martin Den Heijer, Edgar Peters, Marc van Der Valk, Peter Reiss, Maria Prins, **Elske Hoornenborg**
Research Group: ATHENA observational HIV cohort

1071 PROJECTED IMPACT OF IMPROVING HIV CARE ON LIFE EXPECTANCY AMONG BLACK AND WHITE MSM

NIS

Katherine M. Rich, Aima A. Ahonkhai, Krishna P. Reddy, Fatma M. Shebl, Ankur Pandya, John J. Chiosi, Andrea L. Ciaranello, Jodian A. Pinkney, Elena Losina, Kenneth A. Freedberg, Emily P. Hyle

Poster Session-Y09 THE PrEP CASCADE

2:30 PM - 4:00 PM

1071.5 RETENTION IN CARE AMONG PERUVIAN MSM AND TGW IN A REAL-WORLD HIV PrEP PROGRAM

Pamela Ramirez, **Alexander J. Lankowski**, Jorge A. Gallardo-Cartagena, Javier Valencia, Pedro Gonzales, Javier Lama, Javier Salvatierra, Hugo Sanchez, Robinson Cabello, Martin Casapia, Jorge L. Sánchez

1072 PrEP KNOWLEDGE, EVER USE, AND DISCONTINUATION AMONG LAKE VICTORIA FISHERFOLK IN UGANDA

Kauthrah Ntabadde, Gertrude Nakigozi, Joseph Kagaayi, Joseph Lubwama, Robert Ssekubugu, Ping Teresa Yeh, Joseph Ssekasanvu, Lisa A. Mills, Stella Alamo, Lisa J. Nelson, Victor Ssempijja, Steven J. Reynolds, Larry William W. Chang, Mary K. Grabowski

1073 STRUCTURAL INFLUENCES ON PrEP CASCADE AMONG YOUNG WOMEN IN POST-ABORTAL CARE IN KENYA

NIS

Yasaman Zia, Lydia Etyang, Felix Mogaka, Inviolata Wanyama, Margaret Mwangi, Lavender June, Cyprian Nyamwaro, Roy Njiru, Faith Ambiyi, Bernard Nyerere, Elizabeth A. Bukusi, Nelly Mugo, Renee Heffron

1074 HIGH LEVEL OF HIV PREVENTION-EFFECTIVE CONTINUATION IN A LARGE PrEP PROGRAM IN KENYA

Kenneth Mugwanya, Margaret Mwangi, Nelly Mugo, Dominic Mwangi, Simon Maina, Stephen Gakuo, Lydia Etyang, Vallery Ogello, Emma Owidi, Jared M. Baeten, Kenneth Ngure
Research Group: Efficiency Study Team

1075 DEPRESSION ASSOCIATED WITH PrEP HOLIDAYS AMONG KEY POPULATIONS IN NAMIBIA

Laimi Ashipala, Kaitlyn Atkins, Leonard Bikinesi, Justine Heita, Denis Mali, Abubakari Mwinyi, Robyn Eakle, Jane Schueller, Kelly Curran, Jason Reed

Poster Session-Y10 RESPONSE DURING CRISES

2:30 PM - 4:00 PM

1076 CONDUCTING RESEARCH IN A SETTING OF SEVERE POLITICAL INSTABILITY: THE GHESKIO MODEL

Samuel Pierre, Carl Frederic Duchatellier, Vanessa Rivera, Nancy Dorvil, Marie Flore Pierre, Joseph Marie Bajo Joseph, Alexandra Apollon, Sean E. Collins, Denis Israelski, Stephano St Preux, Sanjana Sundaresan, Hongjue Wang, Patrice Severe, Jean William Pape, Serena Koenig

1077 A MODEL OF SUCCESSFUL ART INITIATION IN THE CONTEXT OF MASSIVE CIVIL UNREST IN HAITI

Jean Bernard Marc, Samuel Pierre, Vanessa Rivera, Zion Abigail, David Montreuil, Fabienne Homeus, David Andre, Carl Frederic Duchatellier, Elizabeth Fox, Vanessa Rouzier, Bernard Liautaud, Patrice Severe, Collette Guiteau, Jean William Pape, Serena Koenig

1078 EMERGENCY RESPONSE TO RESTORE HIV TREATMENT SERVICES IN AMHARA REGION, ETHIOPIA: 2022

Chanie Temesgen Bayieh, Minesh Shah, Solomon Ahmed, Tekeste Kebede, Ismael Ahmed, Dereje Habte, Aduugna Tesfaye, Mirte Getachew Meselu, Gashu Kindu Akale, Hiwot Debebe, Abdulkerim Mengistu Yimam, Jemal Aliy, Zenebe Melaku, Caroline A Ryan, Melkamu Abte
Research Group: National and Amhara Regional Emergency Response Team

Poster Session-Y11 RETENTION IN HIV CARE

2:30 PM - 4:00 PM

1079 8-YEAR CARE TRAJECTORIES IN AN URBAN COHORT OF PWH RECEIVING CARE: WASHINGTON, DC**Amanda D. Castel**, Elisabeth Andersen, Shannon Barth, Michael A. Horberg, Anne Monroe**1080 PREDICTORS OF RETENTION IN THE WOMEN'S INTERAGENCY HIV STUDY: 2011-2019****Caitlin A. Moran**, Brittany W. Jacob, Cyra C. Mehta, Anandi N. Sheth, Sarah Krier, Zenoria Causey-Pruitt, Deborah Jones Weiss, Andrew Edmonds, Gypsyamber D'Souza, Kathleen Weber, Jennifer Cohen, Lakshmi Goparaju, Susan Holman, Adebola Adedimeji, Cecile D. Lahiri**1081 RETENTION IN OPIOID AGONIST THERAPY AMONG PEOPLE LIVING WITH HIV IN BRITISH COLUMBIA**

NP

Kiana Yazdani, Kate Salters, Katerina Dolguikh, Monica Ye, Jason Trigg, Ronald Joe, David Moore, Julio Montaner, Rolando Barrios, **K. Junine Toy****1082 A RANDOMIZED CONTROL TRIAL OF AN HIV CARE INTERVENTION BUNDLE FOR PEOPLE WITH HIV****Joseph D. Perazzo**, Tamilyn Bakas, Qutaibah Oudat, Joshua Lambert, Carl J. Fichtenbaum**1083 LONG-TERM OUTCOMES OF RAPID ANTIRETROVIRAL THERAPY IN AN INTEGRATED HEALTH SYSTEM**

NIS

Avani Dalal, Earl Clark, Christian Lee-Rodriguez, Zahra Samiezade-Yazd, Jennifer O. Lam, Mitchell N. Luu**1084 MODELLING OF CARE ENGAGEMENT PATTERNS IN A LONGITUDINAL COHORT OF PWH: WASHINGTON, DC****Amanda D. Castel**, **Elisabeth Andersen**, Shannon Barth, Michael A. Horberg, Anne Monroe

Poster Session-Y15 TREATMENT OF COVID-19 AND MPOX

2:30 PM - 4:00 PM

1101 COST EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR FOR MILD-MODERATE COVID-19 IN SPAIN

LB

Philip E. Wikman-Jorgensen, Miriam Navarro, Jose María Ibarra, Carlos Devesa, Jose Miguel Seguí-Ripoll, Jorge Peris-García, Vicente Giner-Galvañ, Jara Llenas-García**1102 OUTCOMES OF A TELEHEALTH VISIT MODEL TO DELIVER TECOVIRIMAT FOR MPOX IN NYC**

LB

Ofole Mgbako, David Ditullio, Patricia Pagan-Pirallo, Dana Mazo, Robert Pitts, Dorothy Knutsen, Andrew Wallach, Angelica C. Kottkamp, Isaac Holmes, **Justin Chan**

POSTER SESSIONS BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Posters should be displayed for the duration of the conference and are located in the Exhibit Hall.

A. VIROLOGY OF HIV, SARS-CoV-2, OR MPOX VIRUS

- P-A1 HIV-1 ENTRY (Monday)
- P-A2 IFN AND ANTIVIRAL FACTORS (Tuesday)
- P-A3 VIRUS REPRODUCTION (Wednesday)
- P-A4 VIRUS DIVERSITY IN POPULATIONS (Wednesday)

B. PATHOGENESIS OF HIV, SARS-CoV-2, OR MPOX VIRUS: HUMAN STUDIES AND ANIMAL MODELS

- P-B1 GENETICS, EARLY HIV INFECTION, NATURAL CONTROL (Monday)
- P-B2 HIV AND THE MICROBIOME (Wednesday)
- P-B3 HIV NON IMMUNO PATHOGENESIS, COINFECTION (Tuesday)
- P-B4 HIV AND AGING (Wednesday)
- P-B5 HIV IMMUNOPATHOGENESIS (Tuesday)
- P-B6 SARS-CoV-2 PATHOGENESIS (Monday)
- P-B7 LONG COVID (Tuesday)
- P-B8 MPOX PATHOGENESIS (Wednesday)

C. HIV-ASSOCIATED TUMOR VIRUSES

- P-C1 BASIC SCIENCE OF TUMOR VIRUSES: HTLV, HBV, EBV, AND ENDOGENOUS RETROVIRUSES (Tuesday)

D. HOST IMMUNE RESPONSES, VACCINES, AND IMMUNOTHERAPIES: HIV, SARS-CoV-2, OR MPOX VIRUS

- P-D1 ANTIBODY AND BROADLY NEUTRALIZING RESPONSES (Monday)
- P-D2 ELITE CONTROLLERS (Monday)
- P-D3 IMMUNE MODULATION AND VACCINES (Tuesday)
- P-D4 LYMPH NODES (Wednesday)
- P-D5 NK CELLS, NEUTROPHILS, AND B CELL (Monday)
- P-D6 SARS-CoV-2 IMMUNOPATHOGENESIS (Monday)
- P-D7 SARS-CoV-2 VACCINES AND PREVENTION (Tuesday)
- P-D8 MPOX VACCINES AND IMMUNOPATHOGENESIS (Wednesday)

E. HIV RESERVOIRS, LATENCY, AND CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY

- P-E01 CONTROLLERS AND POSTTREATMENT CONTROLLERS (Monday)
- P-E02 DYNAMICS OF THE HIV RESERVOIR (Monday)
- P-E03 IMMUNE PRESSURE ON THE RESERVOIR (Wednesday)
- P-E04 HIV RESERVOIRS IN CELLS AND TISSUES (Tuesday)
- P-E05 INNOVATIVE APPROACHES TO TARGET THE RESERVOIR (Wednesday)
- P-E06 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND (Tuesday)
- P-E07 MECHANISMS OF HIV LATENCY (Monday)
- P-E08 DYNAMICS OF PROVIRAL INTEGRATION SITES (Tuesday)
- P-E09 HIV RESERVOIRS IN CHILDREN AND YOUTH (Tuesday)

F. NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-COV-2 INFECTION AND NEUROLOGIC COMPLICATIONS OF HIV IN ADULTS

- P-F1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV (Monday)

- P-F2 INTERPLAY BETWEEN VASCULAR AND NERVOUS SYSTEM FUNCTION IN HIV (Monday)
- P-F3 ANTIRETROVIRAL EFFECTS ON CENTRAL NERVOUS SYSTEM OUTCOMES (Monday)
- P-F4 PSYCHIATRIC SYMPTOMS, SLEEP DISTURBANCE, AND ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV (Tuesday)
- P-F5 CNS HIV INFECTION, PERSISTENCE, AND CURE STUDIES (Tuesday)
- P-F6 MECHANISMS OF HIV NEUROPATHOGENESIS (Wednesday)
- P-F7 COINFECTIONS AND THE NERVOUS SYSTEM IN PEOPLE WITH HIV (Wednesday)
- P-F8 POST-ACUTE NERVOUS SYSTEM SEQUELAE OF COVID-19 IN PEOPLE WITH AND WITHOUT HIV (Monday)

G. CLINICAL PHARMACOLOGY IN ADULTS

- P-G1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV (Monday)
- P-G2 DRUG-DRUG INTERACTIONS: A FOCUS ON TB, EFAVIRENZ SWITCHING (Tuesday)
- P-G3 PHARACOKINETICS/PHARMACODYNAMICS OF SARS-CoV-2 THERAPEUTICS (Wednesday)

H. ANTIVIRAL THERAPY: PRE-CLINICAL DATA, RANDOMIZED TRIALS, EFFICACY, AND EFFECTIVENESS STUDIES IN HIV OR SARS-CoV-2 OR MPOX VIRUS IN ADULTS

- P-H1 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING? (Tuesday)
- P-H2 ANTIRETROVIRAL THERAPY: PROSPECTIVE CLINICAL TRIALS (Wednesday)
- P-H3 ANTIRETROVIRAL THERAPY: OBSERVATIONS FROM COUNTRIES, CLINICS, AND PWH (Monday)
- P-H4 ANTIRETROVIRAL THERAPY: COMPARTMENTS, HIV-2, AND NANOFORMULATIONS (Wednesday)
- P-H5 NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES (Monday)
- P-H6 CAN ANTIVIRAL AGENTS PREVENT SARS-CoV-2 TRANSMISSION? (Monday)
- P-H7 SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESIVIR (Tuesday)
- P-H8 SARS-CoV-2 TREATMENT: CLINICAL AND ANTIVIRAL ACTIVITY (OR NOT) (Wednesday)

I. RESISTANCE OF HIV OR SARS-CoV-2 TO SMALL MOLECULES AND ANTIBODIES IN ADULTS

- P-I1 HIV RESISTANCE EMERGENCE AND OUTCOMES (Tuesday)
- P-I2 HIV RESISTANCE TO NEUTRALIZING ANTIBODIES (Monday)
- P-I3 PRETREATMENT HIV DRUG RESISTANCE (Wednesday)

J. HEPATITIS VIRUSES AND LIVER COMPLICATIONS IN ADULTS

- P-J1 HBV PREVENTION AND TREATMENT (Tuesday)
- P-J2 NEW DEVELOPMENTS IN HCV EPIDEMIOLOGY AND TREATMENT (Tuesday)
- P-J3 VIRAL HEPATITIS IN SUB-SAHARAN AFRICA (Wednesday)
- P-J4 LIFE AFTER SVR (Wednesday)
- P-J5 STEATOSIS AND STEATOHEPATITIS (Monday)
- P-J6 PATHOGENESIS AND NATURAL HISTORY (Wednesday)

K. AIDS-RELATED MALIGNANCIES

- P-K1 NON-AIDS DEFINING CANCERS: PATHOGENESIS (Wednesday)
- P-K2 CANCER (GENERAL): RISK AND MORTALITY (Wednesday)
- P-K3 KAPOSI SARCOMA AND KHSV-RELATED DISEASES: PATHOGENESIS AND TREATMENT (Monday)

- P-K4 CERVICAL CANCER: SCREENING AND TREATMENT (Monday)
 P-K5 ANAL CANCER: PATHOGENESIS, PREVENTION, AND SCREENING (Wednesday)

L. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P-L1 PLAQUE (Monday)
 P-L2 LIPID METABOLISM (Monday)
 P-L3 HYPERTENSION, VASCULAR DISEASE, AND PLATELET FUNCTION (Tuesday)
 P-L4 INFLAMMATION AND CARDIOVASCULAR DISEASE (Wednesday)
 P-L5 THE GUT MICROBIOME AND COMORBIDITIES (Wednesday)

M. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY IN ADULTS

- P-M1 DOES WHAT GOES UP ALWAYS COME DOWN? (Wednesday)
 P-M2 METABOLIC COMPLICATIONS (Tuesday)
 P-M3 BONE, RENAL, PULMONARY, AND HEMATOLOGIC DISEASE (Tuesday)
 P-M4 BIOMARKERS OF MORBIDITY AND MORTALITY (Monday)
 P-M5 FRAILTY, FUNCTIONAL STATUS, AND HEALTH (Tuesday)
 P-M6 WEIGHT GAIN AND ADIPOSE TISSUE (Wednesday)

N. CLINICAL COMPLICATIONS OF EMERGING DISEASES (COVID-19) IN ADULTS

- P-N1 PASC (LONG COVID) (Monday)
 P-N2 COVID IN THOSE WITH HIV AND IMMUNOCOMPROMISING CONDITIONS (Tuesday)
 P-N3 COVID-19: CLINICAL AND PROGNOSTIC FEATURES AND EFFECTS OF THERAPEUTIC INTERVENTIONS (Tuesday)

O. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS, INCLUDING THE IMPACT OF HIV OR SARS-CoV-2 IN ADULTS

- P-O1 PREDICTORS OF TB TREATMENT OUTCOMES (Monday)
 P-O2 ADVERSE REACTIONS ASSOCIATED WITH TB DRUGS (Monday)
 P-O3 OUTCOMES ASSOCIATED WITH OPPORTUNISTIC INFECTIONS IN THE CURRENT ERA (Monday)
 P-O4 NOVEL TB AND OI DIAGNOSTICS AND THEIR PREDICTIVE VALUE (Wednesday)

P. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P-P1 HIV INCIDENCE AND PrEP IN PREGNANCY (Wednesday)
 P-P2 OBESITY, INFLAMMATION, AND HIV IN PREGNANCY (Tuesday)
 P-P3 UNDERSTANDING MOTHER-TO-CHILD TRANSMISSION (Wednesday)
 P-P4 USING ANTIRETROVIRALS IN PREGNANCY (Tuesday)
 P-P5 NOVEL UNDERSTANDINGS OF BIRTH OUTCOMES WITH ART (Monday)
 P-P6 COVID-19 IN PREGNANCY: EVOLVING INSIGHTS (Tuesday)

Q. HIV, SARS-CoV-2, OR MPOX VIRUS, AND OTHER EMERGING INFECTIONS, IN INFANTS, CHILDREN, AND ADOLESCENTS

- P-Q9 HIV RESERVOIRS IN CHILDREN AND YOUTH (Tuesday)
 P-Q1 OUTCOMES OF HIV-EXPOSED UNINFECTED (Monday)
 P-Q2 INFLAMMATION AND IMMUNITY IN CHILDREN (Tuesday)
 P-Q3 REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV (Tuesday)
 P-Q4 COMORBIDITIES AND COMPLICATIONS AND IN CHILDREN AND YOUTH WITH HIV (Wednesday)
 P-Q5 ARVs AND bNABs FOR CHILDREN AND ADOLESCENTS (Monday)
 P-Q6 SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN, AND ADOLESCENTS (Wednesday)

R. EPIDEMIOLOGY OF HIV IN ADULTS

- P-R1 MOLECULAR HIV EPIDEMIOLOGY (Monday)
- P-R2 RECENT HIV INFECTIONS (Monday)
- P-R3 HIV INFECTION CLUSTERS (Monday)
- P-R4 SEX, GENDER, AND VIOLENCE AND ASSOCIATION WITH OUTCOMES (Tuesday)
- P-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION (Tuesday)
- P-R6 HIV MORTALITY (Monday)
- P-R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV (Wednesday)

S. EPIDEMIOLOGY OF COVID-19, MPOX, AND OTHER EMERGING INFECTIONS

- P-S1 COVID-19 CHARACTERISTICS AND OUTCOMES (Monday)
- P-S2 IMPACT OF COVID-19 ON HIV AND MALARIA SERVICES AND OUTCOMES (Monday)
- P-S3 MPOX EPIDEMIOLOGY, IMPACT ON SEXUAL BEHAVIORS, AND STIGMA (Tuesday)
- P-S4 MPOX CHARACTERISTICS AND OUTCOMES (Tuesday)
- P-S5 SARS-CoV-2 SEROPREVALENCE AND SURVEILLANCE (Wednesday)
- P-S6 MODELLING MPOX AND COVID-19 (Wednesday)

T. HIV TESTING IN ADULTS: NEW TESTS, POPULATION STUDIES, AND SCALE-UP

- P-T1 HIV SELF-TESTING (Monday)
- P-T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING (Tuesday)
- P-T3 HIV TESTING IN CLINICAL SETTINGS (Wednesday)
- P-T4 NEW DIAGNOSTICS AND USE OF TESTS (Wednesday)

U. TESTING FOR COVID-19, MPOX, AND OTHER EMERGING INFECTIONS: DIAGNOSTIC TESTS, POPULATION STUDIES, AND SCALE-UP

- P-U1 MPOX TESTING (Monday)
- P-U2 SARS-CoV-2 SELF-TESTING (Tuesday)
- P-U3 SARS-CoV-2 DIAGNOSTICS (Wednesday)

V. HIV PREVENTION INTERVENTIONS IN ADULTS

- P-V1 COST EFFECTIVENESS OF PEP AND PrEP (Monday)
- P-V2 PrEP AND PEP: ADHERENCE MEASURES AND STIs (Monday)
- P-V3 OPTIMIZING PrEP ROLLOUT (Tuesday)
- P-V4 PrEP USE IN SPECIAL POPULATIONS (Wednesday)
- P-V5 EARLY STUDIES OF NEW PREVENTION AGENTS (Wednesday)
- P-V6 PrEP PRODUCT UPDATE AND EFFECTIVENESS (Tuesday)

W. PREVENTION OF COVID-19, MPOX, AND OTHER EMERGING INFECTIONS

- P-W1 MPOX PREVENTION (Monday)
- P-W2 SARS-CoV-2 VACCINE STRATEGIES (Tuesday)

X. CONTRACEPTION, SEXUALLY TRANSMITTED INFECTIONS, AND REPRODUCTIVE HEALTH IN ADULTS

- P-X1 SPECIAL TOPICS IN SRH AND HIV (Monday)
- P-X2 STI EPIDEMIOLOGY IN POPULATIONS AFFECTED BY HIV (Tuesday)
- P-X3 NEW PERSPECTIVES ON HUMAN PAPILLOMAVIRUS AND HIV (Wednesday)

P-X4 INTERTWINED: MPOX AND STI EPIDEMIOLOGY (Tuesday)

Y. IMPLEMENTATION AND SCALE-UP OF PREVENTION AND TREATMENT FOR HIV AND IMPACT OF COVID-19 AND OTHER EMERGING INFECTIONS ON HIV-RELATED PROGRAMS

- P-Y01 ACCESS TO ART (Monday)
- P-Y02 MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION (Monday)
- P-Y03 ACHIEVING TARGETS (Monday)
- P-Y04 HIV TESTING (Monday)
- P-Y05 PRESENTATION FOR CARE (Tuesday)
- P-Y06 LONG-ACTING ART (Tuesday)
- P-Y07 ART REGIMENS (Tuesday)
- P-Y08 HIV CARE CASCADE (Wednesday)
- P-Y09 PrEP CASCADE (Wednesday)
- P-Y10 RESPONSE DURING CRISES (Wednesday)
- P-Y11 RETENTION IN HIV CARE (Wednesday)
- P-Y12 ADVANCED HIV DISEASE (Tuesday)
- P-Y13 PREVENTION AND PrEP MODELS (Tuesday)
- P-Y14 COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES (Tuesday)
- P-Y15 TREATMENT OF COVID-19 AND MPOX (Wednesday)

INDEX OF PRESENTERS

The following index lists CROI presenters as of January 24, 2023. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook on the CROI website.

-A-

Abassi, Mahsa 749
 Abela, Irene A. 352, 353
 ✓ Abelman, Rebecca A 679
 Abu-Raddad, Laith J 1005
 Adekogbe, Adebola Sunday 939
 Adesse, Daniel 496
 Agarwal, Mahesh 219
 Agathis, Nickolas T 811
 Agustí, Cristina 949
 ✓ Agyemang, Nana 505
 Ake, Julie A 430
 Aldred, Bruce 906
 Amstutz, Alain 560
 Anand, Priyanka 769
 Andersen, Elisabeth 1084
 Anderson, Albert 485
 ✓ Anderson, Kim 778
 Anderson, Peter L 20
 Andrzejewski, Jack 985
 Antar, Annukka A R 722
 Arentoft, Noline Stender 687
 Armstrong-Hough, Mari 1050
 ✓ Arsuffi, Stefania 700
 Arumugam, Viswanathan 1043
 Ashipala, Laimi 1075
 Ashokkumar, Swetha 916
 ✓ Atkins, Kaitlyn 951, 1025
 Atkinson, Andrew 1021
 Augello, Matteo 344
 Augustin, Max 720
 ✓ Aung, Sai W 862
 Aung, Su 583
 Avihingsanon, Anchalee 116
 ✓ Ayieko, James 200

-B-

Bachina, Preetham 1054
 Bailin, Samuel S 708
 Baker, Owen 961
 Baker, Pieter 1016
 Balachandran, Harikrishnan 340
 Balkus, Jennifer 785
 ✓ Bardon, Ashley R 977
 Barr, Elizabeth 1023
 Bassett, Ingrid 999, 1039
 Bassler, John R 877

Batista, Facundo 44
 Bayer, Cara 855
 Bayieh, Chanie Temesgen 1078
 ✓ Bayon-Gil, Angel 246
 Bazzi, Angela R 212
 Bean, David 351
 Bedimo, Roger 709
 ✓ Begré, Lorin 586
 Béguelin, Charles 8
 Behrens, Georg 45
 Bekerman, Elena 992
 Bender Ignacio, Rachel A 571
 Benet, Susana 378
 Benito, José M 245
 Berenguer, Juan 608, 703
 Bernardi, Stefania 834
 Berry, Mark 718
 ✓ Berton, Mattia 506
 ✓ Bettonte, Sara 508
 Betts, Michael R 3
 Bhatt, Nilesh 213
 Bhattacharya, Romit 660
 Bieniasz, Paul D 107
 Birnbaum, Michael 5
 Bishop, Marley D 779
 ✓ Black, Danae 825
 Blair, Jessica 657
 ✓ Blázquez Bondia, Carlos 670
 Blower, Sally 1037
 ✓ Board, Nathan L 401
 Boltz, Valerie F 240
 ✓ Bone, Benjamin R 450
 Borghetti, Alberto 574
 ✓ Borgognone, Alessandra 481
 ✓ Bosch, Bronwyn E 671
 Boswell, Kristin L 180
 ✓ Bouba, Yagai 928
 Bouhaddou, Mehdi 108
 ✓ Bouqdayr, Meryem 241
 Bourgi, Kassem 674
 Bramante, Carolyn 170
 Brañas, Fátima 701
 Brew, Bruce 715
 ✓ Bricker, Katherine M 252
 Brooks, John 39
 Brooks, Kelsie 279
 ✓ Brown, Erin E. 1027
 Brown, Todd T 987

Brumme, Zabrina 366
 ✓ Buck, Amanda M 424
 Bunge, Katherine E 127
 Burdorf, Rachel M 577
 Butt, Adeel 559
 Butt, Adeel 569, 570, 618, 624, 729
 Byakwaga, Helen 150

-C-

 Cabrera, Cecilia 222
 Cachay, Edward 644
 Cai, Chenrongrong 342
 ✓ Cai, Renying 695
 Cameron, Cheryl 269
 Cannon, Chase 948
 ✓ Capoferri, Adam A 106
 Carlin, Aaron 543
 Carlson, Jesse J 1033
 Carpino, Thomas 900
 Carson, Joanne M 603
 Cartwright, Emily J 1014
 Castagna, Antonella 293
 Castel, Amanda D 1004
 Castel, Amanda D 1079
 Cavallari, Eugenio Nelson 1029, 1030
 ✓ Ceriani, Cristina 444
 Cevik, Muge 109
 Chabala, Chishala 824
 Chaganti, Joga 492
 Chahroudi, Ann 29
 Chalira, Davie D 126
 Chamie, Gabriel 112
 Chan, Justin 1102
 Chan, Phillip 464
 Chandasana, Hardik 832
 Chang, Michelle 1010
 Chappell, Catherine 597
 Charalambous, Salome 745
 Charpentier, Charlotte 1031
 Chaturvedi, Sonali 235
 Chemaitelly, Hiam 842
 Chen, Wanyi 517
 Chen, Yuxuan 234
 Chen, Yufen 484
 Cherkos, Ashenafi S 800, 801
 Chevalier, Joshua M 958
 Chew, Kara W 31
 Chew, Kara W 428
 Cholli, Preetam A 912
 Chomont, Nicolas 1, 247

- Choudhary, Manish C 168
 Chow, Felicia C 183
 Christ, Frauke 216
 ✓ Clark, Kolin 447
 Clement, Meredith E 994
 ✓ Coburn, Sally B 628
 Coghill, Anna E 626
 Collercandy, Nived 853
 Collura, Randall 157
 Contreras, German A 886
 Cooley, Sarah 468, 487
 Coppock, Dagan 865
 Corley, Michael 383
 Corley, Michael 480
 ✓ Corma-Gómez, Anaïs 606, 607, 904
 ✓ Corrigan, Angela 423
 Costa, Alvaro 909
 ✓ Cotugno, Nicola 458
 Coutinho, Carolina 915
 Cowan, Frances M 123
 Cowden, Jessica J 1007
 ✓ Cox, Sarah N 1051
 Crabtree-Ramirez, Brenda E 727
 Craig, Cosette 974
 Cressey, Tim R. 826
-D-
 ✓ Dabral, Prerna 448
 Dahal, Subha 546
 Dai, Lili 521
 ✓ Dalal, Avani 1083
 Daly, Michele B 989
 Damas, José 461
 Dastgheyb, Raha M 473
 ✓ Daultrey, Harriet 681
 Davis, Dominique 791
 de Armas, Lesley 808
 ✓ De Clercq, Jozefien 415
 De Cock, Kevin M 13
 De La Rosa, Guy 541
 de Ledinghen, Victor 589
 de Oliveira, Tulio 18
 De Paris, Kristina 789
 ✓ de Voux, Alex 970
 Deere, Jesse 459
 Degli Antoni, Melania 733
 Deleage, Claire 175
 Deo, Rinki 171
 Desai, Pankaja 889
 Deshmukh, Ashish 638
 Deveau, Tyler-Marie 414
 Di Chiara, Costanza 841
 Di Gennaro, Francesco 888, 894
 Diamond, Tracy Lauren 585
 ✓ Díaz-García, Claudio 178
 Dickey, Brittney 625
 Diedhiou, Cyrille K 238
 Dimitrov, Dobromir 1002
 Dirajlal-Fargo, Sahera 285, 816
 ✓ Ditshwanelo, Doreen 600
 Dolci, Giovanni 732
 ✓ Donoso, Ana 843
 Dorvil, Nancy 742
 Dos Santos, Jéssica C 313, 314
 Dovel, Kathryn 1067
 ✓ Dragoni, Filippo 454
 Dross, Sandra 373
 Du, Li 549
 Dubé, Mathieu 406
 Duncan, Maggie 370
 Dunk, Caroline E 787
 ✓ Duran Castells, Clara 385
 Durieux, Jared C 717
 Durstenfeld, Matthew S 666
 Dziarski, Alisha 495
-E-
 ✓ Ebasone, Peter-Vanes 656
 Ebeunuwa, Ifechukwude C 684
 Eden, Arvid 189, 483
 Edun, Olanrewaju 868
 ✓ Ekwunife, Obinna I 930
 Ellis, Ronald J 474
 Else, Laura J 527
 Engels, Eric 629
 Enriquez, Ana B 182
 Epling, Brian 747
 Erlandson, Kristine 648, 697
 Eron, Joseph J 193
 ✓ Eschbach, Jenna E 102
 Eshleman, Susan H 160
 Espinoza, Raquel M 910
 Eustaquio, Patrick C 861
 Evering, Teresa H 721
 ✓ Ezeonwumelu, Ifeanyi Jude 591
-F-
 ✓ Fandl, Hannah 467
 Farley, Shannon M 873, 960
 Feinberg, Judith 594
 Felizarta, Franco 519
 Fellenstein, Brian A 622
 Ferrand, Rashida 125
 ✓ Ferré, Valentine M 354, 359, 1032
 Feser, Mary 763
 Fielding-Miller, Rebecca 210
 Figueroa, Jose 1063
 Fischer, William 169
 Fisher, Karla N 972
 ✓ Fisher, Katie 416
 Floren, Alexander J 833
 Flynn, Jacob K 249
 Fofana, Djeneba B. 599
 ✓ Fofana, Josiane 427
 Foldyna, Borek 649
 Folgosi, Victor A 946
 Folkvord, Joy 243
 ✓ Fombellida-Lopez, Céline 429
 ✓ Fonseca, Fernanda F 1057
 Foster, Caroline 822
 ✓ Foster, Emma G 784
 Fracella, Matteo 839
 Frange, Pierre 830
 Fray, Emily 388
 Fredericks, Megan N 290
 Fredericksen, Rob 860
 Frey, Sharon 41
 Friedrich, Nikolas 308
 ✓ Frola, Claudia E 859
 Fromage, Yeleen 501
 ✓ Frouard, Julie 421
-G-
 ✓ Gachogo, Rachael 299
 Gaiha, Gaurav 315
 Gala, Akshay 381
 ✓ Gallego Cortés, Ana 418
 Gandhi, Monica 518, 1038.5
 Gandhi, Rajesh T 392
 Ganesan, Anuradha 689
 Garcia, Elizabeth A 735
 Garcia, Federico 531
 Garcia-Mesa, Yoelvis 482
 Garneau, William M 907
 Garrett, Nigel 1012, 1056
 ✓ Garrido-Rodríguez, Vanesa 254
 ✓ Gasca-Capote, Carmen 452
 ✓ Gatechompol, Sivaporn 759
 ✓ Gausi, Kamunhwala 751
 Geba, Maria C 641
 Gelpi, Marco 253
 ✓ George, Ashley F 337
 Ghosh, Sukanya 316
 Ghosn, Jade 36, 208, 236
 Gill, Michelle M 790
 Gils, Tinne 1086
 Giordano, Thomas P 947
 Girometti, Nicolo 736
 Giron, Leila 260, 266

- Gisslen, Magnus 184
 ✓ Glenn, Jeffrey S 167
 Godot, Veronique 362
 Gómez, Laurén A 766
 González-Hernández, Luz A 682
 Goodreau, Steven M 866
 Goswami, Ria 400
 Goulder, Philip JR 28
 Govindaraj, Sakthivel 796
 Goyal, Ravi 420
 Goyal, Vishal 503
 Graham, Susan M 535
 Grattoni, Alessandro 165
 Griesel, Rulan 110, 507
 Gross, Robert 509
 Guaraldi, Giovanni 617
 Guardiola, Josep 942
 Guenthoer, Jamie 310
 Guerri-Fernandez, Robert 542
 Gutierrez Sanchez, Luz Helena 6
 Gutierrez, Jose 1055
- H-**
 Haaland, Richard 118
 Habte, Dereje 812
 Hafer, Terry L 440
 ✓ Hage, Kris 604
 Hagins, Debbie 522
 Hahn, Judith A 743
 Haidar, Lara 659
 Hall, Kirsten 893
 Hallmark, Camden J 851
 Hamann, Martin 425
 Hamilton, Deven T 1044
 Han, Dong 962
 ✓ Han, Win Min 596, 612, 1053
 Hanna, David B 661
 Hansen, Megan A 963
 Harfouch, Omar 642
 ✓ Harris, Savannah 879
 ✓ Hartana, Ciputra A 311
 Haughey, Norman J. 446
 Hausler, Harry P 1040
 Hazra, Aniruddha 981
 Hearps, Anna 334
 Hechter, Rulin 1017
 Hedskog, Charlotte 562
 Heilmann, Elizabeth 795
 Heinrich, Norbert 114
 Helmold Hait, Sabrina 307
 Henderson, Heather 172
 ✓ Henderson, Merle 185, 823
 ✓ Herrera, Carolina 995
- Hewavisenti, Rehana V 645
 Hightow-Weidman, Lisa 21
 ✓ Hikichi, Yuta 103
 Hileman, Corrielyn O 712
 ✓ Hiner, Christopher R 411
 ✓ Hiransuthikul, Akarin 996
 Ho, Ya-Chi 4
 Hodcroft, Emma B 19
 Hoffman, Risa 774
 Hoffmann, Christopher 1066
 Hogan, Joseph W 707
 Hoornenborg, Elske 897, 911, 1070
 Hoover, Karen 986
 Hora, Bhavna 304
 Hosek, Sybil 162
 Hsieh, Evelyn 686
 Huang, Ya-Lin A 997
 Hughes, Michael D 9
 Humeniuk, Rita 514
 Hyatt, Ana 675
 Hyle, Emily P 145
- I-**
 Ichihashi, Genki 166
 Ignacio, Caroline 387
 Imaz, Arkaitz 537, 677
 ✓ Inghels, Maxime 1069
 Isaacs, Stuart N 40
 Ishii, Hiroshi 177
 Isnard, Stephane 276
 ✓ Itell, Hannah L 105
 Izquierdo-Pujol, Jon 838
- J-**
 Jackson, Charlotte 134
 ✓ Jacobs, Tom G 831
 Jacobson, Denise L 799
 Jain, Mamta K 728
 Jalloh, Sallieu 267
 Jamieson, Denise J 27
 Jang, Hyukjin 258
 Jao, Jennifer 775
 Jassat, Waasila 885
 Javanbakht, Marjan 982
 Jeger-Madiot, Raphaël 332
 ✓ Jeong, Dahn 620
 ✓ Jiang, Danting 251
 Jilg, Nikolaus 283
 Johansson, Emil 335
 Johnson Lyons, Shacara 878
 Johnson, Kelly A 204
 Joly, Véronique A 539
 Jonnalagadda, Sasi 1049
 ✓ Jordans, Carljin 943
 Joseph Davey, Dvora 786
 Joseph, Fokam 239
 Joy, Jaimy 326
- K-**
 ✓ Kabami, Jane 130
 ✓ Kablawi, Dana 611
 Kaftan, David 924
 Kagan, Ron M 955
 Kailembo, Alexander 757
 Kailembo, Alexander 936
 ✓ Kakande, Elijah 124
 Kalata, Newton L 872
 Kalata, Newton L 872
 ✓ Kamori, Doreen D 578
 Kamy, Moses 128
 Kane, Melissa 104
 Kang, C. Yong 357
 ✓ Kangethe, James 635
 Kankasa, Chipepo 131
 Kapombe, Priscilla 923
 Karmarkar, Ellora 913
 Karthigeyan, Krithika P 780
 ✓ Katusiime, Mary Grace 807
 Keele, Brandon F 391
 Kelley, Colleen 34
 Kelly, Sherrie L 927
 Kengni Ngueko, Aurelie Minelle 284
 ✓ Keniyopoullos, Renos 658
 ✓ Kennedy, Brooke D 386
 Kennedy, Caitlin E 206
 ✓ Kenney, Stephanie 516
 Kenny, Grace 272
 Kiarie, James 35
 Kileel, Emma 706
 ✓ Kim, Eun Hye Grace 477
 Kim, H. Nina 7
 Kim, Sangwon 147
 Kim, Sung-Han 726
 Kincer, Laura P 478
 Kitsou, Konstantina 297
 Kizito, Samuel 814
 Klock, Ethan 959
 Knudsen, Andreas D 655
 Knudsen, Andreas D 667
 Kolossváry, Márton 274
 Koss, Catherine 975
 Koss, Catherine 975
 Kroidl, Arne 132
 Kroidl, Inge 869
 Krolikowski, Kristyn 1034
 Krolikowski, Kristyn 908
 Kuchel, George A 38
 Kufera, Joshua T 455
 Kuhn, Louise 815
 Kulkarni, Smita 225
 ✓ Kulkarni, Vandana P 760
 ✓ Kulsuptrakul, Jessie 228
 ✓ Kuo, Alexandra 1090

- Kupritz, Jonah 379
 Kuriakose, Safia 515
 Kuzmichev, Yury V 438
 Kvaratskhelia, Mamuka 100
-L-
 Lacourse, Sylvia M 794
 Laeyendecker, Oliver 154
 Lahiri, Cecile D 610
 Lake, Jordan E 647
 Lang, Raynell 688
 Lanini, Simone 563, 564, 734
 Lankowski, Alexander J 1071.5
 Laouénan, Cédric 737
 Lapadula, Giuseppe 730, 896
 Larson, Heidi J 48
 Laverdure, Sylvian 917
 Lebouché, Bertrand 534
 Lee, Cheng-Yi 355
 ✓ Lee, Eunok 407
 Lee, Guinevere Q 412
 Lee, Jane J 867
 Lehner, Paul J 37
 Leone, Peter 520
 ✓ Leskov, Konstantin 262
 Leslie, Hannah H 937
 Levy, Yves 324
 Lewis, Lara 1042, 1093
 Li, Chenglei 215
 Li, Jonathan Z 32
 Li, Jun 702
 Li, Wei 820
 Li, Yifan 347
 Li, Yijia 725
 Li, Zichong 439
 Liang, Chen 884, 1006
 Lima, Viviane D 10
 ✓ Linden, Noemi L 451
 Liu, Jerry 349
 Liu, Wang-Da 368, 1020
 Lok, Anna S 16
 Lombardi, Francesca 693
 ✓ Loosli, Tom 576
 Lopez, Brianna 402
 Loubet, Paul 365
 Loutfy, Mona 498
 Lowenthal, Elizabeth D 817
 Luetkemeyer, Anne F 120
 Luo, Kai 668
 ✓ Lwilla, Anange F 129
 ✓ Lwin, Hay Mar Su 696
-M-
 ✓ Ma, Tongcui 380
 Madlala, Hlengiwe P 776
 Mahomed, Sharana 988
 ✓ Mainella, Vincent A 500
 Makarova, Natalia 990
 Makonokaya, Lucky D 1019
 Malaba, Thokozile R 792
 Malambo, Warren 719
 Malech, Harry 545
 ✓ Mancebo Pérez, Cristina 643
 Mandomando, Inacio 133, 890
 Manne-Goehler, Jennifer 704
 ✓ Manzanares, Mario 432
 Mara, Elise S 1000
 Marc, Jean Bernard 1077
 Marchetti, Giulia C 287
 ✓ Marin, Miguel 318
 Marrazzo, Jeanne 163
 ✓ Martin Carmona, Jessica 605
 Martin, Haley R 966
 Martin, Thomas 1068
 Martinello, Marianne 194
 ✓ Martínez-Sanz, Javier 690
 Martin-Gayo, Enrique 327
 ✓ Marwa, Mary M 773
 ✓ Marziali, Megan E 858
 Marzinke, Mark A 159
 Masaba, Rose 964
 Mateu, Lourdes 723
 Matic, Nancy 953
 ✓ Matovu Kiweewa, Flavia 685
 Matrajt, Laura 1009
 Matthews, Gail 198
 Matubu, Taguma Allen 918
 Matus Nicodemos, Rodrigo A 227
 Matusali, Giulia 364
 Matveev, Vitaliy 369
 Mave, Vidya 45
 Mayer-Blackwell, Koshlan 360
 Mazzitelli, Maria 502
 Mazzotta, Valentina 374, 375, 376, 565, 566
 McAlpine, Lindsay S 190, 493
 McCluskey, Suzanne M 579
 McCormick Viens, Laura J. 636, 772
 McFall, Allison M 863, 931
 McGettrick, Pdraig 653
 McLaughlin, Angela 211
 ✓ McMyn, Natalie F 396
 ✓ McWhirter, Joseph B 298
 Meade, Christina 466
 Meeder, Elise M. G. 472
 Mehta, Sanjay 845
 Meintjies, Graeme 761
 Mgodi, Nyaradzo M 23
 Milali, Masabho 967
 Miller, Michael J 892
 Miller, Michelle 552
 Milligan, Emma C 840
 Mills, Anthony M 197
 Mizushima, Daisuke 588
 ✓ Mogaka, Jerusha N 767
 Mogere, Peter 1091
 ✓ Mohammadi, Abbas 137
 Molina, Jean-Michel 119, 196
 Monroe-Wise, Aliza 153
 Montaner, Luis J 384, 431
 Monterosso, Analise 895
 Moore, Mia 921
 Moore, Penny L 42
 ✓ Moraka, Natasha O 582
 Moraleda, Cinta 837
 Moran, Caitlin A 1080
 ✓ More, Jessica 777
 Moreira, Rodrigo 654
 ✓ Moreno de Lara, Laura 333
 Moreno, Elena 271
 ✓ Morgan, Camille 598
 Morris, Benjamin C 321
 ✓ Morris, Daniel 302
 Morrison, Corey 818
 ✓ Morrocchi, Elena 806
 Moschese, Davide 377
 Moscicki, Anna-Barbara 1028
 Moseholm, Ellen 804
 ✓ Moseithi, Maureen 828
 ✓ Moskovljevic, Milica 389
 Mota, Talia 413
 Mothe Pujades, Beatriz 433
 Mouchati, Christian 288
 Mozaffari, Essy 556, 557, 558
 ✓ Mueller, April 410
 Mugundu Ramien, Parthasarathy 152
 Mugwanya, Kenneth 1074
 ✓ Muhomah, Teresia A 242
 Mukoka, Madalo 956
 Muñoz, Olivia 422
 Muñoz-López, Francisco 887
 Mustanski, Brian 979
 Mutascio, Simona 174
 Muyanjanja, Stella Z 744

-N-

Nabeemeeah, Firdaus 746
 Nabeta, Henry W 554
 Naggie, Susanna 572
 ✓ Naggirinya, Agnes Bwanika 202
 Naidoo, Anushka 827
 Namayanja, Grace 528
 ✓ Nanvubya, Annet 1024
 Nassau, Tanner B 1100
 ✓ Nayan, Mohammad Ullah 540
 Ndhlovu, Zaza 331
 ✓ Ndlovu, Nkosiphile 526
 Neary, Megan 553
 Nelson, LaRon 24
 Nemphos, Sydney 256
 Nevot, Maria 711
 ✓ Ngure, Kenneth 973
 Nguyen, Don 445
 Nguyen, Hao T 764
 Nguyen, Thu 765
 Nguyen, Thuy Thi Thu 393
 Nichols, Brooke 593
 Niehaus, Emily 1035
 Nielsen-Saines, Karin 457
 ✓ Niesar, Aischa 141
 Ninsiima, Josephine C 634
 Nkengasong, John 15
 Novitsky, Vlad 854
 Nowak, Piotr 372
 ✓ Nsangi, Laura J 748
 Ntabadde, Kauthrah 1072
 Nuwagaba-Biribonwoha, Harriet 1048
 ✓ Nyemba, Dorothy C 768

-O-

Obermeier, Martin J 954
 ✓ Ocampo, Ferron F 490, 494
 O'Connor, Erin E 716
 O'Connor, Megan A 257
 Ogale, Yasmin 950
 Ogbuagu, Onyema 523
 Okoye, Afam A 264
 ✓ Okurut, Samuel 489
 ✓ Olivera, Kristen M A 330
 ✓ Ollerton, Matthew 265
 Omo-Emmanuel, Ughweroghene 1097, 1098
 ✓ Onovo, Amobi A 847
 ✓ Oom, Aaron 1001
 ✓ Opsteen, Skye 350, 683
 Orentas, Rimas 399
 Orkin, Chloe 173
 Orrell, Catherine 22, 205
 Ortblad, Katrina F 929

Ortiz, Alexandra 322

Otten, Twan JW 371

Ouk, Vichea 848

-P-

Paiardini, Mirko 329
 Palmer, Clovis C 289
 Pampena, M.Betina 319
 Pang, Alina 443
 ✓ Panigrahi, Soumya 255
 Panovska-Griffiths, Jasmina 925
 Parczewski, Miłosz 731
 ✓ Pardons, Marion 397
 Parisi, Christina E 536
 Park, Juwon 286, 339
 Parkes-Ratanshi, Rosalind 1038
 ✓ Parra-Rodriguez, Luis 469
 ✓ Pascom, Ana Roberta 1058
 ✓ Pasin, Chloe 300, 301, 1022
 Passanduca, Alfeu 810
 Patel, Deesha 935
 Patel, Eshan U 920
 Patel, Rena 788
 ✓ Pathak, Rajiv 442
 Patick, Amy 544
 Paton, Nicholas 113
 Paul, Robert 188
 Paul, Robert 460
 Peluso, Michael J 33, 273, 282, 435
 Pepper, Marion 43
 ✓ Perazzo, Hugo 592
 Perazzo, Joseph D. 1082
 ✓ Perea, David 338
 Pereira Ribeiro, Susan 143
 Perelson, Alan S 12, 568
 ✓ Perez Solans, Belen 753, 754
 Pérez-Caballero, Raúl 345
 Perez-Zsolt, Daniel 548
 Permar, Sallie R 328
 Petersen, Kalen J 186, 475
 Petrara, Maria Raffaella 819
 Phillips, Andrew 968
 Phillips, Gregory 898
 Philpott, David CE 903
 Pickering, Suzanne 231
 ✓ Pieren, Daan K.J 325, 361
 ✓ Pierre, Samuel 1076
 ✓ Piñeirúa-Menéndez, Alicia 1059
 Pines, Heather A 932
 Pinto, Tara 1045
 Pinto-Cardoso, Sandra 248
 Pintye, Jillian 771

✓ Plaza-Jennings, Amara 187
 Poirot, Eugenie 940
 Polk, Christopher 944
 Poloni, Chad 363
 Popoola, Victor O 857
 Post, Frank 1095
 Post, Frank 739
 Powis, Kathleen M. 783, 793, 803
 Prates, Gabriela S 294
 ✓ Premeaux, Thomas 691
 Pry, Jake M 1052
 ✓ Pryke, Luke 680
 Puray-Chavez, Maritza N 224
 Puryear, Sarah 883

-R-

Rallón, Norma 441, 627
 Ramaswami, Ramya 632
 Ramgopal, Moti N. 191
 ✓ Ramos-Martín, Fernando 320
 Raphael, Yvette A 14
 Rappaport, Amy 323
 Ratzan, Scott C 46
 ✓ Rava, Marta 871
 Rebeiro, Peter F 875
 ✓ Reddy, Kavidha 395
 Reeves, R. Keith 479
 ✓ Reimer Jensen, Anne Marie 651
 ✓ Reis, Karl 756
 ✓ Remera, Eric 993
 ✓ Rich, Katherine M 1071
 Riddler, Sharon A 164
 ✓ Ridolfi, Felipe 741
 ✓ Riebensahm, Carlotta 602, 616
 ✓ Riggs, Patricia K 491
 ✓ Rist, Michael 139
 Roan, Nadia R 2
 ✓ Robinson, Jake A 663
 ✓ Rocco, Joseph 367, 631
 Roche, Stephanie 978
 Rodriguez, Lauren 561
 ✓ Rodriguez-Centeno, Javier 692
 Roen, Ashley 623
 ✓ Romero, Elena V 226
 Romo, Matthew L 533
 ✓ Rosen, Joseph G 1041, 1047
 ✓ Roseto, Isabelle C 453
 Rossotti, Roberto 899
 ✓ Rothemejer, Frederik H 403
 Routy, Jean-Pierre 856
 Rouzier, Vanessa 813

- Roy, Upal 471
 ✓ Royston, Léna 633
 Rubenstein, Emma 195
 Rubinstein, Paul 434
 Ruderman, Stephanie 698, 699
 Rudolph, Jacqueline E 155
 Ruiz, Felicitas 309
-S-
 Saber, Lindsay 965
 Sabin, Caroline 874
 Sachdev, Darpun 209
 Sahu, Maitreyi 665
 Saini, Pratima 341
 Sainz, Talía 809, 821
 Saito, Suzue 199
 Salloum, Shadi 295
 Samet, Jeffrey H 203
 ✓ Sánchez Gaona, Nerea 312
 Sardo, Luca 426
 Savinelli, Stefano 277
 Sax, Paul 532
 ✓ Schnittman, Samuel R 348, 646
 Schuetz, Alexandra 268
 ✓ Schwarzmüller, Magdalena 306
 Scott, Hyman 161
 Scully, Eileen P 270
 Sebastiani, Giada 614
 Selzer, Lisa 580
 Sereti, Irini 250
 Serghides, Lena 805
 Serrano-Villar, Sergio 148, 405
 ✓ Serwin, Karol 151
 Shah, N. Sarita 755
 Shahmanesh, Maryam 976
 Shaik, Naveed A 504
 Shaikh, Simran 941
 Shamier, Marc C 926
 ✓ Shankwitz, Kimberly 802
 Shapiro, Adrienne E 111
 Shapiro, Roger 30
 Sharma, Ashish Arunkumar 181
 Shen, Yanhan 567
 Shi, Guoli 232
 Shi, Yuhang 223
 Shiino, Teiichiro 938
 ✓ Shmakova, Anna 296
 ✓ Sikombe, Kombatende 201
 Siliciano, Janet M 26
 Silva, Mayara S. T. 905
 Silvera, Richard J 590
 Silverberg, Michael J 1089
 Simpson, Jennifer 176
 Singh, Meera 465
 Singh, Sonia 934
 Singogo, Emmanuel 1087
 ✓ Siribelli, Alessia 615
 Sivile, Suilanji 524
 Smith, Amanda J 933
 Smith, Lauren N 303
 Smith, Robert A 538
 Sodeke, Olutomi 758
 Søggaard, Ole S 136
 ✓ Solis-Leal, Antonio 417
 Solomon, Sunil S 25
 ✓ Songane, Mario 1085
 Sousa, Ana E. 218
 Spagnuolo, Vincenzo 291
 Spinelli, Matthew A 1011, 1094
 Sponaugle, Alexis 409
 Spudich, Serena 1
 Squires, Kathleen E 192
 Srinivasa, Suman 144
 ✓ Stansfield, Sarah E 969
 ✓ Stephens, Reno 849
 Stewart, Jenell 121
 Stone, Julie 510, 511
 ✓ Storti, Samuele 470
 ✓ Struyve, Tine 449
 Stuart, Robyn 1015
 Stumpf, Julia 762
 ✓ Su, Hang 404
 ✓ Sudderuddin, Hanwei 575
 ✓ Sudsila, Pupe 1060
 Sun, Hsin-Yun 595
 Sun, Jing 214
 Sun, Jing 678
 ✓ Sun, Weiwei 135
 Suprasert, Bow 983
 Surial, Bernard 117
 Surial, Bernard 149
 Suryawanshi, Rahul K 275
 Suthar, Amitabh B. 848
 Szojka, Zsófia I 244
-T-
 Taddese, Maraake 115
 Tagarro, Alfredo 835, 836
 Taha, Taha Y 233
 Taiwo, Babafemi 581
 Takaori-Kondo, Akifumi 230
 Tambe, Lisa Arrah Mbang 922
 Tan, Darrell H. S 146, 292
 Tang, Weiming 1088
 Tapley, Asa 1013
 Tate, Moranda 864
 Tatham, Lee 555
 Tchounga, Boris K 945, 957
 ✓ Teeraananchai, Sirinya 1046
 Tefera, Fana 637
 Teyssou, Elisa 278
 Thiebaut, Rodolphe 382, 1008
 ✓ Thomas, Dorothy 984
 Thomson, Michael M 573
 Tiendrebeogo, Thierry 705, 1061
 Tindle, Hilary A 664
 Titanji, Boghuma K 207, 952
 Tobin, Nicole H 798
 Tomalka, Jeffrey A 221
 Tong, Xiao 551
 Torgersen, Jessie 613
 Torres, Thiago S 850, 901
 Townsley, Samantha 336
 Toy, K. Junine 1064
 ✓ Toy, K. Junine 1081
 Traeger, Michael W 122
 Tram, Khai Hoan 919
 Treurnicht, Florette K 237
 Trickey, Adam 156, 619
 ✓ Trigueros, Macedonia 263
 Trunfio, Mattia 462, 488
 Truong, Hong-Ha M 1026
 Tsimas, Billy M 1092
 Tucker, Emma 891
 ✓ Tusch, Erich 870
 Tuyishime, Simeon 529
 ✓ Twentyman, Joy 217
-U-
 ✓ Umutesi, Grace 601
 Underwood, Mark 694
-V-
 Vaidya, Akanksha 902
 ✓ van den Elshout, Mark 971
 van Eekeren, Louise E 609
 van Rooyen, Heidi 11
 ✓ van Wijk, Rob 740, 752
 Vandekerckhove, Linos 436, 672
 Vargo, Ryan 497
 Vasireddy, Vamsi 1099
 Veenhuis, Rebecca 419
 Veksler, Veronica 486
 Velu, Vijayakumar 317
 Venkatesh, Sreenidhi 356
 Vera, Jaime 476
 Verburgh, Myrthe L 673
 Vieira, Vinicius 829
 Viguerie, Alex 158
 Viox, Elise 179
 Visseaux, Benoit 844, 852
 Vo, Christopher A 914
 Vos, Wilhelm A. J. W. 676

- Vraga, Emily 47
 Vyas, Kartavya 881
-W-
 Waheed, Abdul 101
 Wallace, Michael S 621
 Wandeler, Gilles 587
 ✓ Wang, Qiankun 229
 Wang, Zheng 669
 Wanjalla, Celestine N 650
 ✓ Ward, Adam R 398
 Wei, Yulong 142
 ✓ Weissman, Sam 456
 ✓ Wells, Alan B 261
 Whitehead, Hannah 1018
 Whitehill, Greg 305
 Whitesell, Veronika 530
 Whitney, Bridget 882
 Wikman-Jorgensen,
 Philip E 1101
 ✓ Winchester, Nicole 662
 Winston, Alan 463
 Wise, Jenni 1096
 Woodhouse, Edwin
 Wilbur 1003
 Worobey, Michael 17
 ✓ Wu, Fengting 138
 Wu, Jinzi J. 550
 ✓ Wu, Linxuan 770, 998
 Wu, Richard 499
 Wu, Vincent 390
 ✓ Wu, Xinsheng 1036
 Wu, Yiquan 630
 Wynberg, Elke 710
-X-
 Xing, Enming 547
-Y-
 ✓ Yaffe, Zak A 781
 ✓ Yagnik, Bhругu 140
 Yendewa, George A 724
 Yin, Anna 358
 Yin, Kailin 346
 Yin, Li 797
 Yoshida, Takeshi 220
 ✓ Young, Isabella 991
 Young, Kyrliа C 343
 Yu, Yifan 782
 Yuan, Zhe 394
-Z-
 Zafilaza, Karen 281
 Zalla, Lauren 876
 Zang, Xiao 1065
 Zaniowski, Elizabeth 1062
 Zeichner, Steven 280
 Zemelko, Lily 408
 Zhang, Liao 437
 Zhang, Weiyiing 259
 ✓ Zhao, Ying 525
 Zhou, Shuntai 846
 Zhou, Xiao-Jian 512, 513
 Zhu, Weiming 980
 ✓ Zhu, Xianming 880
 ✓ Zia, Yasaman 1073
 Zisis, Sokratis N 713
 Zisis, Sokratis N 714
 Zou, Roger S 652
 Zucker, Jason 738
 ✓ Zuze, Boitumelo J L 584

SCHOLARSHIP AWARDEE INFORMATION

CROI is committed to supporting new and early-career investigators, as well as international investigators and community educators working in resource-limited countries who would otherwise be unable to attend CROI. New Investigator and International Investigator Scholarship Awardees have completed the scholarship application and are presenting authors on abstracts. Community Educator Scholarship Awardees have shown through their applications and letters of recommendation that they will greatly benefit from the opportunity to participate in CROI. Presenting authors who are New Investigator Scholarship Awardees are indicated throughout the program using the corresponding icons.

ACTIVITIES FOR NEW INVESTIGATOR SCHOLARSHIP AWARDEES

Scott M. Hammer Workshop for New Investigators and Trainees

CME

Widely considered the most informative and comprehensive session at CROI, this workshop highlights advances in HIV and SARS-CoV-2 molecular virology and immunology; advances in HIV treatment strategies, biomedical prevention, and cure; and community perspectives. Scholarship recipients are required to attend the entire workshop.

Meet the Luminary Sessions

CME

Small-group sessions (up to 25 New Investigators) during Monday and Tuesday lunchtimes at CROI host a leader in the field, generally a named lecturer or plenary speaker at CROI. These sessions provide the unique opportunity to meet and network with a leading scientific expert, and to ask one-on-one questions in an intimate setting. Each New Investigator can sign up for 1 session. **Note:** Sign up in advance is required.

Poster Walks (New for CROI 2023)

Daily Poster Walks take place during poster sessions on Monday, Tuesday, and Wednesday, with 6 concurrent Poster Walks per day in the areas of clinical research, basic science, and epidemiology/public health. Each 30- to 40-minute Poster Walk is led by a CROI Program Committee member (Poster Walk Leader) with up to 8 New Investigators though a selection of posters curated by the Poster Walk Leader. Each New Investigator can sign up for 1 Poster Walk. **Note:** Sign up in advance is required.

ACTIVITIES FOR COMMUNITY EDUCATOR SCHOLARSHIP AWARDEES

Community Educator Scholarship Awardees Networking Area

A designated area for Community Educator Scholarship Awardees and other HIV community representatives and advocates in the Ballroom 3 Lobby Area provides a central meeting point for community attendees.

CONFERENCE SERVICES

Services	Location	Hours	
Badge and Conference Materials Pickup	Summit Lobby Level 1	Saturday	3:00 PM – 6:00 PM
Attendee Services		Sunday	7:00 AM – 7:00 PM
Housing Information		Monday to Wednesday	7:30 AM – 6:00 PM
Continental Breakfast	Flex Foyer Level 2	Monday to Wednesday	7:30 AM – 8:30 AM
Bag & Coat Check	Summit Lobby Level 1	Sunday	8:00 AM – 9:30 PM
		Monday to Wednesday	10:00 AM – 6:00 PM
Cyber Café	Ballroom 1 Lobby Level 5	Sunday - Wednesday	7:00 AM – 6:00 PM

Note: Computers with internet are available.

Media Center	Meeting Rooms 421 and 422 Level 4	Sunday	10:00 AM – 7:30 PM
		Monday and Tuesday	8:00 AM – 6:00 PM
		Wednesday	7:00 AM – 6:00 PM

Note: Open exclusively to registered, accredited media, the Media Center is a workspace with WiFi and the location of the daily press conference.

Office	Terrace 1 Level 4	Saturday	3:00 PM – 6:00 PM
		Sunday to Wednesday	7:00 AM – 6:00 PM

Speaker Ready Room	Meeting Rooms 431 and 432 Level 4	Saturday	3:00 PM – 6:00 PM
		Sunday to Wednesday	6:00 AM – 6:00 PM

Note: Oral abstract, themed discussion, and special/invited session speakers must drop off PowerPoint slides here at least 24 hours prior to their presentation.

Personal Considerations and Lactation Room	Near Room 341 (Level 3); Near Room 441 (Level 4)	Saturday	3:00 PM – 6:00 PM
		Sunday	9:00 AM – 7:00 PM
		Monday to Wednesday	8:00 AM – 6:00 PM

Note: The Personal Considerations and Lactation room is set aside for those who require a short-term private space for personal health needs. This room is available on a first-come, first-served basis.

New Investigator Networking Lounge	Signature Room Level 5	Sunday	1:30 PM – 7:00 PM
		Monday to Wednesday	8:00 AM – 6:00 PM

Seattle Visitors Information Booth	Summit Lobby Level 1	Saturday	2:30 PM – 6:30 PM
		Sunday	2:00 PM – 9:00 PM
		Monday to Wednesday	10:00 AM – 6:00 PM

Note: Local information and reservations assistance.

Convention Center Emergency Medical Services	Near Flex C Level 2	Sunday	8:30 AM – 9:00 PM
		Monday to Wednesday	8:30 AM – 6:00 PM

SCHEDULE

TIME	SUNDAY, FEBRUARY 19, 2023	MONDAY, FEBRUARY 20, 2023	TUESDAY, FEBRUARY 21, 2023	WEDNESDAY, FEBRUARY 22, 2023
7:30am	Continental Breakfast 7:30 am–8:30 am	Continental Breakfast 7:30 am–8:30 am	Continental Breakfast 7:30 am–8:30 am	Continental Breakfast 7:30 am–8:30 am
8:30am	Scott M. Hammer Workshop for New Investigators and Trainees 9:00 am–12:30 pm Flex A (Level 2)	Plenary Session 8:30 am - 9:30 am 20 Years of PEPFAR: Looking Back, Striding Forward The Path to Hepatitis B Cure Flex C (Level 2)	Plenary Session 8:30 am - 9:30 am HIV Reservoirs: Obstacles to a Cure Restrictions on Reproductive Rights and Their Impact on People Living with HIV Flex C (Level 2)	Plenary Session 8:30 am - 9:30 am How the HUSH Complex Protects Your Genome From RNA-Derived Retroelements The Science of Aging: Lessons for HIV Flex C (Level 2)
10:00am		Concurrent Oral Abstract Sessions 10:00 AM – 12:00 PM 0-01 Virology/Pathogenesis Ballroom 2 (Level 5) 0-02 TB and Hepatitis Ballroom 1 (Level 5) 0-03 HIV and STI Prevention: New Tools and Approaches Flex C (Level 2) 0-04 Insights into Prevention and Treatment of HIV in Women and Children Flex A (Level 2)	Concurrent Oral Abstract Sessions 10:00 AM – 12:00 PM 0-05 HIV Reservoirs and Cure Strategies Ballroom 1 (Level 5) 0-06 Consternation About Complications Flex A (Level 2) 0-07 Global Epidemiology of HIV Ballroom 2 (Level 5) 0-08 All Modes Lead to PrEP Ballroom 3 (Level 5) 0-09 Late-Breaking Clinical Studies on COVID-19 and Mpox Flex C (Level 2)	Concurrent Oral Abstract Sessions 10:00 AM – 12:00 PM 0-10 Immunopathogenesis and Vaccines Ballroom 3 (Level 5) 0-11 Neuropathogenesis and Neurological Complications of HIV and SARS-CoV-2 Ballroom 2 (Level 5) 0-12 Antiviral Strategies for Treatment and Preventions Ballroom 1 (Level 5) 0-13 Optimizing the HIV Treatment Cascade Flex A (Level 2) 0-14 Epidemiology and Prevention of Mpox and SARS-CoV-2 Flex C (Level 2)
12:00pm		Lunch 12:00 PM – 1:30 PM ** Meet the Luminaries 12:15 PM – 1:15 PM	Lunch 12:00 PM – 1:30 PM ** Meet the Luminaries 12:15 PM – 1:15 PM	Lunch 12:00 PM – 1:30 PM Special Session on the Mpox Virus Outbreak 12:15 PM – 1:15 PM Ballroom 1 (Level 5)
12:30pm	Lunch 12:30 PM – 1:30 PM			
1:30pm	Concurrent Technical Workshops 1:30 PM – 3:30 PM Frontiers in Laboratory Technologies Ballroom 2 (Level 5) Case-Based Liver Workshop Flex A (Level 2) Clinical Trial Design and Analysis Ballroom 3 (Level 5)	Concurrent Themed Discussions 1:30 PM – 2:30 PM TD-01 HIV and the Microbiome: New Themes Flex C (Level 2) TD-02 Steatohepatitis: Sex Differences and Other Risk Factors Ballroom 2 (Level 5) TD-03 Predictors of TB Treatment Outcomes Ballroom 1 (Level 5) TD-04 Understanding Mortality in People with HIV Ballroom 3 (Level 5) TD-05 New Insights Through Recency Testing Flex A (Level 2)	Concurrent Themed Discussions 1:30 PM – 2:30 PM TD-06 Dynamics of Proviral Integration Flex A (Level 2) TD-07 A Virus On My Mind: Unraveling Links Between HIV and Mental Health Symptoms Ballroom 1 (Level 5) TD-08 LAI CAB/RPV: Where Are We Now and Where Are We Going? Flex C (Level 2) TD-09 Advances in PrEP Delivery in Sub-Saharan Africa Ballroom 2 (Level 5)	Concurrent Themed Discussions 1:30 – 2:30 PM TD-10 Cellular Immune Control of HIV Ballroom 2 (Level 5) TD-11 Weight Gain: Does What Goes Up Always Come Down? Ballroom 1 TD-12 HIV Services in Times of Crisis Flex A (Level 2) TD 13 Preclinical Studies of New Prevention Interventions Ballroom 3 (Level 5)
2:30pm		Poster Sessions 2:30 PM – 4:00 PM Exhibit Hall 2 ** Poster Walks	Poster Sessions 2:30 PM – 4:00 PM Exhibit Hall 2 ** Poster Walks	Poster Sessions 2:30 PM – 4:00 PM Exhibit Hall 2 ** Poster Walks
4:00pm		Concurrent Symposia 4:00 PM – 5:30 PM S-01 Viral Origins and Evolution of HIV and SARS-CoV-2 Ballroom 2 (Level 5) S-02 From Rocket Science to Reality: Monitoring Antiretrovirals and Adherence Flex A (Level 2) S-03 Delivering on the Success of Injectable PrEP Ballroom 1 (Level 5)	Concurrent Symposia 4:00 PM – 5:30 PM S-04 Pediatric HIV Cure Ballroom 2 (Level 5) S-05 COVID-19: Where Are We Now? Flex A (Level 2) S-06 Getting PrEPped (and PEPped) for Sex: From HIV to STIs to Mpox Ballroom 1 (Level 5)	Concurrent Symposia 4:00 PM – 5:30 PM S-07 The Viruses They Are A Changing: How the Immune System Responses Ballroom 3 (Level 5) S-08 Case-Based Discussion of Cardio-Metabolic Complications and Consequences for Management Ballroom 1 (Level 5) S-09 Science Communication in the Age of Misinformation Ballroom 2 (Level 5)
5:00pm	Opening Session 5:00 PM – 7:20 PM Reception – 7:20 PM-9:30 PM Garden Terrace (Level 3) Weather Back-up Flex Foyer (Level 2) Bernard Fields Lecture N'Galy-Mann Lecture Martin Delaney Presentation CROI at 30: Progress in HIV Through the Lens of CROI Special Recognition of Dr Anthony Fauci Flex C (Level 2)		Special Session 5:40 PM – 6:00 PM Results from the MOSAICO HIV Vaccine Trial and Future Directions for HIV Vaccines Flex A (Level 2)	

***Please note:** Poster Walks and Meet the Luminaries sessions are limited to New Investigator Scholarship Awardees. Sign up in advance is required.

30th CROI

Conference on Retroviruses
and Opportunistic Infections

